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INTRODUCTION 1 
 
1  Introduction 
The investigation of the relationships between chemical structures and their biological effect 
is the principal aim of medicinal chemical research. Active compounds may be found in a 
library of various different chemical structures by means of high-throughput screening. 
Identified hits can then be used as lead structure for the design of further drugs. However, 
since this common method is time-consuming and expensive, nowadays the computer based 
design represents a wide spread and established method. In this context, drug development 
in pharmaceutical research mostly begins with the identification and characterization of a 
biological target which may be an enzyme or a membrane bound protein like receptors or 
transporters that mediate a physiological effect. 
In general, two different strategies can be pursued: The ta get ased d ug desig  e ui es 
the knowledge of the exact 3D structure of the target in presence of the ligand that may be 
generated by X-ray crystallography. In this case detailed knowledge about the binding site of 
the substrate and kind of interactions of the substrate with the protein complex can be gained. 
By means of respective computer programs ligands can be fit into the binding pocket of the 
ta get do ki g  a d i di g affi ities a  e al ulated as do ki g scores dependent on the 
structure of the substrate. Based on these values potential new structures can be created that 
might have a similar or even better affinity to the corresponding target. 
If the target structure is not known, the liga d ased d ug desig  can be pursued 
alternatively. Based on physiochemical features of known ligands it is intended to design new 
active compounds by means of a pharmacophore model that describes the interactions 
between ligand and target. By means of this model substance libraries can then be screened 
for additional potentially active substances.  
The most active evaluated compounds can serve as basic structures for the development of 
more potent and/or more selective new ones by slight chemical modifications if they fulfill 
given requirements regarding physical and chemical features regarding molecular weight, 
lipophilicity, and solubility. Based on biological test results for related compounds, structure 
activity theories can be set up that might lead to a better understanding of the interactions 
between ligand and target, and thus may again support the further drug research. 
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1.1  CNS diseases and the physiologic significance of GABA 
Diseases based on the central nervous system (CNS) are widely spread around the world. 
Various neurological disorders belong to this field, such as dementia, epilepsy, depression, 
multiple sclerosis, Pa ki so ’s disease or neuropathic pain.[1] Among these, epilepsy affects 
over 50 million patients and is thus one of the most abundant diseases.[2] Though there are 
meanwhile over 15 different antiepileptic drugs approved, about a third of the patients 
continue to have seizures regularly, despite of a comprehensive treatment, and the half of 
them are suffering from complex psychiatric, behavioral, cognitive, and social problems.[3]       
In order to provide an appropriate medical supply for all affected patients, there is the 
continuous need for exploration of new antiepileptic drugs. 
In physiological context, in particular -aminobutyric acid (GABA, 1, Chart 1) represents a 
significant key substance since it is known to be the major inhibitory neurotransmitter in the 
CNS.[4] In the first section, the neurotransmission of this amino acid will be discussed briefly 
as well as the possibilities to increase this neurotransmission in order to treat CNS diseases. 
 
 
 
Figure 1: Structure of -aminobutyric acid 
 
1.1.1  GABA Neurotransmission 
Synthesis of GABA occurs in the presynaptic neuron through enzymatic decarboxylation of the 
excitatory neurotransmitter glutamate by the glutamic acid decarboxylase (GAD). Formed 
GABA is packed into vesicles by a vesicular neurotransmitter transporter (VGAT) for storage.[5] 
Upon depolarization of the presynaptic neuron GABA is released into the synaptic cleft by 
exocytosis and can then bind to its corresponding pre- and post-synaptic receptors of which 
two types of GABA receptors are to differentiate: The ionotropic GABAA receptors are mainly 
located on the postsynaptic side and play as ligand controlled chloride channels the dominant 
role in mediating fast further signal transduction. The metabotropic GABAB receptors are         
G-protein coupled receptors (GPCR) and found on both pre- and post-synaptic neurons.[5] 
GABA (1)
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Binding of GABA to the GABAA receptors causes a hyperpolarization of the postsynaptic 
neuron through the influx of chloride which is leading to a reduced excitability of this neuron. 
The presynaptic GABAB receptors adjust the further release of GABA by a negative feedback 
mechanism. Binding leads to an inhibition by suppressing calcium influx. Postsynaptic GABAB 
receptors convey hyperpolarization of its neuron through the elevated efflux of potassium.[5] 
For the termination of GABAergic signaling, GABA must be removed from the synaptic cleft 
which is mediated by specific GABA transport proteins (GATs) being responsible for the 
reuptake of GABA into the presynaptic neuron or its transport into adjacent glia cells.[6] After 
the reuptake into the presynaptic neuron GABA can be recycled by the packing into vesicles 
again. The transport into glia cells mainly leads to enzymatic decomposition of the 
neurotransmitter to succinic semialdehyde by GABA transaminase (GABA-T).[7] 
The described neurotransmission of GABA is displayed in Figure 2. 
 
Figure 2: GABA neurotransmission according to Owens et al.:[5] GABA is synthetized by GAD and stored in vesicles 
by VGAT. It is released into the synaptic cleft in response to an action potential. In the synaptic cleft it can interact 
with receptors (GABAA and GABAB) for further signal transmission or in the sense of a negative feedback. Reuptake 
of GABA in the presynaptic neuron or glia cells occurs through the activity of GABA transporters (GATs). 
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1.1.2  Pathology and Therapy 
A reduced GABAergic signaling in the CNS leads to an imbalance between the excitatory and 
inhibitory neurotransmission[7] and is assumed to be associated with the pathogenesis of 
epilepsy and other CNS diseases mentioned above.[4] In case of a pathological diminished 
inhibitory activity of GABA, therapeutic active compounds, which aim for an increase of the 
GABAergic neurotransmission, can help to restore the balance between excitatory and 
inhibitory neurotransmitters. Thereby, the different GABA receptors, the GABA decomposing 
transaminase and the GATs represent suitable targets. 
Positive allosteric modulators of the GABAA receptors are represented by the benzodiazepines 
which constitute ligands of a specific allosteric binding site. The occupation of these binding 
sites leads to a conformational change of the receptor upon which in presence of GABA an 
elevated opening frequency of the chloride channels occurs as consequence.[7] As an example 
of drugs that act via this mechanism, diazepam (2, figure 3) should be mentioned as one of 
the most spread benzodiazepines. Another option to increase the neurotransmission of GABA 
can be realized by the binding of an agonist, e.g. baclofen (3, figure 3) to the metabotropic 
GABAB receptor. By the irreversible inhibition of GABA transaminase by vigabatrin (4, figure 3) 
a similar goal can be pursued since the neurotransmitter will not be decomposed in this case. 
Finally, an increased GABA level also occurs when the GABA transporters are blocked since 
GABA will not be removed from the synaptic cleft as a consequence. Tiagabine (5, figure 3) is 
approved as antiepileptic drug and acts as inhibitor of the GABA transporter subtype 1 (GAT1). 
 
 
 
 
 
 
Figure 3: Current drugs with influence of the GABA neurotransmission (eutomers are depicted). 
(S)-Vigabatrin (4)(R)-Baclofen (3) (R)-Tiagabine (5)Diazepam (2)
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1.2  GABA Transporters 
Transporters (solute carriers, SLCs) enable the exchange of ions, neurotransmitters or amino 
acids through cellular membranes. Since their inhibition can lead to an increased GABA level, 
GATs represent an interesting target for the development of new antiepileptic drugs. Different 
aspects of GATs have been investigated in the last years. The knowledge discovered in these 
studies concerning function and structure of these targets as well as the respective ligands 
addressing this target are discussed in the following part. 
 
1.2.1  The SLC6 transporter family 
The most important type of transporters are derived from the solute carrier 6 (SLC6) gene 
family of which 20 different transporters subtypes are known so far.[8] According to the amino 
acid sequence they can be divided up into 4 main subtypes (figure 4): monoamine 
transporters, GABA transporters, and two groups of amino acid transporters.  
 
Figure 4: Transporters of the SLC6-family according to Bröer et al.[9] 
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The monoamine transporters include the transporters for the well-known neurotransmitters 
noradrenaline (NET), dopamine (DAT) and serotonin (SERT). The different GABA transporters 
GAT1, BGT1, GAT2, and GAT3 as well as the transporters for taurine (TauT) and creatine (CT1) 
belong to the group of GABA transporters. The first group of the amino acid transporters 
contains transporters for glycine (GlyT1 and GlyT2), proline (PROT) and one for neutral and 
cationic amino acids (ATB1). The second group of amino acid transporters is involved in 
epithelial and brain amino acid transport. Most members accept a variety of amino acids for 
transportation. The physiological role of the transporter members of this group is not 
completely understood so far.[9] 
These neurotransmitter transporters are also called neurotransmitter-sodium-symporters 
(NSSs) or Na+/Cl- dependent transporters[10] since they entail the co-transport of Na+ of which 
transportation goes along the concentration gradient into the inside of the cell, mediating the 
transport of the actual substrate against its concentration gradient into the same direction. 
Thereby, the Na+/K+-ATPase guarantees for this ongoing mechanism through the maintaining 
of the sodium gradient.[9] The stoichiometric ratio of substrate and the co-transported ions is 
varying within the different types of NSSs. 
The elucidation of the molecular structure of these NSSs was subject to intensive research. 
The isolation of the first NSS was achieved for GAT1 from rat brain by Radian et al.[11] The 
analysis of the amino acid sequence led to the cloning and sequencing of this transporter by 
Gustella et al.[12] followed by the transporters for noradrenalin,[13] dopamine,[14] serotonin[15] 
and glycin.[16] Thereupon, it could already be claimed that the transporters were consisting of 
12 transmembrane helices.[17] However, the final structure was elucidated by Yamashita et 
al.[18] within whose work the successful crystallization of the leucine transporter LeuTAa from 
the bacteria Aquifex aeolicus in the presence of its substrate leucine and two sodium ions 
could be accomplished. Though the identity in the total sequence of LeuTAa as compared to 
that of the eukaryotic SLC6-transporters is just 20-25%, the homology in sequence for areas 
in the region of the substrate binding site amounts to 55-67%.[19] For this reason the results of 
Yamashita et al. concerning LeuTAa constitute a valid base for the understanding of the 
construction and function of neurotransmitter transporters in general.[20] The obtained 
structure of LeuTAa is displayed in Figure 5. 
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Accordingly, the transporter consists of 12 transmembrane helices (TMs) that are connected 
by corresponding loops both intra- and extracellularly. Both the amino- and the carboxy-
terminus are located in the inside. The authors compare the spatial structure of the 
t a spo te  to a shallow shot glass . It consists of an inner ring which is formed by helices 
TM1, 3, 6 and 8 and an outer ring that is represented by TM2, 4, 5, 7, 9 and 10. The inner ring 
contains the binding site for leucine and two sodium ions within the region of TM1 and TM6 
that are arranged antiparallel. Because of an interruption of the helical structure they are 
divided into two proportions (a+b) in the middle so that C=O- and NH-groups are exposed for 
the formation of hydrogen and ionic bonds. The first 10 TMs are characterized by a repeated 
structural element. TM1-5 and TM6-10 are interconvertible by rotation of 176.5° through a 
pseudo-two-fold axis of symmetry that proceeds parallel to the membrane.[18] 
Figure 5: Structure of LeuTAa according to Yamashita et al.[18] 
 
This particular arrangement led to the assumption that the general transport mechanism of 
these NSSs follows the odel of alte ate a ess .[21, 22] In this case, the transporter consists 
of an intra- and extracellular border. Both gates can be alternately open or close to one side 
triggered by a conformational change which is induced by the binding of the substrate and 
leads to a directed transport. During the transport the transporter in general passes several 
conformations. In the initial state of the transport cycle the transporter exists in the outward 
facing open  OFo, Figure 6 left) conformation concerning the extracellular side, enabling the 
substrate and ions to get into the S1 binding site. Subsequently, a conformational change 
follows causing the close of the extracellular gate ( outward facing closed , OF , figure 6 
middle). Thereafter, the transporter changes to the inward facing close  (IFc, not depicted) 
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conformation upon which the intracellular gate opens immediately, and releases the substrate 
and ion to the cytoplasm ( inward facing open , IFo, figure 6 right).[23] 
After the elucidation of the OFc state, Krishnamurty et al. were able to crystallize both the OFo 
and the IFo state and analyzing the same.[24] As a result, a more detailed understanding of the 
different conformations and molecular processes running during the transport was possible 
and mainly confirmed the postulated transport mechanism of Yamashita et al.  
Figure 6: Postulated Transport mechanism of LeuTAa according to Yamashita et al.[18] 
 
These three states of LeuTAa are displayed in figure 6. I  the outwa d facing  o fo atio  
the extracellular site is accessible for the substrates and ions. In this state the two amino acids 
arg30 and asp404, which are mainly responsible for the extracellular gate, do not interact. 
Closing the extracellular side is on the one hand facilitated by the formation of a salt bridge 
between both amino acids and on the other one by the two aromatic amino acids tyr108 and 
phe253 of which interaction leads to a hyd opho i  ap su st ate o luded . Access to the 
intracellular site is blocked by a saltbridge of arg5 and asp369 (intracellular gate) and a dense 
network of the helicale segments TM1a, TM6b and TM8. This region is becoming vacant by 
the conformational change to the inward fa i g  state. Thereby, opening and closing of the 
extra and intracellular gates might be enabled by the movement of the helicale segments 
TM1b-TM6a (extracellular) and TM1a-TM6b (intracellular) relatively to the TM3 and TM8 
backbone and a slight rotation of the latter. In this context, binding and unbinding of substrate 
and ions may stabilize the helices in the different conformational states.[18] 
INTRODUCTION 9 
 
Based on molecular-dynamic simulations and other experimental data Shi at al. reported a 
second binding site S2 which is located above the extracellular gate of LeuT.[25] They claim that 
the occupation of this binding site is necessary for the allosteric release of the substrate to the 
cytoplasm. The existence of S2 was also validated in other studies[26, 27] though its function is 
still discussed.[28, 29] S2 might be relevant as non-competitive binding site for LeuT inhibitors 
upon which binding prevents the transporter going through the conformational changes.[28] 
Recently, Penmatsa et al. were able to crystalize the eukaryotic DAT that was gained from 
Drosophila melanogaster bound to the tricyclic antidepressant nortriptyline.[30] It was found 
that the crystal structure of this NSS is in excellent accordance with the previously published 
structure for prokaryotic LeuT. Lately, also X-ray crystallographic structures of the human SERT 
in complex with the antidepressant (S)-citalopram or paroxetine were described by Coleman 
et. al.[31] In this context likewise the location of an allosteric binding site in the extracellular 
vestibule could be identified. Accordingly, the occupation of this site sterically hinders the 
ligand unbinding from the central binding site. 
These new transporter structures will serve as promising tool for future homology models for 
the mammalian NSS, as it is up to now commonly established for LeuT. 
 
1.2.2  Classification of GABA transporters 
GATs exist in four subtypes with different types of designations dependent from the species 
from which they are derived (Table 1). According to the human genome organization (HUGO) 
these four subtypes are generally named as GAT1, BGT1, GAT2, and GAT3.[32]  However, there 
are also other nomenclatures in use, e.g. when derived from human the four transporters 
were explicitly designated as hGAT1, hBGT1, hGAT2 and hGAT3 and when cloned from mice 
as mGAT1, mGAT2, mGAT3 and mGAT4, respectively.[33] Within this thesis, modeling studies 
will refer to hGAT1, whilst biological data will be measured for mGAT1-4. 
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Table 1: Nomenclature of GATs 
Species GAT designation 
HUGO GAT1 BGT1 GAT2 GAT3 
human hGAT-1 hBGT-1 hGAT-2 hGAT-3 
mouse mGAT1 mGAT2 mGAT3 mGAT4 
 
All subtypes differ both in their expression pattern and their pharmacological significance: 
GAT1 is mainly located in the membranes of presynaptic neurons and represents the most 
abundant and the most important GABA transporter in the brain.[34] According to newer 
studies, BGT1 and GAT2 are mainly located in the liver and kidney instead of the CNS and do 
not have considerable affinity to GABA.[35] BGT1 is preferentially transporting betaine[36] and 
GAT2 particularly carries taurine.[37] Thus, these two subtypes do not play an important role 
in the termination of GABAergic neurotransmission. However, next to GAT1, subtype GAT3 
has an important function in the CNS since it is especially located on the glia cells and therefore 
is also connected with decomposition or recycling of GABA.[38] 
 
1.2.3  GABA transporters as pharmacolocical targets 
Since the inhibition of GABA transporters can increase the residence time of GABA in the 
synaptic cleft and contribute to restore a physiological neurotransmitter balance the same 
represent an interesting target for the drug development. In this context, it is the aim to 
identify compounds that inhibit the GABA uptake effectively, but do not bind to the GABA 
receptors. For the first, acyclic analogue compounds of GABA were developed that were not 
found to be selective to one of the transporter subtypes and additionally turned out to act as 
ligands for the GABAA receptor.[39] In contrast to this, some cyclic amino acids like guvacin       
(6, Table 2) or nipecotic acid (7, Table 2) have proved to be a better starting point for the 
development of GAT inhibitors.[40] Except from mGAT2, the inhibitory potencies (pIC50 values) 
for 6 and 7 (Table 2) are of a similar order of magnitude concerning all subtypes mGAT1-4 and 
do not show pronounced selectivity. For nipecotic acid (7) it has to be recognized the                
(R)-enantiomer is significantly more potent than the (S)-enantiomer concerning inhibitory 
activity towards all GATs. The corresponding pIC50 values for 6 and (R)-7 regarding mGAT1 are 
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located in the range of 5. For the other subtypes mGAT2-4 the values were found to reach 
from about 3 (mGAT2) up to almost 5 (mGAT3, mGAT4), respectively. 
 
Table 2: pIC50-values of small amino acids as GABA analogues   
 
 
 
 
Compound 
GABA uptake inhibition (pIC50 ± SEM)
a 
mGAT1 mGAT2 mGAT3 mGAT4 
6 4.87 ± 0.06 3.31 ± 0.03 4.59 ± 0.05 4.59 ± 0.05 
(R)-7 5.12 ± 0.03 3.40 ± 0.05 4.76 ± 0.05 4.95 ± 0.05 
(S)-7 4.24 ± 0.05 3.13 ± 0.14 3.83 ± 0.04 3.63 ± 0.06 
 
a)  For sake of comparability all listed functional inhibitory potencies (pIC50 values) derive from the biological test 
 of our research group (GABA uptake assay based on HEK293 cells stably expressing the different mGATs). 
 
However, the sole amino acids are highly polar and are moreover present as zwitterion under 
physiological conditions, a circumstance that prevents them to cross the blood brain barrier 
and thus to reach the CNS.[41] Furthermore they simultaneously serve as substrate of the GATs. 
To solve the problem of inefficient CNS penetration lipophilic side chains to the nitrogen of 
the cyclic amino acids were introduced in a next step. Thus constructed compounds were not 
only more lipophilic and able to reach the CNS, but even showed an enhanced subtype 
selectivity towards mGAT1. In this context, compounds like NO711 (8, Table 3),[42] SKF-89976  
(9, Table 3)[43] or tiagabine (10,  Table 3)[44] were introduced of which the latter was finally 
approved as antiepileptic drug in the adjunctive therapy. The pIC50-values towards mGAT1 of 
these compounds were found to be increased by one to two decimal powers (values are in 
the range of 6-7) as compared to compounds 6 and 7 (Table 2) whereas the ones for mGAT2-
4 hardly raised or even decreased (pIC50 values located between 3 and 4). 
 
guvacin (6) (RS)-nipecotic acid ((RS)-7)
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Table 3: Classical mGAT1-selective inhibitors and their pIC50-values. 
 
 
 
 
 
 
 
Compound 
GABA uptake inhibition (pIC50 ± SEM)
a 
mGAT1 mGAT2 mGAT3 mGAT4 
8 6.83 ± 0.06 3.20 ± 0.09 3.62 ± 0.04 3.07 ± 0.05 
9 6.16 ± 0.05 3.43 ± 0.07 3.71 ± 0.04 3.56 ± 0.06 
10 6.88 ± 0.12 50%b 64%b 73%b 
 
a)  For sake of comparability all listed functional inhibitory potencies (pIC50 values) derive from the biological test 
 of our research group (GABA uptake assay based on HEK293 cells stably expressing the different mGATs). 
b)  A complete inhibition curve for determination of pIC50 was not measured if [3H]GABA uptake remained 50% 
 or above already at a concentration of 100 µM inhibitor in two experiments.             
 
The residues of N-substituted nipecotic acid and other cyclic amino acids in general consist of 
a spacer of four or five atoms which partly also includes a hetero atom with an terminal 
attached aromatic moiety. SAR studies of Anderson et al. indicated the 2-biphenyl and the      
2-benzylphenyl residue as aromatic component of the N-substituent for the first time to be 
advantageous concerning inhibitory potency towards mGAT1, as it is the case for compounds 
(R)-11 and (R)-12 (Figure 7).[45] The affinity of N-substituted nipecotic acid derivatives bearing 
the biphenyl type moiety could recently be validated in the study of M. Petrera, in whose 
target compounds the alkoxyalkyl spacer was exchanged through a but-3-en-1-yl linker, 
resulting in compound (RS)-13 (Figure 7).[46] The racemic mixture of this parent compound 
already exhibited a similar inhibitory activity and can be viewed as starting point for the 
development of various further mGAT1 selective inhibitors. Exchanging the 2-biphenyl moiety 
in this structure by a 2-benzylphenyl residue, as it is the case for (RS)-14 (Figure 7), inhibitory 
potencies towards mGAT1 decreased by about one decimal power in this case.  
NO711 (8) Tiagabine (10)SKF-89976 (9)
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Figure 7: New generation of GAT1 selective inhibitors by a) Anderson et al.[45] and b) Petrera et al.[46]                       
 a: pIC50 values calculated from Anderson et al.[45]; values measured in synaptosomal preparations 
 from rat (comparable to mGAT1); b: pIC50 values from Petrera et al.[46]; values refer to mGAT1 
 
Although it is the aim of this thesis to search for new GAT1 selective inhibitors, for sake of 
completeness it should be mentioned that also ligands have been developed that aim at the 
other transporter subtypes BGT1, GAT2 and GAT3, though there are almost none with a 
pronounced subtype selectivity that would allow to gain reliable data on the pharmacological 
profile of the individual transporter. To what extent these transporters can play a role for the 
treatment of epilepsy or other diseases is also topic of various parallel studies.[35-38] 
 
1.2.4  Binding modes of GABA and GAT1 inhibitors 
The findings about LeuT (see chapter 1.2.1) have served as valid base for the understanding 
of also human neurotransmitter transporters such as the GABA transporter, as there is the 
already mentioned similarity between both transporter types. Therefore, many molecular 
modeling studies deal with this transporter type and represent a useful tool for the study and 
development of new and highly potent GAT1 inhibitors. For this reason, two publications that 
resulted from my PhD studies also comprise structure target interactions and binding 
calculations, gained from molecular modeling results. 
     (R)-12
pIC
50
 = 6.99a
        (RS)-14
pIC
50
 = 5.72±0.04b
        (RS)-13
pIC
50
 = 6.79±0.12b
     (R)-11
pIC
50
 = 6.95a 
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In our research group a three dimensional model for the human GABA transporter hGAT1 was 
developed and interactions between GABA and the substrate binding site were investigated 
by docking studies.[47] Thereby, the derived binding modes of GABA in hGAT1 and leucine in 
LeuTAa are both highly similar (Figure 8). The carboxylic group of GABA in hGAT1 is bound to 
one of the sodium ions (Na1) as it is also true for leucine in LeuT and is additionally stabilized 
by hydrogen bonds addressing the hydroxyl function of Tyr140 and the amide of Leu64 and 
Gly65. The amino function is fixed by hydrogen bonds to the hydroxyl function of Thr400 and 
Ser396 and Tyr60 and to the carbonyl function Ser396 and Tyr60. The different substrate 
specificity is mainly the result of 3 amino acid exchanges in hGAT1 compared to LeuT, Ser256 
to Gly297, Asn21 to Tyr60 and Ile359 to Thr400 which results in slightly modified interactions. 
 
Figure 8: Binding mode of a) Leucin in LeuT and b) GABA in hGAT1 according to Wein et al.[47] 
 
A further homology modelling study of hGAT1 was also based on the crystal structure of LeuT 
and investigated the binding modes of GABA, nipecotic acid and Tiagabine.[48] Accordingly, 
nipecotic acid can adopt two different binding poses. In the preferred one, the carboxyl 
function again participates in ionic interactions to the sodium Na1 and polar interactions to 
Tyr140 and Gly65, thus similar as compared to the interactions of GABA. The nitrogen is 
oriented to the intercellular side and exhibits similar hydrogen bonds to Tyr60 and Ser396. 
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Due to its huge lipophilic side chain Tiagabine is present in another binding pose as compared 
to the smaller ligands (Figure 9a). In this case, the nitrogen of the nipecotic acid subunit is 
directed to the extracellular side, shaping a hydrogen bond to Phe294. The hydrophobic side 
chain is outside of the binding site S1 and stabilized by aliphatic sidechains in this region. This 
binding mode requires open-to-out o fo atio  with the extracellular gate between 
Phe294 and Tyr140 to be open.[48] 
Recently, our work group published an overview dealing with the different binding modes of 
a variety of small and large ligands of hGAT1.[49] In this context, the new GAT1 inhibitor 13 
(Figure 7) by M. Petrera was investigated in the same homology model[46] as well, indicating  
a similar binding mode like Tiagabine (Figure 9b). Though, due to the biphenyl moiety, further 
interactions could be observed, facilitated by the side chain of Phe294. This is rather rotated 
towards the terminal phenyl residue of 13 enabling access to the backbone atoms of Thr290 
and Gln291 in the TM6 helix and thus additional interactions as compared to tiagabine. In this 
context, it was additionally demonstrated that substituents (e.g. halogens) of the terminal 
phenyl residue of the biphenyl moiety of compound 13 could lead to even more potent GAT1 
inhibitors by addressing this area. 
 
Figure 9: Binding mode of a) Tiagabine and b) compound 13 in hGAT1 according to Wein et al.[46] 
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1.3  Cross-coupling reactions as synthetic tool in medicinal chemistry 
Cross-coupling reactions are the modern way of forming carbon-carbon bonds and thus also 
represent a powerful tool to the easy access of many stable ligands in medicinal chemistry. 
Within the publications of this thesis in particular the Suzuki and Sonogashira cross coupling 
reactions were applied as they can contribute to the construction of new GAT1 inhibitors that 
are based on N-arylalkenyl or N-arylalkynyl substituents. 
Cross-coupling reactions are generally based on transition-metal catalysts.[50] Among them, 
the palladium-catalyzed ones are the most prominent. The generally accepted mechanism for 
these type of reactions is depicted in Scheme 1.  
 
 
 
 
 
 
 
 
Scheme 1: General reaction cycle of palladium catalyzed cross-coupling reactions 
 
The reaction mechanism generally begins with the oxidative addition (A) of mostly an organic 
halide (R1-X) to the palladium(0)-catalyst, leading to an arylpalladium(II)-halide intermediate. 
Subsequently, the second reaction partner R2M, an organometallic compound, undergoes 
transmetallation (B), whereby the organic residue is transferred to the palladium(II)-species 
by eliminating the functional groups as metal halide (MX). Subsequent reductive elimination 
(C) of the R1-PdII-R2 intermediate follows, forming the new C-C bond and thus delivering the 
respective organic product with simultaneous regeneration of the catalyst.[51] 
 
Transmetallation
Oxidative
 Addition
 Reductive
Elimination
A
B
C
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Several factors determine the success of the reaction. The oxidative addition mostly is the rate 
determining step of the cross-coupling reactions. The ability for the palladium(0)-catalyst to 
insert into the R1-X bond is facilitated when the binding energies of these bonds are reduced. 
Thus, the tendency to undergo oxidative addition can be stated with the reactivity order of 
the leaving group with I > OTf > Br >> Cl.[51] Additionally aryl halides with neighbored electron 
withdrawing groups are more reactive than those with electron pushing substituents. 
The transmetallation is usually facilitated by a base. In case of the Suzuki reaction for example 
the addition of hydroxide to the metal of R2M, here boron, leads to a fourfold coordinated 
boronate complex in this case and therefore a better nucleophilic species to attack the 
electrophile palladium(II).[52] It is also known the base HO- to attack the R1-Pd(II)-X complex 
and to displace the halide. The thus formed R1-Pd(II)-OH intermediate can then react with the 
organometallic compound R2M transferring the organic moiety from the metal M to the 
palladium(II).[52] The high reactivity of the R1-Pd(II)-OH is owed to the basicity of the Pd-OH 
species and the high need of the boron center to form a bond to the oxygen. In case of the 
Sonogashira reaction the base should deprotonate a terminal alkine in order to equally 
increase the nucleophilicity. Since the usually used bases are not strong enough for that 
purpose copper is usually applied as co-catalyst. This Cu(I)-halide as Lewis acid can form a        
π-alkine-complex that mediates deprotonation, resulting in an copper acetylide as 
nucleophilic agent for the transmetallation.[53] 
Also the solvents used and the nature of the bases have an impact on these reactions. 
Whereas Suzuki couplings are mostly performed in a two phase system that arises by adding 
an inorganic base to a homogeneous mixture of organic solvent and water,[52] Sonogashira 
couplings are usually established in amines as solvents that in this case simultaneously 
represent the base. Inorganic bases like carbonates or phosphates are usually combined with 
aqueous systems. These allow the dissolution of the base which may accelerate the reaction. 
Though side reactions like hydrolysis are more likely to appear under these conditions. 
Finally diverse ligands (L) of the palladium have been established in order to stabilize the 
palladium(0) species and to mediate reactivity of the same towards all three steps of the 
catalytic cycle. The use of electron rich phosphines thereby was found to show enhanced rates 
oxidative addition and reductive elimination step.[54]  
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1.4  The use of light for the activity control of ligands 
Since neurotransmission is based on the interaction of ligands with proteins such as 
transporters, there was the idea to modify ligands with a light controllable functional group 
as approach to study the structure and function of their targets in dependence on the different 
activity of those ligands. This chapter will deal with photoswitchable compounds and their 
establishment in medicinal chemistry. 
 
1.4.1  Photochromism and photoswitchable compounds 
A molecular switch is a chemical species that can be reversibly shifted between two or more 
stable states. The molecules may be switched between these states in response to an external 
environmental stimuli, such as changes in pH, light, temperature or an electric current.[55] 
If this transformation is caused by using light of a set wavelength, this phenomenon is also 
known as photochromism. Thereby, different physicochemical properties of the molecule may 
change such as absorption spectra, refractive index, dielectric constant, oxidation/reduction 
potential, and geometrical structure.[56] These molecular changes have been used in various 
fields for example in photonic devices such as erasable optical memory media (Compact Disc), 
in nanotechnology for application in molecular computers or responsive drug delivery systems 
and also play an important role in molecular self-assembly and photo-controlled biological 
systems. In the latter case, photochromic compounds may also occur as ligands for proteins. 
Photochromic reactions include isomerization reactions of C=C or N=N double bounds but also 
pericyclic reactions like rearrangements or ring opening and closing reactions. These are 
mostly unimolecular reactions upon which the thermodynamically stable form reversibly turns 
to a form of a higher energy level under illumination.[56] Back reactions can be caused by light 
of a different wavelength or by heating in the dark (thermal relaxation). For this reason, 
photochromic compounds are also called photoswitchable compounds. Ideal photoswitches 
undergo reversible photochemistry without any side reactions so that many rounds of 
active/inactive states can be produced. 
Isomerization reactions are one of the most spread photochromic reactions and are based on 
this principle. Whereas E/Z-isomerization reactions of C=C double bonds like diarylethenes 
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mostly result in products that are stable under physiologic conditions and additionally may 
form phenanthrene-like side products during irradiation[57] the ones of N=N double bonds like 
azobenzenes rather tend to do back isomerize to the thermodynamically more stable form by 
itself within a characteristic time interval.[58] Furthermore, many isomerization cycles are 
possible without the occurrence of side or decomposition reactions. Therefore, photochromic 
E/Z-isomerization of azobenzenes has been used extensively in molecular switches, e.g. for 
the photo-control of biomolecules, often taking advantage of its geometrical change of shape 
upon isomerization to produce a supramolecular result. 
The thermodynamically stable (E)-isomer of azobenzene can be isomerized to its (Z)-isomer 
by using light with a wavelength of 340 nm. The (Z)-isomer adopts a bent conformation with 
its phenyl rings twisted by about 55° out of the plane from the azo group (Figure 10). This is 
the reason that both isomers strongly differ in their absorption spectra. Whereas (E)-
azobenzene shows a weak n–π* band near 440 nm and a strong π–π* transition near 320 nm 
(Z)-azobenzene has a stronger n–π* band also near 440 nm and shorter wavelength bands at 
280 nm and 250 nm (Figure 8). Back isomerization can be induced by light with a wavelength 
of 450 nm or by thermal relaxation.[58] Since the absorption spectra of the (E)- and (Z)-isomer 
overlap substantially, isomerization never runs in a quantitative scale and irradiation produces 
a photostationary state with up to 95% of the (E)-isomer.[58] However, thermal relaxation of 
the (Z)-isomer leads to essentially 100% of the original (E)-isomer. Unmodified azobenzene 
undergoes thermal relaxation on a timescale of days at room temperature.[58] 
 
Figure 10: a) chemical and b) 3D structures of (E)- and (Z)-azobenzene; c) UV spectra of (E)- and (Z)-azobenzene[58] 
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1.4.2  Establishments of photoswitchable ligands 
Provided a particular molecule can be made light sensitive by a simple modification, the light 
induced management of neuronal activity represents an elegant possibility to control a target 
since light can be regulated with high temporal and spatial precision. This can be achieved if 
some basic requirements are fulfilled. Accordingly, the modified molecule must absorb light 
effectively at a wavelength compatible with biological systems (λ = 340 nm up to 800nm). The 
modification must allow a photochemical reaction with high efficiency so that the light dosage 
required to trigger an effect is not too high, but it should simultaneously modify the ligand in 
a manner that leads to substantial change in biological activity. Finally, the modification should 
be inert towards biological conditions and non-toxic both before and after irradiation.  
A variety of approaches have been taken to chemically modify a ligand in a manner aimed at 
endowing it with a light-controlled function. Among them, photoaffinity labeling is based on 
a photochemical reaction between a photo labile group of a ligand and a functional group of 
the protein, in order to interconnect ligand and target covalently.[59] In case of phototriggering 
agi g  a substrate of a target is liberated by removing a photolabile protection group 
agi g  g oup  from an appropriate precursor molecule by means of light and thus releasing 
a key functional group for its activation.[58] Finally, photoswitchable ligands are a class of 
compounds that, as aforementioned, make use of light in order to control activity of a 
biological target reversibly. Ideally, the structural change after irradiation will bring along a 
significant difference of affinity to the targeted biomolecule. In this way, photoswitches offer 
the possibility to introduce light sensitivity to various biological targets, thereby facilitating 
the mentioned precise control of neuronal activity with light. 
In recent time, many studies appeared on this subject using in particular photoswitchable 
ligands based on azobenzene, because it inheres most of the criteria outlined above. Using 
azobenzenes as photoresponsive elements, it was already possible to develop photoswitches 
for targets like epithelial sodium channels,[60] insulin receptors,[61] the acetylcholinesterase,[62] 
µ-opioid receptors,[63] TRPV1-channels,[64] glutamate receptors,[65] NMDA receptors,[66] AMPA 
receptors,[67] local anesthetics[68] as well as cell division.[69] Our research group recently 
described the use of this method for the first time to control the activity of mGAT1 by means 
of a photoswitchable GABA uptake inhibitor.[70]
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2  Aims and Scope 
Even though a large number of different antiepileptic drugs (1.1.2 Pathology and Therapy) 
exists, not all epilepsy patients show a sufficient therapeutic response to medical treatment 
with antiepileptic drugs. In this context, GATs represent an interesting target for the drug 
development. The principle aim of this study was to find new ligands acting as highly potent 
and selective inhibitors for mGAT1 as well as new photoswitchable ligands for this target. 
 
2.1  Nipecotic acid derivatives with N-arylalkenyl and N-arylalkynyl substituents 
Recently, M. Sindelar from our group created a variety of GABA uptake inhibitors based on 
the hydrazone containing structure (RS)-15 (Scheme 2).[71] Outgoing from these structures it 
was intended to exchange the hydrolytically sensitive hydrazone-type spacer through the 
hydrocarbon analogous pent-4-en-1yl-spacer in order to obtain the stable carba analogue 
structures (RS)-16 (Scheme 2) for all identified hydrazone based hit compounds. The effects 
to the targeted mGAT1 should be comparably investigated for both types of compounds. 
Synthetic access to these carba analogue compounds may be inspired by the synthetic 
approaches of M. Petrera[46] that were already leading to the homologue compounds with 
but-3-in-1-yl spacer (see (RS)-13, Figure 7), but were intended to be optimized in scope of 
syntheses of the representatives with the longer spacer. 
 
 
 
 
 
 
 
 
Scheme 2: Potent GAT1 inhibitors by M. Sindelar[71] and stable carba analogue target compounds 
Transformation into stable 
carba analog compounds
X = Y = H, Cl, F
(RS)-16(RS)-15
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Beyond, a new spacer type should be established as part of the N-substituent of nipecotic acid 
that typically links the amino acid with the aryl moiety. Since compounds containing a double 
bond in the spacer, linking an appropriate aromatic residue with nipecotic acid, in the past 
mostly delivered compounds with promising affinities to mGAT1, it was now intended to 
investigate analogue structures bearing a triple bond instead of the double bond in (apart 
from that) identical compounds, in order to explore the influence of the different geometry 
of ligands, resulting from a more linear spacer type, on the biological activity. Compounds may 
be represented by the basic structure (RS)-17 (Scheme 3). 
As shown in Scheme 3 target compounds were considered to be made by N-alkylation of 
nipecotic acid ester 18 (Scheme 3) with the but-3-ynyl or pent-4-ynyl halide 19, followed by a 
Sonogashira cross-coupling reaction in order to introduce a first phenyl moiety as key step. 
Thereby, the electrophile that may be used for this purpose should also bear a second halogen 
function in order to link a second phenyl moiety to the thus gained coupling product in a next 
step. For this reason, 1-bromo-2-iodo benzene (20) could represent a suitable component for 
the Sonogashira reaction. By means of an ensuing Suzuki cross-coupling reaction, different 
phenyl moieties, that may exhibit different substituents in the 2´ or 4´ position, could be 
attached in a flexible manner. In this context, appropriate substituted phenylboronic acid 
derivatives (21) could be employed as building blocks for the terminal phenyl moiety. 
 
 
 
 
 
 
 
 
Scheme 3: Basic target structure for GABA uptake inhibitors with alkynyl spacer and retro synthesis plan 
 
 
(RS)-17
19
20 21
X = leaving group
18
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2.2  Nipecotic acid derivatives with photoswitchable N-substituents 
Since photoswitchable GAT inhibitors may open up the possibility for the selective and precise 
control of the activity of GATs and may thus allow the further investigation of their structure 
and function, a series of new photoswitchable GAT1 inhibitors was intended to be developed.  
As an progression towards the already existing photoswitchable GABA uptake inhibitors like 
(R)-22 (Scheme 4),[70] which is characterized by an ethoxyethyl spacer, derivatives based on an 
unsaturated spacer type with four or five carbon atoms including either a double or triple 
bond were envisaged. In this context, the photosensitive subunit should be represented by a 
diphenyldiazene or a naphthylphenyldiazene with either ortho-, meta- or para-connection of 
both aromatic systems (see general Structure 23, Scheme 4). 
 
 
 
 
 
 
 
Scheme 4: Already existing most efficient phtotswitchable GAT1 inhibitor and design of the desired new ones 
 
Among the already existing photoswitchable GAT1 inhibitors, the most effective compound 
(R)-22 (Scheme 4) exhibited a pIC50 of 6.39±0.08 for its pure (E)-configuration. After irradiation 
with light, a decreased value of 5.78±0.03 could be observed in the biological test.[70] In order 
to get compounds whose activity can be increased by the use of light, new derivatives should 
exhibit a low inhibitory activity towards the transporter in their ground states and a preferably 
significant higher one in their photoirradiated ones.  
23(R)-22
spacer length:
C
4
 or C
5
spacer type:
double or triple bond
substitution:
ortho, meta or para
terminal residue:
phenyl or naphtyl
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Synthesis of these series of compounds was intended to be achieved either by a convergent 
synthesis route interconnecting the pre-built photosensitive subunit with the nipecotic acid 
derivative that already bears the spacer with a terminal alkyne or vinyl boronic acid ester. 
Alternatively, a linear synthesis route, starting from the diaryldiazene and establishing one 
cross coupling reaction in order to introduce the spacer first, followed by the connection of 
the thus gained final N-substituent with nipecotic acid, could be developed. 
Besides the final photoswitchable ligands, it might be useful to have diaryldiazenes units that 
are characterized by a specific substitution pattern as it is shown for structure 24 in Scheme 
5. Provided a given diphenyldiazene to bear substituents like halogens at one of the two 
phenyl moieties in the ortho- or para-position of the diazene function, the resulting 
photosensitive subunit might not only lead to enhanced interactions with the target as it was 
found in previous studies,[71] but may also allow to tune the isomerization kinetics of the 
photosensitive compounds as well as the wavelength of the necessary light used for that 
purpose. A halogen function on the other phenyl moiety would make it possible to assemble 
it to the final photosensitive target compounds by cross coupling reactions. 
 
 
 
Scheme 5: General composition of substituted diphenyldiazenes 
 
The synthetic access to these unsymmetrically substituted diphenyldiazenes may be possible 
by the establishment of an azo coupling reaction using diazotized aniline with leaving function 
and an N-protected aniline derivative, which might also bring along a further substituent, as 
coupling components. The N-protection group should enable a regio selective azo coupling, 
activate this building block for electrophilic aromatic substitution, and should be introduced 
before and cleaved after the azo coupling in an easy and selective manner, respectively. The 
resulting amine function may also be transformed into a further halogen at the end.
    halogen function
for coupling reactions
        substituents for the
control of physiochemical and 
       biological properties
24
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3  Summary of manuscripts and published results 
3.1  Focused Pseudostatic Hydrazone Libraries Screened by MS Binding Assay – 
Optimizing Affinities towards γ-Aminobutyric Acid Transporter 1 
Screening of compound libraries, generated by simple and most efficient reactions commonly 
used in dynamic combinatorial chemistry displays a valuable tool for the fast hit identification 
among a high amount of compounds differing in their kind of composition of the building 
blocks set in respectively. 
This publication applies this method for the hit identification of potential mGAT1 inhibitors. 
The latter were generated as hydrazones from the in situ reaction of a nipecotic acid derived 
hydrazine as one fixed building block and a library of diverse aromatic aldehydes as variable 
second building blocks with complementary reactivity. Generation of the libraries was 
performed in presence of the target under conditions appropriate for a subsequent MS 
binding assay of the same sample. To facilitate hit detection, libraries were kept pseudostatic, 
meaning that the thus generated one-dimensional libraries staying almost constant in their 
composition but still dynamic in their natural entity. This was achieved by reacting sets of 
different aldehydes with an excess of the hydrazine derived nipecotic acid. After library 
generation was performed, addition of the native MS marker NO711 to the same sample 
directly enabled detection of active libraries by the MS binding assay. 
In this manner a hydrazone generated from biphenyl-2-carbaldehyde was identified as one of 
two hits from a first screening round (pKi = 6.186 ± 0.028). In this context, another aim was to 
further improve the affinities to mGAT1 by substitution of the biphenyl residue. Accordingly, 
hydrazone libraries comprising compounds with different substituted biphenyl moieties were 
generated and screened under the same conditions. In this way the screening of various 
focused pseudostatic hydrazone libraries revealed many hydrazone hits with even higher 
affinities than the original hit compound generated from the sole biphenyl-2-carbaldehyde. 
The most potent hit compounds exhibited halogen substituents in the ortho- and/or the para-
position of the terminal phenyl moiety. For these compounds pKi values up to 8.094 ± 0.098 
could be observed and thus almost 2 log units higher than that of the original lead compound. 
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A choice of the most potent hydrazone derivatives found in this way should serve as template 
for the synthesis of stable carba analogue compounds since the hydrazones tend to be 
sensitive towards hydrolysis. For this reason, the hydrazone containing spacer of overall 5 
atoms, interconnecting the nitrogen of nipecotic acid with the biphenyl subunit, was 
exchanged by a hydrocarbon type pent-4-en-1-yl spacer that entails the most similarity to the 
hydrazone spacer concerning length and molecule geometry. 
Synthetic access was realized similar to a method of M. Petrera[46] by the synthesis of an            
N-alkylated nipecotic acid derivative bearing a vinyl boronic acid ester at the ω-position of the 
spacer, which could be subjected to two consecutive Suzuki-Miyaura reactions. By means of 
the first one, 1-bromo-2-iodobenzene was attached that already exhibited a further halogen 
in order to tie on the second terminal phenyl moieties which were employed as substituted 
phenyl boronic acid derivatives, by means of a second Suzuki reaction. 
The thus gained carba analogue compounds were tested under the described conditions by 
MS binding assay. Though all this compounds showed a slightly less affinity at the targeted 
mGAT1, the rank order of potency of these carba analogues in the binding studies was the 
same as the one of the corresponding hydrazone derivatives. Thus, it could be demonstrated 
that the hydrazone based hit compounds found by the screening can be successfully used as 
starting point for the development of almost equally potent stable lead structures. 
 
Declaration of contributions: 
The main intention of this study, the application of MS binding assay for the screening of 
compound libraries was introduced by Miriam Sindelar as well as the development and 
implementation of the described screening method leading to the hydrazone based hit 
compounds including synthesis and analytic of these derivatives. Synthesis and analytic of all 
carba analogue compounds and precursors was done by me. 
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3.2  Development of highly potent GAT1 Inhibitors:                                   
Synthesis of Nipecotic Acids Derivatives with N-arylalkynyl substituents 
GABA uptake inhibitors based on an alkenyl spacer interconnecting the nitrogen of nipecotic 
acid with an appropriate aromatic residue, such as a 2-biphenyl moiety, were recently found 
to exhibit high affinity towards mGAT1.[46] 
In this publication a further new stable spacer type for the assembly of potential GABA uptake 
inhibitors that was based on a triple bond was introduced and the affinities of the thus gained 
compounds towards mGAT1 were characterized by biological evaluation. New nipecotic acid 
derivatives were derived from the known highly potent GAT1 inhibitors based on an alkenyl 
type spacer by exchanging the but-3-en-1-yl or pent-4-en-1-yl linker by the more linear but-3-
in-1-yl or pent-4-in-1-yl analogue one. The aromatic part of the N-substituent was again 
represented by diverse substituted biphenyl moieties since a homology modeling study with 
accompanied docking experiments, employed within this publication, revealed compounds 
bearing these types of aromatic residues as possibly highly potent. 
In order to get access to these new type of ligands an appropriate synthesis route was 
developed. Accordingly, nipecotic acid derived terminal alkynes were established as suitable 
precursor molecules for the establishment of subsequent Sonogashira reactions in order to 
attach the aromatic residues. For this reason, three different aromatic electrophiles were 
used: 2-iododiphenylmethane, 2-iodobiphenyl and 2-bromoiodobenzene. Though the alkyne 
was used as starting material with just one equivalent – the nucleophile commonly needs to 
be used in excess for Sonogashira reactions[53] – yields for these cross couplings could be 
optimized to a high scale of up to 84%. The first two electrophiles delivered the finished 
preliminary parent compounds as GABA uptake inhibitors in just one key step. The third one 
was established in order to have a second halide for a subsequent Suzuki reaction upon which 
by reaction with diverse substituted phenylboronic acid derivatives as nucleophiles a variety 
of different terminal phenyl moieties could be introduced. For the construction of the biphenyl 
subunit a catalyst system established by the group of Buchwald[54] for the same purpose was 
successfully employed and adopted here since the former used Pd-catalyst (first publication) 
tended to form side reactions due to the neighbored triple bond of the spacer. 
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In accordance to the studies of M. Petrera,[46] among the basic structures, compounds bearing 
the biphenyl type residue as aromatic part were observed to exhibit higher binding affinities 
to mGAT1 than those with the 2-diphenylmethane subunit. Compounds with but-3-in-1-yl 
spacer turned out to contain the more appropriate spacer length for biologic activity than 
derivatives bearing the homologous longer one. As compared to the N-substituted nipecotic 
acid derivative with but-3-en-1-yl spacer and a terminal attached 2-biphenyl residue (RS)-13 
(Figure 7, pKi = 7.15±0.07, pIC50 = 6.79±0.12), the biological test of the analogue parent 
compound (RS)-17 (Scheme 3) with but-3-in-1-yl spacer exhibited an increased affinity and 
inhibitory activity towards mGAT1 (pKi = 7.61±0.03, pIC50 = 7.00±0.06). Inspired by the 
homology modeling results and the intention of a further activity enhancement a series of 
related compounds of the lead structure (RS)-17 (Scheme 3) with different substituents in the 
positions 2´ and 4´ of the terminal phenyl residue was synthesized and biologically 
characterized. This way binding affinities up to 8.33±0.01 (pKi) and uptake inhibitory potencies 
up to 7.72±0.02 (pIC50) of the enantiopure nipecotic acid derivatives could be observed. Thus, 
the new mGAT1 inhibitors are among the most potent ones known so far. All new compounds 
did not show considerable inhibitory activity towards the other GABA transporters which 
means the inhibitory effect to be selective towards mGAT1. 
 
Declaration of contributions: 
Thomas Wein did the hGAT1 homology modeling study this publication is based on for all GAT 
inhibitors including calculation of docking scores. Synthesis of all compounds and precursor 
molecules was done by myself including evaluation of all corresponding analytical data. The 
practical performance of the biological test of all compounds was carried out by the technical 
assistants of the group under supervision of Georg Höfner. 
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3.3  Development of new photoswitchable azobenzene bound GABA uptake   
inhibitors with distinctly enhanced potency upon photoactivation 
The use of light as trigger to control the activity of GABA uptake inhibitors may be achieved 
by the establishment of ligands bearing a photoswitchable subunits with different inhibitory 
effects towards GAT1 dependent from the configurational states of this subunit. 
Within this study a series of photosensitive nipecotic acid derivatives was synthesized and 
their inhibitory activity towards mGAT1 was characterized before and after photoirradiation. 
Thereby, the previous introduced alkenyl and alkinyl spacer types were used for construction 
of linkers with 4 or 5 carbon atoms. The biphenyl subunit was exchanged by a photosensitive 
one represented by either a diphenyldiazene or a naphthylphenyldiazene. Substitution of the 
internal phenyl unit was chosen to be meta or para in relation to the spacer because of the 
ortho-substitution from the outset did not seem to deliver potent GAT inhibitors according to 
a homology modeling study that was set in within this study in order to evaluate binding 
affinities to hGAT1 for both configurational states of the N-N-double bond in each case. 
Synthesis of photoswitchable GAT1 inhibitors containing a double bond in the spacer was 
accomplished by a convergent synthesis route subjecting nipecotic acid derived vinylboronic 
acid esters to Suzuki cross-coupling reactions with the pre-built photosensitive subunits as 
electrophile, in order to generate the finished GAT1 inhibitors in just one key step. However, 
for compounds with alkyne spacer, a linear synthesis route turned out to be more efficient 
and was principally used for the construction of these type of GAT1 inhibitors. It started from 
the photoswitchable subunit and used but-3-in-1-ol or pent-4-in-1-ol as substrates for 
Sonogashira cross-coupling reactions, followed by the transformation of the alcohols into 
leaving groups and the final reaction of the gained electrophiles with nipecotic acid ester. 
The appropriate wavelengths for the isomerization of the photosensitive subunits were found 
by UV spectroscopy and irradiation with light of different wavelength in the range of 350 nm 
or 375 nm. A stock solution in DMSO of all synthetized compounds was then irradiated 
immediately before the biological test until the photo stationary state was reached. The 
proportion of (ZN=N)-isomer was determined by 1H NMR-spectroscopy. Uptake inhibition 
experiments towards mGAT1 were performed subsequently for both photoirradiated and not 
photoirradiated samples of each compound. 
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Compounds containing an alkinyl- instead of an alkenyl-spacer turned out to exhibit higher 
differences in the biological activity at mGAT1 for their ground states as compared to their 
photoexcited ones, caused by irradiation. Thereby, the (E)-configured alkyne derivatives with 
C4 spacer were found to display higher inhibitory potencies at mGAT1 than the homologues 
compounds with the C5 linker. Commonly, mGAT1 inhibitors bearing photoswitchable 
subunits with a meta-substitution were observed to be less active for their (E)-configuration, 
but significantly more active for their photoequilibrium mixture after irradiation, whilst for the 
para-substituted ones the opposite was true. For mGAT1 inhibitors bearing diphenyldiazene 
subunits, potency differences before and after irradiation in general were found to be more 
distinctive than for those with naphthylphenyldiazene moieties. 
The (R)-nipecotic acid derivative with but-3-in-1-yl spacer and an attached meta-substituted 
diphenyldiazene subunit was found to be the most efficient photoswitchable mGAT1 inhibitor. 
The functional inhibitory activity towards mGAT1 for its ground state was determined to be 
4.65±0.05 (pIC50). After irradiation, a distinctive higher one of 6.38±0.04 could be observed. 
Concerning this matter, it is the first GAT1 inhibitor that can be switched on  effectively. 
Forward and back isomerization under physiological conditions (phosphate buffer, pH 7,4) was 
achieved by monochromatic light of 350 nm or 420 nm, resulting in a proportion of the more 
active (Z)-isomer of about 95% or 25%, respectively. The half-life of thermal relaxation was 
determined to be 15 days in DMSO or 22 days in phosphate buffer (pH 7,4) at 25 °C. 
 
Declaration of contributions: 
Thomas Wein did the modeling study for the photoswitchable GAT1 inhibitors. Synthesis of all 
compounds and precursor molecules was done by myself including evaluation of all 
corresponding analytical data. I also did all isomerization experiments and the measuring of 
kinetical data. The biological studies were carried out by the technical assistants of the group 
under supervision of Georg Höfner.  
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3.4  A general approach to substituted diphenyldiazenes 
Azo compounds have found widespread chemical and pharmaceutical application e.g. as dyes 
and pigments, food additives, indicators for pH-measurements, initiators for radical reactions 
or as therapeutic agents. Meanwhile a major focus of diaryldiazenes is on their use as light 
sensitive molecular switches (see chapter 1.3.1). 
Within this publication, a general approach to various specific substituted diphenyldiazenes   
as well as a method easily leading to different naphthylphenyldiazenes was introduced.   
According to Scheme 5 in chapter 2.2, diphenyldiazenes should bear a halogen function at one 
of the two phenyl moieties, allowing the assembly of the final photosensitive compounds by 
cross coupling reactions. Further substituents such as halogens or alkyl groups should be 
located preferentially in the ortho- and/or the para-position of the second phenyl moiety since 
substituents in these positions were on the one hand expected to improve binding affinities 
to mGAT1, and halogens in this position additionally might allow to adjust the isomerization 
kinetics and size of wavelength for photoisomerization. 
However, the substitution pattern of aromatic azo compounds accessible by the classical 
reaction types or sequences is in general quite limited and leads to a mixture of symmetrically 
and unsymmetrically substituted diphenyldiazenes in the most cases and poor yields in 
consequence.  In order to come to such specifically substituted diphenyldiazenes, within this 
study, the well-known azo coupling reaction method was used as key reaction step for the 
construction and two appropriate building blocks were established for this reaction type. This 
was realized by employing a phenyldiazonium derivative with an iodine substituent as first 
building block and an N-protected aniline derivative that might also bring along a further 
substituent, as second coupling component. Thereby, the N-protecting group was represented 
by a N,N-diallyl group and could as such fulfil two necessary requirements during synthesis:   
It prevents this coupling component to directly react by its primary aromatic amino function 
with the diazonium salt, leading to triazene formation and a lot of byproducts formed through 
rearrangements, and should nevertheless guarantee a sufficient electron density to undergo 
the desired electrophilic aromatic substitution. 
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The azo coupling reactions were found to run in useful to excellent yields dependent from the 
further substituent of the N-protected coupling component that might be present. Reaction 
conditions were optimized concerning pH, temperature and reaction time. Furthermore, after 
the azo coupling reaction, the N,N-diallyl protection group could be cleaved in an easy and 
selective way by establishing a method effecting C-C double bond isomerization, followed by 
hydrolysis of the resulting divinylamine. For this purpose, the use of the transition metal 
catalyst RuClH(CO)(PPh3)3 for the former and the ensuing application of hydroxylamine 
hydrochloride and triethylamine for the latter, under respectively adopted reaction 
conditions, delivered quantitative yields for both steps. The thus released primary aromatic 
amino function in the para-position provides the opportunity for a broad array of 
transformation reactions in a next step. This was exemplified on the one hand by its 
replacement by hydrogen in order to get a mono- (ortho-) substituted terminal phenyl moiety, 
and on the other one by employing adopted Sandmeyer or Schiemann type reactions in order 
to introduce chlorine or fluorine substituents for the construction of alternatively mono- 
(para-) or disubstituted (ortho and para) terminal phenyl moieties. All transformation 
reactions run with the common yields for these reaction types. 
In context with this procedure also 1-naphthylamine was employed as coupling component 
and found to undergo the azo coupling without N-protection selectively and in quantitative 
scale to directly obtain the primary amine for possible further transformations. 
 
Declaration of contributions: 
Synthesis of substituted diphenyldiazenes and all precursor molecules was done by myself 
including evaluation of the analytical data of all compounds. Patrick Spanner did some 
preliminary experiments for the azo coupling reaction employing sole N,N-diallylaniline as 
basic coupling component within his bachelor thesis under my supervision. 
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4  Conclusions 
As one of the most abundant CNS diseases, epilepsy is associated with a diminished GABAergic 
neurotransmission. Inhibition of GAT1, the most important GAT subtype in the brain leads to 
a higher GABA level and thus may help to alleviate symptoms resulting from that neurological 
disorder as it was already proved for the GAT1 selective inhibitor Tiagabine. 
Within the first two studies of this thesis a series of nipecotic acid derivatives with new stable 
biphenyl alkenyl and biphenyl alkinyl residues as N-substituents were synthetized and 
characterized for their binding affinity and inhibitory potency at mGAT1. For the latter, a new 
synthesis route was developed giving flexible access to a wide range of aryl alkinyl substituents 
in general. Among the mentioned compounds, those bearing a pent-4-en-1-yl spacer could 
serve as hydrolytically stable carba analogues to the corresponding hydrazone derived 
nipecotic acid derivatives, though they exhibited a slightly lower binding affinity and functional 
inhibitory activity at mGAT1. However, compounds based on a but-3-in-1-yl spacer in both 
respects were found to be in a comparable scale potent as analogue nipecotic acid derivatives 
derived from a but-3-en-1-yl or an oxime spacer type which belong to the most potent mGAT1 
inhibitors known so far. As compared to the latter the new alkinyl spacer types likewise are 
inert towards hydrolytic and oxidative influences. The new N-substituents may act as starting 
point for the development of further similar mGAT1 inhibitors. The N-substituted nipecotic 
acid derivative bearing the 2-biphenylbut-3-in-1-yl residue for example could already serve as 
starting material for the synthesis of the related derivative comprising a (Z)-but-3-en-1-yl 
spacer by stereo selective reduction of the triple bond of the spacer.[46] The optimized 
Sonogashira cross-coupling reaction conditions developed for the assembly of the biphenyl 
alkinyl residues as N-substituent could be equally used for the final construction of nipecotic 
acid derivatives with the same substituents but in 4 position.[72] 
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Within the next two studies, a series of new highly efficient photoswitchable GABA uptake 
inhibitors as well as a general synthesis route for new photosensitive subunits was introduced. 
For the design of nipecotic acid derivatives bearing a photosensitive subunit, N-substituents 
were varied regarding the length and saturation degree of the spacer as well as the types of 
diaryldiazenes and kind of their substitution. Among the 16 final photoswitches, a derivative 
bearing an N-but-3-in-1-yl linker with a terminal diphenyldiazene unit, revealed distinctly 
enhanced potency upon photoirradiation. In this manner, the highest inhibitory potency 
towards mGAT1 as well as the highest difference in inhibitory activity between its two 
configurational shapes could be observed for this compound. This property is described for 
the first time for the mentioned target and may be a valuable feature for biological studies.   
It may help to gain a more detailed knowledge about the structure and function of GAT1 by 
analyzing and comparing structure activity relationship for both isomeric compounds. 
Additionally, it may serve as template for the design of similar GAT1 inhibitors bearing various 
substituted photoswitchable diphenyl diazenes for the adjustment of isomerization kinetics. 
On this occasion, also a general method for the construction of different substituted 
diphenyldiazenes as well as naphthylphenyldiazens was developed. The final products of this 
approach can be used as building blocks for the assembly of a variety of photoswitchable 
target compounds in general. Thereby, the halogen substituents in the ortho- or para-position 
at one of the phenyl moieties may allow a faster isomerization kinetic without becoming 
considerable more polar as it is true for hydroxyl or amino functions. Among this choice of 
photoswitchable units, a naphthylphenyldiazene, that was gained this manner, was already 
used for the construction of the first photoswitchable GAT inhibitor.[70] 
Overall, the new introduced compounds might represent a useful tool and intermediate step 
for the further progression in search of new mGAT1 selective inhibitors that one day possibly 
may serve as final active substances for the successful treatment of neurological diseases. 
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5  Further experiments 
Besides the previous listed publications and manuscripts there were done further experiments that 
were not content of one of these studies. These are described in the following section. 
 
5.1  Nipecotic acid derivatives with 2-thienylphenyl moiety 
In context of the carba analogue compounds of the first publication two more nipecotic acid 
derivatives containing a 2-thienylphenyl moiety instead of the biphenyl subunit at the ω-position of 
the pent-4-en-1-yl-spacer (Scheme 6) were synthesized. Synthesis was achieved by a similar method 
as described in this publication (see Scheme 6). 
  
 
 
 
 
 
 
 
 
Scheme 6: Synthesis of nipecotic acid derivatives with 2-thienylphenyl moiety. Reagents and conditions:                   
a) PdOAc2 (2 mol%), SPhos (4 mol%), K3PO4 (5.0 equiv), 2-Thiopheneboronic acid MIDA ester (1.5 equiv) or              
3-Methyl-2-thiopheneboronic acid MIDA ester (1.5 equiv), dioxane/water, 80 °C, 3 h; b) NaOH, EtOH, rt, 3 h. 
 
For synthesis of this two target compounds, Ethyl 1-[(E)-5-(2-bromophenyl)pent-4-enyl]piperidine-3-
carboxylate (25) was subjected to a Suzuki cross-coupling reaction with 2-Thiopheneboronic acid MIDA 
(= N-methyliminodiacetic acid) ester or 3-Methyl-2-thiopheneboronic acid MIDA ester to give the 
corresponding coupling products 26-27 as precursor molecules in good yields (81-83%). These could 
be cleaved into the final nipecotic acid derivatives 28-29 by basic hydrolysis (yield: 92-93%). 
 
 
R = H:   
R = CH
3
:
26
27
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a) b)
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The free nipecotic acid derivatives 28 and 29 were equally characterized for their binding affinities at 
mGAT1 and inhibitory potencies towards mGAT1-4 (Table 4). Both characteristics were found to be in 
a similar scale as compared to the other carba analogue compounds described in this publication. 
 
Table 4: binding affinities (pKi) at mGAT1 and inhibitory potencies (pIC50) towards mGAT1-4 of 27 and 28 
Compound 
pKi (± SEM) pIC50 (± SEM) 
mGAT1 mGAT1 mGAT2 mGAT3 mGAT4 
28 6.04 ± 0.04 5.39 ± 0.09 67%a 73%a 55%a 
29 5.89 ± 0.10 5.05 ± 0.10 52%a 69%a 36%a 
a percentages represent remaining [3H]GABA uptake in presence of 100 µM inhibitor 
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5.2  Sonogashira cross-coupling optimization reactions 
The reaction conditions for the Sonogashira cross-coupling reactions of the second publication were 
extensively optimized (Table 5). This was done by the reaction of ethyl 1-but-3-yn-1-ylpiperidine-3-
carboxylate (30) as alkyne component and 2-biphenylhalide (Ar-X, 31) as electrophile in order to get 
the coupling product ethyl 1-[4-(2-biphenyl)but-3-yn-1-yl]piperidine-3-carboxylate (32, Scheme 7).  
 
 
 
 
 
 
 
Scheme 7: Sonogashira cross-coupling model reaction. Reagents and conditions: see Table 5. 
 
Starting from compounds 30 and 31 using standard conditions (10 mol% CuI, 5 mol% Pd(PPh3)2Cl2, 
amine base pure or in a 1:1 mixture with THF, Table 1 entry 1-5) did not deliver the coupling product 
32 in useful yields. For the first, Et3N as base and dioxane as solvent were found to be most suitable. 
Changing the palladium catalyst to Pd(dppf)2Cl2 (Table 5, entry 6) did not significantly raise the yield 
but made the reaction rate faster. A higher temperature of 80° C instead of 60° C (Table 5, entry 7) 
turned out to form more side products instead of the desired one though at room temperature no 
reaction took place. However, by the exchange of the amine base through inorganic K2CO3 and the use 
a 5:1 mixture of dioxane and water, yields could be distinctly raised up to 45% dependent from the 
equivalents of the base used (Table 5 entry 8-12). A further clear improvement originated from the use 
of Ar-I as electrophile instead of Ar-Br (Table 5, entry 13) upon which the reaction time could be 
simultaneously lowered to 4 hours. In a next step the influence of the concentration of the copper 
catalyst was studied (Table 5, entry 14-18). The amount of 20 mol% was found to deliver the best yields 
whilst both a lower or higher concentration resulted in a distinct decrease of the same. Other 
established palladium catalysts (Table 5, entry 19-21) as well as a higher or lower concentration than 
5 mol% of the Pd(dppf)2Cl2 (Table 5, entry 22-23) did not seem to be beneficial. Under the improved 
reaction conditions the organic base Et3N (pure or in a 1:1 mixture with dioxane) likewise did not lead 
to useful results (Table 5, entry 19-20). Also the use of 3 equiv of Et3N in combination with 3 equiv of 
30 31 32
Sonogashira
cross-coupling
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K2CO3 impaired the result noticeably (Table 5, entry 26) as compared to the sole use of K2CO3 in water 
under equal reaction conditions (Table 5, entry 16). The more polar solvent EtOH instead of dioxane 
(Table 5, entry 27) failed as well as the sole use of dioxane without water (Table 5, entry 28). A change 
of the proportion of dioxane/water from 5:1 to 4:2 (= 2:1) at the same total solvent amount and thus 
the same reaction concentration was done in order to enable the dissolution and usage of 6 equiv of 
K2CO3 but led to similar results (Table 5, entry 29) as compared to the original solvent proportion of 
5:1 containing just 3 equiv of K2CO3 (Table 5, entry 16). In this context, the slightly stronger base K3PO4 
delivered yields that were somewhat higher, independent from whether the 5:1 mixture of dioxane 
and water with 2 equiv of K3PO4 was used (Table 5, entry 30), or the 2:1 system in which 4 equiv could 
be dissolved (Table 5, entry 31). However, in the latter solvent proportion 3 equiv seemed to be 
sufficient (Table 5, entry 32) and delivered a more clearly aqueous phase. After the raise of the 
concentration of the total reaction mixture from 0.33 molar to 0.5 molar by halving the amount of 
organic solvent (ratio: 1:1), the reaction was finished within 3 hours (Table 5, entry 33). Since it is 
known that within a Sonogashira reaction the alkyne is mainly responsible for side reactions, this was 
reviewed by the use of 1.2 equiv of this component, resulting in an almost quantitative scale of the 
reaction (Table 5, entry 34). However, the alkyne 30 had to be synthesized first before the reaction 
with different commercially available electrophiles like 31 could be performed. Since the alkyne was 
completely consumed after all reactions and should for the mentioned reason not be used in excess, 
yields were intended to be referred to this building block. Finally, since the addition of any amine base 
was not tolerated and it might be possible that the piperidine derivative 30 – and thus the starting 
material – partially might be wasted for the initial reduction of the palladium catalyst, there was the 
attempt to cause this required reduction by sodium ascorbate. Though, its addition could not further 
improve the reaction yields (Table 5, entry 35+36). The found best results (Table 5, entry 33) were 
finally used for the synthesis of compounds within the second publication. 
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Table 4: Optimization studies of the Sonogashira cross-coupling reaction of Scheme 7 
1 the base was used in excess (pure or in a 1:1 mixture with an additional solvent) 
2 3 equiv of both K2CO3 and Et3N were used 
3 the total concentration of the reaction mixture was raised from 0.33 molar to 0.5 molar 
4 1.2 equiv of the alkyne component were used in this case 
5 1.0 equiv sodium ascorbate was added to the reaction mixture 
 
 
Entry Ar-X Cu (mol%) Pd (mol%) base solvent cond. yield 
1 X = Br CuI (10%) Pd(PPh3)2Cl2 (5%) Et3N1 - 60°C, 72 h 11% 
2 X = Br CuI (10%) Pd(PPh3)2Cl2 (5%) piperidine1 THF 60°C, 72 h 5% 
3 X = Br CuI (10%) Pd(PPh3)2Cl2 (5%) iPr2NH1 THF 60°C, 72 h 0% 
4 X = Br CuI (10%) Pd(PPh3)2Cl2 (5%) Et3N1 THF 60°C, 72 h 12% 
5 X = Br CuI (10%) Pd(PPh3)2Cl2 (5%) Et3N1 dioxane 60°C, 72 h 13% 
6 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) Et3N1 dioxane 60°C, 24 h 14% 
7 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) Et3N1 dioxane 80°C, 24 h   7% 
8 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) - diox/H2O (5/1) 60°C, 24 h 0% 
9 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) K2CO3, 1eq diox/H2O (5/1) 60°C, 24 h 30% 
10 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) K2CO3, 2eq diox/H2O (5/1) 60°C, 24 h 36% 
11 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 24 h 45% 
12 X = Br CuI (10%) Pd(dppf)2Cl2 (5%) K2CO3, 4eq diox/H2O (5/1) 60°C, 24 h 44% 
13 X = I CuI (10%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 61% 
14 X = I - Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 0% 
15 X = I CuI (5%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 53% 
16 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 72% 
17 X = I CuI (50%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 57% 
18 X = I CuI (100%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 48% 
19 X = I CuI (20%) Pd(PPh3)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 40% 
20 X = I CuI (20%) Pd(PPh3)4  (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 35% 
21 X = I CuI (20%) Pd(OAc)2 / S-Phos K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 38% 
22 X = I CuI (20%) Pd(dppf)2Cl2 (10%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 58% 
23 X = I CuI (20%) Pd(dppf)2Cl2 (2%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 66% 
24 X = I CuI (10%) Pd(dppf)2Cl2 (5%) Et3N1 - 60°C, 4h 10% 
25 X = I CuI (20%) Pd(dppf)2Cl2 (5%) Et3N1 dioxane 60°C, 4h 25% 
26 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3/Et3N2 diox/H2O (5/1) 60°C, 4h 45% 
27 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq EtOH/H2O (2/1) 60°C, 4h 47% 
28 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq dioxane 60°C, 4h 41% 
29 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 6eq diox/H2O (2/1) 60°C, 4h 70% 
30 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K3PO4, 2eq diox/H2O (5/1) 60°C, 4h 74% 
31 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K3PO4, 4eq diox/H2O (2/1) 60°C, 4h 75% 
32 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K3PO4, 3eq diox/H2O (2/1) 60°C, 4h 76% 
33 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K3PO4, 3eq diox/H2O (1/1) 60°C, 3h 76%3 
34 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (5/1) 60°C, 4h 96%4 
35 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K2CO3, 3eq diox/H2O (2/1) 60°C, 4h 68%5 
36 X = I CuI (20%) Pd(dppf)2Cl2 (5%) K3PO4, 3eq diox/H2O (2/1) 60°C, 4h 71%5 
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5.3  Alternative synthesis route for photoswitchable GABA uptake inhibitors 
Originally, photoswitchable GABA uptake inhibitors containing an alkinyl spacer were intended to be 
synthesized by a linear synthesis route displayed in scheme 6. Thereby, the terminal alkynes 33-34 
should be reacted with o-, m- or p-iodoaniline (35) by Sonogashira cross-coupling reactions under the 
reaction conditions developed for the second publication in order to give the corresponding coupling 
products 36-37. These primary aromatic amines should then be condensed with nitrosobenzene (38) 
to give the diphenyldiazene derivatives 39-40 as preliminary stages of the final photoswitches. 
  
 
 
 
 
 
 
 
Scheme 6: Alternative synthesis route to photoswitchable GABA uptake inhibitors containing alkinyl spacers. 
Reagents and conditions: a) Pd(dppf)2Cl2 ∙ CH2Cl2 (5 mol%), CuI (20 mol%), K3PO4 (3 equiv), dioxane/water, 60 °C, 
4 h; b) nitrosobenzene (1.2 or 1.5 equiv), HOAc, 60 °C, 3-4 h 
 
It was found that by means of the Sonogashira reaction of 33-34 with 35, the desired coupling products 
36-37 could be obtained in moderate to useful yields (31-73%). However, the subsequent 
condensation with nitrosobenzene in order to build the final diphenyldiazenes 39-40 remained 
unsuccessfully as either no reaction occurred or a complex mixture of products was formed from which 
35-36 were not able to be purified in a satisfactory way. For this reason a new way (see third 
publication) was developed and pursued for the synthesis of these and related compounds. 
Nevertheless, the intermediates 36-37 might be valuable synthetic building blocks and are 
characterized in the next chapter. 
 
 
a)
b)
31-73%
n = 1: 
n = 2:
o-35, m-35, p-35
34
n = 1: 
n = 2:
n = 1: 
n = 2:
33
34
o-36, m-36, p-36
o-37, m-37, p-37
o-39, m-39, p-39
o-40, m-40, p-40
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5.4  Syntheses and compound characterization data 
All reactions of compounds listed in chapter 5.1-5.3 were carried out under nitrogen atmosphere in 
distilled and degassed solvents. Fo  flash olu  h o atog aphy CC  sili a gel −  µ  was used. 
NMR spectra were measured with a Jeol Eclipse +400 (400 MHz) or a Jeol Eclipse +500 (500 MHz) 
spectrometer. 1H NMR chemical shifts were referenced to TMS or CH3OH, 13C NMR chemical shifts to 
CHCl3 or CH3OH. The coupling constants were stated with an accuracy of 0.4 Hz. MestreNova software 
was used for further analysis of the spectra. IR spectra were recorded with a FT-IR spectrometer 
Paragon 1000 (PerkinElmer). Samples were measured either as KBr pellets or as films on NaCl plates. 
Mass spectra were measured with a mass spectrometer 59827A with 59980 particle beam LC/MS 
interface (Hewlett-Packard). High resolution mass spectrometry was carried out with a JMS GCmate II. 
 
General Procedure for the Suzuki-Coupling using Phenylboronic acid MIDA esters (GP1): 
PdOAc2 (0.02 equiv), SPhos (0.04 equiv), K3PO4 (5.0 equiv), phenylboronic acid MIDA ester (1.5 equiv) 
and ethyl 1-[(E)-5-(2-bromophenyl)pent-4-enyl]piperidine-3-carboxylate (1.0 equiv) were dissolved in 
1,4-dioxane (2.0 mL/mmol) and water (1.0 mL/mmol). The mixture was heated to 80° C and stirred for 
3 h. After addition of water (10 mL/mmol) organic products was extracted with CH2Cl2 (10 mL/mmol). 
The combined organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by CC on silica gel (hexane/EtOAc = 8:2). 
 
General Procedure for the hydrolysis of nipecotic acid ethyl ester derivatives (GP2):  
The nipecotic acid ethyl ester derivatives (1.0 equiv) were dissolved in EtOH (5.0 mL/mmol). 2M NaOH 
(3.0 equiv) was added and the mixture was stirred for 4 h at rt. After the end of the reaction EtOH was 
removed under reduced pressure. The solid residue was dissolved in 25 mL/mmol of H2O and the pH 
was adjusted to 6-7 (indicator paper) and the organic product was extracted with CH2Cl2. The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure.  
 
General Procedure for the Sonogashira coupling of terminal alkynes and iodoanilines (GP3): 
Pd(dppf)2Cl2 (0.05 equiv), CuI (0.2 equiv), K3PO4 (3.0 equiv), and the aryl iodide (1.0 equiv) were 
introduced in a Schlenk tube. The alkyne (1.0 equiv) in dioxane (2 mL/mmol) and degassed H2O                 
(1 mL/mmol) were added. The mixture was heated to 60 °C and stirred for 4 h. After cooling to rt,     
H2O (10 mL/mmol) was added and the organic components were extracted with CH2Cl2 (10 mL/mmol). 
The organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The 
crude product was purified by CC (hexane/ethyl acetate = 1:1) to give the pure coupling product. 
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Ethyl 1-{(E)-5-[2-(2-thienyl)phenyl]pent-4-enyl}piperidine-3-carboxylate (26): 
 
 
 
 
 
 
 
According to GP1 starting from PdOAc2 (1.0 mg, 4.0 µmol), SPhos (3.5 mg, 8.0 µmol), K3PO4 (212 mg, 
1.00 mmol), 2-Thiopheneboronic acid MIDA ester (73 mg, 0.30 mmol) and Ethyl 1-[(E)-5-(2-
bromophenyl)pent-4-enyl]piperidine-3-carboxylate (76 mg, 0.20 mmol) 26 was obtained as slightly 
yellow oil (64 mg, 83%). Rf ≈ .2 (hexane/EtOAc = 8:2). IR (NaCl): ṽ = 3060, 2938, 2861, 2805, 2768, 
1729, 1468, 1445, 1370, 1306, 1179, 1151, 1099, 1031, 967, 850, 757, 697 cm-1. 1H NMR (400 MHz, 
CDCl3, TMS, 21 °C): δ = 1.24 (t, J = 7.1 Hz, 3 H, OCH2CH3), 1.43 (qd, J = 12.0/4.1 Hz, 1 H, NCH2CHCHaxHeq), 
1.51–1.76 (m, 4 H, NCH2CHaxHeqCH2CH, NCH2CH2CH2CHCH, NCH2CHaxHeqCH2CH), 1.96 (m, 2 H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.13 (t, J = 10.7 Hz, 1 H, NCHaxHeqCH), 2.20 (qd, J = 7.3/1.3 Hz, 2 
H, CH2CHCHC), 2.38 (dd, J = 8.9/6.6 Hz, 2 H, NCH2CH2CH2CHCH), 2.56 (tt, J = 10.6/3.8 Hz, 1 H, NCH2CHax), 
2.77 (dbr, J = 11.2 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J = 9.7 Hz, 1 H, NCHaxHeqCH), 4.12 (q, J = 7.1 
Hz, 2 H, OCH2CH3), 6.13 (dt, J = 15.7/6.9 Hz, 1 H, CH2CHCHC), 6.62 (d, J = 15.7 Hz, 1 H, CH2CHCHC), 7.06 
(dd, J = 3.5/1.3 Hz, 1 H, SCCH), 7.09 (dd, J = 5.0/3.5 Hz, 1 H, SCHCH), 7.23 (td, J = 7.5/1.6 Hz, 1 H, 
CH2CHCHCCHCHCH), 7.29 (td, J = 7.5/1.6 Hz, 1 H, CH2CHCHCCHCH), 7.34 (dd, J = 5.1/1.3 Hz, 1 H, SCH), 
7.39 (dd, J = 7.5/1.4 Hz, 1 H, CH2CHCHCCCH), 7.52 (dd, J = 7.7/1.4 Hz, 1 H, CH2CHCHCCH) ppm. 13C NMR 
(101 MHz, CDCl3, TMS, 21 °C): δ = 14.20 (q, 1 C, OCH2CH3), 24.62 (t, 1 C, NCH2CH2CH2CH), 26.44 (t, 1 C, 
NCH2CH2CH2CHCH), 27.03 (t, 1 C, NCH2CHCH2CH), 31.06 (t, 1 C, CH2CHCHC), 41.90 (d, 1 C, NCH2CH), 
53.83 (t, 1 C, NCH2CH2CH2CH), 55.50 (t, 1 C, NCH2CH), 58.37 (t, 1 C, NCH2CH2CH2CHCH), 60.24 (t, 1 C, 
OCH2CH3), 125.47 (d, 1 C, SCH), 126.52 (d, 1 C, CH2CHCHCCH), 126.80 (d, 1 C, CH2CHCHCCHCHCH), 
127.08 (d, 1 C, SCCH), 127.20 (d, 1 C, SCHCH), 127.83 (d, 1 C, CH2CHCHCCHCH), 129.17 (d, 1 C, 
CH2CHCHC), 130.47 (d, 1 C, CH2CHCHCCCH), 132.11 (d, 1 C, CH2CHCHC), 132.55 (s, 1 C, SCC), 136.63 (s, 
1 C, CH2CHCHC), 142.50 (s, 1 C, SC), 174.23 (s, 1 C, C=O) ppm. MS (EI) m/z: 383.2 [M]+. HRMS (EI): [M]+ 
calcd for C23H29NO2S: 383.1919; found: 383.1910. 
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Ethyl 1-{(E)-5-[2-(3-methyl-2-thienyl)phenyl]pent-4-enyl}piperidine-3-carboxylate (27): 
 
 
 
 
 
 
 
According to GP1 starting from PdOAc2 (1.0 mg, 4.0 µmol), SPhos (3.5 mg, 8.0 µmol), K3PO4 (212 mg, 
1.0 mmol), 3-Methyl-2-thiopheneboronic acid MIDA ester (76 mg, 0.30 mmol) and Ethyl 1-[(E)-5-(2-
bromophenyl)pent-4-enyl]piperidine-3-carboxylate (76.1 mg, 0.20 mmol) 27 was obtained as slightly 
yellow oil (64 mg, 81%). Rf ≈ .2 (hexane/EtOAc = 8:2). IR (NaCl): ṽ = 3060, 2938, 2861, 2805, 1729, 
1468, 1447, 1369, 1303, 1178, 1151, 1099, 1030, 966, 756 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 21 °C): 
δ = 1.25 (t, J = 7.1 Hz, 3 H, OCH2CH3), 1.42 (qd, J = 11.8/4.1 Hz, 1 H, NCH2CHCHaxHeq), 1.50–1.65 (m, 3 
H, NCH2CHaxHeqCH2CH, NCH2CH2CH2CHCH), 1.71 (dp, J = 14.8/3.8 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.89–
1.99 (m, 2 H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.02 (s, 3 H, CCH3), 2.07–2.18 (m, 3 H, NCHaxHeqCH, 
CH2CHCHC), 2.29–2.37 (m, 2 H, NCH2CH2CH2CHCH), 2.55 (tt, J = 10.6/3.8 Hz, 1 H, NCH2CHax), 2.75 (dbr, 
J = 11.1 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.97 (dbr, J = 10.5 Hz, 1 H, NCHaxHeqCH), 4.12 (q, J = 7.1 Hz, 2 H, 
OCH2CH3), 6.16 (dt, J = 15.8/6.7 Hz, 1 H, CH2CHCHC), 6.27 (d, J = 15.9 Hz, 1 H, CH2CHCHC), 6.91 (d, J = 
5.1 Hz, 1 H, SCHCH), 7.19–7.28 (m, 3 H, SCH, SCCCH, SCCCHCH), 7.31 (td, J = 7.5/1.7 Hz, 1 H, 
CH2CHCHCCHCH), 7.57 (d, J = 7.8 Hz, 1 H, CH2CHCHCCH) ppm. 13C NMR (101 MHz, CDCl3, TMS, 21 °C): 
δ = 14.21 (q, 1 C, OCH2CH3), 14.40 (q, 1 C, CCH3), 24.59 (t, 1 C, NCH2CH2CH2CH), 26.51 (t, 1 C, 
NCH2CH2CH2CHCH), 27.03 (t, 1 C, NCH2CHCH2CH), 31.08 (t, 1 C, CH2CHCHC), 41.87 (d, 1 C, NCH2CH), 
53.80 (t, 1 C, NCH2CH2CH2CH), 55.46 (t, 1 C, NCH2CH), 58.31 (t, 1 C, NCH2CH2CH2CHCH), 60.26 (t, 1 C, 
OCH2CH3), 123.86 (d, 1 C, SCH), 125.24 (d, 1 C, CH2CHCHCCH), 126.38 (d, 1 C, SCCCHCH), 128.13 (d, 1 
C, CH2CHCHCCHCH), 128.44 (d, 1 C, CH2CHCHC), 129.63 (d, 1 C, SCHCH), 131.55 (d, 1 C, CH2CHCHC), 
131.62 (d, 1 C, SCCCH), 132.33 (s, 1 C, SCC), 134.91 (s, 1 C, CCH3), 136.13 (s, 1 C, SC), 137.64 (s, 1 C, 
CH2CHCHC), 174.24 (s, 1 C, C=O) ppm. MS (EI) m/z: 397.2 [M]+. HRMS (EI): [M]+ calcd for C24H31NO2S: 
397.2075; found: 397.2070. 
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1-{(E)-5-[2-(2-thienyl)phenyl]pent-4-enyl}piperidine-3-carboxylic acid (28): 
 
 
 
 
 
 
 
According to GP2 from 26 (38.4 mg, 0.100 mmol) and 2 N NaOH (0.15 ml, 0.30 mmol) 28 was obtained 
as colourless gum (33 mg, 93%). Rf ≈ .  CH2Cl2/CH3OH = 9:1). IR (KBr): ṽ = 3415, 3062, 2951, 2864, 
1712, 1597, 1475, 1446, 1385, 1247, 1216, 1081, 1041, 969, 850, 756, 700, 663 cm-1. 1H NMR (400 
MHz, CD3OD + 5 eq 1M NaOD, 21 °C): δ = 1.31 (qd, J = 12.6/4.0 Hz, 1 H, NCH2CHCHaxHeq), 1.55 (qt, J = 
13.0/3.8 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.62–1.73 (m, 3 H, NCH2CHaxHeqCH2CH, NCH2CH2CH2CHCH), 1.88 
(td, J = 12.0/2.8 Hz, 1 H, NCHaxHeqCH2CH2CH), 1.92–2.02 (m, 2 H, NCH2CHCHaxHeq, NCHaxHeqCH), 2.15 (q, 
J = 6.7 Hz, 2 H, CH2CHCHC), 2.30–2.41 (m, 3 H, NCH2CHax, NCH2CH2CH2CHCH), 2.87 (dbr, J = 11.1 Hz, 1 
H, NCHaxHeqCH2CH2CH), 3.09 (dbr, J = 11.2 Hz, 1 H, NCHaxHeqCH), 6.14 (dt, J = 15.7/6.9 Hz, 1 H, 
CH2CHCHC), 6.54 (d, J = 15.8 Hz, 1 H, CH2CHCHC), 7.01 (dd, J = 3.5/1.2 Hz, 1 H, SCCH), 7.10 (dd, J = 
5.1/3.5 Hz, 1 H, SCHCH), 7.21–7.34 (m, 3 H, CH2CHCHCCHCHCH, CH2CHCHCCHCH, CH2CHCHCCCH), 7.44 
(dd, J = 5.2/1.2 Hz, 1 H, SCH), 7.51 (dd, J = 7.7/1.2 Hz, 1 H, CH2CHCHCCH) ppm. 13C NMR (101 MHz, 
CD3OD + 5 eq 1M NaOD, 21 °C): δ = 25.63 (t, 1 C, NCH2CH2CH2CH), 26.59 (t, 1 C, NCH2CH2CH2CHCH), 
29.25 (t, 1 C, NCH2CHCH2CH), 32.11 (t, 1 C CH2CHCHC), 46.15 (d, 1 C, NCH2CH), 54.65 (t, 1 C, 
NCH2CH2CH2CH), 57.92 (t, 1 C, NCH2CH), 59.59 (t, 1 C, NCH2CH2CH2CHCH), 126.84 (d, 1 C, SCH), 127.52 
(d, 1 C, H2CHCHCCH), 128.05 (d, 1 C, SCCH), 128.23 (d, 1 C, SCHCH), 128.28 (d, 1 C, CH2CHCHCCHCHCH), 
129.12 (d, 1 C, CH2CHCHCCHCH), 130.27 (d, 1 C, CH2CHCHC), 131.32 (d, 1 C, SCCCH), 132.96 (d, 1 C, 
CH2CHCHC), 133.71 (s, 1 C, SCC), 137.60 (s, 1 C, SCCC), 143.39 (s, 1 C, SC), 183.14 (s, 1 C, C=O) ppm. MS 
(EI) m/z: 355.2 [M]+. HRMS (EI): [M]+ calcd for C21H25NO2S: 355.1606; found: 355.1600.  
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1-{(E)-5-[2-(3-methyl-2-thienyl)phenyl]pent-4-enyl}piperidine-3-carboxylic acid (29): 
 
 
 
 
 
 
 
According to GP2 from 27 (39.8 mg, 0.100 mmol) and 2 N NaOH (0.15 ml, 0.30 mmol) 29 was obtained 
as colourless gum (34 mg, 92%). Rf ≈ .  CH2Cl2/CH3OH = 9:1). IR (KBr): ṽ = 3406, 3059, 2942, 2861, 
1710, 1596, 1477, 1448, 1383, 1217, 1009, 968, 832, 755, 711, 662 Cm-1. 1H NMR (400 MHz, CD3OD + 
5 eq 1M NaOD, 21 °C): δ = 1.30 (qd, J = 12.9/4.2 Hz, 1 H, NCH2CHCHaxHeq), 1.48–1.71 (m, 4 H, 
NCH2CHaxHeqCH2CH, NCH2CH2CH2CHCH, NCH2CHaxHeqCH2CH), 1.86 (td, J = 11.7/2.5 Hz, 1 H, 
NCHaxHeqCH2CH2CH), 1.92–2.0 (m, 5 H, NCH2CHCHaxHeq, NCHaxHeqCH, CH3), 2.06–2.13 (m, 2 H, 
CH2CHCHC), 2.28–2.39 (m, 3 H, NCH2CH2CH2CHCH, NCH2CHax), 2.84 (dbr, J = 11.1 Hz, 1 H, 
NCHaxHeqCH2CH2CH), 3.06 (dbr, J = 11.1 Hz, 1 H, NCHaxHeqCH), 6.11–6.25 (m, 2 H, CH2CHCHC, CH2CHCHC), 
6.93 (d, J = 5.1 Hz, 1 H, SCHCH), 7.17 (dd, J = 7.6/1.2 Hz, 1 H, SCCCH), 7.23 (td, J = 7.4/1.3 Hz, 1 H, 
SCCCHCH), 7.30–7.36 (m, 2 H, CH2CHCHCCHCH, SCH), 7.59 (d, J = 7.1 Hz, 1 H, CH2CHCHCCH) ppm. 13C 
NMR (101 MHz, CD3OD + 5 eq 1M NaOD, 21 °C): δ = 14.50 (q, 1 C, CH3), 25.66 (t, 1 C, NCH2CH2CH2CH), 
26.66 (t, 1 C, NCH2CH2CH2CHCH), 29.28 (t, 1 C, NCH2CHCH2CH), 32.16 (t, 1 C, CH2CHCHC), 46.17 (d, 1 C, 
NCH2CH), 54.67 (t, 1 C, NCH2CH2CH2CH), 57.95 (t, 1 C, NCH2CH), 59.53 (t, 1 C, NCH2CH2CH2CHCH), 125.09 
(d, 1 C, SCH), 126.35 (d, 1 C, CH2CHCHCCH), 127.64 (d, 1 C, SCCCHCH), 129.46 (d, 1 C, CH2CHCHC), 
129.53 (d, 1 C, CH2CHCHCCHCH), 130.75 (d, 1 C, SCHCH), 132.44 (d, 1 C, SCCCH), 132.46 (d, 1 C, 
CH2CHCHC), 133.50 (s, 1 C, SCCCH), 136.02 (s, 1 C, CH3C), 137.03 (s, 1 C, SC), 138.70 (s, 1 C, CH2CHCHC), 
183.09 (s, 1 C, C=O) ppm. MS (EI) m/z: 369.2 [M]+. HRMS (EI): [M]+ calcd for C22H27NO2S: 369.1762; 
found: 369.1755.  
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Ethyl 1-[4-(2-aminophenyl)but-3-ynyl]piperidine-3-carboxylate (o-36): 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(but-3-yn-1-yl)piperidine-3-carboxylate (105 mg, 0.500 mmol), 
3-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) o-36 was obtained as colorless oil (76 mg, 51%). Rf ≈ .5 (hexane/EtOAc = 1:1). IR 
(NaCl): ṽ = 3463, 3374, 3205, 3073, 3028, 2942, 2854, 2810, 2215, 1727, 1615, 1492, 1455, 1370, 1308, 
1181, 1154, 1132, 1101, 1031, 747 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 21 °C): δ  = 1.25 (t, J = 7.1 Hz, 
3 H, OCH2CH3), 1.47 (qd, J = 11.5/3.5 Hz, 1 H, NCH2CHCHaxHeq), 1.52–1.63 (m, 1 H, NCH2CHaxHeqCH2CH), 
1.75 (dp, J = 13.2/3.6 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.95 (dq, J = 13.0/4.0 Hz, 1 H, NCH2CHCHaxHeq), 2.10 
(td, J = 10.9/2.7 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.27 (t, J = 10.6 Hz, 1 H, NCHaxHeqCH), 2.56 (tt, J = 10.4/3.8 
Hz, 1 H, NCH2CHax), 2.62–2.70 (m, 4 H, NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J = 11.1 Hz, 1 H,  
NCHaxHeqCH2CH2CH), 3.04 (dbr, J = 10.9/2.6 Hz, 1 H, NCHaxHeqCH), 4.12 (q, J = 7.1 Hz, 2 H, OCH2CH3), 4.35 
(s, 2 H, H2N), 6.61–6.69 (m, 2 H, H2NCCH, H2NCCHCHCH), 7.07 (td, J = 8.1/1.6 Hz, 1 H, H2NCCHCH), 7.21 
(dd, J = 7.6/1.5 Hz, 1 H, H2NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS):  = 14.14 (t, 1 C, 
OCH2CH3), 17.88 (t, 1 C, NCH2CH2C≡C , .  t,  C, NCH2CH2CH2CH), 26.81 (t, 1 C, NCH2CHCH2CH), 
41.76 (d, 1 C, NCH2CH), 53.35 (t, 1 C, NCH2CH2CH2CH), 55.01 (t, 1 C, NCH2CH), 57.43 (t, 1 C, 
NCH2CH2C≡C , .  t,  C, OCH2CH3 , .  s,  C, C≡CCCH), 93.78 (s, 1 C, C≡CCCH , .  s,  C, 
H2NCC), 113.92 (d, 1 C, H2NCCH), 117.49 (d, 1 C, H2NCCHCHCH), 128.91 (d, 1 C, H2NCCHCH), 131.45 (d, 
1 C, H2NCCCH), 148.13 (s, 1 C, H2NC) 174.06 (s, 1 C, C=O) ppm. MS (ESI+) m/z: 301.8 ([M+H]+). HRMS 
(EI): [M]+ calcd for C18H24N2O2, 300.1838; found: 300.1837.
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Ethyl 1-[4-(3-aminophenyl)but-3-ynyl]piperidine-3-carboxylate (m-36): 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(but-3-yn-1-yl)piperidine-3-carboxylate (105 mg, 0.500 mmol), 
3-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) m-36 was obtained as colorless oil (98 mg, 33 %). Rf ≈ .4 (hexane/EtOAc = 1:1). 
IR (NaCl): ṽ = 3455, 3374, 3219, 3046, 2977, 2943, 2854, 2811, 2234, 1724, 1622, 1599, 1580, 1491, 
1468, 1447,  1371, 1313, 1183, 1153, 1101, 1031, 862, 781, 688 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 
21 °C): δ  = 1.25 (t, J = 7.1 Hz, 3 H, OCH2CH3), 1.44 (qd, J = 11.9/4.0 Hz, 1 H, NCH2CHCHaxHeq), 1.52–1.64 
(m, 1 H, NCH2CHaxHeqCH2CH), 1.74 (dp, J = 13.3/3.7 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.95 (dq, J = 12.5/3.8 
Hz, 1 H, NCH2CHCHaxHeq), 2.11 (td, J = 11.0/2.8 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.28 (t, J = 10.7 Hz, 1 H, 
NCHaxHeqCH), 2.52–2.61 (m, 3 H, NCH2CHax, NCH2CH2C≡C , . –2.72 (m, 2 H, NCH2CH2C≡C , .  dbr, J 
= 11.2 Hz, 1 H,  NCHaxHeqCH2CH2CH), 3.04 (dbr, J = 11.1 Hz, 1 H, NCHaxHeqCH), 3.67 (s, 2 H, H2N), 4.13 (q, 
J = 7.1 Hz, 2 H, OCH2CH3), 6.59 (ddd, J = 8.1/2.4/1.0 Hz, 1 H, H2NCCHCH), 6.71 (t, J = 1.7 Hz, 1 H, 
H2NCCHC), 6.79 (dt, J = 7.7/1.2 Hz, 1 H, H2NCCHCCH), 7.06 (t, J = 7.8 Hz, 1 H, H2NCCHCH) ppm. 13C NMR 
(101 MHz, CDCl3, 21 °C, TMS):  = 14.13 (t, 1 C, OCH2CH3), 17.50 (t, 1 C, NCH2CH2C≡C , .  t,  C, 
NCH2CH2CH2CH), 26.75 (t, 1 C, NCH2CHCH2CH), 41.75 (d, 1 C, NCH2CH), 53.26 (t, 1 C, NCH2CH2CH2CH), 
55.00 (t, 1 C, NCH2CH), 57.43 (t, 1 C, NCH2CH2C≡C , .  t,  C, OCH2CH3 , .  s,  C, C≡CCCH), 
87.61 (s, 1 C, C≡CCCH , .  d,  C, H2NCCH), 117.78 (d, 1 C, H2NCCHC, 121.81 (d, 1 C, H2NCCHCCH), 
124.30 (s, 1 C, CH2C≡CC), 129.05 (d, 1 C, (H2NCCHCH),  146.13 (s, 1 C, H2NC) 174.08 (s, 1 C, C=O) ppm. 
MS (ESI+) m/z: 302.0 ([M+H]+). HRMS (EI): [M]+ calcd for C18H24N2O2, 300.1838; found: 300.1831.
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Ethyl 1-[4-(4-aminophenyl)but-3-ynyl]piperidine-3-carboxylate (p-36): 
 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(but-3-yn-1-yl)piperidine-3-carboxylate (105 mg, 0.500 mmol), 
4-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) p-36 was obtained as colorless oil (110 mg, 73%). Rf ≈ .3 (hexane/EtOAc = 1:1). 
IR (NaCl): ṽ = 3463, 3357, 3221, 3033, 2942, 2811, 2215, 1723, 1622, 1608, 1514, 1468, 1446, 1371, 
1294, 1177, 1153, 1100, 1031, 828 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 21 °C): δ  = 1.25 (t, J = 7.1 Hz, 
3 H, OCH2CH3), 1.44 (qd, J = 12.1/4.0 Hz, 1 H, NCH2CHCHaxHeq), 1.51–1.65 (m, 1 H, NCH2CHaxHeqCH2CH), 
1.74 (dp, J = 13.3/3.7 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.94 (dq, J = 13.0/4.0 Hz, 1 H, NCH2CHCHaxHeq), 2.11 
(td, J = 11.0/2.8 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.27 (t, J = 10.7 Hz, 1 H, NCHaxHeqCH), 2.52–2.62 (m, 3 H, 
NCH2CHax, NCH2CH2CH2C≡C , . –2.71 (m, 2 H, NCH2CH2CH2C≡C , .  dbr, J = 11.1 Hz, 1 H, 
NCHaxHeqCH2CH2CH), 3.04 (dbr, J = 11.2/2.9 Hz, 1 H, NCHaxHeqCH), 3.75 (s, 2 H, H2N), 4.13 (q, J = 7.1 Hz, 
2 H, OCH2CH3), 6.54–6.61 (m, 2 H, H2NCCH), 7.16–7.22 (m, 2 H, H2NCCHCH) ppm. 13C NMR (101 MHz, 
CDCl3, 21 °C, TMS):  = 14.16 (t, 1 C, OCH2CH3), 17.59 (t, 1 C, NCH2CH2C≡C , .  t,  C, 
NCH2CH2CH2CH), 26.80 (t, 1 C, NCH2CHCH2CH), 41.82 (d, 1 C, NCH2CH), 53.32 (t, 1 C, NCH2CH2CH2CH), 
55.08 (t, 1 C, NCH2CH), 57.69 (t, 1 C, NCH2CH2C≡C , 60.28 (t, 1 C, OCH2CH3 , .  s,  C, C≡CCCH), 
85.65 (s, 1 C, C≡CCCH , .  s,  C, CH2C≡CC), 114.64 (d, 2 C, H2NCCH), 132.69 (d, 2 C, H2NCCHCH), 
146.02 (s, 1 C, H2NC) 174.12 (s, 1 C, C=O) ppm. MS (ESI+) m/z: 301.0 ([M+H]+). HRMS (EI): [M]+ calcd for 
C18H24N2O2, 300.1838; found: 300.1837. 
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Ethyl 1-[5-(2-aminophenyl)pent-4-ynyl]piperidine-3-carboxylate (o-37): 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(pent-4-yn-1-yl)piperidine-3-carboxylate (112 mg, 0.500 mmol), 
3-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) o-37 was obtained as colorless oil (87 mg, 55 %). Rf ≈ .4 (hexane/EtOAc = 1:1). 
IR (NaCl): ṽ = 3463, 3374, 3205, 3073, 3028, 2938, 2854, 2810, 2215, 1726, 1618, 1560, 1492, 1458, 
1375, 1308, 1154, 1102, 1029, 749 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 21 °C): δ  = 1.25 (t, J = 7.1 Hz, 
3 H, OCH2CH3), 1.46 (qd, J = 12.0/3.8 Hz, 1 H, NCH2CHCHaxHeq), 1.52–1.63 (m, 1 H, NCH2CHaxHeqCH2CH), 
1.73 (dp, J = 13.5/3.7 Hz, 1 H, NCH2CHaxHeqCH2CH), 1.81 (p, J = 7.2 Hz, 2 H, NCH2CH2CH2C≡C , .  d , 
J = 13.2/3.8 Hz, 1 H, NCH2CHCHaxHeq), 2.03 (td, J = 10.9/2.3 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.20 (t, J = 10.4 
Hz, 1 H, NCHaxHeqCH), 2.47–2.52 (m, 4 H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C , .  tt, J = 10.5/3.8 Hz, 
1 H, NCH2CHax), 2.76 (dbr, J = 10.9 Hz, 1 H,  NCHaxHeqCH2CH2CH), 2.98 (dbr, J = 9.9 Hz, 1 H, NCHaxHeqCH), 
4.13 (q, J = 7.1 Hz, 2 H, OCH2CH3), 4.18 (s, 2 H, H2N), 6.63–6.69 (m, 2 H, H2NCCH, H2NCCHCHCH), 7.07 
(td, J = 7.8/1.6 Hz, 1 H, H2NCCHCH), 7.23 (dd, J = 7.6/1.5 Hz, 1 H, H2NCCCH) ppm. 13C NMR (101 MHz, 
CDCl3, 21 °C, TMS):  = 14.15 (t, 1 C, OCH2CH3), 17.54 (t, 1 C, NCH2CH2CH2C≡C), 24.49 (t, 1 C, 
NCH2CH2CH2CH), 26.16 (t, 1 C, NCH2CH2CH2C≡C , .  t,  C, NCH2CHCH2CH), 41.79 (d, 1 C, NCH2CH), 
53.80 (t, 1 C, NCH2CH2CH2CH), 55.42 (t, 1 C, NCH2CH), 57.62 (t, 1 C, NCH2CH2CH2C≡C , .  t,  C, 
OCH2CH3 , .  s,  C, C≡CCCH), 95.10 (s, 1 C, C≡CCCH , .  s,  C, H2NCC), 114.05 (d, 1 C, 
H2NCCH), 117.71 (d, 1 C, H2NCCHCHCH), 128.78 (d, 1 C, H2NCCHCH), 131.92 (d, 1 C, H2NCCCH), 147.60 
(s, 1 C, H2NC) 174.15 (s, 1 C, C=O) ppm. MS (ESI+) m/z: 316.2 ([M+H]+). HRMS (EI): [M]+ calcd for 
C19H26N2O2, 314.1994; found 314.1997. 
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Ethyl 1-[5-(3-aminophenyl)pent-4-ynyl]piperidine-3-carboxylate (m-37): 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(pent-4-yn-1-yl)piperidine-3-carboxylate (112 mg, 0.500 mmol), 
3-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) m-37 was obtained as colorless oil (96 mg, 31%). Rf ≈ .3 (hexane/EtOAc = 1:1). 
IR (NaCl): ṽ = 3461, 3375, 3218, 3046, 3028, 2942, 2808, 2771, 2233, 1724, 1621, 1599, 1580, 1491, 
1468, 1447, 1372, 1306, 1203, 1180, 1152, 1104, 1029, 861, 780, 688 cm-1. 1H NMR (400 MHz, CDCl3, 
TMS, 21 °C): δ  = 1.26 (t, J = 7.1 Hz, 3 H, OCH2CH3), 1.45 (qd, J = 11.8/3.4 Hz, 1 H, NCH2CHCHaxHeq), 1.52–
1.64 (m, 1 H, NCH2CHaxHeqCH2CH), 1.69–1.82 (m, 3 H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C , .  d , 
J = 13.0/3.8 Hz, 1 H, NCH2CHCHaxHeq), 2.02 (td, J = 10.9/2.3 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.18 (t, J = 10.6 
Hz, 1 H, NCHaxHeqCH), 2.42 (t, J = 7.1 Hz, 2 H, NCH2CH2CH2C≡C , . –2.51 (m, 2 H, NCH2CH2CH2C≡C , 
2.57 (tt, J = 10.4/3.8 Hz, 1 H, NCH2CHax), 2.77 (dbr, J = 11.0 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J = 
11.1 Hz, 1 H, NCHaxHeqCH), 3.66 (s, 2 H, H2N), 4.13 (q, J = 7.1 Hz, 2 H, OCH2CH3), 6.59 (ddd, J = 8.0/2.4/0.9 
Hz, 1 H, H2NCCHCH), 6.72 (t, J = 1.7 Hz, 1 H, H2NCCHC), 6.79 (dt, J = 7.6/1.2 Hz, 1 H, H2NCCHCCH), 7.06 
(t, J = 7.8 Hz, 1 H, H2NCCHCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS):  = 14.16 (t, 1 C, OCH2CH3), 
17.33 (t, 1 C, NCH2CH2CH2C≡C , .  t,  C, NCH2CH2CH2CH), 25.98 (t, 1 C, NCH2CH2CH2C≡C , .  t, 
1 C, NCH2CHCH2CH), 41.81 (d, 1 C, NCH2CH), 53.80 (t, 1 C, NCH2CH2CH2CH), 55.41 (t, 1 C, NCH2CH), 57.69 
(t, 1 C, NCH2CH2CH2C≡C), 60.26 (t, 1 C, OCH2CH3 , .  s,  C, C≡CCCH), 89.16 (s, 1 C, C≡CCCH , .  
(d, 1 C, H2NCCH), 117.81 (d, 1 C, H2NCCHC, 121.85 (d, 1 C, H2NCCHCCH), 124.52 (s, 1 C, CH2C≡CC), 
129.06 (d, 1 C, (H2NCCHCH),  146.13 (s, 1 C, H2NC) 174.23 (s, 1 C, C=O) ppm. MS (ESI+) m/z: 315.7 
([M+H]+). HRMS (EI): [M]+ calcd for C19H26N2O2, 314.1994; found 314.1991. 
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Ethyl 1-[5-(4-aminophenyl)pent-4-ynyl]piperidine-3-carboxylate (p-37): 
 
 
 
 
 
 
 
According to GP3 starting from ethyl 1-(pent-4-yn-1-yl)piperidine-3-carboxylate (112 mg, 0.500 mmol), 
4-iodoaniline (112 mg, 0.500 mmol), Pd(dppf)2Cl2 (20 mg, 25 µmol), CuI (40 mg, 0.10 mmol) and K3PO4 
(328 mg, 1.50 mmol) p-37 was obtained as colorless oil (101 mg, 64%). Rf ≈ .2 (hexane/EtOAc = 1:1). 
IR (NaCl): ṽ = 3454, 3374, 3220, 3033, 2940, 2808, 2772, 2218, 1719, 1624, 1608, 1514, 1467, 1449, 
1371, 1296, 1176, 1152, 1103, 1028, 828 cm-1. 1H NMR (400 MHz, CDCl3, TMS, 21 °C): δ  = 1.25 (t, J = 
7.1 Hz, 3 H, OCH2CH3), 1.45 (qd, J = 12.1/3.8 Hz, 1 H, NCH2CHCHaxHeq), 1.51–1.64 (m, 1 H, 
NCH2CHaxHeqCH2CH), 1.68–1.82 (m, 3 H, NCH2CHCHaxHeq, NCH2CH2CH2C≡C , . –2.04 (m, 2 H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.17 (t, J = 10.6 Hz, 1 H, NCHaxHeqCH), 2.41 (t, J = 7.1 Hz, 2 H, 
NCH2CH2CH2C≡C , . –2.51 (m, 2 H, NCH2CH2CH2C≡C , .  tt, J = 10.6/3.8 Hz, 1 H, NCH2CHax), 2.78 
(dbr, J = 11.0 Hz, 1 H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J = 10.8/2.1 Hz, 1 H, NCHaxHeqCH), 3.75 (s, 2 H, H2N), 
4.13 (q, J = 7.1 Hz, 2 H, OCH2CH3), 6.55–6.61 (m, 2 H, H2NCCH), 7.17–7.21 (m, 2 H, H2NCCHCH) ppm. 13C 
NMR (101 MHz, CDCl3, 21 °C, TMS):  = 14.18 (t, 1 C, OCH2CH3), 17.41 (t, 1 C, NCH2CH2CH2C≡C , .  
(t, 1 C, NCH2CH2CH2CH), 26.20 (t, 1 C, NCH2CH2CH2C≡C  .  t,  C, NCH2CHCH2CH), 41.87 (d, 1 C, 
NCH2CH), 53.82 (t, 1 C, NCH2CH2CH2CH), 55.47 (t, 1 C, NCH2CH), 57.79 (t, 1 C, NCH2CH2CH2C≡C , .  
(t, 1 C, OCH2CH3 , .  s,  C, C≡CCCH), 87.20 (s, 1 C, C≡CCCH , .  s,  C, CH2C≡CC), 114.67 (d, 2 
C, H2NCCH), 132.67 (d, 2 C, H2NCCHCH), 145.91 (s, 1 C, H2NC) 174.27 (s, 1 C, C=O) ppm. MS (ESI+) m/z: 
316.2 ([M+H]+). HRMS (EI): [M]+ calcd for C19H26N2O2, 314.1994; found 314.1996. 
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5.5  Thermal relaxation rates of photoswitchable compounds 
For the third publication, the thermal relaxation rates of the (ZN=N)-isomer of all photoswitchable 
compounds was determined by kinetic experiments using UV/vis or NMR spectroscopy at 25 °C. In the 
following section measurement data for all compounds, leading to the calculated half-life’s of thermal 
relaxation within this publication, is given. 
Experiments were performed as described in this publication (see appendix). For all photoswitches 
containing a C4 spacer the thermal relaxation was measured both in DMSO by NMR spectroscopy and 
in aqueous media (phosphate buffer (PB), 10 mM, pH 7.4) by UV/Vis spectroscopy. In this case, UV/Vis 
measurements were done by a Cary50 spectrometer (Varian). Recording of full UV/Vis spectra within 
a kinetic experiment was possible. In case of long relaxation times, further measurements at 350 nm 
or 375 nm were done. 
The half-life’s of thermal relaxation of photoswitches with C5 spacer were reviewed in aqueous media 
(phosphate buffer (PB), 10 mM, pH 7.4) by using a SpectraMax M2e UV/vis spectrometer. Within a 
kinetic experiment just one wavelength (350 nm or 375 nm) could be pursued. Half-life’s of ompounds 
with long relaxation times were determined by several singe point measurements within two weeks. 
For sake of clarity in the following data tables the nomenclature of the photoswitchable compounds is 
derived from the corresponding publication (see appendix). 
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.00 5.93 6.93 85.6
1 1.03 4.58 5.61 81.6 14.5
2 1.02 3.51 4.53 77.5 13.9
3 1.03 2.95 3.98 74.1 14.4
5 1.03 2.18 3.21 67.8 14.8
7 1.04 1.64 2.68 61.2 14.5
10 1.01 1.00 2.01 50.2 13.0
14 1.03 0.74 1.77 41.8 13.5
*average integration for 1H (E) and 1H (Z) of isol. arom. signals
Half-life (Z )-m -12a in DMSO 
y = 86.377e-0.051x
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100
0 2 4 6 8 10 12 14 16
Z
 (
%
)
time (days)
Thermal relaxation of (Z)-m-12a
t(1/2) = 14 d
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.02 5.86 6.88 85.2
4 1.02 2.87 3.89 73.8 19.3
8 1.00 1.83 2.83 64.7 20.1
12 1.00 1.34 2.34 57.3 21.0
20 1.03 0.99 2.02 49.2 25.2
28 1.02 0.74 1.76 42.0 27.4
36 1.02 0.54 1.56 34.6 27.7
48 1.02 0.43 1.45 29.6 31.4
*average integration for 1H (E) and 1H (Z) of isol. arom. signals 
Half life of (Z )-p -12a in DMSO
y = 78.757e-0.022x
0.0
20.0
40.0
60.0
80.0
100.0
0 10 20 30 40 50
Z
 (
%
)
time (h)
Thermal relaxation of (Z)-p-12a
t(1/2) = 1.3 d
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.02 3.66 4.68 78.2
2 1.03 2.09 3.12 67.0 9.0
4 1.03 1.32 2.35 56.2 8.4
6 1.05 0.98 2.03 48.0 8.5
8 1.04 0.71 1.75 40.4 8.4
12 1.05 0.41 1.45 28.5 8.3
16 1.01 0.26 1.27 20.3 8.3
20 1.03 0.17 1.20 14.2 8.2
24 1.03 0.14 1.17 11.9 8.8
*average integration for 1H (E) and 1H (Z) of isol. arom. signals 
Half-life of (Z )-m -12b in DMSO
y = 77.596e-0.082x
0.0
20.0
40.0
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100.0
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Thermal relaxation of (Z)-m-12b
t(1/2) = 8.5 h
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time (min) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.02 1.54 2.56 60.2
15 1.00 0.88 1.88 46.8 41.3
30 1.01 0.55 1.56 35.3 39.2
45 1.00 0.37 1.37 27.1 39.1
60 1.00 0.26 1.26 20.6 38.8
75 1.01 0.19 1.20 15.8 39.0
90 1.01 0.15 1.16 12.9 40.6
*average integration for 1H (E) and 1H (Z) of isol. arom. signals 
Half-life of (Z )-p -12b in DMSO
y = 60.305e-0.018x
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Thermal relaxation of (Z)-p-12b
t(1/2) = 40 min
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time (d) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.01 4.23 5.24 80.7
1 1.03 3.07 4.10 74.9 9.3
3 1.01 2.04 3.05 66.8 11.0
5 1.01 1.46 2.47 59.1 11.2
7 1.02 1.15 2.17 53.0 11.5
10 1.00 0.80 1.80 44.4 11.6
14 1.00 0.53 1.53 35.6 12.1
21 1.02 0.35 1.37 26.6 13.1
*average integration for 1H (E) and 1H (Z) of aromatic signals 
Half-life of (Z )-m -20a in DMSO
y = 78.639e-0.047x
0.0
20.0
40.0
60.0
80.0
100.0
0 2 4 6 8 10 12 14 16 18 20 22
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time (days)
Thermal relaxation of (Z)-m-20a in DMSO
t1/2 = 15 d
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.03 4.27 5.30 80.6
4 1.02 2.34 3.36 69.6 18.8
8 1.01 1.43 2.44 58.6 17.4
12 1.00 0.96 1.96 49.0 16.8
16 1.01 0.74 1.75 42.2 17.1
20 1.02 0.61 1.63 37.4 17.9
24 1.02 0.51 1.53 33.3 18.6
*average integration for 1H (E) and 1H (Z) of isol. arom. signals 
Half-life of (Z )-p -20a in DMSO
y = 79.62e-0.038x
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Thermal relaxation of (Z)-p-20a in DMSO
t(1/2) = 18 h
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.01 4.84 5.84 82.8
8 1.01 3.68 4.69 72.7 42.6
16 1.00 1.65 2.65 63.2 41.0
24 1.01 1.22 2.23 54.7 40.1
32 1.01 0.94 1.95 48.2 40.9
40 1.00 0.68 1.68 40.5 38.8
48 0.98 0.52 1.5 34.5 38.0
72 1.02 0.28 1.3 21.8 37.4
*average integration for 1H (E) and 1H (Z) of isol. arom. signals
Half-life of (Z )-m -20b in DMSO
y = 84.771e-0.019x
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Themal relaxation of (Z)-m-20b
t(1/2) = 1.5 d
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time (h) 1H (E)* 1H (Z)* total* Z (%) t(1/2)
0 1.04 1.94 2.98 65.1
1 1.03 1.12 2.15 52.1 3.1
2 1.00 0.69 1.69 40.8 3.0
3 1.00 0.48 1.48 32.5 3.0
4 1.00 0.33 1.33 25.0 2.9
5 1.03 0.26 1.29 20.2 3.0
6 1.01 0.19 1.20 16.7 3.1
9 1.00 0.09 1.09 8.3 3.0
12 1.01 0.04 1.05 4.0 3.0
*average integration for 1H (E) and 1H (Z) of isol. arom. signals 
Half-life of (Z )-p -20b in DMSO
y = 64.977e-0.231x
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
0 2 4 6 8 10 12 14
Z
 (
%
)
time (h)
Thermal relaxation of (Z)-p-20b
t(1/2) = 3.0 h
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A(t) (350 nm) time (d) Z (%) t (1/2)
0.066 0 81.8
0.090 1 72.0 5.3
0.102 2 66.9 6.9
0.110 3 63.6 8.7
0.118 4 60.2 9.9
0.125 5 57.2 10.3
0.138 7 51.7 10.6
0.155 10 44.5 11.4
0.166 14 39.8 13.4
A (Z) = 0.024   (calculated)   c = 25 µm
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
A (Z/E) = 0.066   (measured)   c = 25 µm
Calculations:
A (E) = 0.260   (measured)   c = 25 µm
UV/Vis-spectra (kinetic tracking over the first 3 days):
Half-life of (Z )-m -12a in PB  (pH 7.4)
y = 75.265e-0.052x
20.0
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60.0
80.0
100.0
0 2 4 6 8 10 12 14 16
Z
 (
%
)
time (d)
Thermal Relaxation of (Z)-m-12a
t(1/2) = 13 d
 A(t) 350 nm time (h) Z (%) t(1/2)
0.207 0 85.2
0.319 8 68.7 25.8
0.395 16 57.5 28.2
0.462 24 47.7 28.7
0.528 32 38.0 27.5
0.600 40 27.5 24.5
0.654 48 19.5 22.6
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
A (Z/E) = 0.207   (measured)   c = 50 µm
A (E) = 0.787   (measured)   c = 50 µm
A (Z) = 0.137   (calculated)   c = 50 µm
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
UV/Vis-spectra (kinetic tracking over 48 hours):
Half-life of (Z )-p -12a in PB (pH = 7,4)
y = 89.483e-0.027x
0.0
20.0
40.0
60.0
80.0
100.0
0 8 16 24 32 40 48 56
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%
)
time (h)
Thermal relaxation of (Z)-p-12a
t(1/2) = 1.1 d
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 A(t) 375 nm time (h) Z (%) t(1/2)
0.125 0 78.2
0.130 2 72.8 19.4
0.134 4 68.9 21.9
0.137 6 65.0 22.5
0.141 8 61.2 22.6
0.149 12 54.4 22.9
0.155 16 48.5 23.2
0.161 20 42.7 22.9
0.166 24 37.8 22.8
A (Z/E) = 0.125    (measured)   c = 20 µm
A (E) = 0.205   (measured)   c = 20 µm
A (Z) = 0.102   (calculated)   c = 20 µm
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
Half-life of (Z )-m -12b in PB (pH = 7,4)
UV/Vis-spectra (kinetic tracking over 24 hours):
y = 77.802e-0.031x
20.0
40.0
60.0
80.0
100.0
0 4 8 12 16 20 24 28
Z
 (
%
)
time (h)
Thermal relaxation of (Z)-m-12b
t(1/2) = 22 h
A(t) 375 nm time (h)  Z (%) t(1/2)
0.154 0.0 60.0
0.166 0.5 42.8 1.0
0.175 1.0 30.0 1.0
0.180 1.5 22.8 1.1
0.184 2.0 17.1 1.1
0.187 2.5 12.8 1.1
0.189 3.0 10.0 1.2
0.190 3.5 8.6 1.2
0.191 4.0 7.1 1.3
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Half-life of (Z )-p -12b in PB (pH = 7.4)
UV/Vis-spectra (kinetic tracking over 6 hours):
A (E) = 0.196   (measured)   c = 10 µm
A (Z) = 0.126   (calculated)   c = 10 µm
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
A (Z/E) = 0.154   (measured)   c = 10 µm
y = 53.739e-0.558x
0.0
20.0
40.0
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Thermal relaxation of (Z)-p-12b
t(1/2) = 1.2 h
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A (t) 350 nm time (d) Z (%) t(1/2)
0.202 0 80.2
0.212 1 78.1 26.2
0.223 2 75.7 24.0
0.234 3 73.3 23.1
0.256 5 68.6 22.2
0.285 7 62.8 19.8
0.307 10 57.6 20.9
0.339 14 50.8 21.3
0.378 21 42.4 22.8
0.411 28 35.3 23.6
A (Z/E) = 0.154   (measured)   c = 50 µm
A (E) = 0.575   (measured)   c = 50 µm
A (Z) = 0.110   (calculated)   c = 50 µm
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
Half-life of (Z )-m -20a in PB (pH = 7.4)
UV/Vis-spectra (kinetic tracking within the first 72 hours):
y = 79,361e-0,031x
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Thermal relaxation of (Z)-m-20a
t(1/2) = 22 d
 A(t) 350 nm time (d) Z (%) t(1/2)
0.128 0.0 80.6
0.158 0.5 75.0 4.8
0.186 1.0 69.8 4.8
0.211 1.5 65.2 4.8
0.235 2.0 60.7 4.9
0.279 3.0 52.7 4.9
0.316 4.0 45.7 4.9
0.348 5.0 39.8 4.9
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Half-life of (Z )-p -20a in PB (pH = 7,4)
UV/Vis-spectra (kinetic tracking within the first 48 hours):
A (E) = 0.563   (measured)   c = 25 µm
A (Z) = 0.023   (calculated)   c = 25 µm
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
A (Z/E) = 0.128   (measured)   c = 25 µm
y = 80.411e-0.143x
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Thermal relaxation of (Z)-p-20a
t(1/2) = 4.8 d
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 A(t) 375 nm time (h) Z (%) t(1/2)
0.066 0 81.0
0.086 4 70.7 20.4
0.106 8 60.5 19.0
0.123 12 51.8 18.6
0.138 16 44.1 18.2
0.151 20 37.4 17.9
0.163 24 31.2 17.4
A (Z/E) = 0.066   (measured)   c = 20 µm
A (E) = 0.224   (measured)   c = 20 µm
A (Z) = 0.029   (calculated)   c = 20 µm
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
UV/Vis kinetic tracking over 24 hours:
Half-life of (Z )-m -20b in PB (pH = 7,4)
y = 82.509e-0.038x
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Thermal relaxation of (Z)-m-20b
t(1/2) = 18 h
A(t) 375 nm time (h) Z (%) t(1/2)
0.088 0 60.0
0.103 1 49.2 3.5
0.117 2 39.1 3.2
0.128 3 31.1 3.2
0.137 4 24.6 3.1
0.143 5 20.3 3.2
0.149 6 15.9 3.1
0.158 9 9.4 3.3
0.163 12 5.7 3.4
Calculations:
A (Z) = A (E) + (A (Z/E) - A (E)) / Z (%)
Half-life of (Z )-p -20b in PB (pH = 7.4)
UV/Vis-spectra (kinetic tracking over 24 hours):
A (E) = 0.171 (measured)   c = 10 µm
A (Z) = 0.033   (calculated)   c = 10 µm
Z (%) = (A (Z/E) - A (E)) / (A (Z) - A (E))
A (Z/E) = 0.088   (measured)   c = 10 µm
y = 57.129e-0.201x
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Time (h)
Thermal Relaxation of (Z)-p-20b
t(1/2) = 3.4 h
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A(t) (350 nm) time (d) Z (%) t (1/2)
0.045 0 85.2
0.077 3 67.7 9.1
0.098 7 56.3 11.7
0.118 10 45.3 11.0
0.131 14 38.3 12.1
A (E) = 0.201                A (Z) = 0.018                   c = 20 µm
Half-life of (Z )-m -13a in PB (pH 7.4)
y = 82.833e -0.057x
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)
time (d)
Thermal Relaxation of (Z)-m-13a
t(1/2) = 12 d
 A(t) 350 nm time (h) Z (%) t(1/2)
0.205 0 89.2
0.290 8 75.4 33.0
0.329 16 69.0 43.2
0.375 24 61.5 44.7
0.411 32 55.6 46.9
0.452 40 48.9 46.1
0.486 48 43.4 46.2
A (E) = 0.752                 A (Z) = 0.139                  c = 50 µm
Half-life of (Z )-p -13a in PB (pH = 7,4)
y = 87.203e-0.015x
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time (h)
Thermal relaxation of (Z)-p-13a
t(1/2) = 1.9 d
 A(t) 375 nm time (h) Z (%) t(1/2)
0.124 0 83.1
0.156 4 57.6 8.6
0.170 8 46.4 9.5
0.180 12 38.4 10.8
0.189 16 31.2 11.3
0.197 20 24.8 11.5
0.204 24 19.2 11.4
A (E) = 0.228                 A (Z) = 0.103                  c = 20 µm
Half-life of (Z )-m -13b in PB (pH = 7,4)
y = 77.184e-0.061x
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0 4 8 12 16 20 24 28
Z
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)
time (h)
Thermal relaxation of (Z)-m-13b
t(1/2) = 11 h
A(t) 375 nm time (h)  Z (%) t(1/2)
0.149 0.0 63.8
0.157 0.5 50.8 1.5
0.164 1.0 39.3 1.4
0.170 1.5 29.5 1.3
0.175 2.0 21.3 1.3
0.179 3.0 14.8 1.4
0.181 4.0 11.4 1.6
A (E) = 0.188                 A (Z) = 0.127                  c = 10 µm
Half-life of (Z )-p -13b in PB (pH = 7.4)
y = 60.327e -0.448x
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Time (h)
Thermal relaxation of (Z)-p-13b
t(1/2) = 1.5 h
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A (t) 350 nm time (d) Z (%) t(1/2)
0.069 0 81.3
0.084 3 71.3 15.8
0.118 7 55.1 14.5
0.134 10 46.5 15.2
0.145 14 40.6 16.0
A (E) = 0.221                 A (Z) = 0.034                  c = 20 µm
Half-life of (Z )-m -21a in PB (pH = 7.4)
y = 81.127e-0.047x
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time (days)
Thermal relaxation of (Z)-m-21a
t(1/2) = 15 d
 A(t) 350 nm time (d) Z (%) t(1/2)
0.121 0 80.3
0.162 1 70.1 5.1
0.187 2 63.8 6.0
0.207 3 58.9 6.7
0.230 4 53.3 6.8
0.246 5 49.4 7.1
A (E) = 0.448                A (Z) = 0.039                  c = 20 µm  
Half-life of (Z )-p -21a in PB (pH = 7,4)
y = 78.397e-0.102x
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time (d)
Thermal relaxation of (Z)-p-21a
t(1/2) = 6.8 d
 A(t) 375 nm time (h) Z (%) t(1/2)
0.064 0 83.2
0.076 4 76.2 31.5
0.083 8 72.3 39.5
0.089 12 68.9 44.1
0.108 24 58.2 46.5
0.137 48 41.8 48.3
A (E) = 0.211                 A (Z) = 0.034                  c = 20 µm
Half-life of (Z )-m -21b in PB (pH = 7,4)
y = 81.573e-0.016x
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Thermal relaxation of (Z)-m-21b
t(1/2) = 1.8 d
A(t) 375 nm time (h) Z (%) t(1/2)
0.088 0 65.0
0.095 0.5 58.9 3.5
0.100 1 54.7 4.0
0.105 1.5 50.4 4.1
0.109 2 47.0 4.3
0.116 3 41.0 4.5
0.122 4 35.8 4.6
A (E) = 0.164                  A (Z) = 0.047                 c = 10 µm
Half-life of (Z )-p -21b in PB (pH = 7.4)
y = 63.663e-0.158x
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Thermal Relaxation of (Z)-p-21b
t(1/2) = 4.3 h
LIST OF ABBREVIATIONS 67 
 
6  List of abbreviations 
Aa   Aquifex aeolicus (bacterium) 
CNS   central nervous system 
DAT    dopamine transporter 
EI    electron ionization 
ESI   electrospray ionization 
GABA   -aminobutyric acid 
GABA-T  GABA transaminase 
GAD   glutamic acid decarboxylase 
GAT   GABA transporter 
GlyT   glycine transporter 
GPCR   G-protein coupled receptors 
HRMS    high resolution mass spectrometry 
HUGO   human genome organization 
IC50   half maximal inhibitory concentration 
Ki   inhibition constant 
L    ligand (for palladium catalyst) 
LeuT   leucine transporter 
mGAT1  u i e -aminobutyric acid transporter subtype 1 
MIDA   N-methyliminodiacetic acid 
MS   mass spectrometry 
NET   noradrenalin transporter 
NMR   nuclear magnetic resonance 
NSS   neurotransmitter-sodium-symporters 
ProT   proline transporter  
SERT    serotonin transporter 
SLC   solute carrier 
t1/2   half-life  
TM   transmembrane helix 
VGAT   vesicular neurotransmitter transporter 
WHO  world health organization
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ABSTRACT: Mass spectrometric (MS) binding assays, a powerful
tool to determine affinities of single drug candidates toward chosen
targets, were recently demonstrated to be suitable for the screening of
compound libraries generated with reactions of dynamic combinatorial
chemistry when rendering libraries pseudostatic. Screening of small
hydrazone libraries targeting γ-aminobutyric acid transporter 1
(GAT1), the most abundant γ-aminobutyric acid (GABA) transporter
in the central nervous system, revealed two nipecotic acid derived
binders with submicromolar affinities. Starting from the biphenyl
carrying hit as lead structure, the objective of the present study was to
discover novel high affinity GAT1 binders by screening of biphenyl
focused pseudostatic hydrazone libraries formed from hydrazine 10 and
36 biphenylcarbaldehydes 11c−al. Hydrazone 12z that carried a 2′,4′-dichlorobiphenyl residue was found to be the most potent
binder with low nanomolar affinity (pKi = 8.094 ± 0.098). When stable carba analogues of representative hydrazones were
synthesized and evaluated, the best binder 13z was again displaying the 2′,4′-dichlorobiphenyl moiety (pKi = 6.930 ± 0.021).
■ INTRODUCTION
γ-Aminobutyric acid (GABA, 1, Chart 1) is the most abundant
inhibitory neurotransmitter in the central nervous system
(CNS).1−3 A reduced GABAergic neurotransmission, in
consequence an imbalance in the neurotransmitter equilibrium,
is associated with neurological disorders, e.g., schizophrenia,4
Parkinson’s disease,5 epilepsy,6 Alzheimer’s disease,7 neuro-
pathic pain,8 Huntington’s disease,9 depression,10−12 panic,10,12
and mania.10,12
To restore the neurotransmitter equilibrium, GABAergic
neurotransmission can be enhanced by CNS-active drugs
targeting GABA receptors, metabolic enzymes, or GABA
transport proteins (GATs). The last targets are membrane
bound proteins encoded by genes assigned to the solute carrier
6 (SLC6) family13 and mediate the transport of GABA across
cell membranes utilizing a co-transport of sodium and chloride
ions as energy supply.
Four different subtypes named mGAT1, mGAT2, mGAT3,
and mGAT4 when cloned from murine brain cells are known.
For other species, the nomenclature for GATs differs, e.g., for
the human GATs, the declaration is given by the human
genome organization (HUGO) resulting in GAT1, BGT1,
GAT2, and GAT3 as corresponding transport proteins.14
mGAT1 and mGAT4 are the most abundant GABA trans-
porters in the CNS, from which mGAT1 is mainly responsible
for the neuronal reuptake of GABA and mGAT4 is
predominantly located in cell membranes of glial cells.15 In
contrast, the expression of mGAT2 and mGAT3 in the brain is
very limited. That excludes a significant role in termination of
GABA neurotransmission for these proteins for which high
densities have been reported in liver and kidney.16
When GATs were defined as pharmacological CNS targets,17
a first generation of inhibitors was disclosed including cyclic
analogues of GABA (1). These small cyclic amino acids like
nipecotic acid (2) and guvacine (3) (Chart 1) were in the
1970s found to be potent in vitro inhibitors.18,19 Nevertheless,
their potency was not confirmed in vivo because of their
hydrophilic character preventing them from passing the blood−
brain barrier in sufficient amount.20 Consequently, a second
generation of GAT inhibitors was born by substitution of the
small amino acids with characteristic lipophilic side chains at
the amino function that enabled them to cross the blood−brain
barrier.21 Examples of the affinity enhancing side chains are
represented in SK&F-89976-A (4), tiagabine (5), and NO711
(6) that proved to have high affinity at and subtype selectivity
for mGAT1 compared to the nonsubstituted amino acids
(Chart 1).22 In addition, 5 has successfully undergone clinical
trials and is now in use as add-on medication for the treatment
of epilepsy.23
On the basis of this success, further selective and potent
inhibitors were developed in the style of these potent GAT1
inhibitors representing the third generation of mGAT1
inhibitory drugs. These were characterized by new side chains
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including the lipophilic aromatic domain attached to the amino
group of the amino acid moiety (Chart 1). To this group
belong a number of nipecotic acid based compounds in which
the amino group of the hydrophilic amino acid moiety was
connected via spacers differing in length and functionalities, like
oxime and ether groups, to lipophilic aromatic residues. A
selection of these third generation inhibitors, which had been
developed by Andersen at al. in 1999 and 2001,24 is displayed
in Chart 1 (compounds 7−9).
For GAT1, a screening method was developed several years
ago that tested single drug candidates via a competitive MS
binding assay, employing 6 as native MS marker.25 This assay
allowed the indirect determination of binding affinities toward
GAT1 in analogy to radioligand binding studies, circumventing
the necessity to apply radioactively labeled compounds.
Recently, we described a new method that applies MS
binding assays,26,27 which so far had been used for the
characterization of the binding affinities of single test
compounds toward a target only, to the screening of compound
libraries generated by efficient and the most fundamental
reactions known from dynamic combinatorial chemistry
(DCC).28 Both library generation and screening were
performed in the presence of the protein target to improve
assay performance. To facilitate hit detection, libraries were
rendered pseudostatic. This was achieved by reacting sets of
compounds with varying structure with a large excess of a single
compound of complementary reactivity, the thus generated
one-dimensional libraries being almost constant in composition
but still dynamic in nature. After library generation was
performed, addition of a native MS marker to the same sample
directly enabled detection of active libraries by MS binding
assays. The feasibility of this concept was demonstrated for
mGAT1, a well established target for which, as mentioned
above, a MS binding assay utilizing 6 as native marker was
already known.25 Screening of libraries, each of which consisted
of four hydrazone compounds 12 (Scheme 1) and had been
generated by reacting nipecotic acid derived hydrazine 10 with
four different aldehydes 11, revealed new GAT1 inhibitors
resembling structures 8 and 9 (Chart 1).
In this study, a specific limit of maximum remaining marker
binding caused by 10 μM hydrazones was chosen to define a
library as active. As such, a 20% level (IC20 = 4 IC50) was
selected that attributed a minimum potency (IC50) of 2.5 μM
to a single hydrazone based on the assumption that all other
library members were inactive. In deconvolution experiments
testing the single aldehydes in combination with hydrazine 10,
Chart 1. Structures of GABA and GAT1 Inhibitors
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out of each of the two libraries fulfilling this condition, a single
hydrazone was identified to mostly represent the activity of the
individual library. Thus, comparable to structure 8 (Chart 1)
(E)-1-(2-{2-[1-(2′,4′-dichlorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic acid (12a) (Chart 2)
resulting from the reaction of hydazine 10 with biphenyl-2-
carbaldehyde was found to reduce remaining marker binding in
the deconvolution experiment to a value below the lower limit
of quantification of the MS marker 6 (<5%), indicating an IC50
equal to or below 0.53 μM (IC05 = 19 IC50). Resynthesis of 12a
and characterization in a full range competitive MS binding
experiment finally revealed a pKi of 6.186 ± 0.028 for this
compound. The second hit, hydrazone 12b, was derived from
2-thiophen-2-ylbenzaldehyde and gave rise to a remaining
marker binding of 8.2 ± 0.4% in the deconvolution experiment
and to a pKi of 6.229 ± 0.039 in a full range competitive MS
binding assay for the resynthesized compound.28 That these
mGAT1 binders are also functionally active was confirmed in
[3H]GABA uptake assays with mGAT1 expressing HEK293
cells, the pIC50 values amounting to 5.308 ± 0.096 (12a) and
5.542 ± 0.107 (12b), respectively (Chart 2).
As we identified these two hits, 12a and 12b, with
submicromolar potencies in the first library screening assays,
the aim of the present study was to develop exemplarily for one
of the two hits, compound 12a, a focused library by introducing
various substituents in the biaryl moiety to further optimize the
affinity toward mGAT1 (Figure 1).
Biaryl focused pseudostatic hydrazone libraries (12c−al,
Scheme 1) each derived from libraries of four biarylaldehydes
(11c−al, Scheme 1) were therefore intended to be generated
and subsequently screened by the MS binding assay, again
employing 6 as native MS marker. As we aimed at improved
affinities of desired hits compared to the hits searched in the
first screening, the limit to define a library as active was further
tightened by lowering it from 20% used in the original study28
to 10%. In theory, this equals an IC50 of ∼1 μM for the
compound, effecting reduction of marker binding to this limit
when employed at 10 μM (IC10 = 9 IC50). Hits contained in
active libraries (<10% marker binding) were to be identified by
applying the original deconvolution procedure and to be further
evaluated after resynthesis.28 As hydrazones are prone to
hydrolysis,29,28 liver-toxic,30−32 and unstable against air,33−35
they are not suitable as lead structures for drug discovery. But
the results obtained from the screening of hydrazone libraries
Scheme 1. Condensation of Hydrazine Derived Nipecotic
Acid Building Block 10 with Diverse Aldehydes 11
Chart 2. Hydrazone Based GAT1 Inhibitors
Figure 1. Focused hydrazone library generation and screening toward GAT1. After hit identification and validation of potent derivatives of
hydrazone 12a, corresponding carba analogues 13 were synthesized and evaluated.
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may nevertheless be of high value for drug discovery and
support the development of stable analogues, which to
demonstrate was a further aim of this study. Carba derivatives
in which the hydrazone linker had been replaced by an all
carbon chain with a double bond (CHN−NH−CH2−CH2
→ CHCH−CH2−CH2−CH2) were considered a good
choice as stable substitutes of the hydrazone inhibitors. Thus,
the synthesis and biological evaluation of carba analogues of a
series of representative hydrazone inhibitors were also included
in this study.
■ CHEMISTRY
Synthesis of Biarylcarbaldehydes. In general, biphenyl-
carbaldehydes 11c−11al (Chart 3) required for library
generation were synthesized via the Suzuki−Miyaura36 reaction
except for 4′-fluorobiphenyl-2-carbaldehyde (11e) and biphen-
yl-3-carbaldehyde (11n) that were purchased from Alfa Aesar
and Sigma-Aldrich, respectively.
Thus, 2′-fluorobiphenyl-2-carbaldehyde (11c)37,38 was ob-
tained from 2-bromobenzaldehyde and 2-fluorophenylboronic
acid, applying a literature method39 that had been successfully
employed in the synthesis of diversely substituted biphenyl-2-
carbaldehydes (reaction conditions: 2-bromobenzaldehyde/
substituted phenylboronic acid = 1:1, 5 mol % Pd(OAc)2,
DMF/H2O = 2:1, 25 °C). For the preparation of the biphenyl-
2-carbaldehydes 11d, 11f, 11h, 11i, 11j, 11k, 11m, 11o, 11p,
11q, 11r, 11t, 11u, 11v, 11w, 11x, 11ac, 11ad, and 11ae this
procedure had to be modified by adding common phosphine
ligands (triphenylphosphine, dibenzylideneacetone, tri-o-tolyl-
Chart 3. Libraries Consisting of Biphenylcarbaldehydes 11c−al
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phosphine, or tri-tert-butylphosphine) and increasing the
temperature from room temperature to 80 °C to improve the
reaction rates and the yields (see Supporting Information).
The latter protocol could not be successfully applied to the
synthesis of 11y starting from 2-bromobenzaldehyde and 2-
fluoro-4-chlorophenylboronic. But coupling of 2-bromobenzal-
dehyde and 2-fluoro-4-chlorophenylboronic acid to yield 11y
could be realized following a related literature method that had
originally been used for coupling of pentafluorophenylboronic
acid with halogenated benzene derivatives by means of CsF,
Ag2O, Pd(dba)3·CHCl3, and tri-o-tolylphosphine in pure DMF
at 100 °C 40 (see Supporting Information).
In the case of other sterically demanding phenylboronic acid
derivatives carrying electron withdrawing residues (2,4-
difluorophenylboronic acid, 2,4-dichlorophenylboronic acid,
2,6-difluorophenylboronic acid, 2,4,6-trifluorophenylboronic
acid, 2-chloro-4-fluorophenylboronic acid), the coupling with
2-bromobenzaldehyde gave poor yields or no coupling products
at all under the applied conditions for the preparation of, for
example, 11d. However, an alternative approach starting from
2-formylphenylboronic acid, instead of 2-bromobenzaldehyde,
and an appropriate halogenated benzene derivative instead of
the corresponding phenylboronic acid gave access to the
desired aldehydes. Thus, 11g, 11z, 11aa, 11ab, and 11ah were
obtained by reacting 2-formylphenylboronic acid with the
appropriately halogen substituted benzene derivatives following
a literature method that originally had been used for coupling
of 1-bromo-2,3,4,5,6-pentafluorobenzene with 2-formylphenyl-
boronic acid.41
The same reaction conditions that had been used for the
coupling reactions of 2-formylphenylboronic acid with various
aryl halides were finally also tested for the preparation of
aldehydes 11s, 11ab, 11af, 11ag, 11ai, 11aj, 11ak, and 11al by
coupling 2-bromobenzaldehyde again with the respective
phenylboronic acid derivatives, leading to the desired
compounds in yields of up to 90% (toluene/ethanol/2 M
Na2CO3(aq) = 1:1:1, tetrakis(triphenylphosphine)-
palladium(0)) (see Supporting Information).
Synthesis of the Hydrazones. Synthesis of individual
hydrazones required for full scale competition experiments was
carried out by combining 1 equiv of aldehyde with 1 equiv of
hydrazine 10 according to Scheme 1, again following the
Scheme 2. Synthesis of Nipecotic Acid Derived Carba Analogues 13a
aReagents and conditions: (a) TsCl, Et3N, CH2Cl2, 0 °C to rt, 20 h; (b) pinacolborane, chloridobis(cyclopentadienyl)hydridozirconium no solvent,
rt, 48 h; (c) ethyl nipecotate, no solvent, rt, 16 h; (d) Pd(dppf)Cl2·CH2Cl2, 1-bromo-2-iodobenzene, K2CO3, 1,4-dioxane/H2O 2:1, 72 h, rt; (e)
Pd(dppf)Cl2·CH2Cl2, RPhBO2H, K2CO3, 1,4-dioxane/H2O 2:1, 3 h, 60 °C; (f) NaOH, EtOH, 4 h, rt.
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original protocol for hydrazone synthesis described previ-
ously.28
Synthesis of the Carba Analogues. For the synthesis of
the carba analogues of the hydrazone derivatives the reaction
sequence outlined in Scheme 2 has been developed. It features
the vinylboronic acid derivative 18 as a key compound, which
by two consecutive Suzuki−Miyaura reactions allows high
flexibility with regard to construction and the substitution
pattern of the biaryl moiety present in the target compounds
13. For the synthesis of 18, first pentynol 15 was transformed
into the tosyl ester 16 by reaction with TsCl according to a
literature method.42 The resulting alkyne 16 was subsequently
reacted with pinacolborane in the presence of Cp2ZrHCl in
analogy to a literature procedure,43 to give the boronic acid
ester 17, which upon treatment with ethyl nipecotate provided
18 in 92% yield. Compound 18 allowed stepwise establishment
of the biaryl moiety present in the final compounds 13. Thus, a
first Suzuki−Miyaura cross-coupling reaction between 18 and
1-bromo-2-iodobenzene yielded the monoaryl derivative 19.
Compound 19 was then subjected to a second Suzuki−Miyaura
cross-coupling reaction with differently substituted phenyl-
boronic acid derivatives [2-fluorophenylboronic acid (20c), 2,4-
difluorophenylboronic acid (20g), 2-chlorophenylboronic acid
(20p), 2-chloro-4-fluorophenylboronic acid (20ah), and 2,4-
dichlorophenylboronic acid (20z)] to give the desired biaryl
substituted nipecotic acid ester derivatives 21c, 21g, 21p, 21ah,
and 21z (yield 91−93%). These last compounds were finally
converted to the free nipecotic acid derivatives 13c, 13g, 13p,
13ah, and 13z by basic hydrolysis of the ethyl ester function
(yield 86−90%).
■ RESULTS AND DISCUSSION
General Aspects of Library Generation and Screening.
Libraries were generated and screened as described earlier.28
Therefore, the respective experimental conditions are given
here only in short form. To generate the hydrazone libraries,
aldehyde libraries of four aldehydes each at 10 μM were reacted
with a 2.5-fold excess of hydrazine 10 (100 μM initial
concentration) at 37 °C for 4 h, in which the time span had
turned out to be sufficient for complete conversion in the
former28 and in the present study. In addition, library
generation was again performed in the presence of the target
mGAT1 to improve assay performance. The activity of the
libaries was finally analyzed by means of competitive MS
binding experiments. To this end, following incubation of
libraries with MS marker 6 (for 40 min), the amount of
specifically protein-bound MS marker 6 was quantified by LC−
ESI-MS/MS (after isolation of protein−ligand complexes and
liberation of the bound ligands from the target), low amounts
of remaining marker binding representing high library activity
and vice versa. As for the original procedure, in addition to each
screening experiment, control experiments employing aldehyde
libraries (11) and hydrazine 1044 alone were perfomed to
ensure that the building blocks in the concentrations used do
not affect marker binding to a remarkable extent.
Screening and Deconvolution of Focused Biphenyl-2-
carbaldehyde Derived Hydrazone Libraries. In our former
study28 that applied pseudostatic hydrazone libraries on
mGAT1, 12a, the hydrazone derived from biphenyl-2-
carbaldehyde (11a), had been uncovered to display sub-
micromolar affinity to mGAT1 (pKi = 6.186 ± 0.028).
28 To
further optimize the affinity of 12a for mGAT1 in the present
study, 36 aldehydes mainly delineated from biphenyl-2-
carbaldehyde (11a) by additional small substituents in the
phenyl rings (biphenylcarbaldehydes 11c−11al) were selected
for hydrazone generation and screening. These were grouped
into nine libraries of four aldehydes (Chart 3), converted into
hydrazone libraries (Scheme 3), and analyzed by competitive
Scheme 3. Example for the Conversion of an Aldehyde Library into a Hydrazone Library (Aldehyde Library 1 → Hydrazone
Library 1)
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MS binding assays as described above. Clearly, a higher number
of aldehydes than four could be employed in library formation
under otherwise identical conditions. But this would require
reduction of the concentration of the individual aldehydes to
further warrant the excess of hydrazine 10 over the aldehydes
employed and thus the pseudostatic character of the libraries.
However, with lowering hydrazone concentrations, the
conditions for a library to be classified as active will also
become more stringent (IC50 corresponds to the initial
aldehyde concentration).
Table 1 summarizes the screening values of the aldehyde and
hydrazone libraries 1−9. All hydrazone libraries were found to
be highly active, reducing the remaining MS marker binding
not only below 10%, the limit set for libraries to be considered
as active, but even below the lower limit of quantitation
(LLOQ) for the MS marker 6 of 5% (Table 1). Also library 5,
which was the only exception, displayed a very low remaining
marker binding of 6 ± 1%.
Showing very high activity in the screening step reducing MS
marker binding below 10%, all libraries were also included in
subsequent deconvolution experiments to identify the most
active compounds. These experiments were performed
analogous to the library screening except that single aldehydes
were employed instead of the libraries.
In the deconvolution study of the hydrazone libraries, 21 of
the 36 hydrazones were found to strongly influence MS marker
binding, reducing it to 10% and below (Figure 2). Taking into
account that a reduction of MS marker binding to 10%
corresponds to an IC50 of ∼1 μM (IC10 = 9 IC50), we
considered it worthwhile to resynthesize most of the hydrazone
derivatives that had reached this limit in the screening and to
establish their pKi values in MS competition experiments
comprising complete competition curves. The data of these
studies that had also been established to provide an improved
insight on the influence of the substituent effects on the
potency of the compounds are given in the section “Biphenyl-2-
carbaldehyde Derived Hydrazone Hits”.
Interestingly, one of the pure aldehyde libraries (tested in the
absence of hydrazine 10) had also given rise to a significant
reduction of MS marker binding. For aldehyde library 7 for
which the screening value had amounted to 35 ± 1% (Table 1,
entry 7), a deconvolution experiment (in the absence of
hydrazine 10) revealed aldehyde 11ab to be by far the most
potent binder of this group, reducing MS marker binding to 49
± 1% (Figure 2). Accordingly, as a rough estimate, an IC50 of
∼10 μM can be attributed to this aldehyde.28
Biphenyl-2-carbaldehyde Derived Hydrazone Hits.
Table 2 summarizes the pKi values that had been found in
full scale competitive MS binding assays for the separately
resynthesized biphenyl-2-carbaldehyde derived hydrazones that
had turned out as the most active ligands at mGAT1 in the
deconvolution experiments (reduction of MS marker binding
to ≤10%). Hydrazones 12d, 12i, 12j, 12k, 12n, 12o, 12q, 12s,
12t, 12u, 12w, 12x, 12ai, 12aj, and 12al did not reach this limit
and were excluded from further analysis.
The compounds that achieved the desired value below 10%
are sorted according to the substitutents of the biaryl moiety
starting with hydrazones exhibiting only F-substituents (Table
2, entries 2−9), F- and CH3O-substituents (Table 2, entries 10
and 11), followed by those with either CH3- (Table 2, entries
12−14), CF3- (Table 2, entry 15), Cl- (Table 2, entries 16−
18), or F- and Cl-substituents (Table 2, entries 19−22).
An F-substituent in the 2′-position increased the affinity by
almost 1 order of magnitude, resulting in a pKi of 6.914 ± 0.061
for 12c (Table 2, entry 2) compared to the parent compound
12a (6.186 ± 0.028, Chart 2, Table 2, entry 1), while a 4′-F-
substituent (structure 12e) caused a smaller increase, the
affinity of 12e amounting to a pKi of 6.546 ± 0.067 (Table 2,
entry 3). With F-substituents present in both the 2′- and 4′-
position, a gain in binding energy (compared to 12a) was
observed that was roughly the sum of the increase of binding
energies effected by the two F-substituents in 12c and 12e,
Table 1. Libary Screening Values of Aldehyde Libraries and
Hydrazone Libraries
library screeninga (%)
entry library aldehyde library hydrazone library
1 library 1 82 ± 2 <5
2 library 2 81 ± 2 <5
3 library 3 88 ± 2 <5
4 library 4 79 ± 3 <5
5 library 5 91 ± 11 6 ± 1
6 library 6 85 ± 4 <5
7 library 7 35 ± 1 <5
8 library 8 81 ± 1 <5
9 library 9 81 ± 1 <5
aPercentage of remaining specific binding of NO711 (6) in the
presence of pure aldehyde libraries and corresponding hydrazone
libraries after an incubation time of 4 h for library generation and 40
min for marker binding to mGAT1, n = 4, ±SD, <5% = <50 pM
derived from the LLOQ of NO711 (50 pM, as 1−2 nM of 20 nM
applied NO711 is maximally bound to the membrane preparation).
Control experiment for 100 μM hydrazine 10 was obtained
comparable to published results. See ref 28.
Figure 2. Deconvolution results of libraries 1−9. The limit for further
analysis of a library was defined as 10% remaining marker binding.
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hydrazone 12g displaying a pKi of 7.449 ± 0.023 (Table 2,
entry 4). Comparing this effect with the difluoro substitution in
12h (2′,3′-F2, Table 2, entry 5), 12f (3′,4′-F2, Table 2, entry 6),
and 12aa (2′,6′-F2, Table 2, entry 7), the pKi values of the
compounds amounting to 6.690 ± 0.036, 6.204 ± 0.054, and
6.883 ± 0.035, respectively, clearly reveals that the 2′,4′-F2
substitution in 12g represents the most favorable substitution
pattern for the difluoro substituted compounds. In contrast to
F-substituents in 2′- and 4′-position, a 3′-F-substituent
decreases affinity compared to the parent compound 12a,
with hydrazone 12d reducing MS marker binding in the
deconvolution experiments far less (16 ± 1%, 12d, Figure 2)
than the reference compound 12a (<5%). In line with that,
upon transition from the 2′-F-substituted 12c (pKi = 6.914 ±
0.061, Table 2, entry 2) to the 2′,3′-F2 hydrazone 12h, a
decrease in affinity occurs (pKi = 6.690 ± 0.036, Table 2, entry
5). But the positive effect of the 2′-F-substituent clearly
outweighs the negative effect of the 3′-F-substituent as the
affinity of 12h is still far higher than that of the parent
compound 12a (Table 2, entry 1). In addition, 12aa (2′,6′-F2,
Table 2, entry 7) revealed that a second F-substituent in 6′-
position is tolerated but does not improve the affinity toward
mGAT1, expressed by a pKi of 6.883 ± 0.035 very close to the
pKi of 12c (2′-F2 pKi = 6.914 ± 0.061, Table 2, entry 2).
Accordingly, the 2′,4′,6′-trifluoro substituted derivative 12ab
(2′,4′,6′-F3, Table 2, entry 8), displayed a similar affinity, the
pKi being 7.514 ± 0.030, close to that of 12g (2′,4′-F2, pKi =
7.449 ± 0.023, Table 2, entry 4), again indicating that a 6′-F-
substituent does not significantly change affinity. Obviously a 4-
F-substituent in the first ring does not lead to a beneficial effect,
the affinity of the 4,2′-difluoro substituted hydrazone 12ac
(Table 2, entry 9) with a pKi of 6.578 ± 0.057 being lower than
that of the 2′-monofluoro substituted hydrazone 12c (2′-F,
6.914 ± 0.061, Table 2, entry 2). Like the 4-fluoro substituent
Table 2. Binding affinities (pKi) of Resynthesized Biphenyl Derived Hydrazones Determined from Competitive MS Binding
Assays and Inhibitory Potencies (pIC50) at mGAT1 from [
3H]GABA Uptake Experiments
compda (substitution pattern of the biphenyl
moiety of 12a) biological testing
entry compd 4 2′ 3′ 4′ 6′ binding affinity pKi (n = 3 ± SEM)
b inhibitory potency pIC50
c (n = 3 ± SEM)b
1 12a H H H H H 6.186 ± 0.028 5.308 ± 0.096
2 12c H F H H H 6.914 ± 0.061 6.277 ± 0.061
3 12e H H H F H 6.546 ± 0.067 5.746 ± 0.078
4 12g H F H F H 7.449 ± 0.023 6.891 ± 0.078
5 12h H F F H H 6.690 ± 0.036 5.824 ± 0.033
6 12f H H F F H 6.204 ± 0.054 5.479 ± 0.095
7 12aa H F H H F 6.883 ± 0.035 6.001 ± 0.014
8 12ab H F H F F 7.514 ± 0.030 6.594 ± 0.046
9 12ac F F H H H 6.578 ± 0.057 5.763 ± 0.037
10 12m H F H H OCH3 6.354 ± 0.062 5.648 ± 0.103
11 12l H OCH3 H F H 6.119 ± 0.037 5.134 ± 0.094
12 12ae H CH3 H H H 6.666 ± 0.044 5.806 ± 0.064
13 12v H H H CH3 H 6.325 ± 0.065 5.468 ± 0.118
14 12af H CH3 H CH3 H 7.135 ± 0.095 6.078 ± 0.020
15 12ag H CF3 H CF3 H 6.769 ± 0.081 5.549 ± 0.047
16 12p H Cl H H H 7.184 ± 0.063 6.320 ± 0.070
17 12r H H H Cl H 6.762 ± 0.001 6.012 ± 0.121
18 12z H Cl H Cl H 8.094 ± 0.098 7.213 ± 0.085
19 12ad F Cl H H H 6.981 ± 0.060 5.909 ± 0.081
20 12ak F H H Cl H 6.630 ± 0.040 5.708 ± 0.078
21 12y H F H Cl H 7.607 ± 0.043 6.899 ± 0.147
22 12ah H Cl H F H 7.835 ± 0.081 6.535 ± 0.082
aIndividually resynthesized from appropriate biphenyl-2-carbaldehydes and evaluated hydrazones. bData points for specific binding of NO711 (mean
± SD from triplicate values) in the presence of different concentrations of test compounds (M) resulted in binding curves for Ki determination by
nonlinear regression. pKi ± SEM obtained from three independent experiments,.
cpIC50 values from [
3H]GABA uptake assays performed with
mGAT1 expressing HEK293 cells. Value ± SEM obtained from three independent experiments.
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in 12ac, the 4-fluoro substituent in hydrazone 12w also has a
negative effect on the binding affinity, which in the latter case
was even more pronounced reducing remaining MS marker
binding to only 13 ± 2% in the deconvolution experiments,
thus not reaching the limit of 10%, which is the condition
hydrazones had to fulfill to be evaluated with regard to their pKi
values.
A methoxy function in 6′-position of the 2′-fluoro substituted
system (2′-F,6′-OCH3, 12m, Table 2, entry 10) had an adverse
effect on the affinity, as well, the pKi value of 12m (pKi = 6.354
± 0.062) ranging distinctly below that of the 2′-fluoro
monosubstituted compound 12c (pKi = 6.914 ± 0.061, Table
2, entry 2) and close to that of the parent compound 12a (pKi
= 6.186 ± 0.028, Table 2, entry 1). This was not unexpected as
the 2′-OCH3 substituted hydrazone 12o had reduced MS
marker binding in the deconvolution experiments no lower
than 19 ± 1%. Anyway, the gain in binding affinity effected by
the 2′-fluoro substituent in 12c (2′-F) was nearly completely
abolished by the additional 6′-OCH3 substituent (in 12m). A
similar effect was observed for 12l. The additional 2′-OCH3-
residue, by which this compound differs from 12e, exhibiting a
4′-F-substituent, causes a pKi reduction from 6.546 ± 0.067 (of
12e, Table 2, entry 3) to 6.119 ± 0.037 (12l, Table 2, entry
11), 12l thus being just as potent as the parent compound 12a
(pKi = 6.186 ± 0.028, Table 2, entry 1).
Compared to a 2′-F substituent (12c, 2′-F, pKi = 6.914 ±
0.061, Table 2, entry 2), the binding enhancing effect of a 2′-
CH3 is less pronounced (12ae, pKi = 6.666 ± 0.044, Table 2,
entry 12). The 4′-CH3 substituted hydrazone 12v (4′-CH3)
gave rise to a pKi of 6.325 ± 0.065 (Table 2, entry 13), the 4′-
CH3 substituent thus having slightly improved the potency of
the parent compound 12a (pKi = 6.186 ± 0.028, Table 2, entry
1) though the deconvolution value (percentage of remaining
MS marker binding) of 12v amounting to 10 ± 1% had been
higher than that of 12a (<5%), suggesting the opposite effect.
This discrepancy is possibly attributed to the uncertainties of
the experimental data that are commonly relatively large for
biological systems. The positive effects of the 2′-methyl (as in
12ae, 2′-CH3) and the 4′-methyl group (as in 12v, 4′-CH3)
were combined in the 2′,4′-disubstituted hydrazone 12af (2′,4′-
CH3, Table 2, entry 14), reaching an affinity of pKi = 7.135 ±
0.095. Among the 2′,4′-disubstituted derivatives, 12ag (2′,4′-
(CF3)2) exhibiting two CF3 groups was also found to be more
potent than the parent compound 12a (pKi = 6.186 ± 0.028,
Table 2, entry 1) displaying a pKi of 6.769 ± 0.081 (Table 2,
entry 15) but less than the 2′,4′-dimethyl and 2′,4′-difluoro
substituted hydrazones 12af and 12g (12af, 2′,4′-(CH3)2, pKi =
7.135 ± 0.095, Table 2, entry 14; 12g, 2′,4′-F2, pKi = 7.449 ±
0.023, Table 2, entry 4).
The largest increase in affinity by a single substituent was
observed for a 2′-Cl residue, the respective compound 12p (2′-
Cl, Table 2, entry 16) achieving a pKi of 7.184 ± 0.063 close to
that of the 2′,4′-difluoro substituted derivative (12g, pKi =
7.449 ± 0.023, Table 2, entry 4). An additional 4-F-substituent
in the first ring again gave rise to a reduced affinity (12ad, 4-
F,2′-Cl pKi = 6.981 ± 0.060, Table 2, entry 19), in line with the
results described above. The affinity of the 4′-Cl biphenylhy-
drazone 12r (4′-Cl) with a pKi of 6.762 ± 0.001 (Table 2, entry
17) was also higher than that of the 4′-F substituted analogue
12e (pKi = 6.546 ± 0.067, Table 2, entry 3). An additional 4-F
substituent again led to a decrease in affinity, the pKi of 12ak
(4-F,4′-Cl, pKi = 6.630 ± 0.040, Table 2, entry 20) being lower
than that of 12r with a single 4′-Cl substituent (pKi = 6.762 ±
0.001, Table 2, entry 17). But this decrease was less
pronounced than that for the transition from 12p (2′-Cl,
Table 2, entry 16) to 12ad (4-F,2′-Cl, Table 2, entry 19).
Combining the 2′- and the 4′-Cl-substitution in one
compound led to the most potent biphenylhydrazone of this
study, compound 12z (2′,4′-Cl2), with an affinity in the lower
nanomolar range (pKi = 8.094 ± 0.098, Table 2, entry 18), as
the pKi of this hydrazone derivative surpassed that of the parent
compound 12a (pKi = 6.186 ± 0.028, Table 2, entry 1) by
almost 2 log units.
Further high affinity ligands were obtained by mixed halogen
substitution of the 2′,4′-position of the biphenyl moiety in 12a.
Compound 12ah, the 2′-Cl,4′-F substituted compound, turned
out to be the second most potent biphenylhydrazone derivative
of this series (pKi = 7.835 ± 0.081, Table 2, entry 22) followed
by 12y (2′-F,4′-Cl), exhibiting the reverse halogen substitution
pattern, with a slightly diminished potency (pKi = 7.607 ±
0.043, Table 2, entry 21).
In conclusion of these results, substitution in 2′,4′-position of
the biphenyl moiety was most favorable to gain highly potent
derivatives of the parent compound 12a. Most of all, the
presence of halogen substitutents such as F and even more Cl
in these positions augmented binding affinities remarkably. This
is best underlined by the high affinity displayed by the 2′,4′-Cl2
biphenylhydrazone 12z (2′,4′-Cl2, pKi = 8.094 ± 0.098, Table
2, entry 18). Besides, as demonstrated by these results, the
screening data are in general in good accord with the results of
the MS binding assays and can thus already be considered a
good estimate for the potency of the studied compounds.
In addition to their binding affinities (pKi values) all
compounds were also characterized with respect to their
inhibitory potencies (IC50) in functional [
3H]GABA uptake
assays performed with mGAT1 expressing HEK293 cells. As
already stated in previous papers,28 the pIC50 values of the
uptake assay are generally lower than the pKi values describing
the binding affinity. This may be ascribed to the different assay
conditions used for the [3H]GABA uptake and for the MS
binding assays. Most importantly MS binding assays are
performed in a buffer system containing 1 M NaCl whereas
for [3H]GABA uptake assays a physiological buffer with 120
mM NaCl is used.45 The high NaCl concentration in the MS
binding assays is needed to improve ligand affinity of the MS
marker 6, which is otherwise, when NaCl is present in
physiological concentration (like in the buffer for the
[3H]GABA uptake assay), about 1 log unit lower25,49 under
which conditions these assays were more difficult to perform
(to avoid uncontrolled loss of specifically bound MS marker 6
during the separation of the protein−ligand complex from the
rest of the incubation system).
As the high NaCl concentration (1 M) affects the affinity of
every test compound in a manner similar to the affinity of the
MS marker 6, their pKi values being a half to 1 log unit higher
than those measured in the presence of physiological NaCl
concentration, the differences observed between the pKi values
from MS binding assays (in the presence of 1 M NaCl) and the
pIC50 values from [
3H]GABA uptake assays (in the presence of
physiological NaCl concentration) can be largely ascribed to
this phenomenon. Regardless of that, the rank order of potency
that results from the pIC50 values of the [
3H]GABA uptake
assays is in good accord with that resulting from the pKi values
of the MS binding assays. Thus, in line with that, hydrazone
12z, which displays the highest binding affinity (pKi) for
mGAT1 of the compounds studied, turned out to also be the
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most potent inhibitor in the [3H]GABA uptake assay of
mGAT1 expressing HEK293 cells, its pIC50 amounting to 7.213
± 0.085 (Table 2, entry 18).
Carba Analogues for Biphenyl Derived Hydrazones.
The final step of this study was aimed at the development of
stable analogues of the hydrazone derivatives that can substitute
the latter as lead structure for drug development, a purpose
hydrazones are in general not suitable for because of their
instability28,33−35 and various harmful effects.30−32
A carba moiety in which the two nitrogen atoms of the
hydrazone function (CHN−NH) are replaced by carbon
atoms transforming said function into an allyl group (CH
CH−CH2) was considered to be a suitable substitute that at
least with respect to the overall geometry should be able to
mimic the original functional group. For this transformation a
set of hydrazone derivatives was selected covering diverse
activities ranging from medium to highly potent. Thus, for the
hydrazones 12c, 12p, 12g, 12ah, and 12z the corresponding
carba analogues 13c, 13p, 13g, 13ah, and 13z were synthesized
(Table 3) and evaluated.
As shown in Table 3, the potencies of the hydrazone
derivatives 12c, 12p, 12g, 12ah, and 12z ranging from pKi of
6.914 ± 0.061 (12c) to 8.094 ± 0.098 (12z) were not fully
reached by the carba analogues 13c, 13p, 13g, 13ah, and 13z,
the pKi values of the latter compounds being roughly 1 log unit
lower than those of the corresponding hydrazone derivatives.
But the rank order of potency remained mostly unchanged.
Thus, also for the carba analogues, the 2′,4′-dichloro
substituted derivative 13z appeared to be the most potent
compound in this series with a pKi of 6.930 ± 0.021 followed
by the 2′-chloro-4′-fluorocarba derivative 13ah (pKi of 6.505 ±
0.039) and the 2′,4′-difluorocarba derivative 13g (pKi of 6.228
± 0.014). The rank order of potency for the carba analogues
was in line with the respective rank order of potency for the
hydrazones. Only the 2′-fluoro (13c, pKi = 6.189 ± 0.020) and
the 2′-chloro substituted carba analogue (13p, pKi = 6.079 ±
0.037) deviated from the rank order of potency observed for
the hydrazone derivatives, this time the 2′-fluoro derivative 13c
being more potent than the 2′-chloro derivative 13p. But
similar to the hydrazone derivatives 12c and 12p, the
differences in potencies were also very small for the carba
analogues 13c and 13p, rendering this change in the rank order
of potency less meaningful.
The carba analogues were finally also characterized with
respect to their potencies in [3H]GABA uptake assays (Table
3). Again the pIC50 values for the [
3H]GABA uptake assays
were somewhat lower than the corresponding pKi values
resulting from the MS binding assays, the reasons for this
phenomenon being most likely those given in the section
“Biphenyl-2-carbaldehyde Derived Hydrazone Hits”. The
sequence of potencies (pIC50) was roughly in line with that
of the affinities (pKi) found for these compounds, 13c, 13p,
and 13g being nearly equally potent (13c, pIC50 = 5.477 ±
0.095; 13p, pIC50 = 5.448 ± 0.105, 13g, pIC50 = 5.547 ±
0.032), whereas 13z showed an increased potency (13z, pIC50
= 6.114 ± 0.107). Only 13ah (pIC50 = 5.399 ± 0.052) was
slightly less potent than expected and equipotent to 13c, 13p,
and 13g.
According to the results described above, structure−activity
data obtained from screening of hydrazone libraries represent
valuable information regarding drug target binding which can
be used for the construction of stable analogues as lead
structures but should also be useful in guiding the optimization
of these compounds. The reduced potency of the carba
analogues versus the parent screening hits is attributed to the
lower polarity of the all-carbon spacer and possibly also to its
inability to participate in hydrogen bonds in contrast to the
hydrazone function.
■ CONCLUSION
Recently, competitive MS binding assays have been shown to
be applicable as a readout for the screening of compound
Table 3. Comparison of hydrazones 12c, 12p, 12g, 12z, 12ah with Carba Analogues 13c, 13p, 13g, 13z, 13ah
aData points for specific binding of NO711 (mean ± SD from triplicate values) in the presence of different concentrations of test compounds (M)
resulted in binding curves for Ki determination by nonlinear regression. pKi ± SEM obtained from three independent experiments.
bpIC50 values
from [3H]GABA uptake assays performed with mGAT1 expressing HEK293 cells. Value ± SEM obtained from three independent experiments.
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libraries, generated by simple and most efficient reactions
commonly used in dynamic combinatorial chemistry. A key
feature of this method is to take special means to render the
libraries pseudostatic in order to obtain well-defined library
compositions with almost equal concentrations of test
compounds. Furthermore, by generation of the libraries in
the presence of the target under conditions appropriate for the
MS binding assay, library generation and screening are
performed in the same sample, thus enhancing the assay
performance. When this concept was applied to mGAT1 as
target employing pseudostatic hydrazone libraries, two hits,
hydrazones 12a and 12b, were identified as moderate
(submicromolar) binders of mGAT1. Both hits displayed a
biaryl system representing the lipophilic part that was attached
via a spacer to a more polar residue, in the present case a
nipecotic acid moiety that is characteristic of most mGAT1
inhibitors. The aim of the current study was to further improve
the affinities for mGAT1 by optimizing the biphenyl system of
12a, one of the two hits that had been identified in the first
screening round. Accordingly, focused hydrazone libraries
comprising compounds with differently substituted biphenyl
moieties were generated under pseudostatic conditions and
screened by the aforementioned method developed for
mGAT1 which is based on competitive MS binding experi-
ments utilizing NO711 (6) as native MS marker. The screening
of 9 biaryl focused pseudostatic hydrazone libraries comprising
36 hydrazones revealed 21 hydrazone hits with higher affinities
than the original lead system 12a (pKi = 6.186 ± 0.028). The
most potent hit, 12z, displaying a 2′,4′-dichloro substituted
biphenyl moiety, exhibited an affinity in the lower nanomolar
range, the pKi = 8.094 ± 0.098 being almost 2 log units higher
than of the original compound 12a. Actually, 2′,4′-disubstituted
biphenyl units appeared to be most favorable for increased
binding affinities toward mGAT1 with Cl and F substituents
being most rewarding. A set of representative metastable
hydrazone derivatives was chosen to explore the suitability of
these compounds as models for the construction of stable
analogues as lead structures for further drug development. Of
five representative biphenylhydrazones the corresponding
stable carba analogues were synthesized and tested in
competitive MS binding experiments and [3H]GABA uptake
assays. Again, a 2′,4′-dichloro substituted compound, i.e., 13z,
was found to be the most potent mGAT1 binder (pKi = 6.930
± 0.021), though the pKi value of 13z was 1 log unit lower than
that of the hydrazone derivative 12z. This is possibly a result of
the reduced polarity of the carba analogue compared to the
corresponding hydrazone derivative. But pleasingly, the rank
order of potency of the five carba analogues in the binding
studies was the same as that of the corresponding hydrazone
derivatives. Thus, this study clearly demonstrated that screening
of focused hydrazone libraries under pseudostatic conditions is
a powerful tool to detect hits and that these can be successfully
used as a starting point for the development of almost equally
potent lead structures.
■ EXPERIMENTAL SECTION
Chemistry. Solvents used were of analytical grade and freshly
destilled before use except for DMSO. Ethyl nipecotate was purchased
from Sigma-Aldrich and freshly destilled before use. Other purchased
reagents and reactants were used without further purification. TLC
was carried out on precoated silica gel F254 glass plates (Merck). Flash
column chromatography (CC) was performed on Merck silica gel 60
(mesh 0.040−0.063 mm). Solvents used for elution are reported in
parentheses. 1H NMR spectra were recorded on a JNMR-GX (JEOL,
400 or 500 MHz) at room temperature unless otherwise described.
DMSO-d6 was applied for at least 5 min to ultrasonic degassing before
use. 1H chemical shifts were internally referenced to TMS or MeOH
for samples solved in D2O or CD3OD. The spectra were processed
with the NMR software MestReNova (version 5.1.1-3092, 2007,
Mestrelab Research S. L., Santiago de Compostela, Spain). Broadened
signals in 1H NMR spectra were supplemented by the index “br” (sbr,
dbr, tbr). IR spectroscopy was performed with an FTIR spectrometer
410 (Jasco). Samples were measured either as KBr pellets or as films
on NaCl plates. A Hewlett-Packard 5989 A with 59.980 B particle
beam LC−MS interface was used for mass spectrometry (ionization:
chemical (CH5
+) or electron impact (70 eV)). High resolution mass
spectrometry was carried out with a LTQ FT (ThermoFinnigan), FAB
(Xenon, 6 kV, MBA, reference PEG), or a JMS GCmate II (Jeol).
Purity testing was done by means of analytical HPLC on an Agilent
1100 instrument (G1329A ALS autosampler, G1316A column
compartment, G1315B DAD detector, G1312A binary pump,
G1322A degasser), equipped with a Lichrospher 100 RP-18 (5 μm)
in a LiChroCART 125-4 column, with elution at 1 mL/min with
phosphate buffer (5 mM NaH2PO4·H2O, 5 mM Na2HPO4·2H2O, pH
7.0) to CH3CN 40:60. Carba analogues 13c, 13g, 13p, 13z, 13ah were
≥95% pure. Because of the tendency of hydrazones to hydrolyze,
necessitating specific means to render compound libraries pseudo-
static, HPLC analysis did not appear to be reasonable. Because of
autoxidation of hydrazones and hydrazines, starting material and
products were stored under Ar.
General Procedure for the Preparation of Hydrazones (GP1).
According to the published procedure,28 1 equiv of the corresponding
aldehyde in DMSO-d6 (c = 0.1 M) was added to hydrazine 10. For
practical reasons NMR spectra were directly measured from this
solution after at least five min. When all NMR measurements were
finished, DMSO-d6 was evaporated to give the desired hydrazone.
46
According to 1H NMR spectra, hydrazones existed to ≥98% as E-
isomers.
General Procedure for the Suzuki Coupling of 19 and
Phenylboronic Acid Derivatives (GP2). Under nitrogen atmos-
phere Pd(dppf)Cl2·CH2Cl2 (0.015 mmol, 5 mol %), the appropriate
phenylboronic acid derivative (0.33 mmol), and compound 19 (114
mg, 0.300 mmol) were dissolved in 1,4-dioxane (0.6 mL), K2CO3 (124
mg, 0.90 mmol), and 0.3 mL of water. The resulting mixture was
heated to 60 °C and stirred for 3 h. After addition of water (5 mL) the
mixture was extracted three times with CH2Cl2 (5 mL). The combined
organic layers were dried over Na2SO4, and the solvent was evaporated
in vacuo. The crude product was purified by flash column
chromatography on silica gel (n-pentane/CH2Cl2/EtOAc = 8/1/1 +
2% Et3N).
General Procedure for the Hydrolysis of N-Substituted
Piperidine-3-carboxylic Acid Ethyl Ester Derivatives 21 (GP3).
The chosen piperidine-3-carboxylic acid ethyl ester derivative (0.2
mmol) was dissolved in EtOH (0.8 mL) followed by addition of
NaOH (24.0 mg, 0.60 mmol, 0.050 mL, 12 M aqueous) (TLC
monitoring). Upon completion of the reaction (approximately 4 h)
water (5 mL) was added and the basic solution was washed with Et2O
(5 mL). Afterward the pH of the aqueous phase was adjusted to pH 6
with 1 M HCl and phosphate buffer solution (1 M, pH 7) and the
product was extracted several times with CH2Cl2. The combined
organic layers were dried over Na2SO4, and the solvent was removed
in vacuo to give the appropriate product.
(E)-1-(2-{2-[1-(2′-Fluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12c). According
to GP1 from hydrazine 10 (8.71 mg, 46.5 μmol) and 11c (9.31 mg,
46.5 μmol), 12c was obtained as colorless, amorphous solid (17.2 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.38 (m, 1H),
1.37−1.49 (m, 1H), 1.53−1.65 (m, 1H), 1.70−1.83 (m, 1H), 1.99 (tbr,
J = 9.5 Hz, 1H), 2.12 (tbr, J = 9.8 Hz, 1H), 2.38 (tt, J = 9.9/3.9 Hz,
1H), 2.42 (t, J = 6.8 Hz, 2H), 2.56−2.67 (m, 1H), 2.81 (dbr, J = 10.6
Hz, 1H), 3.11 (t, J = 6.6 Hz, 2H), 7.14−7.25 (sbr, 1H), 7.20 (dd, J =
7.6/1.2 Hz, 1H), 7.25−7.35 (m, 5H), 7.35−7.40 (m, 1H), 7.43−7.52
(m, 1H), 7.87 (dd, J = 7.9/1.2 Hz, 1H) ppm. 13C NMR (101 MHz,
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DMSO-d6): δ 23.9, 26.4, 41.0, 45.4, 53.2, 55.3, 56.3, 115.5 (d,
2JCF =
22.1 Hz), 123.7, 124.5 (d, 3/4JCF = 3.6 Hz), 126.8, 127.2 (d,
2JCF = 16.3
Hz), 127.9, 129.7 (d, 3JCF = 8.1 Hz), 130.4, 131.5, 131.8 (d,
3/4JCF =
3.3 Hz), 132.8, 134.4, 158.9 (d, 1JCF = 244.3 Hz), 175.0 ppm.
19F
NMR (471 MHz, DMSO-d6): δ −115.00 ppm. MS (ESI+) m/z: 370
[M + H]+. HRMS (ESI+): [M + H]+ calcd for C21H25O2N3F,
370.1931; found, 370.1923.
(E)-1-(2-{2-[1-(4′-Fluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12e). According
to GP1 from hydrazine 10 (8.55 mg, 45.6 mmol) and 11e (9.13 mg,
45.6 μmol), 12e was obtained as slightly yellow, amorphous solid
(16.9 mg, yield 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.26−1.40
(m, 1H), 1.38−1.50 (m, 1H), 1.54−1.66 (m, 1H), 1.71−1.83 (m, 1H),
2.02 (tbr, J = 10.0 Hz, 1H), 2.15 (tbr, J = 10.2 Hz, 1H), 2.39 (tt, J = 8.9/
3.9 Hz, 1H), 2.45 (t, J = 6.7 Hz, 2H), 2.56−2.69 (m, 1H), 2.82 (dbr, J
= 10.3 Hz, 1H), 3.13 (t, J = 6.6 Hz, 2H), 7.01−7.18 (sbr, 1H), 7.17−
7.23 (m, 1H), 7.24−7.31 (m, 3H), 7.31−7.39 (m, 3H), 7.43 (s, 1H),
7.85 (dd, J = 7.7/1.3 Hz, 1H) ppm. 13C NMR (101 MHz, DMSO-d6):
δ 23.9, 26.4, 41.0, 45.5, 53.2, 55.3, 56.4, 115.1 (d, 2JCF = 21.0 Hz, 2C),
124.2, 126.9, 127.4, 130.0, 131.3 (d, 3JCF = 8.0 Hz, 2C), 132.0, 133.6,
136.2 (d, 4JCF = 3.3 Hz), 138.2, 161.4 (s,
1JCF = 240.7 Hz), 175.0 ppm.
19F NMR (471 MHz, DMSO-d6): δ −115.42 ppm. MS (ESI+) m/z:
370 [M + H]+. HRMS (ESI+): [M + H]+ calcd for C21H25O2N3F,
370.1931; found, 370.1923.
(E)-1-(2-{2-[1-(3′,4′-Difluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12f). According
to GP1 from hydrazine 10 (10.2 mg, 54.5 μmol) and 11f (11.9 mg,
54.5 μmol), 12f was obtained as a yellow, amorphous solid (21.1 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.39 (m, 1H),
1.38−1.50 (m, 1H), 1.55−1.65 (m, 1H), 1.71−1.83 (m, 1H), 2.01 (tbr,
J = 9.5 Hz, 1H), 2.14 (tbr, J = 9.9 Hz, 1H), 2.39 (tt, J = 9.9/3.9 Hz,
1H), 2.45 (t, J = 6.7 Hz, 2H), 2.58−2.68 (m, 1H), 2.84 (dbr, J = 9.7
Hz, 1H), 3.15 (t, J = 6.6 Hz, 2H), 7.13−7.18 (m, 1H), 7.19−7.26 (sbr,
1H), 7.23 (dd, J = 7.6/1.3 Hz, 1H), 7.29 (td, J = 7.4/1.4 Hz, 1H), 7.35
(td, J = 7.7/1.1 Hz, 1H), 7.39−7.46 (m, 1H), 7.44 (s, 1H), 7.52 (dt, J
= 10.8/8.5 Hz, 1H), 7.85 (dd, J = 7.8/1.0 Hz, 1H) ppm. 13C NMR
(101 MHz, DMSO-d6): δ 23.9, 26.5, 40.9, 45.4, 53.2, 55.3, 56.4, 117.3
(d, 2JCF = 16.9 Hz), 118.4 (d,
2JCF = 16.9 Hz), 124.2, 126.4 (d, JCF =
6.4/3.4 Hz), 126.9, 127.8, 130.0, 131.5, 133.6, 137.1 (d, JCF = 1.4 Hz),
137.4 (dd, JCF = 6.1/3.8 Hz), 148.9 (d,
1/2JCF = 245.7/12.8 Hz), 149.0
(d, 1/2JCF = 245.7/12.8 Hz), 175.1 ppm.
19F NMR (471 MHz, DMSO-
d6): δ −140.87 (m, 1 F), −138.46 (m, 1 F) ppm. MS (ESI+) m/z: 388
[M + H]+. HRMS (ESI+): [M + H]+ calcd for C21H24O2N3F2,
388.1837; found, 388.1828.
(E)-1-(2-{2-[1-(2′,4′-Difluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12g). According
to GP1 from hydrazine 10 (10.8 mg, 57.9 μmol) and 11g (12.6 mg,
57.9 μmol), 12g was obtained as a yellow, amorphous solid (22.6 mg,
yield 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.25−1.51 (m, 2H),
1.53−1.66 (m, 1H), 1.70−1.83 (m, 1H), 1.99 (tbr, J = 10.4 Hz, 1H),
2.12 (tbr, J = 10.6 Hz, 1H), 2.30−2.48 (m, 3H), 2.62 (dbr, J = 11.8 Hz,
1H), 2.82 (dbr, J = 9.7 Hz, 1H), 3.12 (t, J = 6.4 Hz, 2H), 7.12−7.25
(m, 3H), 7.25−7.33 (m, 2H), 7.33−7.45 (m, 3H), 7.86 (d, J = 7.9 Hz,
1H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 23.9, 26.4, 40.9, 45.4,
53.2, 55.3, 56.3, 103.9 (t, 2JCF = 26.2 Hz), 111.6 (dd,
2/4JCF = 21.3/3.4
Hz), 123.8, (dd, 2/4JCF = 15.6/3.5 Hz) 123.8, 126.8, 128.1, 130.5,
131.2, 131.9, 132.8 (dd, 3/3JCF = 9.6/4.8 Hz), 134.5, 159.0 (dd,
1/3JCF =
246.6/12.4 Hz), 161.8 (dd, 1/3JCF = 246.6/11.9 Hz), 175.1 ppm.
19F
NMR (471 MHz, DMSO-d6): δ −110.87 (dt, J = 16.0/8.2 Hz),
−110.40 (q, J = 8.0 Hz) ppm. MS (ESI+) m/z: 388.2 [M + H]+.
HRMS (ESI+): [M + H]+ calcd for C21H24F2N3O2, 388.1837; found,
388.1829.
(E)-1-(2-{2-[1-(2′,3′-Difluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12h). According
to GP1 from hydrazine 10 (8.78 mg, 46.9 μmol) and 11h (10.2 mg,
46.9 μmol), 12h was obtained as a yellow, amorphous solid (18.0 mg,
yield 99%). 1H NMR (500 MHz, DMSO-d6): δ 1.25−1.38 (m, 1H),
1.38−1.50 (m, 1H), 1.54−1.65 (m, 1H), 1.71−1.83 (m, 1H), 1.99 (tbr,
J = 9.6 Hz, 1H), 2.12 (tbr, J = 9.7 Hz, 1H), 2.38 (tt, J = 9.8/3.7 Hz,
1H), 2.42 (t, J = 6.7 Hz, 2H), 2.57−2.67 (m, 1H), 2.81 (dbr, J = 10.4
Hz, 1H), 3.12 (t, J = 6.6 Hz, 2H), 7.10−7.18 (m, 1H), 7.19−7.27 (m,
2H), 7.27−7.34 (m, 3H), 7.37−7.44 (m, 1H), 7.44−7.52 (m, 1H),
7.84−7.89 (m, 1H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 23.9,
26.4, 40.9, 45.5, 53.2, 55.3, 56.4, 116.7 (d, 2JCF = 17.1 Hz), 123.9, 124.8
(dd, 3/4JCF = 7.5/4.6 Hz), 126.8, 127.0 (mCF), 128.4, 129.7 (d,
2JCF =
12.8 Hz), 130.3, 131.0, 131.3 (s, 3JCF = 2.5 Hz), 134.4, 146.8 (dd,
1/2JCF = 246.4/12.7 Hz,), 149.7 (dd,
1/2JCF = 246.3/13.1 Hz), 175.0
ppm. 19F NMR (471 MHz, DMSO-d6): δ −140.82 (d, J = 23.21 Hz),
−138.54 (d, J = 27.07 Hz) ppm. MS (ESI+) m/z: 388.7 [M + H]+.
HRMS (ESI+): [M + H]+ calcd for C21H24F2N3O2, 388.1837; found,
388.1828.
(E)-1-(2-{2-[1-(4′-Fluoro-2′-methoxybiphenyl-2-yl)-
methylidene]hydrazinyl}ethyl)piperidine-3-carboxylic Acid
(12l). According to GP1 from hydrazine 10 (13.2 mg, 70.3 μmol)
and 11l (16.2 mg, 70.3 μmol), 12l was obtained as colorless,
amorphous solid (28.1 mg, yield 99%). 1H NMR (500 MHz, DMSO-
d6): δ 1.27−1.38 (m, 1H), 1.38−1.50 (m, 1H), 1.53−1.65 (m, 1H),
1.69−1.83 (m, 1H), 2.00 (tbr, J = 10.4 Hz, 1H), 2.14 (tbr, J = 9.8 Hz,
1H), 2.38 (tt, J = 9.7/3.9 Hz, 1H), 2.42 (t, J = 7.0 Hz, 2H), 2.56−2.67
(m, 1H), 2.81 (dbr, J = 11.3 Hz, 1H), 3.09 (t, J = 6.7 Hz, 2H), 3.71 (s,
3H), 6.84 (td, J = 8.4/2.5 Hz, 1H), 7.01 (dd, J = 11.5/2.4 Hz, 1H),
7.08 (dd, J = 7.6/1.3 Hz, 1H), 7.13 (dd, J = 8.3/7.0 Hz, 1H), 7.19 (s,
1H), 7.23 (td, J = 7.4/1.5 Hz, 1H), 7.26−7.33 (m, 1H), 7.81 (dd, J =
7.9/1.2 Hz, 1H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 23.9, 26.4,
40.9, 45.5, 53.2, 55.3, 55.7, 56.4, 99.5 (d, 2JCF = 25.7 Hz), 106.6 (d,
2JCF = 21.0 Hz), 123.3, 124.8 (d,
4JCF = 2.8 Hz), 126.6, 127.2, 130.5,
131.8 (d, 3JCF = 10.0 Hz), 132.7, 134.4, 135.3, 157.5 (d,
3JCF = 10.2
Hz), 162.6 (d, 1JCF = 243.5 Hz), 175.1 ppm.
19F NMR (471 MHz,
DMSO-d6): δ 111.80 (ddd, J = 11.4/8.4/7.2 Hz) ppm. MS (CI, CH5
+)
m/z: 400 [M + H]+. HRMS (ESI+): [M + H]+ calcd for
C22H27N3O3F, 400.2036; found, 400.2029.
(E)-1-(2-{2-[1-(2′-Fluoro-6′-methoxybiphenyl-2-yl)-
methylidene]hydrazinyl}ethyl)piperidine-3-carboxylic Acid
(12m). According to GP1 from hydrazine 10 (4.72 mg, 25.5 μmol)
and 11m (5.80 mg, 25.2 μmol), 12m was obtained as a yellow,
amorphous solid (10.8 mg, yield 100%). 1H NMR (500 MHz, DMSO-
d6): δ 1.25−1.36 (m, 1H), 1.35−1.48 (m, 1H), 1.52−1.64 (m, 1H),
1.70−1.81 (m, 1H), 1.96 (tbr, J = 9.9 Hz, 1H), 2.09 (tbr, J = 9.1 Hz,
1H), 2.32−2.39 (m, 1H), 2.39 (t, J = 6.7 Hz, 2H), 2.55−2.65 (m, 1H),
2.79 (dbr, J = 9.7 Hz, 1H), 3.07 (t, J = 6.6 Hz, 2H), 3.70 (s, 3H), 6.90
(t, J = 8.6 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 7.06−7.14 (sbr, 1H), 7.09
(dd, J = 7.6/1.0 Hz, 1H), 7.15 (s, 1H), 7.24 (td, J = 7.5/1.4 Hz, 1H),
7.31 (td, J = 7.7/1.0 Hz, 1H), 7.41 (td, J = 8.4/7.1 Hz, 1H), 7.83 (d, J
= 7.9 Hz, 1H) ppm. 13C NMR (101 MHz, DMSO-d6): δ 23.9, 26.4,
40.9, 45.4, 53.2, 55.3, 55.9, 56.3, 107.3, 107.6 (d, 1 C, 2JCF = 22.9 Hz),
116.0 (d, 2JCF = 19.41 Hz), 123.4, 126.5, 127.7, 128.9, 129.8 (d, 1 C,
3JCF = 19.4 Hz), 131.0, 131.9, 134.9, 157.7 (d,
3JCF = 7.3 Hz), 159.5 (d,
1JCF = 241.6 Hz), 175.0 ppm.
19F NMR (471 MHz, DMSO-d6): δ
−113.70 (t, J = 7.8 Hz) ppm. MS (ESI+) m/z: 400 [M + H]+. HRMS
(ESI+): [M + H]+ calcd for C22H27O3N3F, 400.2036; found, 400.2028.
(E)-1-(2-{2-[1-(2′-Chlorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12p). According
to GP1 from hydrazine 10 (12.7 mg, 68.1 μmol) and 11p (14.8 mg,
68.4 μmol), 12p was obtained as a yellow, amorphous solid (26.3 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.37 (m, 1H),
1.37−1.48 (m, 1H), 1.54−1.63 (m, 1H), 1.69−1.82 (m, 1H), 1.97 (tbr,
J = 9.9 Hz, 1H), 2.04−2.19 (m, 1H), 2.32−2.44 (m, 3H), 2.60 (dbr, J =
10.5 Hz, 1H), 2.80 (dbr, J = 10.8 Hz, 1H), 3.08 (t, J = 6.6 Hz, 2H),
7.09−7.13 (m, 1H), 7.12 (s, 1H), 7.18 (sbr, 1H), 7.25−7.33 (m, 2H),
7.33−7.39 (m, 1H), 7.40−7.47 (m, 2H), 7.53−7.61 (m, 1H), 7.86 (dd,
J = 8.0/0.7 Hz, 1H) ppm. 13C NMR (126 MHz, DMSO-d6): δ 23.9,
26.4, 40.9, 45.3, 53.2, 55.3, 56.2, 123.5, 126.6, 127.2, 127.9, 129.2,
129.3, 129.8, 131.1, 131.7, 132.4, 134.1, 136.5, 138.6, 175.0 ppm. MS
(ESI+) m/z: 386 [M + H]+. HRMS (ESI+): [M + H]+ calcd for
C21H25ClN3O2, 386.1635; found, 368.1629.
(E)-1-(2-{2-[1-(4′-Chlorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12r). According
to GP1 from hydrazine 10 (9.65 mg, 51.6 μmol) and 11r (11.1 mg,
51.6 μmol), 12r was obtained as a yellow, amorphous solid (20.0 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.28−1.39 (m, 1H),
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1.39−1.50 (m, 1H), 1.55−1.66 (m, 1H), 1.69−1.84 (m, 1H), 2.02 (tbr,
J = 9.6 Hz, 1H), 2.15 (tbr, J = 10.0 Hz, 1H), 2.39 (tt, J = 9.9/3.8 Hz,
1H), 2.45 (t, J = 6.7 Hz, 2H), 2.58−2.67 (m, 1H), 2.83 (dbr, J = 11.6
Hz, 1H), 3.14 (t, J = 6.6 Hz, 2H), 7.20 (sbr, 1H), 7.21 (dd, J = 7.6/1.3
Hz, 1H), 7.29 (td, J = 7.4/1.5 Hz, 1H), 7.31−7.37 (m, 3H), 7.43 (s,
1H), 7.49−7.54 (m, 2H), 7.85 (dd, J = 7.8/1.3 Hz, 1H) ppm. 13C
NMR (126 MHz, DMSO-d6): δ 23.9, 26.4, 40.9, 45.5, 53.2, 55.3, 56.4,
124.3, 126.9, 127.6, 128.2 (2C), 129.8, 131.2 (2C), 131.8, 132.0, 133.5,
137.9, 138.7, 175.0 ppm. MS (ESI+) m/z: 386.1 [M + H]+. HRMS
(ESI+): [M + H]+ calcd for C21H25ClN3O2, 386.1635; found,
386.1629.
(E)-1-(2-{2-[1-(4′-Methylbiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12v). According
to GP1 from hydrazine 10 (11.1 mg, 59.5 μmol) and 11v (11.7, 59.5
μmol), 12v was obtained as colorless, amorphous solid (21.6 mg, yield
100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.39 (m, 1H), 1.39−
1.51 (m, 1H), 1.53−1.66 (m, 1H), 1.69−1.84 (m, 1H), 2.01 (tbr, J =
10.2 Hz, 1H), 2.15 (tbr, J = 10.3 Hz, 1H), 2.36 (s, 3H), 2.39 (tt, J =
9.9/2.8 Hz, 1H), 2.45 (t, J = 6.5 Hz, 2H), 2.58−2.67 (m, 1H), 2.82
(dbr, J = 9.5 Hz, 1H), 3.13 (t, J = 6.7 Hz, 2H), 7.08 (s, 1H), 7.15−7.23
(m, 3H), 7.23−7.34 (m, 4H), 7.47 (s, 1H), 7.78−7.87 (m, 1H) ppm.
13C NMR (126 MHz, DMSO-d6): δ 20.6, 23.9, 26.4, 40.9, 45.5, 53.2,
55.3, 56.4, 124.2, 126.9, 127.1, 128.8 (2C), 129.2 (2C), 129.9, 132.5,
133.4, 136.2, 136.9, 139.3, 175.0 ppm. MS (ESI+) m/z: 366.2 [M +
H]+. HRMS (ESI+): [M + H]+ calcd for C22H28N3O2, 366.2182;
found, 366.2174.
(E ) -1 - (2 - {2 - [1 - (4 ′ -Chloro-2 ′ -fluorobiphenyl -2-y l ) -
methylidene]hydrazinyl}ethyl)piperidine-3-carboxylic Acid
(12y). According to GP1 from hydrazine 10 (9.40 mg, 50.2 μmol)
and 11y (11.8 mg, 50.3 μmol), 12y was obtained as a yellow,
amorphous solid (20.3 mg, yield 100%). 1H NMR (500 MHz, DMSO-
d6): δ 1.28−1.39 (m, 1H), 1.38−1.50 (m, 1H), 1.54−1.66 (m, 1H),
1.71−1.84 (m, 1H), 2.00 (tbr, J = 9.9 Hz, 1H), 2.14 (tbr, J = 10.1 Hz,
1H), 2.39 (tt, J = 9.8/3.8 Hz, 1H), 2.43 (t, J = 6.8 Hz, 2H), 2.57−2.68
(m, 1H), 2.82 (dbr, J = 9.2 Hz, 1H), 3.12 (t, J = 6.6 Hz, 2H), 7.14−
7.25 (sbr, 1H), 7.19 (dd, J = 7.7/1.1 Hz, 1H), 7.27−7.29 (m, 1H), 7.30
(dd, J = 7.4/1.3 Hz, 1H), 7.33−7.43 (m, 3H), 7.53 (dd, J = 9.7/1.9 Hz,
1H), 7.85 (dd, J = 8.0/1.0 Hz, 1H) ppm. 13C NMR (126 MHz,
DMSO-d6): δ 23.9, 26.4, 40.9, 45.5, 53.2, 55.3, 56.3, 116.1 (d,
2JCF =
26.3 Hz), 123.9, 124.8 (d, 4JCF = 3.7 Hz), 126.4 (d,
2JCF = 16.4 Hz),
126.8, 128.3, 130.3, 131.2, 131.6, 133.0 (d, 3JCF = 4.0 Hz), 133.1 (d,
3JCF = 10.4 Hz), 134.4, 158.9 (d,
1JCF = 248.0 Hz), 175.0 ppm.
19F
NMR (471 MHz, DMSO-d6): δ −111.84 (m) ppm. MS (ESI+) m/z:
404.2 [M + H]+. HRMS (ESI+): [M + H]+ calcd for C21H24ClFN3O2,
404.1541; found, 404.1534.
(E)-1-(2-{2-[1-(2′,4′-Dichlorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12z). According
to GP1 from hydrazine 10 (18.2 mg, 97.0 μmol) and 11z (24.4 mg,
97.0 μmol), 12z was obtained as a yellow, amorphous solid (40.6 mg,
yield 99%). 1H NMR (500 MHz, DMSO-d6, 60 °C): δ 1.28−1.50 (m,
2H), 1.56−1.66 (m, 1H), 1.72−1.83 (m, 1H), 2.02 (t, J = 9.1 Hz, 1H),
2.16 (t, J = 10.3 Hz, 1H), 2.34−2.46 (m, 3H), 2.55−2.64 (m, 1H),
2.80 (dd, J = 11.1/3.3 Hz, 1H), 3.10 (t, J = 6.7 Hz, 2H), 7.10 (dd, J =
7.6/1.0 Hz, 1H), 7.16 (s, 1H), 7.28 (td, J = 7.5/1.4 Hz, 1H), 7.32 (d, J
= 8.2 Hz, 1H), 7.34−7.39 (m, 1H), 7.48 (dd, J = 8.2/2.1 Hz, 1H), 7.68
(d, J = 2.1 Hz, 1H), 7.83 (dd, J = 8.0/1.2 Hz, 1H) ppm. 13C NMR
(126 MHz, DMSO-d6, 60 °C): δ 23.9, 26.5, 41.1, 45.7, 53.2, 55.4, 56.4,
124.0, 126.6, 127.3, 128.1, 128.7, 129.7, 131.3, 132.9, 133.0, 133.6,
134.4, 135.4, 138.0, 174.9 ppm. 19F NMR (471 MHz, DMSO-d6): δ
−111.84 (m) ppm. MS (ESI+) m/z: 420 [M + H]+. HRMS (ESI+):
[M + H]+ calcd for C21H24N3O2Cl2, 420.1246; found, 420.1210.
(E)-1-(2-{2-[1-(2′,6′-Difluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12aa). According
to GP1 from hydrazine 10 (6.51 mg, 34.7 μmol) and 11aa (7.57 mg,
34.7 μmol), 12aa was obtained as a yellow, amorphous solid (13.3 mg,
yield 99%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.50 (m, 2H),
1.53−1.65 (m, 1H), 1.70−1.83 (m, 1H), 1.99 (tbr, J = 9.4 Hz, 1H),
2.13 (tbr, J = 10.1 Hz, 1H), 2.33−2.45 (m, 3H), 2.56−2.66 (m, 1H),
2.81 (dbr, J = 9.7 Hz, 1H), 3.10 (t, J = 6.7 Hz, 2H), 7.14−7.27 (m,
5H), 7.31 (td, J = 7.5/1.3 Hz, 1H), 7.41 (td, J = 7.7/1.0 Hz, 1H), 7.52
(tt, J = 8.4/6.6 Hz, 1H), 7.87 (dd, J = 8.0/1.0 Hz, 1H) ppm. 13C NMR
(126 MHz, DMSO-d6): δ 23.9, 26.4, 40.9, 45.4, 53.2, 55.3, 56.3, 111.7
(d, 2JCF = 25.8 Hz, 2C), 116.3 (t,
2JCF = 21.8 Hz), 124.1, 125.8, 126.7,
128.6, 130.3 (t, 3JCF = 10.4 Hz), 130.8, 130.9, 135.1, 159.4 (d,
1JCF =
245.4 Hz, 2C), 175.0 ppm. 19F NMR (471 MHz, DMSO-d6): δ
−112.40 (t, J = 6.5 Hz) ppm. MS (ESI+) m/z: 388.3 [M + H]+.
HRMS (ESI+): [M + H]+ calcd for C21H24N3O2F2, 388.1837; found,
388.1834.
(E)-1-(2-{2-[1-(2′,4′,6′-Trifluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12ab). According
to GP1 from hydrazine 10 (10.9 mg, 58.4 μmol) and 11ab (13.8 mg,
58.4 μmol), 12ab was obtained as a yellow, amorphous solid (24.5 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.27−1.39 (m, 1H),
1.38−1.50 (m, 1H), 1.53−1.66 (m, 1H), 1.68−1.85 (m, 1H), 1.99 (tbr,
J = 9.8 Hz, 1H), 2.13 (tbr, J = 10.2 Hz, 1H), 2.34−2.45 (m, 3H), 2.55−
2.69 (m, 1H), 2.82 (dbr, J = 10.7 Hz, 1H,), 3.11 (t, J = 6.4 Hz, 2H),
7.22 (dd, J = 7.6/0.9 Hz, 1H), 7.19−7.28 (sbr, 1H), 7.27 (s, 1H),
7.29−7.36 (m, 3H), 7.38−7.46 (m, 1H), 7.81−7.87 (m, 1H) ppm. 13C
NMR (126 MHz, DMSO-d6): δ 23.9, 26.4, 40.9, 45.5, 53.2, 55.3, 56.3,
100.7 (t, 2JCF = 28.0 Hz, 2C), 113.2 (td,
2/4JCF = 22.2/4.8 Hz), 124.4,
124.9, 126.8, 128.8, 130.9, 131.0, 135.2, 159.6 (ddd, JCF = 246.1/15.5/
10.1 Hz, 2C), 161.7 (dt, JCF = 246.1/15.9 Hz), 175.0 ppm.
19F NMR
(471 MHz, DMSO-d6): δ −109.39 (t, J = 6.8 Hz), −108.58 (tt, J =
9.3/6.4 Hz) ppm. MS (ESI+) m/z: 406.0 [M + H]+. HRMS (ESI+):
[M + H]+ calcd for C21H23F3N3O2, 406.1742; found, 406.1735.
(E)-1-(2-{2-[1-(4,2′-Difluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12ac). According
to GP1 from hydrazine 10 (9.55 mg, 51.0 μmol) and 11ac (11.1 mg,
51.0 μmol), 12ac was obtained as a yellow, amorphous solid (21.0 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.38 (m, 1H),
1.38−1.49 (m, 1H), 1.53−1.65 (m, 1H), 1.70−1.84 (m, 1H), 1.99 (tbr,
J = 9.5 Hz, 1H), 2.12 (tbr, J = 10.0 Hz, 1H), 2.38 (tt, J = 9.9/3.8 Hz,
1H), 2.43 (t, J = 6.7 Hz, 2H), 2.58−2.66 (m, 1H), 2.81 (d, J = 9.8 Hz,
1H), 3.13 (tbr, J = 6.2 Hz, 2H), 7.11 (td, J = 8.4/2.8 Hz, 1H), 7.20 (t, J
= 2.3 Hz, 1H), 7.25 (dd, J = 8.5/5.9 Hz, 1H), 7.28−7.35 (m, 3H),
7.43−7.51 (m, 2H), 7.56 (dd, J = 10.8/2.8 Hz, 1H) ppm. 13C NMR
(126 MHz, DMSO-d6): δ 23.9, 26.4, 40.9, 45.3, 53.2, 55.3, 56.2, 109.2
(d, 2JCF = 22.9 Hz), 113.6 (d,
2JCF = 22.1 Hz), 115.5 (d,
2JCF = 22.1
Hz), 124.6 (d, 4JCF = 3.5 Hz), 126.3 (d,
2JCF = 16.1 Hz), 128.8 (d,
4JCF
= 2.7 Hz), 129.4 (mCF), 129.9 (d,
3JCF = 8.1 Hz), 132.0 (d,
4JCF = 3.2
Hz), 132.6 (d, 3JCF = 8.5 Hz), 137.0 (d,
3JCF = 9.0 Hz), 159.0 (s-d,
1JCF
= 244.2 Hz), 162.0 (s-d, 1JCF = 244.0 Hz), 175.0 ppm.
19F NMR (471
MHz, DMSO-d6): δ −115.08 to −114.96 (td, J = 7.1/3.5 Hz),
−114.06 to −113.90 (m) ppm. MS (ESI+) m/z: 388.3 [M + H]+.
HRMS (ESI+): [M + H]+ calcd for C21H24N3O2F2, 388.1837; found,
388.1833.
(E)-1-(2-{2-[1-(2′-Chloro-4-fluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12ad). According
to GP1 from hydrazine 10 (7.17 mg, 38.3 μmol) and 11ad (8.99 mg,
38.3 μmol), 12ad was obtained as a yellow, amorphous solid (16.2 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.37 (m, 1H),
1.37−1.47 (m, 1H), 1.54−1.63 (m, 1H), 1.70−1.82 (m, 1H), 1.97 (tbr,
J = 10.2 Hz, 1H), 2.10 (tbr, J = 10.1 Hz, 1H), 2.32−2.44 (m, 3H),
2.56−2.63 (m, 1H), 2.79 (dbr, J = 9.2 Hz, 1H), 3.05−3.13 (m, 2H),
7.03 (d, J = 2.0 Hz, 1H), 7.10 (td, J = 8.4/2.8 Hz, 1H), 7.13−7.19 (m,
1H), 7.28−7.34 (m, 1H), 7.40−7.49 (m, 3H), 7.54 (dd, J = 10.8/2.7
Hz, 1H), 7.56−7.59 (m, 1H) ppm. 13C NMR (126 MHz, DMSO-d6):
δ 23.9, 26.4, 40.9, 45.2, 53.1, 55.3, 56.1, 108.9 (d, 2JCF = 23.1 Hz),
113.3 (d, 2JCF = 22.3 Hz), 127.2, 129.2 (mCF), 129.3 (d,
4JCF = 2.4 Hz),
129.5, 131.8, 132.0 (d, 3JCF = 8.50 Hz), 132.5 (d,
4JCF = 3.0 Hz), 132.6,
136.9 (d, 1 C, 3JCF = 8.2 Hz), 137.7, 161.8 (d,
1JCF = 243.3 Hz), 175.0
ppm. 19F NMR (471 MHz, DMSO-d6): δ −114.03 ppm. MS (ESI+)
m/z: 404.3 [M + H]+. HRMS (ESI+): [M + H]+ calcd for
C21H24N3O2F2, 404.1541; found, 404.1538.
(E)-1-(2-{2-[1-(2′-Methylbiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12ae). According
to GP1 from hydrazine 10 (10.3 mg, 58.4 μmol) and 11ae (11.5 mg,
58.4 μmol), 12ae was obtained as a yellow, amorphous solid (21.3 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6): δ 1.26−1.37 (m, 1H),
1.36−1.47 (m, 1H), 1.53−1.63 (m, 1H), 1.71−1.81 (m, 1H), 1.93−
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2.02 (m, 1H), 2.00 (s, 3H), 2.06−2.18 (m, 1H), 2.33−2.40 (m, 1H),
2.40 (t, J = 6.7 Hz, 2H), 2.55−2.63 (m, 1H), 2.74−2.84 (m, 1H), 3.07
(t, J = 6.7 Hz, 2H), 7.03−7.15 (m, 3H), 7.10 (s, 1H), 7.22−7.35 (m,
5H), 7.85 (dd, J = 7.8/1.0 Hz, 1H) ppm. 13C NMR (126 MHz,
DMSO-d6): δ 19.7, 23.8, 26.4, 40.9, 45.4, 53.2, 55.3, 56.3, 123.4, 125.7,
126.7, 127.2, 127.4, 129.5, 129.7, 131.7, 133.8, 135.4, 138.9, 139.6,
175.0 ppm. MS (ESI+) m/z: 366.2 [M + H]+. HRMS (ESI+): [M +
H]+ calcd for C22H28N3O2, 366.2182; found, 366.2175.
(E)-1-(2-{2-[1-(2′,4′-Dimethylbiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12af). According
to GP1 from hydrazine 10 (17.6 mg, 94.1 μmol) and 11af (19.7 mg,
94.1 μmol), 12af was obtained as a yellow, amorphous solid (38.5 mg,
yield 100%). 1H NMR (500 MHz, DMSO-d6, 60 °C): δ 1.29−1.40 (m,
1H), 1.38−1.49 (m, 1H), 1.53−1.65 (m, 1H), 1.69−1.82 (m, 1H),
1.96 (s, 3H), 1.98−2.05 (m, 1H), 2.12−2.20 (m, 1H), 2.32 (s, 3H),
2.33−2.44 (m, 3H), 2.54−2.62 (m, 1H), 2.74−2.82 (m, 1H), 3.08 (t, J
= 6.7 Hz, 2H), 6.96 (d, J = 7.6 Hz, 1H), 7.01−7.08 (m, 2H), 7.10 (s,
1H), 7.13 (s, 1H), 7.24 (td, J = 7.4/1.4 Hz, 1H), 7.29 (td, J = 7.4/0.9
Hz, 1H), 7.83 (dd, J = 7.8/1.1 Hz, 1H) ppm. 13C NMR (126 MHz,
DMSO-d6, 60 °C): δ 19.6, 20.6, 23.9, 26.5, 41.0, 45.7, 53.2, 55.3, 56.4,
123.6, 126.2, 126.7, 127.0, 129.5, 129.7, 130.4, 132.4, 134.2, 135.2,
136.4, 136.8, 139.1, 174.8 ppm. MS (ESI+) m/z: 380.5 [M + H]+.
HRMS (ESI+): [M + H]+ calcd for C23H30N3O2, 379.2260; found,
380.2334.
(E)-1-(2-{2-[1-(2′,4′-Bistrifluoromethylbiphenyl-2-yl)-
methylidene]hydrazinyl}ethyl)piperidine-3-carboxylic Acid
(12ag). According to GP1 from hydrazine 10 (14.4 mg, 77.1 μmol)
and 11ag (24.5 mg, 77.1 μmol), 12ag was obtained as a yellow,
amorphous solid (35.1 mg, yield 93%). 1H NMR (500 MHz, DMSO-
d6): δ 1.25−1.47 (m, 2H), 1.52−1.63 (m, 1H), 1.71−1.81 (m, 1H),
1.94 (t, J = 10.5 Hz, 1H), 2.02−2.15 (m, 1H), 2.25−2.41 (m, 3H),
2.53−2.60 (m, 1H), 2.71−2.84 (m, 1H), 3.03 (t, J = 6.7 Hz, 2H), 7.05
(s, 1H), 7.13 (d, J = 7.6 Hz, 1H), 7.13−7.23 (sbr, 1H), 7.22−7.31 (m,
1H), 7.37−7.44 (m, 1H), 7.56−7.63 (m, 1H), 7.81 (d, J = 7.7 Hz,
1H), 8.11 (d, J = 8.1 Hz, 1H), 8.15 (s, 1H) ppm. 13C NMR (126 MHz,
DMSO-d6): δ 23.8, 26.4, 40.9, 45.5, 53.1, 55.3, 56.4, 122.9 (mCF),
123.1 (q, 1JCF = 274.8 Hz), 123.4 (q,
1JCF = 272.8 Hz), 124.0, 126.0,
128.5, 128.7 (q, 2JCF = 32.8 Hz), 128.8 (q,
2JCF = 32.2 Hz), 128.9
(mCF), 129.3, 131.1, 133.7, 134.1, 134.5, 143.8, 175.0 ppm.
19F NMR
(471 MHz, DMSO-d6): δ −61.12 (m), −57.61 (d, J = 2.5 Hz) ppm.
MS (ESI+) m/z: 488.3 [M + H]+. HRMS (ESI+): [M + H]+ calcd for
C23H24F6N3O2, 487.1694; found, 488.1768.
(E ) -1 - (2 - {2 - [1 - (2 ′ -Chloro-4 ′ -fluorobiphenyl -2-y l ) -
methylidene]hydrazinyl}ethyl)piperidine-3-carboxylic Acid
(12ah). According to GP1 from hydrazine 10 (9.93 mg, 53.0 μmol)
and 11ah (12.4 mg, 53.0 μmol), 12ah was obtained as a yellow,
amorphous solid (21.3 mg, yield 100%). 1H NMR (400 MHz, DMSO-
d6): δ 1.26−1.50 (m, 2H), 1.53−1.65 (m, 1H), 1.70−1.84 (m, 1H),
1.98 (t, J = 10.2 Hz, 1H), 2.12 (t, J = 10.0 Hz, 1H), 2.30−2.47 (m,
3H), 2.55−2.65 (m, 1H), 2.80 (d, J = 10.6 Hz, 1H), 3.09 (t, J = 6.7 Hz,
2H), 7.03−7.22 (m, 3H), 7.22−7.43 (m, 4H), 7.56 (dt, J = 8.9/2.3 Hz,
1H), 7.84 (d, J = 7.9 Hz, 1H) ppm. 13C NMR (126 MHz, DMSO-d6):
δ 24.0, 26.5, 41.0, 45.5, 53.3, 55.4, 56.4, 114.5 (d, 2JCF = 21.3 Hz),
116.5 (d, 2JCF = 24.7 Hz), 123.7, 126.7, 128.1, 130.0, 131.2, 133.0 (d,
3JCF = 8.7 Hz), 133.4 (d,
3JCF = 10.5 Hz), 134.4, 135.3 (d,
4JCF = 3.6
Hz), 135.6, 161.4 (d, 1JCF = 247.8 Hz), 175.1 ppm.
19F NMR (471
MHz, DMSO-d6): δ −112.61 (tdd, J = 8.8/6.3/2.4 Hz) ppm. MS (ESI
+) m/z: 404.3 [M + H]+. HRMS (ESI+): [M + H]+ calcd for
C21H24ClFN3O2, 404.1541; found, 404.1537.
(E)-1-(2-{2-[1-(4′-Chloro-4-fluorobiphenyl-2-yl)methylidene]-
hydrazinyl}ethyl)piperidine-3-carboxylic Acid (12ak). According
to GP1 from hydrazine 10 (8.91 mg, 47.6 μmol) and 11ak (11.2 mg,
47.6 μmol), 12ak was obtained as a yellow, amorphous solid (19.3 mg,
yield 100%). 1H NMR (400 MHz, DMSO-d6): δ 1.24−1.42 (m, 1H),
1.37−1.51 (m, 1H), 1.53−1.67 (m, 1H), 1.70−1.84 (m, 1H), 2.00 (t, J
= 10.3 Hz, 1H), 2.13 (tbr, J = 10.3 Hz, 1H), 2.38 (tt, J = 9.8/3.7 Hz,
1H), 2.44 (t, J = 6.6 Hz, 2H), 2.56−2.67 (m, 1H), 2.82 (dbr, J = 10.7
Hz, 1H), 3.15 (t, J = 6.5 Hz, 2H), 7.10 (td, J = 8.4/2.8 Hz, 1H), 7.25
(dd, J = 8.5/5.9 Hz, 1H), 7.29−7.37 (m, 3H), 7.38−7.48 (m, 1H),
7.48−7.54 (m, 2H), 7.52−7.56 (m, 1H) ppm. 13C NMR (101 MHz,
DMSO-d6): δ 23.9, 26.4, 41.0, 45.3, 53.2, 55.3, 56.3, 109.5 (d,
2JCF =
22.7 Hz) 113.7 (d, 2JCF = 22.1 Hz), 128.3 (2C), 129.7 (d,
4JCF = 2.7
Hz), 131.3 (2C), 132.1 (d, 3JCF = 8.7 Hz), 132.1, 134.1 (d,
4JCF = 2.5
Hz), 136.2, 137.8, 161.7 (d, 1JCF = 244.3 Hz), 175.0 ppm.
19F NMR
(471 MHz, DMSO-d6): δ −114.45 (m) ppm. MS (ESI+) m/z: 404.2
[M + H]+. HRMS (ESI+): [M + H]+ calcd for C21H24ClFN3O2,
404.1541; found, 404.1539.
[(E)-5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pent-1-
enyl] -4-methylbenzene Sulfonate (17) . Chlorobis -
(cyclopentadienyl)hydridozirconium (258 mg, 1.00 mmol) was
added to a mixture of pent-4-ynyl-4-methylbenzenesulfonate43 (2.38
g, 10.0 mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.41 g,
11.0 mmol). The mixture was stirred at room temperature for 48 h and
afterward diluted with CH2Cl2. The solution was filtered through a
short pad of silica gel (2 cm) and washed with CH2Cl2. The filtrate
was concentrated and dried in vacuo to give 17 as a colorless, high
viscous liquid (3.48 g, 95%). 1H NMR (400 MHz, CDCl3): δ 1.24 (s,
12H), 1.75 (p, J = 6.9 Hz, 2H), 2.15 (q, J = 6.9 Hz, 2H), 2.44 (s, 3H),
4.01 (t, J = 6.4 Hz, 2H), 5.33 (dt, J = 17.9/1.4 Hz, 1H), 6.47 (dt, J =
18.0/6.4 Hz, 1H), 7.33 (dd, J = 8.0/0.6 Hz, 2H), 7.77 (d, J = 8.4 Hz,
2H) ppm. 13C NMR (101 MHz, CDCl3): δ 21.6, 24.7 (4C), 27.3, 31.3,
69.8, 83.1 (2C), 120.0,47 127.9 (2C), 129.8 (2C), 133.0, 144.7, 151.7
ppm. MS (ESI+) m/z: 367.1 [M + H]+. HRMS (EI, 70 eV): M+ calcd
for C18H27BO5S, 366.1672; found, 366.1670.
Ethyl 1-[(E)-5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-
pent-1-enyl]piperidine-3-carboxylate (18). Ethyl nipecotate (1.96
g, 12.5 mmol) was added to [(E)-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)pent-4-enyl]-4-methylbenzene sulfonate (1.83 g,
5.00 mmol), and the mixture was stirred at room temperature for
16 h. Then water was added, and the aqueous phase was extracted with
CH2Cl2. The organic phase was washed with water and concentrated
under reduced pressure. The residue was dissolved in Et2O and filtered
through a short pad of silica gel (3 cm). The filtrate was concentrated
and dried in high vacuum to give 18 as a pale yellow liquid (1.62 g, 4.6
mmol, 92%). The product was used without further purification. 1H
NMR (400 MHz, CDCl3): δ 1.19−1.26 (m, 15H), 1.33−1.45 (m,
1H), 1.46−1.64 (m, 3H), 1.68 (dp, J = 10.4/3.5 Hz, 1H), 1.84−1.97
(m, 2H), 2.01−2.17 (m, 3H), 2.23−2.34 (m, 2H), 2.51 (tt, J = 10.6/
3.7 Hz, 1H), 2.72 (d, J = 11.1 Hz, 1H), 2.94 (d, J = 10.1 Hz, 1H), 4.09
(q, J = 7.2 Hz, 2H), 5.40 (d, J = 18.0 Hz, 1H), 6.60 (dt, J = 17.9/6.4
Hz, 1H) ppm. 13C NMR (101 MHz, CDCl3): δ 14.14, 24.53, 24.7
(4C), 25.3, 27.0, 33.6, 41.8, 53.7, 55.4, 58.2, 60.2, 82.9 (2C), 154.0,
174.2 ppm. MS (ESI+) m/z: 352 [M + H]+. HRMS (EI, 70 eV): M+
calcd for C19H34BNO4, 351.2580; found, 351.2572.
Ethyl 1-[(E)-5-(2-Bromophenyl)pent-1-enyl]piperidine-3-car-
boxylate (19). Under nitrogen atmosphere Pd(dppf)Cl2·CH2Cl2 (41
mg, 0.025 mmol), 1-bromo-2-iodobenzene (312 mg, 1.10 mmol), and
compound 18 (351 mg, 1.00 mmol) were dissolved in a mixture of
1,4-dioxane/water 2:1 (1.5 mL) and K2CO3 (414 mg, 3.00 mmol).
The resulting mixture was stirred at room temperature for 72 h. After
addition of water (5 mL) the mixture was extracted three times with
CH2Cl2 (10 mL). The combined organic layers were dried over
Na2SO4, and the solvent was removed in vacuo. The residue was
purified by flash column chromatography on silica gel (n-pentane/
CH2Cl2/EtOAc = 8/1/1 + 2% Et3N, Rf = 0.3) to give the 19 as a
colorless oil (342 mg, 90%). 1H NMR (400 MHz, CDCl3): δ 1.25 (t, J
= 7.1 Hz, 3H), 1.44 (qd, J = 12.2/4.0 Hz, 1H), 1.52−1.65 (m, 1H),
1.65−1.77 (m, 3H), 1.90−2.03 (m, 2H), 2.15 (t, J = 10.6 Hz, 1H,),
2.27 (q, J = 6.9 Hz, 2H), 2.37−2.43 (m, 2H), 2.57 (tt, J = 10.6/3.8 Hz,
1H), 2.79 (d, J = 11.0 Hz, 1H), 3.01 (d, J = 10.4 Hz, 1H), 4.13 (q, J =
7.1 Hz, 2H), 6.16 (dt, J = 15.6/6.9 Hz, 1H), 6.71 (d, J = 15.7 Hz, 1H),
7.05 (td, J = 7.9/1.5 Hz, 1H), 7.24 (td, J = 7.5/0.7 Hz, 1H), 7.48 (dd, J
= 7.8/1.4 Hz, 1H), 7.52 (dd, J = 8.0/0.7 Hz, 1H) ppm. 13C NMR (101
MHz, CDCl3): δ 14.2, 24.6, 26.3, 27.0, 30.9, 41.9, 53.8, 55.4, 58.2,
60.2, 123.1, 126.7, 127.3, 128.1, 128.9, 132.7, 133.5, 137.5, 174.2 ppm.
MS (CI, CH5
+) m/z: 381 [M + H]+. HRMS (EI, 70 eV): M+ calcd for
C19H26BrNO2, 379.1147; found, 379.1128.
Ethyl 1-[(E)-5-(2′-Fluorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylate (21c). According to the GP2 from 19
(114 mg, 0.300 mmol) and 20c (46 mg, 0.33 mmol), 21c was obtained
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as a slightly yellow oil (110 mg, 93%). 1H NMR (500 MHz, CDCl3): δ
1.24 (t, J = 7.1 Hz, 3H), 1.42 (qd, J = 11.9/3.6 Hz, 1H), 1.50−1.61 (m,
3H), 1.70 (dp, J = 13.0/3.7 Hz, 1H), 1.89−1.97 (m, 2H), 2.06−2.14
(m, 3H), 2.28−2.33 (m, 2H), 2.53 (tt, J = 10.7/3.8 Hz, 1H), 2.73 (d, J
= 11.1 Hz, 1H), 2.95 (d, J = 10.0 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H),
6.13 (dt, J = 15.7/6.7 Hz, 1H), 6.21 (d, J = 16.0 Hz, 1H), 7.13 (ddd, J
= 9.8/8.2/1.1 Hz, 1H), 7.18 (td, J = 7.4/1.1 Hz, 1H), 7.21−7.28 (m,
3H), 7.31−7.37 (m, 2H), 7.59 (d, J = 7.7 Hz, 1H) ppm. 13C NMR
(126 MHz, CDCl3): δ 14.2, 24.6, 26.4, 27.0, 31.0, 41.9, 53.8, 55.4,
58.2, 60.2, 115.5 (d, 2JCF = 22.4 Hz), 123.8 (d,
4JCF = 3.7 Hz), 125.3,
126.6, 128.0, 128.2, 128.5 (d, 2JCF = 16.3 Hz), 129.1 (d,
3JCF = 7.9 Hz),
130.5, 131.8, 132.1 (d, 3JCF = 3.5 Hz), 134.0, 136.5, 159.6 (d,
1JCF =
246.6 Hz), 174.3 ppm. MS (CI, CH5
+) m/z: 396 [M + H]+. HRMS
(EI, 70 eV): M+ calcd for C25H30FNO2, 395.2261; found, 395.2265.
Ethyl 1-[(E)-5-(2′,4′-Difluorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylate (21g). According to GP2 from 19 (114
mg, 0.300 mmol) and 20g (52 mg, 0.33 mmol), 21g was obtained as a
slightly yellow oil (113 mg, 91%). 1H NMR (500 MHz, CDCl3): δ
1.25 (t, J = 7.1 Hz, 3H), 1.42 (qd, J = 11.9/3.8 Hz, 1H), 1.49−1.64 (m,
3H), 1.71 (dp, J = 13.0/3.6 Hz, 1H), 1.89−1.97 (m, 2H), 2.05−2.16
(m, 3H), 2.28−2.35 (m, 2H), 2.54 (tt, J = 10.6/3.8 Hz, 1H), 2.74 (d, J
= 10.6 Hz, 1H), 2.97 (d, J = 10.5 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H),
6.08−6.22 (m, 2H), 6.87−6.97 (m, 2H), 7.17−7.23 (m, 2H), 7.27 (td,
J = 7.6/1.3 Hz, 1H), 7.35 (td, J = 7.6/1.2 Hz, 1H), 7.59 (d, J = 7.8 Hz,
1H) ppm. 13C NMR (126 MHz, CDCl3): δ 14.2, 24.6, 26.4, 27.0, 31.0,
41.9, 53.8, 55.5, 58.2, 60.3, 103.9 (dd, 2/2JCF = 26.4/25.2 Hz), 111.0
(dd, 2/4JCF = 21.0/3.8 Hz), 124.61 (dd,
2/4JCF = 16.6/3.8 Hz), 125.5,
126.7, 128.0, 128.2, 130.6, 132.1, 132.7 (dd, 3/3JCF = 9.5/5.0 Hz),
133.0, 136.7, 159.6 (dd, 1/3JCF = 249.2/11.9 Hz), 162.4 (dd,
1/3JCF =
248.4/11.5 Hz), 174.3 ppm. MS (CI, CH5
+) m/z: 414 [M + H]+.
HRMS (EI, 70 eV): M+ calcd for C25H29F2NO2, 413.2166; found,
413.2164.
Ethyl 1-[(E)-5-(2′-Chlorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylate (21p). According to the GP2 from 19
(114 mg, 0.300 mmol) and 20p (52 mg, 0.33 mmol), 21p was
obtained as a slightly yellow oil (115 mg, 93%). 1H NMR (500 MHz,
CDCl3): δ 1.24 (t, J = 7.1 Hz, 3H), 1.40 (qd, J = 11.7/3.7 Hz, 1H),
1.48−1.59 (m, 3H), 1.70 (dp, J = 13.1/3.6 Hz, 1H), 1.90 (m, 2H),
2.02−2.11 (m, 3H), 2.25−2.31 (m, 2H), 2.52 (tt, J = 10.6/3.8 Hz,
1H), 2.72 (d, J = 11.1 Hz, 1H), 2.94 (d, J = 10.4 Hz, 1H), 4.11 (q, J =
7.1 Hz, 2H), 6.02−6.15 (m, 2H), 7.15 (d, J = 7.5 Hz, 1H), 7.21−7.31
(m, 4H), 7.34 (t, J = 7.6 Hz, 1H), 7.43−7.47 (m, 1H), 7.59 (d, J = 7.8
Hz, 1H) ppm. 13C NMR (101 MHz, CDCl3): δ 14.2, 24.6, 26.4, 27.0,
31.0, 41.9, 53.8, 55.4, 58.2, 60.3, 125.0, 126.4 (2C), 128.0 (2C), 128.6,
129.4, 130.0, 131.6, 131.8, 133.5, 136.2, 137.6, 139.8, 174.3 ppm. MS
(CI, CH5
+) m/z: 412 [M + H]+. HRMS (EI, 70 eV): M+ calcd for
C25H30ClNO2, 411.1965; found, 411.1966.
Ethyl 1-[(E)-5-(2′,4′-Dichlorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylate (21z). According to the GP2 from 19
(114 mg, 0.300 mmol) and 20z (63 mg, 0.33 mmol), 21z was obtained
as a slightly yellow oil (123 mg, 92%). 1H NMR (400 MHz, CDCl3, 21
°C, TMS): δ 1.25 (t, J = 7.1 Hz, 3H), 1.42 (qd, J = 12.0/3.7 Hz, 1H),
1.49−1.62 (m, 3H), 1.71 (dp, J = 13.2/3.6 Hz, 1H), 1.89−1.97 (m,
2H), 2.05−2.13 (m, 3H), 2.27−2.32 (m, 2H), 2.53 (td, J = 10.6/5.3
Hz, 1H), 2.73 (d, J = 11.0 Hz, 1H), 2.96 (d, J = 10.6 Hz, 1H), 4.12 (q,
J = 7.1 Hz, 2H), 6.03 (d, J = 15.8 Hz, 1H), 6.13 (dt, J = 15.7/6.7 Hz,
1H), 7.12 (dd, J = 7.5/1.0 Hz, 1H), 7.17 (d, J = 8.2 Hz, 1H), 7.24−
7.31 (m, 2H), 7.36 (td, J = 7.7/1.0 Hz, 1H), 7.49 (t, J = 1.7 Hz, 1H),
7.59 (d, J = 7.8 Hz, 1H) ppm. 13C NMR (101 MHz, CDCl3): δ 14.2,
24.6, 26.4, 27.0, 31.0, 41.9, 53.8, 55.4, 58.2, 60.3, 125.2, 126.6, 126.8,
127.6, 128.3, 129.2, 129.9, 132.2, 132.4, 133.7, 134.4, 136.3, 136.4,
138.5, 174.3 ppm. MS (CI, CH5
+) m/z: 446 [M + H]+. HRMS (EI, 70
eV): M+ calcd for C25H29Cl2NO2, 445.1575; found, 445.1549.
Ethyl 1-[(E)-5-(2′-Chloro-4′-fluorobiphenyl-2-yl)pent-4-en-1-
yl]piperidine-3-carboxylate (21ah). According to the GP2 from 19
(114 mg, 0.300 mmol) and 20ah (58 mg, 0.33 mmol), 21ah was
obtained as slightly yellow oil (117 mg, 91%). 1H NMR (500 MHz,
CDCl3): δ 1.25 (t, J = 7.1 Hz, 3H), 1.42 (qd, J = 12.3/3.9 Hz, 1H),
1.51−1.61 (m, 3H), 1.71 (dp, J = 13.4/3.6 Hz, 1H), 1.89−1.97 (m,
2H), 2.04−2.14 (m, 3H), 2.25−2.33 (m, 2H), 2.53 (tt, J = 10.6/3.8
Hz, 1H), 2.72 (d, J = 10.8 Hz, 1H), 2.96 (d, J = 10.1 Hz, 1H), 4.12 (q,
J = 7.1 Hz, 2H), 6.03 (d, J = 15.8 Hz, 1H), 6.12 (dt, J = 15.6/6.7 Hz,
1H), 7.03 (td, J = 8.3/2.6 Hz, 1H), 7.12 (dd, J = 7.6/1.2 Hz, 1H),
7.18−7.28 (m, 3H), 7.35 (td, J = 7.7/1.1 Hz, 1H), 7.58 (d, J = 7.5 Hz,
1H) ppm. 13C NMR (126 MHz, CDCl3): δ 14.2, 24.6, 26.3, 27.0, 31.0,
41.8, 53.8, 55.4, 58.1, 60.2, 113.8 (d, 2JCF = 20.9 Hz), 116.6 (d,
2JCF =
24.5 Hz), 125.1, 126.5, 127.7, 128.2, 130.1, 132.0, 132.5 (d, 3JCF = 8.6
Hz), 134.2 (d, 3JCF = 10.3 Hz), 136.0 (d,
4JCF = 3.4 Hz), 136.4, 136.6,
161.7 (d, 1JCF = 249.3 Hz), 174.2 ppm. MS (ESI+) m/z: 430 [M +
H]+. HRMS (EI, 70 eV): M+ calcd for C25H29ClFNO2, 429.1871;
found, 429.1875.
1-[(E)-5-(2′-Fluorobiphenyl-2-yl)pent-4-en-1-yl]piperidine-3-
carboxylic Acid (13c). According to GP3 from 21c (79 mg, 0.20
mmol), 13c was obtained as a slightly yellow solid (63 mg, 86%). 1H
NMR (400 MHz, 0.1 M NaOD/CD3OD = 1/2, 60 °C): δ 1.37 (qd, J
= 12.7/4.1 Hz, 1H), 1.52−1.75 (m, 4H), 1.91 (td, J = 11.6/2.5 Hz,
1H), 2.02 (m, 2H), 2.11 (q, J = 7.1 Hz, 2H), 2.29−2.45 (m, 3H), 2.86
(d, J = 10.6 Hz, 1H), 3.11 (d, J = 9.8 Hz, 1H), 6.09−6.26 (m, 2H),
7.16−7.23 (m, 2H), 7.23−7.33 (m, 3H), 7.37 (t, J = 7.6 Hz, 1H),
7.40−7.48 (m, 1H), 7.61 (d, J = 7.9 Hz, 1H) ppm. 13C NMR (101
MHz, NaOD/CD3OD = 1/2, 60 °C): δ 25.8 26.8, 29.4, 32.0, 46.3,
54.8, 58.2, 59.5, 116.4 (d, 2JCF = 22.5 Hz), 125.1 (d,
4JCF = 3.8 Hz),
126.6, 127.7, 129.1, 129.7, 130.0 (s, 2JCF = 16.7 Hz), 130.5 (d,
3JCF =
7.9 Hz), 131.3, 132.8, 133.0 (d, 3JCF = 3.4 Hz), 135.5, 138.0, 161.0 (d,
1JCF = 244.7 Hz), 182.9 ppm. MS (CI, CH5
+) m/z: 368 [M + H]+.
HRMS (EI, 70 eV): M+ calcd for C23H26FNO2, 367.1948; found,
367.1949. Purity: 98.5% (HPLC).
1-[(E)-5-(2′ ,4′-Difluorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylic Acid (13g). According to the GP3, starting
from 21g (83 mg, 0.20 mmol), 13g was obtained as a slightly yellow
solid (68 mg, 88%). 1H NMR (400 MHz, 0.1 M NaOD/CD3OD = 1/
1, 60 °C): δ 1.25 (qd, J = 12.7/4.2 Hz, 1H), 1.35−1.52 (m, 3H), 1.58
(d, J = 13.5 Hz, 1H), 1.68 (td, J = 11.7/2.3 Hz, 1H), 1.80−1.98 (m,
4H), 2.04−2.14 (m, 1H), 2.14−2.26 (m, 1H), 2.33 (tt, J = 12.0/3.8
Hz, 1H), 2.63 (d, J = 10.1 Hz, 1H), 2.96 (d, J = 11.1 Hz, 1H), 5.90−
6.07 (m, 2H), 6.65−6.75 (m, 2H), 6.85−6.95 (m, 2H), 6.99 (t, J = 7.5
Hz, 1H), 7.12 (t, J = 7.4 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H) ppm. 13C
NMR (101 MHz, 0.1 M NaOD/CD3OD = 1/1, 60 °C): δ 25.1, 25.9,
28.7, 31.5, 45.6, 53.6, 57.4, 58.7, 104.4 (d, 2JCF = 26.5 Hz), 111.8 (d,
2JCF = 21.2,
3JCF = 3.5 Hz), 125.4 (dd,
2/4JCF = 16.6/3.1 Hz), 126.4,
127.4, 128.6, 129.1, 131.1, 133.1, 133.28 (dd, 3/3JCF = 9.5/5.0 Hz),
133.6, 137.3, 160.2 (dd, 1/3JCF = 247.2/11.3 Hz), 163.0 (dd,
1/3JCF =
247.7/11.4 Hz), 183.4 ppm. MS (CI, CH5
+) m/z: 386 [M + H]+.
HRMS (EI, 70 eV): M+ calcd for C23H25F2NO2, 385.1853; found,
385.1853. Purity: 100% (HPLC).
1-[(E)-5-(2′-Chlorobiphenyl-2-yl)pent-4-en-1-yl]piperidine-
3-carboxylic Acid (13p). According to the GP3, starting from 21p
(82 mg, 0.20 mmol), 13p was obtained as a slightly yellow solid (67
mg, 87%). 1H NMR (400 MHz, 0.1 M NaOD/CD3OD = 2/1, 60 °C,
MeOH): δ 1.24 (qd, J = 12.8/4.2 Hz, 1H), 1.32−1.51 (m, 3H), 1.57
(d, J = 13.2 Hz, 1H), 1.66 (td, J = 11.5/2.1 Hz, 1H), 1.74−1.98 (m,
4H), 2.00−2.11 (m, 1H), 2.11−2.23 (m, 1H), 2.32 (tt, J = 11.5/3.4
Hz, 1H), 2.61 (d, J = 10.8 Hz, 1H), 2.94 (d, J = 9.6 Hz, 1H), 5.88−
5.99 (m, 2H), 6.83 (d, J = 7.4 Hz, 1H), 6.89−6.97 (m, 2H), 6.99−7.11
(m, 3H), 7.23 (d, J = 7.1 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H) ppm. 13C
NMR (101 MHz, 0.1 M NaOD/CD3OD = 2/1, 60 °C, MeOH): δ
25.1, 26.0, 28.7, 31.6, 45.5, 53.6, 57.5, 58.7, 126.1, 127.3, 127.5, 128.7,
128.9, 129.7, 130.1, 130.6, 132.3, 132.7, 133.9, 136.8, 138.3, 140.5,
183.4 ppm. MS (CI, CH5
+) m/z: 384 [M + H]+. HRMS (EI, 70 eV):
M+ calcd for C23H26ClNO2, 383.1652; found, 383.1635. Purity: 100%
(HPLC)
1-[(E)-5-(2′,4′-Dichlorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylic Acid (13z). According to GP3 from 21z
(89 mg, 0.20 mmol), 13z was obtained as a slightly yellow solid (75
mg, 90%). 1H NMR (400 MHz, 0.1 M NaOD/CD3OD = 2/1, 60 °C):
δ 1.28 (qd, J = 12.4/3.8 Hz, 1H), 1.40−1.54 (m, 3H), 1.60 (d, J = 12.8
Hz, 1H), 1.71 (t, J = 11.3 Hz, 1H), 1.80−2.01 (m, 4H), 2.04−2.16 (m,
1H), 2.22 (m, 1H), 2.34 (tt, J = 11.6/3.6 Hz, 1H), 2.66 (d, J = 10.4
Hz, 1H), 2.99 (d, J = 10.9 Hz, 1H), 5.88−6.03 (m, 2H), 6.81 (d, J =
7.4 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), 6.93−7.04 (m, 2H), 7.13 (t, J =
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7.4 Hz, 1H), 7.24 (s, 1H), 7.42 (d, J = 7.7 Hz, 1H). 13C NMR (101
MHz, 0.1 M NaOD/CD3OD = 2/1, 60 °C): δ 25.4, 26.3, 28.9, 31.8,
45.7, 54.1, 57.9, 59.0, 126.4, 127.4, 127. 7, 128.6, 129.2, 129.8, 130.5,
133.2, 133.3, 134.4, 135.0, 137.1, 137.2, 139.5, 183.1 ppm. MS (CI,
CH5
+) m/z: 418 [M + H]+. HRMS (EI, 70 eV): M+ calcd for
C23H25Cl2NO2, 417.1262; found, 417.1257. Purity: 99.2% (HPLC).
1-[(E)-5-(2′-Chloro-4′-fluorobiphenyl-2-yl)pent-4-en-1-yl]-
piperidine-3-carboxylic Acid (13ah). According to GP3 from 21ah
(86 mg, 0.20 mmol), 13ah was obtained as a slightly yellow solid (75
mg, 90%). 1H NMR (400 MHz, NaOD/CD3OD = 1/2, 60 °C): δ 1.36
(qd, J = 12.6/4.1 Hz, 1H), 1.51−1.65 (m, 3H), 1.71 (dp, J = 13.5/3.3
Hz, 1H), 1.89−2.00 (m, 2H), 2.01−2.13 (m, 3H), 2.27−2.44 (m, 3H),
2.84 (d, J = 11.0 Hz, 1H), 3.06 (d, J = 11.3 Hz, 1H), 6.00−6.17 (m,
2H), 7.11 (dd, J = 7.6/1.0 Hz, 1H), 7.18 (td, J = 8.4/2.5 Hz, 1H),
7.21−7.27 (m, 1H), 7.28−7.36 (m, 2H), 7.40 (td, J = 7.4/1.0 Hz, 1H),
7.61 (d, J = 7.3 Hz, 1H) ppm. 13C NMR (101 MHz, NaOD/CD3OD
= 1/2, 60 °C): δ 25.2, 26.0, 28.8, 31.7, 45.7, 54.3, 57.5, 58.9, 115.0 (d,
2JCF = 21.3 Hz), 117.3 (d,
2JCF = 25.2 Hz), 126.4, 127.7, 128.9, 129.3,
130.8, 133.1, 133.6 (d, 3JCF = 8.8 Hz), 134.9 (s,
3JCF = 10.2 Hz), 137.3,
137.5, 137.8, 163.0 (s, 1JCF = 248.2 Hz), 182.9 ppm. MS (ESI+) m/z:
402 [M + H]+. HRMS (EI, 70 eV): M+ calcd for C23H25ClFNO2,
401.1558; found, 401.1558. Purity: 98.0% (HPLC).
Aldehydes. Detailed synthesis protocols for aldehydes are found in
the Supporting Information.
MS Binding Experiments. mGAT1 Membrane Preparation.
Membrane preparations of HEK293 cells stably expressing mGAT148
were prepared as described previously and stored at −80 °C.25,49 On
the day of the assay, an aliquot was rapidly thawed and diluted in a 20-
fold volume of cold aqueous 0.9% NaCl (m/v). After centrifugation at
15 000 rpm and 4 °C for 20 min (CP56GII, P70AT, Hitachi Ltd.,
Tokyo, Japan), the pellet was resuspended in ice-cold assay buffer (see
below) to a protein concentration of approximately 0.1 mg/mL49 as
previously described.28
Library Screening. Library screening experiments were performed
as reported.28 In short, quadruplicate samples in a total volume of 250
μL were employed. Phosphate buffer, pH 7.1 (12.5 mM
Na2HPO4·2H2O, 12.5 mM NaH2PO4·H2O, 1 M NaCl adjusted with
2 M NaOH), was used as incubation buffer. Each sample contained 1%
DMSO as final concentration. All solutions were added as 10-fold
concentrated stock solutions. Aldehydes were present at 10 μM in the
sample, hydrazine 10 at 100 μM. By addition of the mGAT1
membrane preparation, directly after combining hydrazine and
aldehydes, a first incubation period of 4 h (for library generation) at
37 °C in a shaking water bath was started. The second incubation
period of 40 min was started by addition of the MS marker 6 (20 nM
final concentration in the sample). The binding experiment was
stopped by a vacuum filtration step (96-well filter plate, Acroprep,
glass fiber, 1.0 μm, 350 μL, Pall, Dreieich, Germany, 12-channel pipet).
After multiple washing steps with ice-cold aqueous 1 M NaCl, the filter
was dried (60 min, 50 °C) and cooled to room temperature.
Subsequently the marker was liberated by elution of the filter plate
with MeOH into a 96-deep-well plate. Each sample was supplemented
with 200 μL of 1 nM [2H10]NO711 (in MeOH) as internal standard.
For calibration, matrix blank samples (produced analogously in
absence of NO711) were supplemented with 200 μL of methanolic
calibration standards, 50 pM, 100 pM, 500 pM, or 1 nM NO711, and
200 μL of 1 nM [2H10]NO711 (in MeOH). All samples were dried to
completeness (50 °C). For quantification by LC−ESI-MS/MS,
samples were reconstituted in 200 μL of 10 mM ammonium formate
buffer (pH 7.0)/MeOH (95:5, v/v).
As stated before, each library screening experiment included
samples characterizing the pure aldehyde libraries and the pure
hydrazine 10, as well as matrix blanks and zero samples. Total binding
and nonspecific binding of NO711 were determined as previously
described.28 If the nonspecific binding of the 20 nM NO711
concentration employed was less than 50 pM, the value was
extrapolated by linear regression of the nonspecific binding of
NO711 concentrations, >20 nM.
By employment of the results obtained for the calibration samples,
calibration curves for marker quantitation were generated.
Deconvolution Experiments. The deconvolution experiments
were carried out in the same way28 as described for library screening
except that the single aldehyde (10 μM per sample) was applied
instead of the mixture of four aldehydes.
Competition Experiments Applying Pure Hydrazones. These
experiments were performed as recently described,25,49 applying the
incubation buffer as described for “Library Screening”.
LC−ESI-MS/MS. The methanolic eluates were dried and
reconstituted with 10 mM ammonium formate buffer (pH 7.0)/
methanol (95:5, v/v). Quantitation by LC−ESI-MS/MS was
performed as described utilizing a API 3200 triple-quadrupole mass
spectrometer.25,49
Analysis of Binding Experiments. Marker depletion was
negligible (<10%) in all binding experiments. Specific binding was
defined as the difference between total and nonspecific binding. A
nonspecific binding less than 50 pM was not determined
experimentally but extrapolated by linear regression for nonspecifically
bound NO711 concentrations of ≥50 pM. The concentration of a
competitor that inhibits 50% of specific binding (IC50) was calculated
from competition curves, plotting specifically bound NO711
concentrations vs log competitor concentration (eight different
concentrations per competitor) with Prism 4.02 (GraphPad Software,
San Diego, CA, U.S.) using the equation for one-site competition and
nonlinear curve fitting. Specific binding determined for control
samples in the absence of any competitor was set to 100%, whereas
the bottom level was set to 0% (corresponds to the nonspecific
binding of the employed NO711 concentration). Ki values were
calculated according to Cheng and Prussoff50 and were expressed as
pKi values. All results are expressed as the mean ± SEM (unless stated
otherwise). pKi values were determined in at least three separate
experiments.
GABA Uptake Assays. [3H]GABA uptake assays were performed
as previously described.48
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Development of Highly Potent GAT1 Inhibitors: Synthesis
of Nipecotic Acid Derivatives with N-Arylalkynyl
Substituents
Toni Lutz, Thomas Wein, Georg Hçfner, and Klaus T. Wanner*[a]
Introduction
Epilepsy is a major chronic disease of the central nervous
system (CNS) that affects 50 million people worldwide regard-
less of age and socioeconomic status.[1] Besides current seiz-
ures, affected individuals are often exposed to stigma and dis-
crimination. More than 15 different approved antiepileptic
drugs available to date are still inadequate, as more than half
of treated patients either suffer from adverse side effects or
continue to have seizures.[2] To provide an appropriate medical
supply for all affected patients, there is an ongoing need for
additional exploration of new antiepileptic drugs.
g-Aminobutyric acid (GABA, 1, Figure 1) is the major inhibi-
tory neurotransmitter in the CNS.[3] An imbalance between the
excitatory neurotransmission mediated by glutamate and the
inhibitory neurotransmission effected by GABA due to de-
creased GABAergic signaling[4] is thought to be a major factor
in the pathogenesis of epilepsy.[1, 5] Various pharmacological
mechanisms have been successfully followed to enhance
GABA neurotransmission for the treatment of epilepsy. As GA-
BAergic neurotransmission is terminated by specific GABA
transport proteins responsible for the reuptake of GABA into
the presynaptic neuron or its transport into glia cells,[6] the in-
hibition of GABA transporters (GATs) is a viable strategy for im-
proving GABA signaling,[7] besides drugs that target GABA re-
ceptors or metabolic enzymes responsible for the degradation
of GABA.[4]
GABA transporters are membrane-bound proteins that
belong to the solute carrier family 6 (SLC-6),[8] which are pres-
ent in four different subtypes termed mGAT1, mGAT2, mGAT3,
and mGAT4 when cloned from mice. Different nomenclature is
used for other species. The human GATs are designated GAT1,
BGT1, GAT2, and GAT3 by the human genome organization
(HUGO); these correspond to mGAT1, mGAT2, mGAT3, and
mGAT4, respectively.[7] Of these, GAT1 (GAT1/mGAT1) is locat-
ed mainly on presynaptic neurons and is the most abundant
GABA transporter in the brain.[9]
The first generation of GAT inhibitors reported includes
cyclic analogues of GABA such as (R)-nipecotic acid (2,
Figure 1).[10] Although they exhibit reasonable affinity for and in
vitro potency toward mGAT1 (pKi=4.50:0.05),
[11] these com-
pounds were of limited utility for pharmacological treatment
owing to their inability to cross the blood–brain barrier
(BBB).[12] However, providing nipecotic acid and related com-
pounds with a lipophilic side chain resulted in compounds
such as tiagabine (3, Figure 1) and SKF-88976A (4,
Figure 1),[13,14] which are able to cross the BBB; moreover, they
were found to have substantially improved potency at and
subtype selectivity for GAT1.[11]
We recently introduced compounds 5 and 6 (Figure 1) and
related derivatives, the lipophilic part of which is characterized
by a biphenylvinyl or a benzylphenylvinyl unit. For the parent
compounds 5 and 6, high binding affinities for GAT1 were ob-
served (5 : pKi=7.15:0.07; 6 : pKi=6.16:0.07).
[15] For the bi-
phenyl derivative 5, docking studies indicated that halogen
substitution of the terminal phenyl group might provide com-
pounds with enhanced binding affinities for hGAT1; this was
indeed verified, as halogen-substituted derivatives of 5 were
found to exhibit binding affinities of pKi+8. As an extension of
the aforementioned studies, we intended to explore the bind-
ing affinities of compounds clearly related to 5 and its deriva-
tives, but which have an alkynyl instead of an alkenyl spacer,
[a] T. Lutz, Dr. T. Wein, Dr. G. Hçfner, Prof. Dr. K. T. Wanner
Department for Pharmacy, Center for Drug Research, Ludwig-Maximilians-
Universit-t Menchen, Butenandtstr. 7–13, 81377 Munich (Germany)
E-mail : klaus.wanner@cup.uni-muenchen.de
Supporting information for this article can be found under:
http://dx.doi.org/10.1002/cmdc.201600599.
A new scaffold of highly potent and mGAT1-selective inhibitors
has been developed. Compounds in this class are characterized
by an alkyne-type spacer connecting nipecotic acid with an ar-
omatic moiety. Preliminary evaluations made it apparent that
a nipecotic acid derivative with an N-butynyl linker and a termi-
nal 2-biphenyl residue exhibiting a binding affinity (pKi) of
7.61:0.03 to mGAT1 and uptake inhibition (pIC50) of 7.00:
0.06 selective for mGAT1 could serve as a hit compound. Dock-
ing calculations for compounds based on this structure in an
hGAT1 homology modeling study indicated binding affinities
similar to or even higher than that of the well-known mGAT1
inhibitor tiagabine. Synthesis of the designed compounds was
readily carried out by two consecutive cross-coupling reac-
tions, giving flexible access to variously substituted biphenyl
subunits. With an appropriate substitution pattern of the bi-
phenyl moiety, the binding affinity of enantiopure (R)-nipecotic
acid derivatives to mGAT1 increased to pKi=8.33:0.01, and
the uptake inhibitory potency up to pIC50=7.72:0.02.
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that is, N-substituted nipecotic acid exhibiting various N-arylal-
kynyl residues. A preliminary evaluation revealed the present
compound 17a, with a 2-biphenylbut-3-ynyl moiety (Table 2,
entry 1) to possess a binding affinity for mGAT1 of pKi=7.61:
0.03 and a functional inhibitory activity of pIC50=7.00:0.06,
thus surpassing analogous biphenyl derivative 5 (Figure 1) in
affinity and potency. Docking studies with homology models
for hGAT1 performed with 17a and derivatives substituted at
the terminal aromatic residue revealed a possible increase in
affinity for these compounds over analogous derivatives of
compound 5.
For the efficient preparation of these compounds, we de-
signed a linear synthetic route that makes use of two succes-
sive cross-coupling reactions as key steps. This also preserves
a high degree of flexibility with regard to the substitution pat-
tern of the terminal phenyl residue. The new ligands of nipe-
cotic acid as a whole should then also be inert toward hydroly-
sis and oxidation, advantageous features absent from many
similar potent GAT1 inhibitors.[16,17]
Results and Discussion
Homology modeling
Previous studies by Wein et al.[11] and Petrera et al.[15] have
shown that docking into an hGAT1 model generated by ho-
mology modeling from the X-ray crystallographic structure of
the leucine transporter from Aquifex aeolicus[18] (LeuT, PDB ID:
2A65) featuring a “closed” protein conformation provides
a solid base for interpretation of various binding modes and
biological binding data. This structure of LeuT includes a sub-
strate molecule leucine trapped in the active site, called the S1
site. This S1 site is closed to the outside by a lipophilic pair of
amino acids, phenylalanine and tyrosine, and a salt bridge be-
tween aspartate and arginine and is therefore not accessible
directly from the extracellular medium. Another LeuT X-ray
structure includes two tryptophan molecules which are located
in the S2 above the S1 site oriented toward the extracellular
medium, thus keeping the S1 site open to the outside (PDB
ID: 3F3A).[19] This “open-to-out” structure has been used as
starting point for homology calculations as well, but did not
yield hGAT1 models with significant prediction potential.
To investigate the binding affinities of nipecotic acid deriva-
tives with an N-alkynyl residue with a terminal triple bond and
a biphenyl residue attached to the amino nitrogen atom, we
performed docking calculations with our hGAT1 homology
model described previously[11] and with compounds (R)-17a–
l (Table 2, entries 1–11) characterized by an N-but-3-ynyl
spacer, and (R)-18a–l (Table 2, entries 12–22) by an N-pent-4-
ynyl spacer as ligands. The obtained docking scores for com-
pounds (R)-17a (@11.82 kcalmol@1) and (R)-18a (@11.58 kcal
mol@1), representing the parent structures as well as for the re-
spective substituted analogues (R)-17b–l (in the range of
@11.27 to @12.53 kcalmol@1) and (R)-18b–l (@11.30 to
@12.30 kcalmol@1) were mostly comparable to the scoring
value of tiagabine (3, Figure 1; @11.96 kcalmol@1). However, de-
pending on the substitution pattern of the biphenyl residue,
partly higher and lower docking values were found. According
to the scoring values, nipecotic acid derivatives (R)-17a–l with
a but-3-ynyl spacer should generally possess higher binding af-
finities than the homologous compounds (R)-18a–l, exhibiting
a pent-4-ynyl spacer.
Compound (R)-17 f (Table 2, entry 6a) containing a but-3-
ynyl spacer with a terminal dichloro-substituted biphenyl
moiety (2’=4’=Cl) appears to possess the highest docking
score (@12.53 kcalmol@1), which is higher than that of tiaga-
bine (3, @11.96 kcalmol@1) and also higher than the corre-
sponding compound (R)-18 f (@12.30 kcalmol@1) with a longer
linker. Visual inspection of the docking poses of tiagabine (3),
(R)-17 f, and (R)-18 f reveal almost identical interactions of the
compounds with the hGAT1 protein (Figure 2): the carboxyl
group interacts mainly with the sodium atom Na1 and forms
additional hydrogen bonds with the backbone NH groups of
Leu64 and Gly65. The lipophilic portions interact with Leu64,
Trp68, Arg69, Leu136, Tyr140, Thr290, Gln291, Phe294, and
Ala455, where the dichloro-substituted biphenyl moieties of
(R)-17 f and (R)-18 f are both in the same orientation and posi-
tion. The side chain of Arg69 forms a cation–p interaction with
one of the lipophilic rings of tiagabine or with the terminal
phenyl group of the compounds (R)-17 f and (R)-18 f. The ob-
tained hydrogen bonds between the NH group of the nipecot-
ic acid moiety and the main chain oxygen atom of Phe294 are
significantly different. For tiagabine and (R)-17 f, the distance
of the NH to the oxygen atom is 1.7 and 1.9 a, respectively. In
Figure 1. Structure of GABA and known GAT1 inhibitors derived from nipecotic acid (values refer to mGAT1[11]).
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the case of compound (R)-18 f the NH@O distance is increased
to 2.3 a, and is therefore slightly too long for a perfect hydro-
gen bond; this is a possible reason for the lower docking score
of (R)-18 f than that of (R)-17 f. This unfavorable docking pose
of (R)-18 f is likely to be a result of the strong interactions of
the carboxyl group of (R)-18 f which is trapped in the strong
hydrogen bond network with Na1, Leu64, and Gly65, and the
multiple interactions of the lipophilic regions, forcing it to
adopt a similar position as the lipophilic portions in tiagabine
and (R)-17 f. However, the 5-biphenylpent-4-ynyl linker is then
apparently too long to allow a pose necessary for a reasonable
hydrogen bond between the NH group and the carbonyl
oxygen atom of Phe294.
Chemistry
For the synthesis of the desired nipecotic acid derivatives
17a–l and 18a–l with an N-but-3-ynyl and an N-pent-4-ynyl
residue with a terminal 2-benzylphenyl or 2-biphenyl moiety,
we intended to start from the N-alkynyl-substituted com-
pounds 7 and 8 (Scheme 1). A Sonogashira reaction of these
compounds with the respective aryl halides was expected to
give access to the esters 9, 10, 15, and 16 (Scheme 1), respec-
tively, with a lipophilic aryl subunit attached to the alkyne ter-
minus. In addition, a more flexible approach with regard to the
variation of the substitution pattern of the terminal phenyl
group of the biphenyl moiety of 15a and 16a should be es-
tablished. This was thought to be best achieved by a stepwise
construction of the biphenyl subunit of a biphenyl residue car-
rying nipecotic acid derivatives 15b–l and 16b–l. In other
words, first the monoaryl derivatives 13 and 14 (Scheme 1)
should be synthesized, which upon a Suzuki–Miyaura reaction
with phenyl boronic acids, the structures of which could be
freely chosen, would give the biphenyl-substituted nipecotic
acid derivatives 15b–l and 16b–l. Upon subsequent hydrolysis
of the ester function of the benzylphenyl and biphenyl resi-
dues containing nipecotic acid esters, the free nipecotic acid
Figure 2. Best docking pose of A) tiagabine, B) 17 f and C) 18 f in the “closed” site of hGAT1: tiagabine in cyan, 17 f in magenta, and 18 f in yellow. TM10–
TM12, Thr290, Gln291, and Ala455 are not displayed for clarity. The hydrogen bond from NH to Phe294 C=O is shown with a red dotted line, and the NH@O
distance is given in a.
Scheme 1. Synthesis of GAT inhibitors with N-arylalkynyl residues. Reagents
and conditions : a) 2-iododiphenylmethane (1.0 equiv), Pd(dppf)2Cl2·CH2Cl2
(5 mol%), CuI (20 mol%), K3PO4, dioxane/H2O (1:1), 60 8C, 3 h; b) NaOH (2m),
EtOH, RT, 6 h; c) 2-bromoiodobenzene (1.0 equiv), Pd(dppf)2Cl2·CH2Cl2
(5 mol%), CuI (20 mol%), K2CO3, dioxane/H2O, 60 8C, 3 h; d) 2-iodobiphenyl
(1.0 equiv), Pd(dppf)2Cl2·CH2Cl2 (5 mol%), CuI (20 mol%), K3PO4, dioxane/H2O
(2:1), 60 8C, 3 h; e) phenylboronic acid derivative (1.5 equiv), Pd2(dba)3·CHCl3
(1 mol%), S-Phos (4 mol%), K3PO4, dioxane/H2O (1:1), 60 8C, 6 h.
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derivatives 11, 12, 17a–l, and 18a–l should finally be accessi-
ble.
When subjected to Sonogashira reaction, the two N-alkynyl-
substituted nipecotic acid derivatives 7 and 8 underwent the
coupling reactions as expected. These coupling reactions were
performed by heating the starting material, i.e. , 7 and 8 to-
gether with 20 mol% CuI, 5 mol% Pd(dppf)Cl2·CH2Cl2, and
K2CO3 or K3PO4 with 1.0 equiv of the respective aryl halide in
dioxane/water for 3 h at 60 8C. That way with all three aryl hal-
ides used, i.e. , with 2-iododiphenylmethane, 2-iodobiphenyl,
and 2-bromoiodobenzene, the corresponding coupling prod-
ucts 9 and 10, 13, and 14, as well as 15a and 16a, respective-
ly, could be obtained in good yields (75–84%; Scheme 1). The
building blocks 13 and 14 designed for subsequent Suzuki–
Miyaura reactions, via the aryl bromide function present in
these molecules, for the construction of the terminal biphenyl
residue, were found to be well suited for this purpose. Cou-
pling reactions were performed with a set of phenylboronic
acids carrying one to two additional substituents which were
either chlorine, fluorine, or methyl, by which a substitution pat-
tern has been gained similar to that studied for analogous sys-
tems previously, such as compound 5 (Figure 1).[15]
Pd2(dba)3·CHCl3 (1 mol%) and S-Phos (4 mol%) as catalyst sys-
tems were found to be well suited to effect the desired cou-
pling reactions, providing coupling products 15b–l and 16b–
l after heating for 6 h at 60 8C in dioxane/water in the presence
of K3PO2 in good yields (87–93%). The free nipecotic acid de-
rivatives 11–12, 17a–l, and 18a–l were finally obtained by
basic hydrolysis of the carboxylic acid ester functions of the
precursors 9–10, 15a–l, and 16a–l, with yields ranging from
86 to 93% (Scheme 1).
Biological evaluations
For all free nipecotic acid derivatives synthesized in the con-
text of this study, binding affinities for mGAT1 were deter-
mined in MS Binding Assays with NO711 as MS marker.[20] In
addition, their functional activity was established in uptake
assays at the four GABA transporter subtypes mGAT1–mGAT4
with an assay system based on HEK293 cells stably expressing
the individual mouse GABA transporters.[21] When NO711 bind-
ing or GABA uptake was decreased by at least by 50% at a con-
centration of 100 mm, affinity in binding assays (pKi values) or
inhibitory potencies in uptake assays (pIC50 values) were as-
sessed, otherwise only the percentage of decrease in binding
or uptake was noted.
At first, the influence of the structure of the diaryl moiety at-
tached to the N-alkynyl linker of the test compounds on the
biological activity was analyzed. As can be seen from a compar-
ison of the parent compounds 11 and 17a, both possessing
a C4 linker, the former, however, a terminal 2-benzylphenyl,
and the latter, a 2-biphenyl moiety, the 2-biphenyl moiety
gives rise to a distinctly higher binding affinity, of more than
one log unit, at mGAT1 (Table 1, entry 1, 11, pKi=6.49:0.03;
Table 2, entry 1, 17a, pKi=7.61:0.03). A similar situation was
found for the homologous compounds 12 and 18a with a C5
instead of C4 spacer. Again, the biphenyl derivative 18a
showed a higher affinity for mGAT1 (Table 2, entry 12, pKi=
6.16:0.02) than compound 12 with a 2-benzylphenyl residue
(Table 1, entry 2, pKi=5.66:0.04), although in this case, the
difference was less pronounced. In addition, it was apparent
that the shorter C4 linker is more favorable than the longer C5
for high binding affinity (pKi) at mGAT1.
With regard to the influence of the diaryl moiety on the
binding affinity, these results are in good agreement with
those reported for the analogous system with a C=C double
bond instead of a C/C triple bond in the C4 linker. Also, in that
case with a pKi value of 7.15:0.07, the affinity for mGAT1 of
the biphenyl derivative 5 (Figure 1) was distinctly higher than
that of the corresponding derivative 6 (Figure 1), the pKi of
which amounted to 6.16:0.07. Finally, the inhibitory potencies
(pIC50 values) of 11, 12, 17a, and 18a at mGAT1 were found to
be in good agreement with the binding affinities (pKi values)
determined for this transporter. Moreover, the determination
of inhibitory potencies of these compounds at mGAT2–mGAT4
revealed that they all exhibit high subtype selectivity in favor
of mGAT1, pIC50 values for mGAT1, pIC50 values for mGAT3–
mGAT4 being only around 4.50 and below.
Because of the lower biological activities of the 2-benzyl-
phenyl-residue-carrying compounds 11 and 12 as compared
with the analogous 2-biphenyl derivatives 17a and 18a, only
derivatives of the latter were studied next. Because of the re-
sults obtained in a study of the structure–activity relationship
of 5,[15] substitution was limited to the ortho (2’) and para (4’)
positions of the terminal phenyl residue. In the case of the ni-
pecotic acid derivative 18a having the C5 spacer, substitution
of the terminal phenyl residue had only minor effects on the
already relatively low mGAT1 affinity (pKi=6.16:0.02, Table 2,
entry 12). When 18a was substituted with chlorine, fluorine, or
a methyl group at the ortho position, only a slight tendency
toward higher pKi values (&6.3, Table 2, entries 13–15) could
be observed. In contrast, substitution of 18a with a chlorine at
Table 1. GAT inhibitors with a diphenylmethane moiety and their inhibi-
tory potencies at mGAT1–4 and binding affinities for mGAT1.
Entry Compd n pKi
[a] pIC50
[b]
mGAT1 mGAT1 mGAT2 mGAT3 mGAT4
1 11 1 6.49:0.03 5.87:0.06 70% 66% 57%
2 12 2 5.66:0.04 5.13:0.08 4.11 4.50 4.44
[a] Data are the mean:SEM of three independent experiments, each per-
formed in triplicate. [b] Values are the mean:SEM of three (mGAT1) or
one (mGAT2–4) independent experiment, each performed in triplicate;
percentages are the remaining [3H]GABA uptake in the presence of
100 mm inhibitor.
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the para position, exhibited a slight tendency toward lower
mGAT1 binding affinities (pKi=6.07:0.01, Table 2 entry 16).
Upon substitution of the distal phenyl residue in the 2’- and
4’-positions with two halogens (2’-Cl, 4’-Cl ; 2’-F, 4’-F; 2’-Cl, 4’-F)
or with a 2’-methyl group and a 4’-chloro, mGAT1 affinity in-
creased slightly further (pKi&6.4–6.5, Table 2, entries 17, 18, 20,
21), but remained almost the same as for the parent com-
pound 18a with two methyl groups or one methyl and one
fluorine substituent at the 2’- and 4’-positions (pKi&6.1–6.2,
Table 2, entries 19 and 22).
Substitution of the terminal phenyl ring of nipecotic acid de-
rivative 17a possessing only a C4 instead of C5 spacer, but also
a distinctly higher mGAT1 affinity relative to its homologue
18a gave rise to trends quite similar to those observed for the
latter, 18a. Upon introduction of a chlorine, fluorine, or methyl
substituent at the 2’-position of the distal phenyl group, a dis-
tinct increase in mGAT1 affinity occurs, the methyl derivative
17d exhibiting in this series the highest pKi value
(pKi=8.13:0.05; Table 2, entry 4). In contrast, a chlor-
ine substituent at the 4’-position leads to a decrease
in mGAT1 binding affinity below the level of the
parent compound 17a (17e, pKi 7.37:0.07, Table 2,
entry 5). With two chlorine or two fluorine or one
chlorine at the 2’-position and one fluorine at the 4’-
position, again good binding affinities are obtained
(17 f, pKi=8.16:0.04; 17g, pKi=8.02:0.09; 17 i,
pKi=8.13:0.08; Table 2, entries 6, 7, and 9). But al-
though a first methyl group at the 2’-position (see
17d, Table 2, entry 4) led to a substantial improve-
ment in mGAT1 binding affinity, for a second methyl
group or a chlorine or a fluorine substituent (Table 2,
entries 8, 10, and 11) the opposite is true; the pKi
values relative to the monomethyl derivative 17d
(pKi=8.13:0.05, Table 2, entry 4) are lowered by
about 0.2 to 0.4 log units.
In general, the results obtained in the biological
evaluations confirm the results of the molecular mod-
eling described above regarding the influence of the
length of the alkynyl spacer on GAT1 affinity. Thus,
compounds 17a–l with a but-3-ynyl spacer were
found to be more affine for GAT1 than compounds
18a–l with a pent-4-ynyl spacer. However, the ho-
mology model cannot explain the 1–2 log units the
pKi values for compounds with a C5 spacer are lower
than those with a C4 linker. But the calculated bind-
ing affinities for nipecotic acid derivatives with the
but-3-ynyl spacer were in line with the results of the
biological studies, delivering pKi values close to that
of tiagabine or even better. Regarding these com-
pounds, our homology modeling study indicated the
2’,4’-dichloro-substituted derivative 17 f (Table 2,
entry 6) to possess a particularly high binding affinity
for GAT1 as it had yielded the highest docking
scores. This proved true, as the pKi value of 17 f for
mGAT1 ranged among the highest found in this
study. However, also the three test compounds 17g
(2’-F, 4’-F, Table 2, entry 7), 17 i (2’-Cl, 4’-F, Table 2,
entry 9), and 17d (2’-CH3, Table 2, entry 4) reached comparably
high binding affinities for mGAT1 (pKi), although their docking
scores in molecular modeling had been lower.
The inhibitory potencies of all studied analogues 17a–l and
18a–l at mGAT1 (pIC50) were about a half log unit lower than
the corresponding pKi values. The difference between pIC50
and pKi values is a common phenomenon constantly observed
for mGAT1 inhibitors when characterized in the test systems
used,[20] but apart from this difference the data for binding af-
finity (pKi) and inhibitory potency (pIC50) are still in good agree-
ment with each other. From the inhibitory potencies found at
mGAT2–mGAT4, it also became apparent that all compounds
possess a clear preference for mGAT1.
For mGAT1 inhibitors delineated from nipecotic acid, it is
well known that the biological activity resides mainly in the R
enantiomer. Therefore, of the nipecotic acid derivatives with
the highest mGAT1 binding affinities, that is, 17d, 17 f, 17g,
Table 2. GAT inhibitors with biphenyl moieties and their inhibitory potencies toward
mGAT1–4 and binding affinities toward mGAT1.
Entry Compd n 2’ 4’ pKi
[a] pIC50
[b]
mGAT1 mGAT1 mGAT2 mGAT3 mGAT4
1 17a 1 H H 7.61:0.03 7.00:0.06 70% 66% 57%
2 17b 1 Cl H 7.91:0.03 7.29:0.12 62% 47% 43%
3 17c 1 F H 7.77:0.05 7.12:0.10 45% 74% 52%
4 17d 1 CH3 H 8.13:0.05 7.22:0.06 75% 60% 52%
4a (R)-17d 1 CH3 H 8.32:0.03 7.60:0.12 78% 59% 4.29
5 17e 1 H Cl 7.37:0.07 6.73:0.08 4.11 4.50 4.44
6 17 f 1 Cl Cl 8.16:0.04 7.26:0.08 70% 4.65 4.59
6a (R)-17 f 1 Cl Cl 8.31:0.07 7.72:0.02 71% 4.79 4.38
7 17g 1 F F 8.02:0.09 7.31:0.12 54% 62% 41%
7a (R)-17g 1 F F 8.21:0.06 7.56:0.10 87% 69% 4.32
8 17h 1 CH3 CH3 7.68:0.07 6.68:0.13 57% 49% 4.04
9 17 i 1 Cl F 8.13:0.08 7.35:0.03 4.39 48% 4.33
9a (R)-17 i 1 Cl F 8.33:0.01 7.68:0.10 55% 4.56 4.29
10 17k 1 CH3 Cl 7.78:0.03 6.80:0.08 4.54 4.40 4.49
11 17 l 1 CH3 F 7.90:0.03 7.11:0.10 4.39 47% 55%
12 18a 2 H H 6.16:0.02 5.42:0.10 86% 64% 61%
13 18b 2 Cl H 6.29:0.01 5.80:0.11 54% 82% 48%
14 18c 2 F H 6.29:0.07 5.56:0.13 42% 82% 56%
15 18d 2 CH3 H 6.27:0.06 5.89:0.05 67% 66% 4.26
16 18e 2 H Cl 6.07:0.01 5.47:0.06 45% 4.71 47%
17 18 f 2 Cl Cl 6.55:0.01 6.03:0.06 4.18 4.50 4.44
18 18g 2 F F 6.42:0.09 5.70:0.13 68% 53% 53%
19 18h 2 CH3 CH3 6.09:0.12 5.46:0.12 47% 54% 4.05
20 18 i 2 Cl F 6.46:0.04 5.77:0.08 4.39 46% 4.33
21 18k 2 CH3 Cl 6.40:0.05 6.01:0.06 4.54 4.60 4.63
22 18 l 2 CH3 F 6.18:0.09 5.88:0.05 4.28 4.31 4.43
[a] Data are the mean:SEM of three independent experiments, each performed in
triplicate. [b] Values are the mean:SEM of three (mGAT1) or one (mGAT2–4) inde-
pendent experiment, each performed in triplicate; percentages are the remaining
[3H]GABA uptake in the presence of 100 mm inhibitor.
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and 17 i, the corresponding enantiopure R isomers were also
synthesized and characterized in mGAT1 binding and uptake
assays. As expected, each of these R enantiomers shows
a higher mGAT binding affinity than the racemic compound,
the increase amounting to about 0.2 log units. With mGAT1
binding affinities being in the range of 8.2–8.3 (pKi), enantio-
mers (R)-17d, (R)-17 f, (R)-17g, and (R)-17 i, (Table 2, entries 4a,
6a, 7a, and 9a) are among the best binders known so far for
this target. As compared with the 2’,4’-dichloro-substituted de-
rivative of (R)-4 (pKi=8.33:0.06, pIC50=7.43:0.10),
[15] which
is one of the most active mGAT1 inhibitors, the binding affinity
of the most active mGAT1 inhibitors of this study was found to
be in the same range, and their inhibitory potencies even
somewhat higher. Relative to N-substituted derivatives of gu-
vacine with an oxime spacer that are known to be among the
most potent mGAT1 inhibitors to date,[17] the best of the nipe-
cotic acid derivatives with an alkyne spacer described in this
study generally show inhibitory potencies (pIC50) and binding
affinities (pKi) in a similar range. In contrast to the former, the
N-arylalkynyl substituents have the advantage of being devoid
of a potentially labile oxime function.
Conclusions
In summary, a new series of GABA uptake inhibitors with an
alkyne-type spacer connecting nipecotic acid via the amino ni-
trogen atom as polar substructure with an aromatic subunit
have been synthesized and characterized for their biological
activity at the GABA transporter subtype 1. At the w-position
of the alkynyl linker, the biphenyl-type residue was found to
be more suitable than the 2-benzylphenyl moiety with regard
to biological activity. Moreover, compounds with the shorter
but-3-ynyl spacer linking the nitrogen of nipecotic acid with
the biphenyl subunit turned out to possess higher affinity for
and potency at mGAT1 than those with a C5 linker.
This way compound 17a (Table 2) containing a biphenylbut-
3-ynyl ligand was identified as a parent compound with a dis-
tinctly improved binding affinity of 7.61:0.03 (pKi) and inhibi-
tory potency of 7.00:0.06 (pIC50) as compared to the ana-
logue 5 (Figure 1) with an alkenyl spacer (pKi=7.15:0.07,
pIC50=6.79:0.12). Guided by the results of a homology mod-
eling study, a series of related compounds with different sub-
stituents at the 2’- and 4’-positions of the terminal ring of the
biphenyl residue were synthesized and characterized for their
binding affinity for and inhibitory potency at mGAT1. Synthesis
of these compounds was accomplished by two efficient cross-
coupling reactions. Among the synthesized compounds, the
2’-methyl and 2’,4’-dihalogen-substituted derivatives 17d, 17 f,
17g, and 17 i (Table 2, entries 4, 6, 7, and 9) were found to be
the most potent derivatives with binding affinities up to 8.33:
0.01 (pKi) and uptake inhibitory potencies up to 7.72:0.02
(pIC50) for the more potent R enantiomers. According to the in-
hibitory potencies found for the GABA transporter subtypes
mGAT2–4, this series of compounds appears to be highly sub-
type selective toward mGAT1.
Overall within this study a new type of nipecotic acid deriva-
tive exhibiting a spacer with a triple bond linking the afore-
mentioned polar unit with a 2-biphenyl residue was identified,
possessing outstanding binding affinities and potencies and
clear subtype selectivity toward mGAT1. Because of the stabili-
ty inherent to the N-biphenylalkynyl substituent, these nipe-
cotic acid derivatives are a valuable starting point for further
optimization studies.
Experimental Section
Computational studies
For homology modeling of a “closed” GAT1 conformation the 3D
structure (PDB ID: 2A65)[18] was taken from the RCSB Protein Data
Bank.[22] The only available 3D structure of an “open-to-out” confor-
mation (PDB ID: 3F3A)[19] was chosen as a template for an “open”
GAT1 conformation. The human GAT1 sequence (Swiss-Prot[23] ac-
cession number P30531) was aligned to the LeuT sequence using
the alignment from Skovstrup et al.[24] The Modeller software pack-
age version 9v8[25] was used to generate 30 structures of each con-
former. The two sodium atoms (Na1 and Na2) located close to the
S1 binding site were copied into the hGAT1 structures. A chloride
ion was placed into the putative chloride binding site proposed by
Zomot et al.[26] and Forrest et al.[27] However, the chloride ion has
no direct contact to the active site and its presence has no impact
for the docking calculations. The models with the lowest Modeller
objective function were checked with PROCHECK[28] for structural
consistency and further used for docking calculations.
The molecules for docking were exported from our in-house In-
stant JChem 5.4 database[29] as 2D MDL mol files. Protonation at
pH 7.4 and the 2D to 3D conversion was done using ChemAxon
Marvin 5.4.0.1[30] “cxcalc” and “molconvert”. The command line tool
“prepare_dpf42.py” was used for conversion into AutoDock4
pdbqt input files. Appropriate protein input files were prepared
with the AutoDock tools.[31] Docking grids were calculated with
“autogrid4” and docking was performed with AutoDock4 version
4.2.3.[32] The binding region was defined by a 18 aV18 aV18 a
box centered between the two gatekeeping residues Tyr139 and
Phe294. The side chains of the four gatekeeping residues (Tyr139,
Phe294, Arg69, Asp451) were treated as flexible during docking.
Ten poses for each molecule were generated and scored with the
AutoDock4 scoring function.[32]
Chemistry
All reactions were carried out under nitrogen atmosphere in dis-
tilled solvents. Dioxane was dried over sodium and distilled under
nitrogen. Commercial available reagents were used without further
purification. Flash column chromatography (CC) was performed
using silica gel (40–60 mm). NMR spectra were measured with
a Jeol Eclipse +400 (400 MHz) and a Jeol Eclipse +500 (500 MHz)
spectrometer or an Avance III HD 400 MHz Bruker BioSpin and an
Avance III HD 500 MHz Bruker BioSpin spectrometer. 1H NMR chem-
ical shifts were referenced to TMS and 13C NMR chemical shifts
were referenced to CHCl3. The coupling constants were stated with
an accuracy of 0.5 Hz. MestreNova software was used for further
analysis of the spectra. IR spectra were recorded with a FT-IR spec-
trometer Paragon 1000 (PerkinElmer). Samples were measured
either as KBr pellets or as films on NaCl plates. Spectrum v2.00
software (PerkinElmer) was used for analysis. Mass spectra were
measured with a mass spectrometer 59827A with 59980 particle
beam LC–MS interface (Hewlett–Packard). High resolution mass
spectrometry was carried out with a LTQ FT (ThermoFinnigan), FAB
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(Xenon, 6 kV, MBA, reference PEG), or a JMS GCmate II (Jeol). Opti-
cal rotations were determined by a 241 MC Polarimeter ADP440+
at l=589 cm@1. Purity testing of the enantiopure test compounds
(R)-17d, (R)-17 f, (R)-17g, and (R)-17 i was done by means of analyt-
ical HPLC on a Merck-Hitachi HPLC system (L7400 intelligent pump
and L7400 UV Detector) using elution from a 250 mmV4 mm Li-
Chrospher 100RP-8 column (5 mm particle size), the UV absorbance
detection set at 254 nm, using a flow rate of 1.0 mLmin@1 and as
solvent: phosphate buffer (10 mm)/MeCN=4:6. The purity of all
tested compounds was >95%. See the Supporting Information for
characterization data for the described compounds.
General procedure for the Sonogashira cross-coupling reactions
(GP1): Under nitrogen atmosphere Pd(dppf)2Cl2 (0.05 equiv), CuI
(0.2 equiv), K3PO4 (3.0 equiv), and the aryl iodide (1.0 equiv) were
introduced in a Schlenk tube. Subsequently the alkyne (1.0 equiv)
in dioxane (1 mLmmol@1) and H2O (1 mLmmol
@1) were added. The
mixture was heated at 60 8C and stirred for 3 h. After cooling to
room temperature, CH2Cl2 (10 mLmmol
@1) and H2O (10 mLmmol
@1)
were added and the organic components were extracted with
CH2Cl2. The combined organic layers were dried over Na2SO4 and
the solvent was removed under reduced pressure. The crude prod-
uct was purified by CC (eluting with hexane/EtOAc 8:2) to give the
corresponding coupling product.
General procedure for the Suzuki cross-coupling reactions
(GP2): Under nitrogen atmosphere Pd2(dba)3·CHCl3 (0.01 equiv), S-
Phos (0.04 equiv), K3PO4 (2.0 equiv) and the corresponding phenyl-
boronic acid derivative (1.5 equiv) were introduced in a Schlenk
tube. Subsequently the aryl bromide (1.0 equiv) in dioxane
(1 mLmmol@1) and H2O (1 mLmmol
@1) were added. The mixture
was heated at 60 8C and stirred for 6 h. After cooling to room tem-
perature, CH2Cl2 (10 mLmmol
@1) and H2O (10 mLmmol
@1) were
added and the organic components were extracted with CH2Cl2.
The combined organic layers were dried over Na2SO4 and the sol-
vent was removed under reduced pressure. The crude product was
purified by CC (eluting with hexane/EtOAc 8:2) to give the corre-
sponding coupling product.
General procedure for the hydrolysis of nipecotic acid ethyl
esters (GP3): The corresponding ester was dissolved in EtOH
(5 mLmmol@1) and 2m NaOH (1.5 mLmmol@1, 3.0 equiv) was
added. The mixture was stirred for about 4 h at room temperature
(checked by TLC). After complete conversion, the solvent was re-
moved under reduced pressure. The resulting solid residue was
dissolved in 25 mLmmol@1 of H2O and the pH was adjusted to 6–7
(indicator paper). The amino acid was then extracted several times
with CH2Cl2. The combined organic layers were dried over Na2SO4
and the solvent was removed under reduced pressure. The result-
ing residue was dissolved in MeOH (5 mLmmol@1) followed by the
addition of H2O (50 mLmmol
@1) and was then freeze dried to give
the corresponding amino acid as amorphous solid.
Syntheses
Ethyl 1-but-3-yn-1-ylpiperidine-3-carboxylate (7): Ethyl nipeco-
tate (25 mmol, 4.0 g, 2.5 equiv) was added to but-3-yn-1-yl-4-meth-
ylbenzenesulfonate (10 mmol, 2.2 g, 1.0 equiv) and the mixture
was stirred for 24 h at room temperature. Then CH2Cl2 (100 mL)
and H2O (100 mL) were added and the product was extracted with
CH2Cl2. The combined organic layers were dried over Na2SO4 and
the solvent was removed under reduced pressure. After purifica-
tion by CC (eluting with hexane/EtOAc 1:1) 7 was obtained as col-
orless oil (2.02 g, 96%).
Ethyl 1-pent-4-yn-1-ylpiperidine-3-carboxylate (8): Ethyl nipeco-
tate (25 mmol, 4.0 g, 2.5 equiv) was added to pent-4-yn-1-yl-4-
methylbenzenesulfonate (10 mmol, 2.4 g, 1.0 equiv) and the mix-
ture was stirred for 24 h at room temperature. Then CH2Cl2
(100 mL) and H2O (100 mL) were added and the product was ex-
tracted with CH2Cl2. The combined organic layers were dried over
Na2SO4 and the solvent was removed under reduced pressure.
After purification by CC (eluting with hexane/EtOAc 1:1) 8 was ob-
tained as colorless oil (2.10 g, 94%).
Ethyl 1-[4-(2-benzylphenyl)but-3-yn-1-yl]piperidine-3-carboxyl-
ate (9): According to GP1 starting from 7 (105 mg, 0.50 mmol) and
1-benzyl-2-iodo-benzene (147 mg, 0.500 mmol) 9 was obtained as
colorless oil (145 mg, 77%).
Ethyl 1-[5-(2-benzylphenyl)pent-4-yn-1-yl]piperidine-3-carboxyl-
ate (10): According to GP1 starting from 8 (112 mg, 0.500 mmol)
and 1-benzyl-2-iodo-benzene (147 mg, 0.500 mmol) 10 was ob-
tained as colorless oil (146 mg, 75%).
1-[4-(2-Benzylphenyl)but-3-yn-1-yl]piperidine-3-carboxylic acid
(11): According to GP3 starting from 9 (113 mg, 0.300 mmol) and
2n NaOH (0.450 mL, 0.900 mmol) 11 was obtained as colorless
amorphous solid (95 mg, 91%).
1-[5-(2-Benzylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylic acid
(12): According to GP3 starting from 10 (117 mg, 0.300 mmol) and
2n NaOH (0.450 mL, 0.900 mmol) 12 was obtained as colorless
amorphous solid (101 mg, 93%).
Ethyl 1-[4-(2-bromophenyl)but-3-yn-1-yl]piperidine-3-carboxyl-
ate (13): According to GP1 starting from 7 (2.10 g, 10.0 mmol) and
1-bromo-2-iodo-benzene (2.82 g, 10.0 mmol) 13 was obtained as
colorless oil (3.01 g, 82%).
Ethyl 1-[5-(2-bromophenyl)pent-4-yn-1-yl]piperidine-3-carboxyl-
ate (14): According to GP1 starting from 8 (2.24 g, 10.0 mmol) and
1-bromo-2-iodo-benzene (2.82 g, 10.0 mmol) 14 was obtained as
colorless oil (3.16 g, 84%).
Ethyl 1-[4-(2-phenylphenyl)but-3-yn-1-yl]piperidine-3-carboxyl-
ate (15a): Method 1: According to GP1 starting from 7 (105 mg,
0.500 mmol) and 1-iodo-2-phenyl-benzene (140 mg, 0.500 mmol)
15a was obtained as colorless oil (137 mg, 76%); Method 2: Ac-
cording to GP2 starting from 13 (110 mg, 0.300 mmol),
Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg, 12 mmol),
K3PO4 (131 mg, 0.600 mmol) and phenylboronic acid (55 mg,
0.45 mmol) 15a was obtained as colorless oil (100 mg, 93%). The
analytical data is in accordance with the one described in
method 1.
Ethyl 1-[5-(2-phenylphenyl)pent-4-yn-1-yl]piperidine-3-carboxyl-
ate (16a): Method 1: According to GP1 starting from 8 (112 mg,
0.500 mmol) and 1-iodo-2-phenyl-benzene (140 mg, 0.500 mmol)
16a was obtained as colorless oil (145 mg, 78%); Method 2: Ac-
cording to GP2 starting from 14 (114 mg, 0.300 mmol),
Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg, 12 mmol),
K3PO4 (131 mg, 0.600 mmol), and phenylboronic acid (55 mg,
0.45 mmol) 16b was obtained as colorless oil (105 mg, 94%). The
analytical data is in accordance with the one described in
method 1.
Ethyl 1-{4-[2-(2-chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylate (15b): According to GP2 starting from 13 (110 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-chlorophenylboronic
acid (70 mg, 0.45 mmol) 15b was obtained as colorless oil
(106 mg, 90%).
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Ethyl 1-{5-[2-(2-chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylate (16b): According to GP2 starting from 14 (114 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-chlorophenylboronic
acid (70 mg, 0.45 mmol) 16b was obtained as colorless oil (112 mg,
91%).
Ethyl 1-{4-[2-(2-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylate (15c): According to GP2 starting from 13 (110 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-fluorophenylboronic
acid (63 mg, 0.45 mmol) 15c was obtained as colorless oil (101 mg,
89%).
Ethyl 1-{5-[2-(2-fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylate (16c): According to GP2 starting from 14 (114 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-fluorophenylboronic
acid (63 mg, 0.45 mmol) 16c was obtained as colorless oil (107 mg,
91%).
Ethyl 1-{4-[2-(2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylate (15d): According to GP2 starting from 13 (110 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-methylphenylboronic
acid (61 mg, 0.45 mmol) 15d was obtained as colorless oil
(103 mg, 92%).
Ethyl 1-{5-[2-(2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-
3-carboxylate (16d): According to GP2 starting from 14 (114 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-methylphenylboronic
acid (61 mg, 0.45 mmol) 16d was obtained as colorless oil
(108 mg, 93%).
Ethyl 1-{4-[2-(4-chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylate (15e): According to GP2 starting from 13 (110 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-chlorophenylboronic
acid (70 mg, 0.45 mmol) 15e was obtained as colorless oil
(108 mg, 91%).
Ethyl 1-{5-[2-(4-chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylate (16e): According to GP2 starting from 14 (114 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-chlorophenylboronic
acid (70 mg, 0.45 mmol) 16e was obtained as colorless oil (112 mg,
91%).
Ethyl 1-{4-[2-(2,4-dichlorophenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylate (15 f): According to GP2 starting from 13
(110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-dichloro-
phenylboronic acid (86 mg, 0.45 mmol) 15 f was obtained as color-
less oil (112 mg, 87%).
Ethyl 1-{5-[2-(2,4-dichlorophenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylate (16 f): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-dichloro-
phenylboronic acid (86 mg, 0.45 mmol) 16 f was obtained as color-
less oil (117 mg, 88%).
Ethyl 1-{4-[2-(2,4-difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-
3-carboxylate (15g): According to GP2 starting from 13 (110 mg,
0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos (5.0 mg,
12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-difluorophenylbor-
onic acid (71 mg, 0.45 mmol) 15g was obtained as colorless oil
(103 mg, 87%).
Ethyl 1-{5-[2-(2,4-difluorophenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylate (16g): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-difluoro-
phenylboronic acid (71 mg, 0.45 mmol) 16g was obtained as color-
less oil (106 mg, 86%).
Ethyl 1-{4-[2-(2,4-dimethylphenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylate (15h): According to GP2 starting from 13
(110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-dimethyl-
phenylboronic acid (68 mg, 0.45 mmol) 15h was obtained as color-
less oil (107 mg, 92%).
Ethyl 1-{5-[2-(2,4-dimethylphenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylate (16h): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-dimethyl-
phenylboronic acid (68 mg, 0.45 mmol) 16h was obtained as color-
less oil (110 mg, 91%).
Ethyl 1-{4-[2-(2-chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}pi-
peridine-3-carboxylate (15 i): According to GP2 starting from 13
(110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-chloro-4-flu-
orophenylboronic acid (80 mg, 0.45 mmol) 15 i was obtained as
colorless oil (108 mg, 87%).
Ethyl 1-{5-[2-(2-chloro-4-fluorophenyl)phenyl]pent-4-yn-1-yl}pi-
peridine-3-carboxylate (16 i): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-chloro-4-flu-
orophenylboronic acid (80 mg, 0.45 mmol) 16 i was obtained as
colorless oil (114 mg, 89%).
Ethyl 1-{4-[2-(4-chloro-2-methylphenyl)phenyl]but-3-yn-1-yl}pi-
peridine-3-carboxylate (15k): According to GP2 starting from 13
(110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-chloro-2-
methylphenylboronic acid (77 mg, 0.45 mmol, 1.5 equiv) 15k was
obtained as colorless oil (110 mg, 90%).
Ethyl 1-{5-[2-(4-chloro-2-methylphenyl)phenyl]pent-4-yn-1-yl}pi-
peridine-3-carboxylate (16k): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-chloro-2-
methylphenylboronic acid (77 mg, 0.45 mmol) 16k was obtained
as colorless oil (115 mg, 91%).
Ethyl 1-{4-[2-(4-fluoro-2-methylphenyl)phenyl]but-3-yn-1-yl}pi-
peridine-3-carboxylate (15 l): According to GP2 starting from 13
(110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-fluoro-2-
methylphenylboronic acid (70 mg, 0.45 mmol) 15 l was obtained as
colorless oil (105 mg, 89%).
Ethyl 1-{5-[2-(4-fluoro-2-methylphenyl)phenyl]pent-4-yn-1-yl}pi-
peridine-3-carboxylate (16 l): According to GP2 starting from 14
(114 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-Phos
(5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 4-fluoro-2-
methylphenylboronic acid (70 mg, 0.45 mmol) 16 l was obtained as
colorless oil (108 mg, 88%).
1-[4-(2-Phenylphenyl)but-3-yn-1-yl]piperidine-3-carboxylic acid
(17a): According to GP3 starting from 15a (108 mg, 0.300 mmol)
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and 2n NaOH (0.45 mL, 0.90 mmol) 17a was obtained as colorless
amorphous solid (90 mg, 90%).
1-[5-(2-Phenylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylic acid
(18a): According to GP3 starting from 16a (112 mg, 0.300 mmol)
and 2n NaOH (0.45 mL, 0.90 mmol) 18a was obtained as colorless
amorphous solid (92 mg, 88%).
1-{4-[2-(2-Chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-car-
boxylic acid (17b): According to GP3 starting from 15b (79 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17b was obtained
as colorless amorphous solid (65 mg, 88%).
1-{5-[2-(2-Chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-car-
boxylic acid (18b): According to GP3 starting from 16b (82 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18b was obtained
as colorless amorphous solid (68 mg, 89%).
1-{4-[2-(2-Fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-car-
boxylic acid (17c): According to GP3 starting from 15c (76 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17c was obtained
as colorless amorphous solid (64 mg, 88%).
1-{5-[2-(2-Fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-car-
boxylic acid (18c): According to GP3 starting from 16c (79 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18c was obtained
as colorless amorphous solid (66 mg, 90%).
1-{4-[2-(2-Methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-car-
boxylic acid (17d): According to GP3 starting from 15d (75 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17d was obtained
as colorless amorphous solid (63 mg, 91%).
1-{5-[2-(2-Methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-car-
boxylic acid (18d): According to GP3 starting from 16d (78 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18d was obtained
as colorless amorphous solid (66 mg, 91%).
1-{4-[2-(4-Chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-car-
boxylic acid (17e): According to GP3 starting from 15e (79 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17e was obtained
as colorless amorphous solid (66 mg, 90%): Rf&0.1 (CH2Cl2/CH3OH
9:1).
1-{5-[2-(4-Chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-car-
boxylic acid (18e): According to GP3 starting from 16e (82 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18e was obtained
as colorless amorphous solid (68 mg, 89%).
1-{4-[2-(2,4-Dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylic acid (17 f): According to GP3 starting from 15 f (86 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17 f was obtained
as colorless amorphous solid (70 mg, 87%).
1-{5-[2-(2,4-Dichlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylic acid (18 f): According to GP3 starting from 16 f (89 mg,
0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18 f was obtained
as colorless amorphous solid (71 mg, 86%).
1-{4-[2-(2,4-Difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylic acid (17g): According to GP3 starting from 15g
(79 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17g was
obtained as colorless amorphous solid (66 mg, 89%).
1-{5-[2-(2,4-Difluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylic acid (18g): According to GP3 starting from 16g
(82 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18g was
obtained as colorless amorphous solid (68 mg, 89%).
1-{4-[2-(2,4-Dimethylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylic acid (17h): According to GP3 starting from 15h
(78 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17h was
obtained as colorless amorphous solid (65 mg, 90%).
1-{5-[2-(2,4-Dimethylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-
carboxylic acid (18h): According to GP3 starting from 16h
(81 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18h was
obtained as colorless amorphous solid (68 mg, 91%).
1-{4-[2-(2-Chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-
3-carboxylic acid (17 i): According to GP3 starting from 15 i
(83 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17 i was
obtained as colorless amorphous solid (67 mg, 87%).
1-{5-[2-(2-Chloro-4-fluorophenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylic acid (18 i): According to GP3 starting from 16 i
(86 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18 i was
obtained as colorless amorphous solid (71 mg, 89%).
1-{4-[2-(4-Chloro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylic acid (17k): According to GP3 starting from 15k
(82 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17k was
obtained as colorless amorphous solid (68 mg, 89%).
1-{5-[2-(4-Chloro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylic acid (18k): According to GP3 starting from 16k
(85 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18k was
obtained as colorless amorphous solid (73 mg, 92%).
1-{4-[2-(4-Fluoro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylic acid (17 l): According to GP3 starting from 15 l
(79 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 17 l was
obtained as colorless amorphous solid (66 mg, 90%).
1-{5-[2-(4-Fluoro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperi-
dine-3-carboxylic acid (18 l): According to GP3 starting from 16 l
(82 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) 18 l was
obtained as colorless amorphous solid (69 mg, 91%).
(R)-Ethyl 1-but-3-yn-1-ylpiperidine-3-carboxylate ((R)-7): To but-
3-yn-1-yl-4-methylbenzenesulfonate (5.0 mmol, 1.1 g, 1.0 equiv)
was added (R)-ethyl nipecotate (12.5 mmol, 1.6 g, 3.0 equiv) and
the mixture was stirred for 24 h at room temperature. Then CH2Cl2
(100 mL) and H2O (100 mL) were added and the product was ex-
tracted with CH2Cl2. The combined organic layers were dried over
Na2SO4 and the solvent was removed under reduced pressure.
After purification by CC (eluting with hexane/EtOAc=1:1) (R)-7
was obtained as colorless oil (1.0 g, 95%).
(R)-Ethyl 1-[4-(2-bromophenyl)but-3-yn-1-yl]piperidine-3-carbox-
ylate ((R)-13): According to GP1 starting from (R)-7 (1.1 g,
5.0 mmol, 1.0 equiv) and 1-bromo-2-iodo-benzene (1.4 g, 5.0 mmol,
1.0 equiv) (R)-13 was obtained as colorless oil (1.5 g, 83%).
(R)-Ethyl 1-{4-[2-(2-methylphenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylate ((R)-15d): According to GP2 starting from (R)-
13 (110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-
Phos (5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol) and 2-methyl-
phenylboronic acid (61 mg, 0.45 mmol) (R)-15d was obtained as
colorless oil (101 mg, 91%).
(R)-Ethyl 1-{4-[2-(2,4-dichlorophenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylate ((R)-15 f): According to GP2 starting from (R)-
13 (110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-
Phos (5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-di-
chlorophenylboronic acid (86 mg, 0.45 mmol) (R)-15 f was obtained
as colorless oil (110 mg, 86%).
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(R)-Ethyl 1-{4-[2-(2,4-difluorophenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylate ((R)-15g): According to GP2 starting from (R)-
13 (110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol), S-
Phos (5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2,4-di-
fluorophenylboronic acid (71 mg, 0.45 mmol) (R)-15g was obtained
as colorless oil (104 mg, 88%).
(R)-Ethyl 1-{4-[2-(2-chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}-
piperidine-3-carboxylate ((R)-15 i): According to GP2 starting from
(R)-13 (110 mg, 0.300 mmol), Pd2(dba)3·xCHCl3 (3.2 mg, 3.0 mmol),
S-Phos (5.0 mg, 12 mmol), K3PO4 (131 mg, 0.600 mmol), and 2-
chloro-4-fluorophenylboronic acid (80 mg, 0.45 mmol) (R)-15 i was
obtained as colorless oil (110 mg, 89%).
(R)-1-{4-[2-(2-Methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylic acid ((R)-17d): According to GP3 starting from (R)-15d
(75 mg, 0.20 mmol, 1.0 equiv) and 2n NaOH (0.30 mL, 0.60 mmol)
(R)-17d was obtained as colorless amorphous solid (64 mg, 92%).
(R)-1-{4-[2-(2,4-Dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-
3-carboxylic acid ((R)-17 f): According to GP3 starting from (R)-
15 f (86 mg, 0.20 mmol) and 2n NaOH (0.30 mL, 0.60 mmol) (R)-
17 f was obtained as colorless amorphous solid (71 mg, 88%).
(R)-1-{4-[2-(2,4-Difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-
carboxylic acid ((R)-17g): According to GP3 starting from (R)-15g
(79 mg, 0.20 mmol, 1.0 equiv) and 2n NaOH (0.30 mL, 0.60 mmol)
(R)-17g was obtained as colorless amorphous solid (66 mg, 89%).
(R)-1-{4-[2-(2-Chloro-4-fluoro-phenyl)phenyl]but-3-yn-1-yl}piperi-
dine-3-carboxylic acid ((R)-17 i): According to GP3 starting from
(R)-15 i (83 mg, 0.20 mmol, 1.0 equiv) and 2n NaOH (0.30 mL,
0.60 mmol) (R)-17 i was obtained as colorless amorphous solid
(70 mg, 91%).
Keywords: cross-coupling reactions · GABA uptake inhibitors ·
molecular modeling · nipecotic acid · structure–activity
relationships
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Development of highly potent GAT1 Inhibitors: 
Synthesis of Nipecotic Acids Derivatives with N-arylalkinyl Substituents 
Toni Lutz, Dr. Thomas Wein, Dr. Georg Höfner, and Prof. Dr. Klaus T. Wanner 
Spectral and physical data for compounds 7-14, 15a-l, 16a-l, 17a-l, and 18a-l 
Ethyl 1-but-3-yn-1-ylpiperidine-3-carboxylate (7): 
Rf≈0.5 (hexane/ethyl acetate 1:1). 1H NMR (500 MHz, CDCl3): δ=1.22 (t, J=7.1 Hz, 3H, OCH2CH3), 1.40 (qd, 
J=11.8, 3.9 Hz, 1H, NCH2CHCHaxHeq), 1.48–1.60 (m, 1H, NCH2CHaxHeqCH2CH), 1.70 (dp, J=10.9, 3.8 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.87–1.94 (m, 1H, NCH2CHCHaxHeq), 1.95 (t, J=2.7 Hz, 1H, C≡CH), 2.04 (td, 
J=11.0, 2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.19 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.32–2.38 (m, 2H, 
NCH2CH2C≡CH), 2.52 (tt, J=10.8, 3.8 Hz, 1H, NCH2CHax), 2.58 (t, J=7.9 Hz, 2H, NCH2CH2C≡C), 2.75 (d, 
J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (d, J=11.1 Hz, 1H, NCHaxHeqCH), 4.10 (q, J=7.1 Hz, 2H, 
OCH2CH3) ppm; 13C NMR (126 MHz, CDCl3): δ = 14.30 (OCH2CH3), 16.74 (NCH2CH2C≡C), 24.60 
(NCH2CH2CH2CH), 26.92 (NCH2CHCH2), 41.86 (NCH2CH), 53.43 (NCH2CH2CH2CH), 55.12 (NCH2CH), 
57.34 (NCH2CH2C≡CH), 60.45 (OCH2CH3), 69.10 (C≡CH), 82.85 (C≡CH), 174.20 (C=O) ppm; IR (KBr): 
ṽ=3298, 2944, 2812, 2118, 1731, 1371, 1310, 1180, 1153, 1032 cm-1; M (C12H19NO2) = 209.28. MS (CI, 
CH5+) m/z: 210 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C12H19NO2: 209.1416, found: 209.1430. 
Ethyl 1-pent-4-yn-1-ylpiperidine-3-carboxylate (8): 
Rf≈0.4 (hexane/ethyl acetate 1:1). 1H NMR (400 MHz, CDCl3): δ=1.23 (t, J=7.1 Hz, 3H, OCH2CH3), 1.42 (qd, 
J=11.8, 3.5 Hz, 1H, NCH2CHCHaxHeq), 1.48–1.59 (m, 1H, NCH2CHaxHeqCH2CH), 1.63–1.74 (m, 3H, 
NCH2CH2CH2C≡CH, NCH2CHaxHeqCH2CH), 1.84–1.93 (m, 2H, NCH2CHCHaxHeq, C≡CH), 1.98 (td, J=11.0, 
2.6 Hz, 1H, NCHaxHeqCH2CH2CH), 2.10–2.22 (m, 3H, NCHaxHeqCH, NCH2CH2CH2C≡C), 2.37–2.43 (m, 2H, 
NCH2CH2CH2C≡C), 2.51 (tt, J=10.3, 3.8 Hz, 1H, NCH2CHax), 2.70 (d, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.91 (d, J=10.2 Hz, 1H, NCHaxHeqCH), 4.10 (q, J=7.1 Hz, 2H, OCH2CH3) ppm; 13C NMR (101 MHz, CDCl3): 
δ=14.17 (OCH2CH3), 16.31 (NCH2CH2CH2C≡CH), 24.54 (NCH2CH2CH2CH), 25.77 (NCH2CH2CH2C≡C), 
26.91 (NCH2CHCH2), 41.84 (NCH2CH), 53.79 (NCH2CH2CH2CH), 55.42 (NCH2CH), 57.44 
(NCH2CH2CH2C≡CH), 60.23 (OCH2CH3), 68.30 (C≡CH), 84.23 (C≡CH), 174.18 (C=O) ppm; IR (KBr): 
ṽ=3298, 2943, 2808, 2771, 2117, 1732, 1469, 1371, 1308, 1179, 1152, 1030 cm-1; MS (CI, CH5+) m/z: 224 
[M+H]+; HRMS-EI+ m/z [M]+ calcd for C13H21NO2: 223.1572, found: 223.1572. 
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Ethyl 1-[4-(2-benzylphenyl)but-3-yn-1-yl]piperidine-3-carboxylate (9): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.43 
(qd, J=12.0, 4.0 Hz, 1H, NCH2CHCHaxHeq), 1.50–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.71 (dp, J=13.5/, 3.7 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.92 (dq, J=13.0, 3.8 Hz, 1H, NCH2CHCHaxHeq), 2.02 (td, J=11.0, 2.7 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.24 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.50–2.72 (m, 5H, NCH2CH2C≡C, 
NCH2CH2C≡C, NCH2CHax), 2.80 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.02 (dbr, J=10.5 Hz, 1H, 
NCHaxHeqCH), 4.08–4.16 (m, 4H, OCH2CH3, CCH2C), 7.07–7.23 (m, 6H, C≡CCCCH, C≡CCCHCH, 
H2CCCHCHCH, C≡CCCCHCH, H2CCCH), 7.23–7.30 (m, 2H, H2CCCHCH), 7.40 (dd, J=7.5, 1.3 Hz, 1H, 
C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.16 (OCH2CH3), 17.86 (NCH2CH2C≡C), 24.51 
(NCH2CH2CH2CH), 26.79 (NCH2CHCH2), 40.12 (CCH2C), 41.75 (NCH2CH), 53.38 (NCH2CH2CH2CH), 55.09 
(NCH2CH), 57.50 (NCH2CH2C≡C), 60.28 (OCH2CH3), 80.33 (C≡CCCH), 92.38 (C≡CCCH), 123.36 
(CH2C≡CC), 125.90 (CH2C≡CCCHCH), 125.96 (H2CCCHCHCH), 127.85 (CH2C≡CCCHCHCH), 128.27 (2C, 
H2CCCHCH), 128.87 (2C, H2CCCH), 129.23 (CH2C≡CCCCH), 132.12 (CH2C≡CCCH), 140.72 (CCCH2C), 
142.82 (CCCH2C), 174.05 (C=O) ppm; IR (KBr): ṽ=3388, 3062, 3026, 2941, 2854, 2808, 2224, 1730, 1599, 
1483, 1448, 1369, 1308, 1213, 1180, 1153, 1134, 1101, 1032, 758 cm-1; MS (CI, CH5+) m/z: 376 [M+H]+; 
HRMS-EI+ m/z [M]+ calcd for C25H29NO2: 375.2198, found: 375.2194. 
Ethyl 1-[5-(2-benzylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylate (10): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.44 
(qd, J=11.8, 4.4 Hz, 1H, NCH2CHCHaxHeq), 1.50–1.62 (m, 1H, NCH2CHaxHeqCH2CH), 1.66–1.81 (m, 3H, 
NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.87–2.01 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.15 
(t, J=10.0 Hz, 1H, NCHaxHeqCH), 2.41–2.49 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C) 2.56 (tt, J=10.5, 
3.8 Hz, 1H, NCH2CHax), 2.72 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (dbr, J=10.8 Hz, 1H, 
NCHaxHeqCH), 4.08–4.17 (m, 4H, OCH2CH3, CCH2C), 7.08–7.22 (m, 6H, C≡CCCCH, C≡CCCHCH, 
H2CCCHCHCH, C≡CCCCHCH, H2CCCH), 7.23–7.29 (m, 2H, H2CCCHCH), 7.40 (dd, J=7.5, 1.4 Hz, 1H, 
C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.18 (OCH2CH3), 17.50 (NCH2CH2CH2C≡C), 24.51 
(NCH2CH2CH2CH), 26.00 (NCH2CH2CH2C≡C) 26.91 (NCH2CHCH2), 40.10 (CCH2C), 41.80 (NCH2CH), 
53.78 (NCH2CH2CH2CH), 55.39 (NCH2CH), 57.68 (NCH2CH2CH2C≡C), 60.26 (OCH2CH3), 79.73 (C≡CCCH), 
93.84 (C≡CCCH), 123.58 (CH2C≡CC), 125.90 (CH2C≡CCCHCH), 125.96 (H2CCCHCHCH), 127.73 
(CH2C≡CCCHCHCH), 128.28 (2C, H2CCCHCH), 128.86 (2C, H2CCCH), 129.21 (CH2C≡CCCCH), 132.13 
(CH2C≡CCCH), 140.72 (sCCCH2C), 142.69 (CCCH2C), 174.18 (C=O) ppm; IR (KBr): ṽ=3438, 3060, 3026, 
2941, 2854, 2806, 2771, 2224, 1730, 1599, 1483, 1450, 1371, 1308, 1178, 1151, 1105, 1030, 758 cm -1; MS 
(CI, CH5+) m/z: 390 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C26H31NO2: 389.2355, found: 389.2354. 
1-[4-(2-Benzylphenyl)but-3-yn-1-yl]piperidine-3-carboxylic acid (11): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2,  60 °C): δ=1.33 (qd, J=12.2, 3.8 Hz, 
1H, NCH2CHCHaxHeq), 1.53 (qt, J=12.4, 3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.67 (dp, J=13.2, 3.3 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.92 (dq, J=12.4, 3.0 Hz, 1H, NCH2CHCHaxHeq), 2.08 (tbr, J=10.9 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.20 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.36 (tt, J=11.1, 3.7 Hz, 1H, NCH2CHax), 2.56–
2.71 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.88 (dbr, J=11.6 Hz, 1H, NCHaxHeqCH2CH2CH), 3.05 (dbr, 
J=10.1 Hz, 1H, NCHaxHeqCH), 4.12 (s, 2H, CCH2C), 7.17–7.25 (m, 5H, C≡CCCCH, C≡CCCHCH, 
H2CCCHCHCH, H2CCCH), 7.25–7.32 (m, 3H, C≡CCCCHCH, H2CCCHCH), 7.41 (d, J=7.6 Hz, 1H, 
C≡CCCH) ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.40 (NCH2CH2C≡C), 25.04 
(NCH2CH2CH2CH), 28.58 (NCH2CHCH2), 40.80 (CCH2C), 45.59 (NCH2CH), 53.94 (NCH2CH2CH2CH), 57.20 
(NCH2CH), 57.87 (NCH2CH2C≡C), 81.48 (C≡CCCH), 93.05 (C≡CCCH), 124.09 (CH2C≡CC), 126.92 
(H2CCCHCHCH), 127.23 (CH2C≡CCCHCH), 129.15 (CH2C≡CCCHCHCH), 129.24 (2C, H2CCCHCH), 
129.52 (2C, H2CCCH), 130.50 (CH2C≡CCCCH), 133.10 (CH2C≡CCCH), 141.94 (CCCH2C), 143.82 
(CCCH2C), 182.61 (C=O) ppm. IR (KBr): ṽ=3384, 3061, 3025, 2942, 2860, 2224, 1713, 1596, 1494, 1484, 
1450, 1392, 1305, 1217, 1155, 1100, 1073, 1041, 1030, 757 cm-1; MS (ESI+) m/z: 348 [M+H]+; HRMS-EI+ 
m/z [M]+ calcd for C23H25NO2: 347.1885, found 347.1886. 
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1-[5-(2-Benzylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylic acid (12): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.38–1.52 (m, 1H, 
NCH2CHCHaxHeq), 1.53–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.66–1.75 (m, 1H, NCH2CHaxHeqCH2CH), 1.75–
1.85 (m, 2H, NCH2CH2CH2C≡C), 1.91 (dq, J=13.3, 4.2 Hz, 1H, NCH2CHCHaxHeq), 2.24 (tbr, J=10.7 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.33–2.49 (m, 4H, NCHaxHeqCH, NCH2CHax, NCH2CH2CH2C≡C), 2.59–2.69 (m, 2H, 
NCH2CH2CH2C≡C), 2.86 (dt, J=11.8, 4.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.05 (dbr, J=9.0 Hz, 1H, 
NCHaxHeqCH), 4.13 (s, 2H, CCH2C), 7.16–7.25 (m, 5H, C≡CCCCH, C≡CCCHCH, H2CCCHCHCH, H2CCCH), 
7.25–7.33 (m, 3H, C≡CCCCHCH, H2CCCHCH), 7.42 (dd, J=6.7, 2.6 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 
MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.85 (NCH2CH2CH2C≡C), 24.32 (NCH2CH2CH2CH), 25.30 
(NCH2CH2CH2C≡C), 28.02 (NCH2CHCH2), 40.76 (CCH2C), 44.65 (NCH2CH), 54.32 (NCH2CH2CH2CH), 
57.08 (NCH2CH), 58.23 (NCH2CH2CH2C≡C), 81.20 (C≡CCCH), 94.07 (C≡CCCH), 124.23 (CH2C≡CC), 
126.98 (H2CCCHCHCH), 127.25 (CH2C≡CCCHCH), 129.15 (CH2C≡CCCHCHCH), 129.30 (2C, 
H2CCCHCH), 129.48 (2C, H2CCCH), 130.53 (CH2C≡CCCCH), 133.08 (CH2C≡CCCH), 141.96 (CCCH2C), 
143.70 (CCCH2C), 181.87 (C=O) ppm; IR (KBr): ṽ=3386, 3060, 3025, 2925, 2860, 2224, 1718, 1597, 1493, 
1483, 1449, 1388, 1305, 1217, 1153, 1073, 1029, 758 cm-1; MS (ESI+) m/z: 362 [M+H]+; HRMS-EI+ m/z [M]+ 
calcd for C24H27NO2: 361.2042, found: 361.2047. 
Ethyl 1-[4-(2-bromophenyl)but-3-yn-1-yl]piperidine-3-carboxylate (13): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.45 (qd, 
J=11.5, 3.5 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J=10.8, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.90–2.00 (m, 1H, NCH2CHCHaxHeq), 2.14 (td, J=11.0, 2.7 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.30 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.57 (tt, J=10.7/3.8 Hz, 1H, NCH2CHax), 2.62–
2.69 (m, 2H, NCH2CH2C≡C), 2.71–2.78 (m, 2H, NCH2CH2C≡C), 2.83 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 3.06 (dbr, J=10.7 Hz, 1H, NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.12 (td, 
J=8.0, 1.6 Hz, 1 H, BrCCHCH), 7.22 (td, J=7.6, 1.1 Hz, 1H, BrCCCHCH), 7.42 (dd, J = 7.7, 1.5 Hz, 1H, 
C≡CCCH), 7.55 (dd, J=8.0, 0.8 Hz, 1H, BrCCH) ppm; 13C NMR (125 MHz, CDCl3): δ=14.17 (OCH2CH3), 
17.85 (NCH2CH2C≡C), 24.57 (NCH2CH2CH2CH), 26.78 (NCH2CHCH2), 41.84 (NCH2CH), 53.33 
(NCH2CH2CH2CH), 55.05 (NCH2CH), 57.20 (NCH2CH2C≡C), 60.29 (OCH2CH3), 79.98 (C≡CCCH), 93.47 
(C≡CCCH), 125.36 (CBr), 125.71 (BrCC), 126.84 (BrCCCHCH), 128.76 (BrCCHCH), 132.20 (BrCCH), 
133.26 (BrCCCH), 174.08 (C=O) ppm; IR (KBr): ṽ=3436, 3064, 2943, 2854, 2810, 2231, 1730, 1587, 1557, 
1469, 1434, 1370, 1308, 1180, 1153, 1101, 1052, 1026, 862, 754  cm-1; MS (CI, CH5+) m/z: 364 [M+H]+; 
HRMS-EI+ m/z [M]+ calcd for C18H22BrNO2: 363.0834, found: 363.0835. 
Ethyl 1-[5-(2-bromophenyl)pent-4-yn-1-yl]piperidine-3-carboxylate (14): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.46 
(qd, J=12.0, 3.9 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.62 (m, 1H, NCH2CHaxHeqCH2CH), 1.73 (dp, J=13.0 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.82 (p, J=7.1 Hz, 2H, NCH2CH2CH2C≡C), 1.89–1.95 (m, 1H, NCH2CHCHaxHeq), 
2.04 (td, J=10.9, 2.4 Hz, 1H, NCHaxHeqCH2CH2CH), 2.21 (t, J=10.4 Hz, 1H, NCHaxHeqCH), 2.49–2.59 (m, 5H, 
NCH2CH2CH2C≡C, NCH2CH2CH2C≡C, NCH2CHax), 2.77 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.99 
(dbr, J=9.9 Hz, 1 H, NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.11 (td, J=7.8, 1.7 Hz, 1H, BrCCHCH), 
7.22 (td, J=7.6, 1.2 Hz, 1H, BrCCCHCH), 7.41 (dd, J=7.7, 1.7 Hz, 1H, BrCCCH), 7.55 (dd, J=8.1, 1.2 Hz, 1H, 
BrCCH) ppm; 13C NMR (125 MHz, CDCl3): δ=14.18 (OCH2CH3), 17.50 (NCH2CH2CH2C≡C), 24.56 
(NCH2CH2CH2CH), 25.78 (NCH2CH2CH2C≡C), 26.92 (NCH2CHCH2), 41.85 (NCH2CH), 53.83 
(NCH2CH2CH2CH), 55.47 (NCH2CH), 57.57 (NCH2CH2CH2C≡C), 60.24 (OCH2CH3), 79.52 (CH2C≡C), 94.98 
(CH2C≡C), 125.40 (CBr), 125.86 (BrCC), 126.84 (BrCCCHCH), 128.64 (BrCCHCH), 132.19 (BrCCH), 133.20 
(BrCCCH), 174.23 (C=O) ppm; IR (KBr): ṽ=3376, 3065, 2942, 2807, 2770, 2231, 1730, 1587, 1556, 1469, 
1434, 1371, 1306, 1178, 1151, 1026, 754 cm-1; MS (CI, CH5+) m/z: 378 [M+H]+; HRMS-EI+ m/z [M]+ calcd for 
C19H24BrNO2: 377.0990, found: 377.1000. 
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Ethyl 1-[4-(2-phenylphenyl)but-3-yn-1-yl]piperidine-3-carboxylate (15a): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.41 (qd, 
J=12.1, 3.2 Hz, 1H, NCH2CHCHaxHeq), 1.53 (qt, J=12.1, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.69 (dp, J=13.2, 
3.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.92 (dq, J=12.2, 3.8 Hz, 1H, NCH2CHCHaxHeq), 2.02 (td, J=11.0, 2.6 Hz, 
1H, NCHaxHeqCH2CH2CH), 2.20 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.44–2.58 (m, 5H, NCH2CH2C≡C, 
NCH2CH2C≡C, NCH2CHax), 2.72 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (dbr, J=10.8 Hz, 1H, 
NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.25 (td, J=7.6, 1.5 Hz, 1H, C≡CCCHCH), 7.30–7.37 (m, 
3H, C≡CCCCCHCHCH, C≡CCCCHCH, C≡CCCCH), 7.40 (td, J=7.6, 1.2 Hz, 2H, C≡CCCCCHCH), 7.50 (d, 
J=7.4 Hz, 1H, C≡CCCH), 7.58 (dd, J=8.2, 1.3 Hz, 2H, C≡CCCCCH) ppm; 13C NMR (101 MHz, CDCl3): δ = 
14.15 (OCH2CH3), 17.61 (NCH2CH2C≡C), 24.53 (NCH2CH2CH2CH), 26.77 (NCH2CHCH2), 41.79 (NCH2CH), 
53.12 (NCH2CH2CH2CH), 54.92 (NCH2CH), 57.05 (NCH2CH2C≡C), 60.26 (OCH2CH3), 80.82 (C≡CCCH), 
91.29 (C≡CCCH), 121.96 (CH2C≡CC), 126.85 (CH2C≡CCCHCH), 127.20 (C≡CCCCCHCHCH), 127.74 (2C, 
C≡CCCCCHCH), 127.81 (CH2C≡CCCHCHCH), 129.20 (2C, C≡CCCCCH), 129.33 (CH2C≡CCCCH), 132.91 
(CH2C≡CCCH), 140.61 (C≡CCCC), 143.56 (C≡CCC), 174.06 (C=O) ppm; IR (KBr): ṽ=3438, 3060, 3022, 
2978, 2943, 2854, 2810, 2227, 1730, 1475, 1448, 1433, 1371, 1308, 1180, 1153, 1101, 1032, 758, 737, 700 
cm-1; MS (CI, CH5+) m/z: 362 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H27NO2: 361.2042, found: 361.2041.
Ethyl 1-[5-(2-phenylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylate (16a): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.43 
(qd, J=11.7, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.49–1.60 (m, 1H, NCH2CHaxHeqCH2CH), 1.60–1.74 (m, 3H, 
NCH2CH2CH2C≡C, NCH2CHaxHeqCH2CH), 1.87–1.96 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.10 
(t, J=10.5 Hz, 1H, NCHaxHeqCH), 2.28–2.35 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.53 (tt, J=10.4, 
3.8 Hz, 1 H, NCH2CHax), 2.67 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.90 (dbr, J=9.9 Hz, 1H, 
NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.26 (td, J=7.0, 2.1 Hz, 1H, C≡CCCHCH), 7.29–7.37 (m, 
3H, C≡CCCCCHCHCH, C≡CCCCH, C≡CCCCHCH), 7.38–7.44 (m, 2H, C≡CCCCCHCH), 7.50 (d, J=8.2 Hz, 
1H, CH2CHCHCCH), 7.56–7.60 (m, 2H, C≡CCCCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.18 
(OCH2CH3), 17.45 (NCH2CH2CH2C≡C), 24.54 (NCH2CH2CH2CH), 25.68 (NCH2CH2CH2C≡C), 26.93 
(NCH2CHCH2), 41.83 (NCH2CH), 53.73 (NCH2CH2CH2CH), 55.42 (NCH2CH), 57.55 (NCH2CH2CH2C≡C), 
60.23 (OCH2CH3), 80.25 (CH2C≡C), 92.79 (CH2C≡C), 122.15 (CH2C≡CC), 126.85 (CH2C≡CCCHCH), 
127.17 (C≡CCCCCHCHCH), 127.70 (CH2C≡CCCHCHCH), 127.76 (2C, C≡CCCCCHCH), 129.20 (2C, 
C≡CCCCCH), 129.35 (CH2C≡CCCCH), 132.94 (CH2C≡CCCH), 140.73 (C≡CCCC), 143.54 (C≡CCC), 
174.22 (C=O) ppm; IR (KBr): ṽ=3385, 3060, 2941, 2806, 2770, 2226, 1730, 1476, 1449, 1432, 1370, 1306, 
1178, 1151, 1104, 1030, 757, 736, 699 cm-1; MS (CI, CH5+) m/z: 376 [M+H]+; HRMS-EI+ m/z [M]+ calcd for 
C25H29NO2: 375.2198, found: 375.2192.  
Ethyl 1-{4-[2-(2-chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15b): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.39 (qd, 
J=11.9, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.45–1.57 (m, 1H, NCH2CHaxHeqCH2CH), 1.68 (dp, J=13.1, 3.3 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.86–2.00 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.15 (t, J=10.7 Hz, 
1H, NCHaxHeqCH), 2.33–2.44 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.50 (tt, J=10.4, 3.8 Hz, 1H, 
NCH2CHax), 2.65 (dbr, J=11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 2.88 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH), 4.12 (q, 
J=7.1 Hz, 2H, OCH2CH3), 7.24–7.36 (m, 6H, C≡CCCCH, ClCCCH, ClCCCHCH, ClCCHCH, C≡CCCHCH, 
C≡CCCCHCH), 7.43–7.51 (m, 2H, ClCCH, C≡CCCH,) ppm; 13C NMR (101 MHz, CDCl3): δ=14.16 
(OCH2CH3), 17.42 (NCH2CH2C≡C), 24.51 (NCH2CH2CH2CH), 26.77 (NCH2CHCH2), 41.78 (NCH2CH), 53.03 
(NCH2CH2CH2CH), 54.86 (NCH2CH), 57.08 (NCH2CH2C≡C), 60.27 (OCH2CH3), 80.04 (C≡CCCH), 91.80 
(C≡CCCH), 123.38 (CH2C≡CC), 126.13 (ClCCCHCH), 127.28 (CH2C≡CCCHCHCH), 127.54 
(CH2C≡CCCHCH), 128.65 (ClCCCH), 129.22 (ClCCH), 129.53 (CH2C≡CCCCH), 131.46 (ClCCHCH), 131.83 
(CH2C≡CCCH), 133.28 (ClC), 139.79 (ClCC), 141.80 (ClCCC), 174.08 (C=O) ppm; IR (KBr): ṽ=3360, 3059, 
2977, 2941, 2810, 2229, 1728, 1586, 1490, 1466, 1444, 1366, 1252, 1177, 1153, 1100, 1071, 1033, 757 cm -
1; MS (CI, CH5+) m/z: 396 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H26ClNO2: 395.1652, found: 395.1653. 
- Second publication -
5 
Ethyl 1-{5-[2-(2-chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16b): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.44 
(qd, J=12.1, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.50–1.60 (m, 1H, NCH2CHaxHeqCH2CH), 1.64 (p, J=7.2 Hz, 2H, 
NCH2CH2CH2C≡C), 1.71 (dp, J=13.2, 3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.88–1.97 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.11 (t, J=10.5 Hz, 1H, NCHaxHeqCH), 2.27–2.35 (m, 4H, 
NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.53 (tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.66 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.90 (dbr, J=10.2 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.24–7.34 
(m, 3H, C≡CCCHCH, C≡CCCCH, C≡CCCCHCH), 7.37 (d, J=8.5 Hz, 2H, ClCCH), 7.47–7.52 (m, 3H, 
ClCCHCH, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.34 (OCH2CH3), 17.60 (NCH2CH2CH2C≡C), 
24.72 (NCH2CH2CH2CH), 25.86 (NCH2CH2CH2C≡C), 27.07 (NCH2CHCH2), 42.00 (NCH2CH), 53.96 
(NCH2CH2CH2CH), 55.54 (NCH2CH), 57.75 (NCH2CH2CH2C≡C), 60.41 (OCH2CH3), 80.14 (CH2C≡C), 93.38 
(CH2C≡C), 122.28 (CH2C≡CC), 126.00 (ClCCCHCH), 127.37 (CH2C≡CCCHCH), 127.96 
(CH2C≡CCCHCHCH), 128.13 (ClCCCH), 128.75 (ClCCH),  129.30 (CH2C≡CCCCH), 130.72 (CH2C≡CCCH), 
133.18 (ClCCHCH), 133.35 (ClC), 139.34 (ClCC), 142.43 (ClCCC), 174.37 (C=O) ppm; IR (KBr): ṽ=3435, 
3059, 2941, 2806, 2771, 2229, 1730, 1466, 1441, 1428, 1371, 1306, 1178, 1151, 1104, 1072, 1032, 1005, 
756 cm-1; MS (CI, CH5+) m/z: 410 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H28ClNO2: 409.1809, found: 
409.1811. 
Ethyl 1-{4-[2-(2-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15c): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.40 (qd, 
J=12.0, 3.8 Hz, 1H, NCH2CHCHaxHeq), 1.46–1.58 (m, 1H, NCH2CHaxHeqCH2CH), 1.69 (dp, J=13.4, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.87–1.95 (m, 1H, NCH2CHCHaxHeq), 1.99 (td, J=11.0/2.8 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.17 (t, J=10.7 Hz, 1H, NCHaxHeqCH), 2.39–2.55 (m, 5H, NCH2CH2C≡C, 
NCH2CH2C≡C, NCH2CHax), 2.68 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.91 (dd, J=11.1, 3.1 Hz, 1H, 
NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.10–7.20 (m, 2H, FCCH, FCCCHCH), 7.27–7.37 (m, 4H, 
FCCHCH, C≡CCCCH, C≡CCCCHCH, C≡CCCHCH), 7.41 (td, J=7.5, 1.8 Hz, 1H, FCCCH), 7.50 (dt, J=7.0, 
1.3 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.15 (OCH2CH3), 17.47 (NCH2CH2C≡C), 24.52 
(NCH2CH2CH2CH), 26.77 (NCH2CHCH2), 41.78 (NCH2CH), 53.07 (NCH2CH2CH2CH), 54.88 (NCH2CH), 
57.10 (NCH2CH2C≡C), 60.28 (OCH2CH3), 80.21 (C≡CCCH), 91.39 (C≡CCCH), 115.43 (d, 2JCF=22.4 Hz, 
FCCH), 123.40 (CH2C≡CC), 123.45 (d, 4JCF=3.5 Hz, FCCCHCH), 127.46 (CH2C≡CCCHCH), 127.54 
(CH2C≡CCCHCHCH), 128.42 (d, 2JCF=15.3 Hz, FCC), 129.22 (d, 3JCF=8.1 Hz, FCCHCH), 129.96 
(CH2C≡CCCCH), 131.83 (d, 3JCF=2.8 Hz, FCCCH), 132.24 (CH2C≡CCCH), 138.09 (CH2C≡CCC), 159.67 (s, 
1JCF=247.4 Hz, FC), 174.08 (C=O) ppm; IR (KBr): ṽ=3437, 3061, 2978, 2943, 2854, 2810, 2228, 1730, 1500, 
1472, 1440, 1370, 1305, 1213, 1180, 1153, 1100, 1033, 824, 757 cm-1 ; MS (CI, CH5+) m/z: 380 [M+H]+; 
HRMS-EI+ m/z [M]+ calcd for C24H26FNO2: 379.1948, found: 379.1947. 
Ethyl 1-{5-[2-(2-fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16c): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.43 
(qd, J=12.3, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.48–1.63 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 
1.70 (dp, J=13.1, 3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.86–1.96 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH2CH2CH), 2.09 (t, J=10.5 Hz, 1H, NCHaxHeqCH), 2.22–2.32 (m, J=8.4, 6.8 Hz, 4H, 
NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.52 (tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.65 (dbr, J=11.3 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.88 (dbr, J=10.4 Hz, 1H, NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.10–7.21 
(m, 2H, FCCH, FCCCHCH), 7.27–7.37 (m, 4H, C≡CCCCH, C≡CCCCHCH, C≡CCCHCH, FCCHCH), 7.41 
(td, J=7.5, 1.8 Hz, 1H, FCCCH), 7.51 (dt, J=6.5, 1.5 Hz, 1 H, C≡CCCH); 13C NMR (101 MHz, CDCl3): 
δ=14.18 (OCH2CH3), 17.34 (NCH2CH2CH2C≡C), 24.54 (NCH2CH2CH2C≡C), 25.68 (NCH2CH2CH2CH), 26.94 
(NCH2CHCH2), 41.84 (NCH2CH), 53.71 (NCH2CH2CH2CH), 55.41 (NCH2CH), 57.40 (NCH2CH2CH2C≡C), 
60.24 (OCH2CH3), 79.64 (CH2C≡C), 92.88 (CH2C≡C), 115.45 (d, 2JCF=22.4 Hz, FCCH), 123.49 (d, 4JCF=3.5 
Hz, FCCCHCH), 123.60 (CH2C≡CC), 127.35 (CH2C≡CCCHCH), 127.54 (CH2C≡CCCHCHCH), 128.53 (s, 
2JCF=15.4 Hz, FCC), 129.21 (d, 3JCF=8.0 Hz, FCCHCH), 129.96 (CH2C≡CCCCH), 131.81 (d, 3JCF=3.2 Hz, 
FCCCH), 132.30 (CH2C≡CCCH), 138.01 (CH2C≡CCC), 159.69 (d, 1JCF=247.3 Hz, FC), 174.24 (C=O) ppm; 
IR (KBr): ṽ=3434, 3061, 2942, 2865, 2807, 2771, 2229, 1730, 1500, 1472, 1439, 1371, 1306, 1212, 1179, 
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1152, 1106, 1031, 824, 757 cm-1 ; MS (CI, CH5+) m/z: 394 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H28FNO2: 
393.2104, found: 393.2105.  
Ethyl 1-{4-[2-(2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15d): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.39 (qd, 
J=11.9, 3.8 Hz, 1H, NCH2CHCHaxHeq), 1.44–1.56 (m, 1H, NCH2CHaxHeqCH2CH), 1.67 (dp, J=13.1, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.87–2.00 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.10–2.19 (m, 4H, 
NCHaxHeqCH, H3CC), 2.31–2.39 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.49 (tt, J=10.4, 3.8 Hz, 1H, 
NCH2CHax), 2.64 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.87 (dbr, J=9.8 Hz, 1H, NCHaxHeqCH), 4.12 (q, 
J=7.1 Hz, 2H, OCH2CH3), 7.14–7.34 (m, 7H, HAr), 7.46 (dd, J=7.6, 1.4 Hz, 1H, C≡CCCH) ppm; 13C NMR 
(101 MHz, CDCl3): δ=14.18 (OCH2CH3), 17.45 (NCH2CH2C≡C), 19.96 (H3CC), 24.54 (NCH2CH2CH2CH), 
26.79 (NCH2CHCH2), 41.81 (NCH2CH), 53.05 (NCH2CH2CH2CH), 54.88 (NCH2CH), 57.13 (NCH2CH2C≡C), 
60.28 (OCH2CH3), 80.45 (C≡CCCH), 91.27 (C≡CCCH), 123.26 (CH2C≡CC), 125.17 (CH2C≡CCCCH), 
126.81 (CH2C≡CCCHCH), 127.31 (H3CCCHCH), 127.42 (CH2C≡CCCHCHCH), 129.35 (H3CCCCHCH), 
129.56 (2C, H3CCCCH, H3CCCH), 131.78 (CH2C≡CCCH), 136.13 (H3CC), 140.95 (H3CCC), 144.40 
(CH2C≡CCC), 174.12 (C=O) ppm; IR (KBr): ṽ=3363, 3059, 2940, 2853, 2808, 2228, 1731, 1561, 1473, 1442, 
1370, 1310, 1179, 1152, 1133, 1101, 1033, 757 cm-1 ; MS (CI, CH5+) m/z: 376 [M+H]+; HRMS-EI+ m/z [M]+ 
calcd for C25H29NO2: 375.2198, found: 375.2197.  
Ethyl 1-{5-[2-(2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16d): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.26 (t, J=7.1 Hz, 3H, OCH2CH3), 1.37–
1.59 (m, 4H, NCH2CHCHaxHeq, NCH2CH2CH2C≡C, NCH2CHaxHeqCH2CH), 1.69 (dp, J=13.0, 3.5 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.84–1.95 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.06 (t, J=10.7 Hz, 1H, 
NCHaxHeqCH), 2.12–2.18 (m, 5H, NCH2CH2CH2C≡C, H3CC), 2.22 (t, J=6.9 Hz, 2H, NCH2CH2CH2C≡C), 2.51 
(tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.63 (dbr, J=11.4 Hz, 1H, NCHaxHeqCH2CH2CH), 2.85 (dbr, J=10.3 Hz, 1H, 
NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.15–7.34 (m, 7H, HAr), 7.47 (dd, J=7.2,1.9 Hz, 1H, 
C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.21 (OCH2CH3), 17.27 (NCH2CH2CH2C≡C), 19.97 (H3CC), 
24.56 (NCH2CH2CH2CH), 25.69 (NCH2CH2CH2C≡C), 26.97 (NCH2CHCH2), 41.87 (NCH2CH), 53.68 
(NCH2CH2CH2CH), 55.41 (NCH2CH), 57.24 (NCH2CH2CH2C≡C), 60.23 (OCH2CH3), 79.88 (C≡CCCH), 92.65 
(C≡CCCH), 123.42 (CH2C≡CC), 125.22 (CH2C≡CCCCH), 126.80 (CH2C≡CCCHCH), 127.31 (2 C, 
H3CCCHCH, CH2C≡CCCHCHCH), 129.36 (H3CCCCHCH), 129.58 (2 C, H3CCCCH, H3CCCH), 131.88 
(CH2C≡CCCH), 136.09 (H3CC), 141.04 (H3CCC), 144.27 (CH2C≡CCC), 174.27 (C=O) ppm; IR (KBr): 
ṽ=3357, 3059, 2940, 2807, 2771, 2228, 1731, 1560, 1474, 1442, 1372, 1306, 1178, 1151, 1132, 1104, 1031, 
758 cm-1 ; MS (CI, CH5+) m/z: 390 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C26H31NO2: 389.2355, found: 
389.2354.  
Ethyl 1-{4-[2-(4-chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15e): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.42 (qd, 
J=11.8, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.48–1.59 (m, 1H, NCH2CHaxHeqCH2CH), 1.70 (dp, J=13.2, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.88–1.96 (m, 1H, NCH2CHCHaxHeq), 2.03 (td, J=10.9, 2.6 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.20 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.45–2.58 (m, 5H, NCH2CHax, NCH2CH2C≡C, 
NCH2CH2C≡C), 2.72 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (dbr, J=10.9 Hz, 1H, NCHaxHeqCH), 
4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.24–7.33 (m, 3H, C≡CCCHCH, C≡CCCCH, C≡CCCCHCH), 7.37 (d, 
J=8.4 Hz, 2H, CClCH), 7.47–7.52 (m, 3H, CClCHCH, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.31 
(OCH2CH3), 17.79 (NCH2CH2C≡C), 24.68 (NCH2CH2CH2CH), 26.92 (NCH2CHCH2), 41.95 (NCH2CH), 53.34 
(NCH2CH2CH2CH), 55.09 (NCH2CH), 57.19 (NCH2CH2C≡C), 60.45 (OCH2CH3), 80.67 (CH2C≡C), 91.91 
(CH2C≡C), 122.10 (CH2C≡CC), 127.35 (CH2C≡CCCHCH), 128.08 (3 C, CH2C≡CCCHCHCH, ClCCH), 
129.29 (CH2C≡CCCCH), 130.71 (CH2C≡CCCH), 133.19 (2 C, ClCCHCH), 133.39 (CCl), 139.22 
(ClCCHCHC), 142.44 (CH2C≡CCC), 174.22 (C=O) ppm; IR (KBr): ṽ=3435, 3059, 2943, 2854, 2810, 2227, 
1730, 1597, 1497, 1475, 1442, 1397, 1370, 1305, 1180, 1153, 1091, 1032, 1005 758 cm -1; MS (CI, CH5+) 
m/z: 396 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H26ClNO2: 395.1652, found: 395.1652. 
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Ethyl 1-{5-[2-(4-chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16e): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.44 
(qd, J=12.1, 3.7 Hz, 1H, NCH2CHCHaxHeq), 1.50–1.60 (m, 1H, NCH2CHaxHeqCH2CH), 1.64 (p, J=7.2 Hz, 2H, 
NCH2CH2CH2C≡C), 1.71 (dp, J=13.2, 3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.88–1.97 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.11 (t, J=10.5 Hz, 1H, NCHaxHeqCH), 2.27–2.35 (m, 4H, 
NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.53 (tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.66 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.90 (dbr, J=10.2 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.24–7.34 
(m, 3H, C≡CCCHCH, C≡CCCCH, C≡CCCCHCH), 7.37 (d, J=8.5 Hz, 2H, ClCCH), 7.47–7.52 (m, 3H, 
ClCCHCH, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.34 (OCH2CH3), 17.60 (NCH2CH2CH2C≡C), 
24.72 (NCH2CH2CH2CH), 25.86 (NCH2CH2CH2C≡C), 27.07 (NCH2CHCH2), 42.00 (NCH2CH), 53.96 
(NCH2CH2CH2CH), 55.54 (NCH2CH), 57.75 (NCH2CH2CH2C≡C), 60.41 (OCH2CH3), 80.14 (CH2C≡C), 93.38 
(CH2C≡C), 122.28 (CH2C≡CC), 127.37 (CH2C≡CCCHCH), 127.96 (CH2C≡CCCHCHCH), 128.13 (2 C, 
ClCCH), 129.30 (ClCCHCHC), 130.72 (CH2C≡CCCH), 133.18 (2C, ClCCHCH), 133.35 (ClC), 139.34 
(ClCCHCHCC), 142.43 (CH2C≡CCC), 174.37 (C=O) ppm; IR (KBr): ṽ = 3435, 3059, 2942, 2865, 2807, 2771, 
2227, 1730, 1593, 1497, 1475, 1441, 1371, 1306, 1178, 1151, 1091, 1030, 1004, 831, 759 cm -1; MS (CI, 
CH5+) m/z: 410 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H28ClNO2: 409.1809, found: 409.1811. 
Ethyl 1-{4-[2-(2,4-dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15f): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.36–
1.57 (m, 2H, NCH2CHCHaxHeq, NCH2CHaxHeqCH2CH), 1.70 (dp, J=10.8, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 
1.88–2.02 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.17 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.36–2.45 
(m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.51 (tt, J=10.5, 3.8 Hz, 1H, NCH2CHax), 2.67 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.90 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.21–7.36 
(m, 5H, C≡CCCCH, ClCCHCH, ClCCHCH, C≡CCCHCH, C≡CCCCHCH), 7.46–7.50 (m, 2H, ClCCHCCCl, 
C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.16 (OCH2CH3), 17.55 (NCH2CH2C≡C), 24.51 
(NCH2CH2CH2CH), 26.76 (NCH2CHCH2), 41.77 (NCH2CH), 53.15 (NCH2CH2CH2CH), 54.90 (NCH2CH), 
57.09 (NCH2CH2C≡C), 60.28 (OCH2CH3), 79.81 (C≡CCCH), 92.21 (C≡CCCH), 123.39 (CH2C≡CC), 126.49 
(ClCCHCH), 127.37 (ClCCCCHCH), 127.85 (CH2C≡CCCHCH), 129.06 (ClCCHCCl), 129.47 (ClCCCCH), 
131.98 (CH2C≡CCCH), 132.31 (ClCCHCH), 133.71 (CCl), 134.14 (CCl), 138.36 (ClCCHCHC), 140.59 
(ClCCC), 174.05 (C=O) ppm; IR (KBr): ṽ=3376, 3061, 2941, 2852, 2809, 2229, 1730, 1586, 1466, 1440, 
1372, 1305, 1179, 1152, 1101, 1032, 1004, 863, 812, 760  cm-1; MS (CI, CH5+) m/z: 430 [M+H]+; HRMS-EI+ 
m/z [M]+ calcd for C24H25Cl2NO2: 429.1262, found: 429.1236. 
Ethyl 1-{5-[2-(2,4-dichlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16f): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.38–
1.59 (m, 4H, NCH2CHCHaxHeq, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.71 (dp, J=13.0, 3.6 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.86–1.97 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.09 (t, J=10.5 Hz, 1H, 
NCHaxHeqCH), 2.17–2.22 (m, 2H, NCH2CH2CH2C≡C), 2.25 (t, J=6.9 Hz, 2H, NCH2CH2CH2C≡C), 2.52 (tt, 
J=10.3, 3.7 Hz, 1H, NCH2CHax), 2.64 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.87 (dbr, J=10.5 Hz, 1H, 
NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.19–7.34 (m, 5H, ClCCCCH, ClCCCH, ClCCHCH, 
ClCCCCHCH, C≡CCCHCH), 7.45–7.51 (m, 2H, ClCCHCCl, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): 
δ=14.19 (OCH2CH3), 17.29 (NCH2CH2CH2C≡C), 24.56 (NCH2CH2CH2CH), 25.68 (NCH2CH2CH2C≡C), 26.91 
(NCH2CHCH2), 41.84 (NCH2CH), 53.74 (NCH2CH2CH2CH), 55.37 (NCH2CH), 57.33 (NCH2CH2CH2C≡C), 
60.23 (OCH2CH3), 79.25 (CH2C≡C), 93.61 (CH2C≡C), 123.56 (CH2C≡CC), 126.53 (ClCCCH), 127.26 
(ClCCCCHCH), 127.85 (CH2C≡CCCHCH), 129.10 (ClCCHCCl), 129.46 (ClCCCCH), 132.05 (CH2C≡CCCH), 
132.29 (ClCCHCH), 133.69 (CCl), 134.15 (CCl), 138.48 (ClCCC), 140.48 (ClCCC), 174.20 (C=O) ppm; IR 
(KBr): ṽ=3380, 3061, 2941, 2806, 2771, 2229, 1730, 1586, 1466, 1439, 1373, 1306, 1178, 1151, 1101, 1071, 
1029, 864, 813, 760 cm-1; MS (CI, CH5+) m/z: 444 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H27Cl2NO2: 
443.1419, found: 443.1438. 
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Ethyl 1-{4-[2-(2,4-difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15g): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.42 (qd, 
J=12.0, 3.8, 1H, NCH2CHCHaxHeq), 1.47–1.59 (m, 1H, NCH2CHaxHeqCH2CH), 1.70 (dp, J=13.0, 3.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.92 (dq, J=12.6, 3.8, 1H, NCH2CHCHaxHeq), 2.02 (td, J=10.9, 2.8 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.19 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.40–2.55 (m, 5H, NCH2CH2C≡C, 
NCH2CH2C≡C, NCH2CHax), 2.70 (dt, J=11.2, 3.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.93 (dd, J=11.0, 3.2 Hz, 
1H, NCHaxHeqCH), 4.12 (q, J=7.2 Hz, 2H, OCH2CH3), 6.85–6.97 (m, 2H, FCCHCF, FCCHCH), 7.27–7.42 (m, 
4H, C≡CCCCH, C≡CCCCHCH, C≡CCCHCH, FCCCH), 7.48–7.53 (m, 1H, C≡CCCH) ppm; 13C NMR (101 
MHz, CDCl3): δ=14.15 (OCH2CH3), 17.51 (NCH2CH2C≡C), 24.52 (NCH2CH2CH2CH), 26.76 (NCH2CHCH2), 
41.79 (NCH2CH), 53.16 (NCH2CH2CH2CH), 54.90 (NCH2CH), 57.14 (NCH2CH2C≡C), 60.30 (OCH2CH3), 
80.03 (C≡CCCH), 91.61 (C≡CCCH), 103.39 (d, 2JCF=25.8 Hz, FCCHCF), 110.65 (dd, 2JCF=21.0 Hz, 4JCF=3.7 
Hz, FCCHCH), 123.50 (CH2C≡CC), 124.57 (dd, 2JCF=15.6 Hz, 4JCF=3.8 Hz, FCC), 127.54 (CH2C≡CCCHCH), 
127.71 (CH2C≡CCCHCHCH), 129.99 (CH2C≡CCCCH), 132.38 (CH2C≡CCCH), 132.55 (dd, 3JCF=9.5, 
3JCF=4.9 Hz, FCCCH), 137.11 (CH2C≡CCC), 159.76 (dd, 1JCF=249.9, 3JCF=11.9 Hz, CF), 162.41 (dd, 
1JCF=248.5, 3JCF=11.6 Hz, CF), 174.05 (C=O) ppm; IR (KBr): ṽ=3423, 3061, 2941, 2854, 2811, 2228, 1729, 
1618, 1593, 1510, 1478, 1420, 1370, 1265, 1179, 1152, 1139, 1099, 1032, 963, 849, 761 cm-1; MS (CI, 
CH5+) m/z: 398 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H25F2NO2: 397.1853, found: 397.1848.  
Ethyl 1-{5-[2-(2,4-difluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16g): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.44 
(qd, J=11.8, 3.6 Hz, 1H, NCH2CHCHaxHeq), 1.49 – 1.65 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 
1.71 (dp, J=13.1, 3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.86–1.98 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH2CH2CH), 2.11 (t, J=10.5 Hz, 1H, NCHaxHeqCH), 2.24–2.32 (m, 4H, NCH2CH2CH2C≡C, 
NCH2CH2CH2C≡C), 2.53 (tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.66 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.89 (dbr, J=10.3 Hz, 1H, NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 6.86–6.96 
(m, 2H, FCCHCF, FCCHCH), 7.26–7.42 (m, 4H, C≡CCCCH, C≡CCCCHCH, C≡CCCHCH, FCCCH), 7.47–
7.53 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.17 (OCH2CH3), 17.33 (NCH2CH2CH2C≡C), 
24.56 (NCH2CH2CH2CH), 25.76 (NCH2CH2CH2C≡C), 26.93 (NCH2CHCH2), 41.85 (NCH2CH), 53.78 
(NCH2CH2CH2CH), 55.41 (NCH2CH), 57.45 (NCH2CH2CH2C≡C), 60.25 (OCH2CH3), 79.47 (CH2C≡C), 93.12 
(CH2C≡C), 103.79 (d, 2JCF=25.8 Hz, 1C, FCCHCF), 110.68 (dd, 2JCF=21.1 Hz, 4JCF=3.7 Hz, FCCHCH), 
123.70 (CH2C≡CC), 124.68 (dd, 2JCF=15.6 Hz, 4JCF=3.6 Hz, FCCCH), 127.43 (CH2C≡CCCHCH), 127.72 
(CH2C≡CCCHCHCH), 129.97 (CH2C≡CCCCH), 132.40 (CH2C≡CCCH), 132.52 (dd, 3JCF=9.4 Hz, 3JCF=4.9 
Hz, FCCCH), 137.06 (CH2C≡CCC), 158.41–161.12 (dd, 1JCF = 250.2 Hz, 3JCF = 12.1 Hz, CF), 162.38 (dd, 
1JCF = 248.7 Hz, 3JCF = 11.7 Hz, CF), 174.21 (C=O) ppm; IR (KBr): ṽ=3347, 3061, 2941, 2865, 2806, 2771, 
2230, 1730, 1618, 1593, 1511, 1479, 1420, 1266, 1178, 1140, 1099, 1030, 964, 849, 761 cm -1; MS (CI, 
CH5+) m/z: 412 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H27F2NO2: 411.2010, found: 411.2008.  
Ethyl 1-{4-[2-(2,4-dimethylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15h): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.40 (qd, 
J=12.0, 3.9 Hz, 1H, NCH2CHCHaxHeq), 1.45–1.55 (m, 1H, NCH2CHaxHeqCH2CH), 1.68 (dp, J=13.2, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.86–1.98 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.09–2.18 (m, 4H, 
H3CCCHCC, NCHaxHeqCH), 2.32–2.42 (m, 7H, H3CCC, NCH2CH2C≡C, NCH2CH2C≡C), 2.50 (tt, J=10.5, 3.8 
Hz, 1H, NCH2CHax), 2.64 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.88 (dbr, J=9.5 Hz, 1H, NCHaxHeqCH), 
4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.01 (d, J=8.2 Hz, 1H, H3CCCHCH), 7.04–7.08 (m, 2H, H3CCCHCH, 
H3CCCHC), 7.18 (dd, J=7.5, 1.2 Hz, 1H, C≡CCCCH), 7.25 (td, J=7.5, 1.6 Hz, 1H, C≡CCCHCH), 7.29 (td, 
J=7.5, 1.5 Hz, 1H, C≡CCCCHCH), 7.45 (dd, J=7.6, 1.3 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): 
δ=14.16 (OCH2CH3), 17.56 (NCH2CH2C≡C), 19.87 (H3CCC), 21.11 (H3CCCHCC), 24.52 (NCH2CH2CH2CH), 
26.80 (NCH2CHCH2), 41.79 (NCH2CH), 53.06 (NCH2CH2CH2CH), 54.94 (NCH2CH), 57.17 (NCH2CH2C≡C), 
60.25 (OCH2CH3), 80.61 (C≡CCCH), 91.15 (C≡CCCH), 123.39 (CH2C≡CC), 125.87 (H3CCCHCH), 126.64 
(CH2C≡CCCHCH), 127.36 (CH2C≡CCCHCHCH), 129.53 (2 C, H3CCCHCH, CH2C≡CCCCH), 130.35 
(H3CCCHCC), 131.78 (CH2C≡CCCH), 135.89 (H3CCC), 136.72 (H3CCCHCC), 138.09 (H3CCC), 144.39 
(CH2C≡CCCH), 174.06 (C=O) ppm; IR (KBr): ṽ=3387, 3057, 2941, 2856, 2810, 2228, 1730, 1615, 1476, 
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1441, 1371, 1305, 1217, 1180, 1153, 1133, 1101, 1032, 755 cm -1; MS (CI, CH5+) m/z: 390 [M+H]+; HRMS-
EI+ m/z [M]+ calcd for C26H31NO2: 389.2355, found: 389.2360.  
Ethyl 1-{5-[2-(2,4-dimethylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16h): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.39–
1.57 (m, 4H, NCH2CHCHaxHeq, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.69 (dp, J=13.1, 3.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.85–1.95 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.07 (t, J=10.5 Hz, 1H, 
NCHaxHeqCH), 2.12–2.17 (m, 5H, H3CCCHCC, NCH2CH2CH2C≡C), 2.24 (t, J=6.9 Hz, 2H, 
NCH2CH2CH2C≡C), 2.35 (s, 3H, H3CC), 2.51 (tt, J=10.5, 3.8 Hz, 1H, NCH2CHax), 2.62 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.86 (dbr, J=9.5 Hz, 1H, NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.02 (d, 
J=8.2 Hz, 1H, H3CCCHCH), 7.05–7.08 (m, 2H, H3CCCHCH, H3CCCHC), 7.15–7.19 (m, 1H, C≡CCCCH), 
7.25 (td, J=7.5, 1.6 Hz, 1H, C≡CCCHCH), 7.29 (td, J=7.5, 1.5 Hz, 1H, C≡CCCCHCH), 7.46 (dd, J=7.6, 1.3 
Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.21 (OCH2CH3), 17.32 (NCH2CH2CH2C≡C), 19.91 
(H3CCC), 21.14 (H3CCCHCC), 24.60 (NCH2CH2CH2CH), 25.72 (NCH2CH2CH2C≡C) 26.99 (NCH2CHCH2), 
41.90 (NCH2CH), 53.68 (NCH2CH2CH2CH), 55.41 (NCH2CH), 57.26 (NCH2CH2CH2C≡C), 60.24 (OCH2CH3), 
80.07 (C≡CCCH), 92.48 (C≡CCCH), 123.56 (CH2C≡CC), 125.94 (H3CCCHCH), 126.66 (CH2C≡CCCHCH), 
127.27 (CH2C≡CCCHCHCH), 129.53 (H3CCCHCH or CH2C≡CCCCH), 129.62 (H3CCCHCH or 
CH2C≡CCCCH), 130.43 (H3CCCHCC), 131.92 (CH2C≡CCCH), 135.88 (H3CCC), 136.69 (H3CCCHCC), 
138.19 (H3CCC), 144.25 (CH2C≡CCCH), 174.25 (C=O) ppm; IR (KBr): ṽ=3358, 3057, 2941, 2865, 2806, 
2227, 1731, 1615, 1476, 1440, 1372, 1306, 1178, 1151, 1132, 1104, 1030, 760 cm-1; MS (CI, CH5+) m/z: 404 
[M+H]+; HRMS-EI+ m/z [M]+ calcd for C27H33NO2: 403.2511, found: 403.2520.  
Ethyl 1-{4-[2-(2-chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15i): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, J=7.1 Hz, 3H, OCH2CH3), 1.41 (qd, 
J=11.8, 3.9 Hz, 1H, NCH2CHCHaxHeq), 1.47–1.59 (m, 1H, NCH2CHaxHeqCH2CH), 1.69 (dp, J=10.8, 3.8 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.92 (dq, J=13.0, 4.0 Hz, 1H, NCH2CHCHaxHeq), 2.00 (td, J=11.1, 3.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.18 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 2.35–2.46 (m, 4H, NCH2CH2C≡C, 
NCH2CH2C≡C), 2.51 (tt, J=10.5, 3.9 Hz, 1H, NCH2CHax), 2.68 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.91 (dbr, J=10.7 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.2 Hz, 2H, OCH2CH3), 7.02 (td, J=8.3, 2.6 Hz, 1H, 
FCCHCH), 7.20–7.25 (m, 2H, FCCHCCl, C≡CCCCH), 7.27–7.30 (m, 1H, FCCHCH), 7.30–7.36 (m, 2H, 
C≡CCCHCH, C≡CCCCHCH), 7.47–7.50 (m, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, CDCl3, 25 °C, TMS): 
δ=14.18 (OCH2CH3), 17.50 (NCH2CH2C≡C), 24.51 (NCH2CH2CH2CH), 26.78 (NCH2CHCH2), 41.78 
(NCH2CH), 53.16 (NCH2CH2CH2CH), 54.91 (NCH2CH), 57.15 (NCH2CH2C≡C), 60.33 (OCH2CH3), 79.95 
(C≡CCCH), 92.01 (C≡CCCH), 113.44 (d, 2JCF=20.9 Hz, FCCHCH), 116.53 (d, 2JCF=24.5 Hz, FCCHCCl), 
123.62 (CH2C≡CC), 127.37 (CH2C≡CCCHCHCH), 127.76 (CH2C≡CCCHCH), 129.72 (CH2C≡CCCCH), 
132.00 (CH2C≡CCCH), 132.46 (d, 3JCF=8.6 Hz, FCCHCH), 134.13 (d, 3JCF=10.4 Hz, ClC), 135.99 (d, 4JCF = 
4.1 Hz, ClCC), 140.79 (d, CH2C≡CCC), 161.81 (d, 1JCF = 249.3 Hz, FC), 174.04 (C=O) ppm; IR (KBr): 
ṽ=3062, 2941, 2855, 2807, 2228, 1730, 1604, 1503, 1473, 1442, 1370, 1257, 1201, 1181, 1153, 1100, 1033, 
897, 858, 761 cm-1; MS (EI, 70 eV) m/z: 413 [M]+; HRMS-EI+ m/z [M]+ calcd for C24H25ClFNO2: 413.1558, 
found: 413.1570. 
Ethyl 1-{5-[2-(2-chloro-4-fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16i): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (500 MHz, CDCl3): δ=1.26 (t, J=7.2 Hz, 3H, OCH2CH3), 1.44 
(qd, J=11.8, 4.1 Hz, 1H, NCH2CHCHaxHeq), 1.51–1.62 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 
1.71 (dp, J=13.3, 3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.89–1.98 (m, 2H, NCH2CHCHaxHeq,), 2.11 (t, J=10.8 
Hz, 1H, NCHaxHeqCH2CH2CH), 2.21–2.29 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.55 (tt, J=10.7, 
3.8 Hz, 1H, NCH2CHax), 2.67 (dbr, J=10.4 Hz, 1H, NCHaxHeqCH2CH2CH), 2.90 (dbr, J=10.2 Hz, 1H, 
NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.03 (td, J=8.3, 2.6 Hz, 1H, FCCHCH), 7.20–7.25 (m, 2H, 
FCCHCCl, C≡CCCCH), 7.28–7.31 (m, 1H, FCCHCH), 7.31–7.35 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 
7.46–7.52 (m, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, CDCl3): δ=14.20 (OCH2CH3), 17.32 
(NCH2CH2CH2C≡C), 24.49 (NCH2CH2CH2CH), 25.65 (NCH2CH2CH2C≡C), 26.93 (NCH2CHCH2), 41.77 
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(NCH2CH), 53.74 (NCH2CH2CH2CH), 55.37 (NCH2CH), 57.36 (NCH2CH2CH2C≡C), 60.31 (OCH2CH3), 79.44 
(CH2C≡C), 93.40 (CH2C≡C), 113.51 (d, 2JCF=20.9 Hz, FCCHCH), 116.57 (d, 2JCF=24.5 Hz, FCCHCCl), 
123.78 (CH2C≡CC), 127.28 (CH2C≡CCCHCHCH), 127.77 (CH2C≡CCCHCH), 129.70 (CH2C≡CCCCH), 
132.06 (CH2C≡CCCH), 132.44 (d, 3JCF=8.6 Hz, FCCHCH), 134.15 (d, 3JCF=10.4 Hz, ClC), 136.12 (d, 
4JCF=3.6 Hz, ClCC), 140.72 (CH2C≡CCC), 161.78 (d, 1JCF=249.3 Hz, FC), 174.14 (C=O) ppm; IR (KBr): 
ṽ=3062, 2940, 2807, 2228, 1729, 1604, 1503, 1473, 1442, 1371, 1256, 1201, 1178, 1151, 1029, 897, 857, 
760 cm-1; MS (EI, 70 eV) m/z: 427 [M]+; HRMS-EI+ m/z [M]+ calcd for C25H27ClFNO2: 427.1714, found: 
427.1714. 
Ethyl 1-{4-[2-(4-chloro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15k): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.41 (qd, 
J=11.9, 3.6 Hz, 1H, NCH2CHCHaxHeq), 1.47–1.58 (m, 1H, NCH2CHaxHeqCH2CH), 1.69 (dp, J=10.2, 3.6 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.89–2.00 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.11–2.20 (m, 4H, 
CH3C, NCHaxHeqCH), 2.32–2.43 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.51 (tt, J=10.5, 3.8 Hz, 1H, 
NCH2CHax), 2.66 (dbr, J=11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 2.90 (dbr, J=9.9 Hz, 1H, NCHaxHeqCH), 4.12 (q, 
J=7.1 Hz, 2H, OCH2CH3), 7.10 (d, J=8.1 Hz, 1H, ClCCHCH), 7.13–7.17 (m, 1H, C≡CCCCH), 7.19 (dd, J=8.1, 
1.8 Hz, 1H, ClCCHCH), 7.23–7.34 (m, 3H, ClCCHC, C≡CCCHCH, C≡CCCCHCH), 7.44–7.48 (m, 1H, C6: 
C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.18 (OCH2CH3), 17.58 (NCH2CH2C≡C), 19.88 (CH3C), 
24.52 (NCH2CH2CH2CH), 26.79 (NCH2CHCH2), 41.81 (NCH2CH), 53.17 (NCH2CH2CH2CH), 54.95 
(NCH2CH), 57.16 (NCH2CH2C≡C), 60.28 (OCH2CH3), 80.19 (C≡CCCH), 91.74 (C≡CCCH), 123.33 
(CH2C≡CC), 125.31 (ClCCHCH), 127.15 (CH2C≡CCCHCHCH), 127.51 (CH2C≡CCCHCH), 129.25 
(CH2C≡CCCCH), 129.43 (ClCCHC), 130.90 (ClCCHCH), 131.91 (CH2C≡CCCH), 132.84 (ClC), 138.22 
(H3CC), 139.48 (H3CCC), 143.13 (CH2C≡CCC), 174.05 (C=O) ppm; IR (KBr): ṽ=3059, 3020, 2942, 2854, 
2809, 2228, 1730, 1592, 1472, 1441, 1370, 1305, 1180, 1152, 1098, 1032, 870, 820, 761 cm -1; MS (EI, 70 
eV) m/z: 409 [M]+; HRMS-EI+ m/z [M]+ calcd for C25H28ClNO2: 409.1809, found: 409.1826. 
Ethyl 1-{5-[2-(4-chloro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16k): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.38–
1.61 (m, 4H, NCH2CHCHaxHeq, NCH2CH2CH2C≡C, NCH2CHaxHeqCH2CH), 1.71 (dp, J=12.4, 3.9 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.87–1.97 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.05–2.20 (m, 6H, 
NCHaxHeqCH, H3CC, NCH2CH2CH2C≡C), 2.25 (t, J=6.9 Hz, 2H, NCH2CH2CH2C≡C), 2.53 (tt, J=10.5, 3.8 Hz, 
1H, NCH2CHax), 2.63 (dbr, J=11.6 Hz, 1H, NCHaxHeqCH2CH2CH), 2.87 (dbr, J=10.0 Hz, 1H, NCHaxHeqCH), 
4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 7.11 (d, J=8.2 Hz, 1H, ClCCHCH), 7.12–7.16 (m, 1H, C≡CCCCH), 7.16–
7.20 (m, 1H, ClCCHCH), 7.24 (d, J=2.2 Hz, 1H, ClCCHC), 7.27–7.34 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 
7.44–7.49 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.22 (OCH2CH3), 17.30 
(NCH2CH2CH2C≡C), 19.90 (H3CC), 24.57 (NCH2CH2CH2CH), 25.72 (NCH2CH2CH2C≡C), 26.94 
(NCH2CHCH2), 41.86 (NCH2CH), 53.73 (NCH2CH2CH2CH), 55.37 (NCH2CH), 57.29 (NCH2CH2CH2C≡C), 
60.25 (OCH2CH3), 79.68 (CH2C≡C), 93.04 (CH2C≡C), 123.47 (CH2C≡CC), 125.37 (ClCCHCH), 127.16 
(CH2C≡CCCHCHCH), 127.41 (CH2C≡CCCHCH), 129.29 (ClCCHC), 129.50 (CH2C≡CCCCH), 130.92 
(ClCCHCH), 132.02 (CH2C≡CCCH), 132.83 (ClC), 138.22 (H3CC), 139.59 (H3CCC), 142.99 (CH2C≡CCC), 
174.20 (C=O) ppm; IR (KBr): ṽ=3059, 3020, 2941, 2865, 2807, 2770, 2227, 1730, 1592, 1472, 1441, 1371, 
1305, 1179, 1151, 1097, 1030, 870, 820, 761 cm-1; MS (EI, 70 eV) m/z: 423 [M]+; HRMS-EI+ m/z [M]+ calcd 
for C26H30ClNO2: 423.1965, found: 423.1962. 
Ethyl 1-{4-[2-(4-fluoro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate (15l): 
Rf≈0.3 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.2 Hz, 3H, OCH2CH3,), 1.41 (qd, 
J=11.8/3.7 Hz, 1H, NCH2CHCHaxHeq), 1.46–1.57 (m, 1H, NCH2CHaxHeqCH2CH), 1.68 (dp, J=12.5, 3.8 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.87–2.01 (m, 2H, NCH2CHCHaxHeq, NCH2CHaxHeqCH2CH), 2.12–2.20 (m, 4H, 
H3CC, NCHaxHeqCH), 2.34–2.42 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.50 (tt, J=10.5, 3.8 Hz, 1H, 
NCH2CHax), 2.65 (dbr, J=11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 2.89 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH), 4.12 (q, 
J=7.1 Hz, 2H, OCH2CH3), 6.90 (td, J=8.5, 2.6 Hz, 2H, FCCHCH), 6.95 (dd, J=9.8, 2.9 Hz, 1H, FCCHC), 7.12 
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(dd, J=8.4, 6.0 Hz, 1H, FCCHCH), 7.14–7.18 (m, 1H, C≡CCCCH), 7.24–7.33 (m, 2H, C≡CCCHCH, 
C≡CCCCHCH), 7.43–7.48 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.16 (OCH2CH3), 17.51 
(NCH2CH2C≡C), 20.11 (d, 4JCF=1.0 Hz, H3CC), 24.51 (NCH2CH2CH2CH), 26.78 (NCH2CHCH2), 41.80 
(NCH2CH), 53.15 (NCH2CH2CH2CH), 54.91 (NCH2CH), 57.18 (NCH2CH2C≡C), 60.28 (OCH2CH3), 80.29 
(C≡CCCH), 91.50 (C≡CCCH), 111.93 (d, 2JCF=20.9 Hz, FCCHCH), 116.07 (d, 2JCF=20.9 Hz, FCCHC), 
123.52 (CH2C≡CC), 127.01 (CH2C≡CCCHCH), 127.47 (CH2C≡CCCHCHCH), 129.50 (CH2C≡CCCCH), 
131.02 (d, 3JCF=8.4 Hz, FCCHCH), 131.89 (CH2C≡CCCH), 136.90 (d, 4JCF=3.3 Hz, H3CCC), 138.61 (d, 
3JCF=7.7 Hz, H3CC), 143.34 (CH2C≡CCC), 162.00 (d, 1JCF=245.0 Hz, FC), 174.03 (C=O) ppm; IR (KBr): 
ṽ=3060, 2941, 2855, 2810, 2228, 1730, 1612, 1587, 1476, 1443, 1220, 1152, 1099, 1033, 944, 816, 761 cm -
1; MS (EI, 70 eV) m/z: 393 [M]+; HRMS-EI+ m/z [M]+ calcd for C25H28FNO2: 393.2104, found: 393.2117. 
Ethyl 1-{5-[2-(4-fluoro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylate (16l): 
Rf≈0.25 (hexane/ethyl acetate 8:2). 1H NMR (400 MHz, CDCl3): δ=1.25 (t, J=7.1 Hz, 3H, OCH2CH3), 1.38–
1.60 (m, 4H, NCH2CHCHaxHeq, NCH2CH2CH2CHCH, NCH2CHaxHeqCH2CH), 1.70 (dp, J=12.8, 3.6 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.86–1.96 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.09 (t, J=10.6 Hz, 1H, 
NCHaxHeqCH), 2.14–2.20 (m, 5H, H3CC, NCH2CH2CH2C≡C), 2.24 (t, J=6.9 Hz, 2H, NCH2CH2CH2C≡C), 2.52 
(tt, J=10.3, 3.8 Hz, 1H, NCH2CHax), 2.63 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.86 (dbr, J=10.2 Hz, 1H, 
NCHaxHeqCH), 4.13 (q, J=7.1 Hz, 2H, OCH2CH3), 6.90 (td, J=8.4, 2.4 Hz, 1H, FCCHCH), 6.95 (dd, J=9.9, 3.0 
Hz, 1H, FCCHC), 7.10–7.17 (m, 2H, C≡CCCCH), 7.24–7.33 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 7.45–
7.48 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.20 (OCH2CH3), 17.28 (NCH2CH2CH2C≡C), 
20.13 (d, 4JCF=1.8 Hz, H3CC), 24.55 (NCH2CH2CH2CH), 25.75 (NCH2CH2CH2C≡C), 26.95 (NCH2CHCH2), 
41.86 (NCH2CH), 53.73 (NCH2CH2CH2CH), 55.40, (NCH2CH), 57.29 (NCH2CH2CH2C≡C), 60.24 (OCH2CH3), 
79.76 (CH2C≡C), 92.89 (CH2C≡C), 112.00 (d, 2JCF=20.9 Hz, FCCHCH), 116.15 (d, 2JCF=20.9 Hz, FCCHC), 
123.68 (CH2C≡CC), 127.02 (CH2C≡CCCHCH), 127.37 (CH2C≡CCCHCHCH), 129.51 (CH2C≡CCCCH), 
131.02 (d, 3JCF=8.4 Hz, FCCHCH), 131.97 (CH2C≡CCCH), 137.01 (d, 4JCF=3.1 Hz, H3CCC), 138.59 (d, 
3JCF=7.7 Hz, H3CC), 143.23 (CH2C≡CCC), 161.97 (d, 1JCF=244.9 Hz, FC), 174.20 (C=O) ppm; IR (KBr): 
ṽ=3059, 2941, 2855, 2806, 2228, 1730, 1613, 1587, 1476, 1442, 1220, 1151, 1100, 1030, 944, 860, 761 cm -
1; MS (EI, 70 eV) m/z: 407 [M]+; HRMS-EI+ m/z [M]+ calcd for C26H30FNO2: 407.2261, found 407.2274. 
1-[4-(2-Phenylphenyl)but-3-yn-1-yl]piperidine-3-carboxylic acid (17a): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60°C): δ=1.22 (qd, J=12.7, 3.9 Hz, 
1H, NCH2CHCHaxHeq), 1.38 (qt, J=12.5, 3.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.51 (d, J=13.8 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.66 (td, J=11.6, 3.0 Hz, 1H, NCHaxHeqCH2CH2CH), 1.89 (dbr, J=11.8 Hz, 1H, 
NCH2CHCHaxHeq), 1.99 (t, J=11.3 Hz, 1H, NCHaxHeqCH), 2.18–2.44 (m, 5H, NCH2CH2C≡C, NCH2CH2C≡C, 
NCH2CHax), 2.53 (dbr, J=10.4 Hz, 1H, NCHaxHeqCH2CH2CH), 2.88 (dbr, J=9.2 Hz, 1H, NCHaxHeqCH), 6.81–
6.89 (m, 2H, C≡CCCCCHCHCH, C≡CCCHCH), 6.92 (dd, J=6.9, 2.1 Hz, 1H, C≡CCCCH), 7.09–7.16 (m, 3H, 
C≡CCCCHCH, C≡CCCCCHCH), 7.21–7.28 (m, 3H, C≡CCCH, C≡CCCCCH) ppm;  13C NMR (101 MHz, 1N 
NaOD/CH3OD 1:2, 60 °C): δ=17.98 (NCH2CH2C≡C), 25.67 (NCH2CH2CH2CH), 29.06 (NCH2CHCH2), 46.02 
(NCH2CH), 53.81 (NCH2CH2CH2CH), 57.60 (NCH2CH), 57.93 (NCH2CH2C≡C), 82.50 (C≡CCCH), 93.15 
(C≡CCCH), 122.98 (CH2C≡CC), 128.18 (CH2C≡CCCHCH), 128.63 (C≡CCCCCHCHCH), 129.11 (3C, 
CH2C≡CCCHCHCH, C≡CCCCCHCH), 130.30 (2C, C≡CCCCCH), 130.42 (CH2C≡CCCCH), 134.12 
(CH2C≡CCCH), 141.74 (C≡CCCC), 144.82 (CH2C≡CCC), 183.61 (C=O) ppm; IR (KBr): ṽ=3398, 3058, 2943, 
2858, 2230, 1710, 1595, 1500, 1475, 1448, 1433, 1390, 1300, 1217, 1155, 1101, 1074, 1009, 879, 758, 737, 
700 cm-1; MS (CI, CH5+) m/z: 334 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C22H23NO2: 333.1279, found: 
333.1278. 
1-[5-(2-Phenylphenyl)pent-4-yn-1-yl]piperidine-3-carboxylic acid (18a): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 2:1, 60 °C): δ=1.24 (qd, J=12.6, 4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.35–1.49 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.54 (dbr, J=13.8 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.62 (td, J=11.8, 2.6 Hz, 1H, NCHaxHeqCH2CH2CH), 1.87–1.95 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 1.97–2.19 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.31 (tt, J=11.6, 
- Second publication -
12 
3.9 Hz, 1H, NCH2CHax), 2.51 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.90 (dbr, J=11.8 Hz, 1H, 
NCHaxHeqCH), 6.83–6.89 (m, 2H, C≡CCCCHCH, C≡CCCHCH), 6.91–6.95 (m, 1H, C≡CCCCH), 7.09–7.17 
(m, 3H, C≡CCCCCHCH, C≡CCCCCHCHCH), 7.23–7.31 (m, 3H, C≡CCCH, C≡CCCCCH) ppm; 13C NMR 
(101 MHz, 1N NaOD/CH3OD 2:1, 60 °C): δ=18.69 (NCH2CH2CH2C≡C), 25.70 (NCH2CH2CH2CH), 26.13 
(NCH2CH2CH2C≡C), 29.23 (NCH2CHCH2), 46.05 (NCH2CH), 54.29 (NCH2CH2CH2CH), 58.09 (NCH2CH), 
58.87 (NCH2CH2CH2C≡C), 82.02 (CH2C≡C), 94.31 (CH2C≡C), 123.17 (CH2C≡CC), 128.14 
(CH2C≡CCCHCH), 128.59 (C≡CCCCCHCHCH), 129.02 (CH2C≡CCCHCHCH), 129.12 (2 C, 
C≡CCCCCHCH), 130.28 (2 C, C≡CCCCCH), 130.46 (CH2C≡CCCCH), 134.16 (CH2C≡CCCH), 141.87 
(C≡CCCC), 144.78 (CH2C≡CCC), 183.74 (C=O) ppm; IR (KBr): ṽ=3427, 3057, 3022, 2935, 2858, 2227, 
1709, 1594, 1475, 1449, 1432, 1390, 1186, 1074, 1008, 758, 737, 700 cm -1; MS (CI, CH5+) m/z: 348 [M+H]+; 
HRMS-EI+ m/z [M]+ calcd for C23H25NO2: 347.1885, found: 347.1881.  
1-{4-[2-(2-Chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17b): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, NaOD = 60 °C): δ=1.30 (qd, J=12.6, 
4.0 Hz, 1H, NCH2CHCHaxHeq), 1.51 (qt, J=12.8, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.68 (d, J=13.3 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.83 (tbr, J=11.8 Hz, 1H, NCHaxHeqCH2CH2CH), 1.90 (dbr, J=12.6 Hz, 1H, 
NCH2CHCHaxHeq), 1.98 (t, J=11.4 Hz, 1H, NCHaxHeqCH), 2.23–2.44 (m, 5H, NCH2CHax, NCH2CH2C≡C, 
NCH2CH2C≡C), 2.72 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.91 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH), 
7.17–7.31 (m, 2H, C≡CCCCH, ClCCCH), 7.31–7.41 (m, 4H, C≡CCCCHCH, C≡CCCHCH, ClCCCHCH, 
ClCCHCH), 7.41–7.53 (m, 2H, C≡CCCH, ClCCH) ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): 
δ=17.31 (NCH2CH2C≡C), 25.32 (NCH2CH2CH2CH), 28.83 (NCH2CHCH2), 45.95 (NCH2CH), 53.72 
(NCH2CH2CH2CH), 57.27 (NCH2CH), 57.82 (NCH2CH2C≡C), 81.22 (C≡CCCH), 92.94 (C≡CCCH), 127.61 
(ClCCHCH or ClCCCHCH), 128.65 (CH2C≡CCCHCHCH or CH2C≡CCCHCH), 128.78 (CH2C≡CCCHCHCH 
or CH2C≡CCCHCH), 130.18 (ClCCHCH or ClCCCHCH, ClCCH), 130.35 (CH2C≡CCCCH), 132.31 
(ClCCCH), 132.57 (CH2C≡CCCH), 133.91 (ClC), 140.90 (ClCC), 143.11 (ClCCC), 182.92 (C=O) ppm; IR 
(KBr): ṽ=3428, 3057, 2941, 2859, 2807, 2231, 1710, 1590, 1466, 1441, 1428, 1389, 1217, 1192, 1156, 1127, 
1100, 1071, 1034, 1005, 757 cm-1; MS (CI, CH5+) m/z: 368 [M+H]+; HRMS-EI+ m/z [M]+ calcd for 
C22H22ClNO2: 367.1339, found: 367.1330. 
1-{5-[2-(2-Chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18b): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.32 (qd, J=12.6, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.45–1.60 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.67 (dp, J=13.4, 3.4 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.84–2.04 (m, 3H, NCHaxHeqCH2CH2CH, NCH2CHCHaxHeq, NCHaxHeqCH), 
2.17–2.25 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.32 (tt, J=11.6, 3.8 Hz, 1H, NCH2CHax), 2.75 (dbr, 
J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.96 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH), 7.15–7.22 (m, 1H, 
C≡CCCCH), 7.23–7.29 (m, 1H, ClCCCH), 7.32–7.41 (m, 4H, C≡CCCCHCH, C≡CCCHCH, ClCCCHCH, 
ClCCHCH), 7.41–7.52 (m, 2H, C≡CCCH, ClCCH) ppm; 13C NMR (101 MHz, 1 N NaOD/CH3OD 1:2, 60 °C): 
δ=17.96 (NCH2CH2CH2C≡C), 25.24 (NCH2CH2CH2CH), 25.66 (NCH2CH2CH2C≡C), 28.92 (NCH2CHCH2), 
45.89 (NCH2CH), 54.36 (NCH2CH2CH2CH), 57.67 (NCH2CH), 58.42 (NCH2CH2CH2C≡C), 80.80 (CH2C≡C), 
93.96 (CH2C≡C), 124.33 (CH2C≡CC), 127.69 (ClCCCHCH or ClCCHCH), 128.55 (CH2C≡CCCHCHCH or 
CH2C≡CCCHCH), 128.75 (CH2C≡CCCHCHCH or CH2C≡CCCHCH), 130.28 (ClCCHCH or ClCCCHCH, 
ClCCH), 130.41 (CH2C≡CCCCH), 132.30 (ClCCCH), 132.73 (CH2C≡CCCH), 133.94 (ClC), 141.00 (ClCC), 
143.01 (ClCCC), 182.89 (C=O) ppm; IR (KBr): ṽ=3425, 3056, 2948, 2865, 2230, 1711, 1589, 1466, 1440, 
1428, 1388, 1226, 1146, 1125, 1071, 1033, 1005, 759 cm-1; MS (CI, CH5+) m/z: 382 [M+H]+; HRMS-EI+ m/z 
[M]+ calcd for C23H24ClNO2: 381.1496, found: 381.1493. 
1-{4-[2-(2-Fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17c): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.25 (qd, J=12.7, 4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.45 (qt, J=12.8, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.62 (dp, J=13.4, 3.2 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.79–1.95 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.00 (t, J=11.3 Hz, 1H, 
NCHaxHeqCH), 2.28 (tt, J=11.8, 3.7 Hz, 1H, NCH2CHax), 2.33–2.49 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 
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2.73 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.93 (dbr, J=9.4 Hz, 1H, NCHaxHeqCH), 7.14–7.45 (m, 7H, 
HAr), 7.45–7.51 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.25 
(NCH2CH2C≡C), 25.24 (NCH2CH2CH2CH), 28.76 (NCH2CHCH2), 45.89 (NCH2CH), 53.62 
(NCH2CH2CH2CH), 57.14 (NCH2CH), 57.70 (NCH2CH2C≡C), 81.28 (C≡CCCH), 92.64 (C≡CCCH), 116.26 (d, 
2JCF=22.3 Hz, FCCH), 124.09 (CH2C≡CC), 124.91 (FCCCHCH), 128.84 (CH2C≡CCCCH or 
CH2C≡CCCHCHCH or CH2C≡CCCHCH), 129.36 (d, 2JCF=15.5 Hz, FCC), 130.72 (CH2C≡CCCCH or 
CH2C≡CCCHCHCH or CH2C≡CCCHCH), 130.78 (d, 3JCF=6.7 Hz, FCCHCH), 132.55 (d, 3JCF=3.1 Hz, 
FCCCH), 132.86 (CH2C≡CCCH), 139.32 (CH2C≡CCC), 160.65 (d, 1JCF=244.8, FC), 183.02 (C=O) ppm; IR 
(KBr): ṽ=3432, 3060, 2941, 2858, 2808, 2230, 1711, 1615, 1582, 1500, 1473, 1439, 1393, 1231, 1211, 1154, 
1099, 1007, 823, 758 cm-1; MS (CI, CH5+) m/z: 352 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C22H22FNO2: 
351.1635, found: 351.1624. 
1-{5-[2-(2-Fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18c): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C,): δ=1.32 (qd, J=12.5, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.45–1.62 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.67 (dp, J=13.5, 3.3 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.84–1.97 (m, 2H, NCHaxHeqCH2CH2CH, NCH2CHCHaxHeq,), 2.02 (t, J=11.2 
Hz, 1H, NCHaxHeqCH), 2.20–2.37 (m, 5H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C, NCH2CHax), 2.75 (dbr, 
J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH,), 2.96 (dbr, J=9.5 Hz, 1H, NCHaxHeqCH), 7.14–7.51 (m, 8H, Har) ppm; 
13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ = 17.91 (NCH2CH2CH2C≡C), 25.08 (NCH2CH2CH2CH), 
25.52 (NCH2CH2CH2C≡C), 28.76 (NCH2CHCH2), 45.71 (NCH2CH), 54.23 (NCH2CH2CH2CH), 57.49 
(NCH2CH), 58.32 (NCH2CH2CH2C≡C), 80.90 (CH2C≡C), 93.69 (CH2C≡C), 116.34 (d, 2JCF=22.2 Hz, FCCH), 
124.24 (CH2C≡CC), 125.01 (FCCCHCH), 128.81 (2 C, CH2C≡CCCCH or/and CH2C≡CCCHCHCH or/and 
CH2C≡CCCHCH), 129.46 (d, 2JCF=15.2 Hz, FCC), 130.78 (CH2C≡CCCCH or CH2C≡CCCHCHCH or 
CH2C≡CCCHCH), 130.87 (3JCF=2.7 Hz, FCCHCH), 132.54 (d, 3JCF=2.7 Hz, FCCCH), 132.98 (CH2C≡CCCH), 
139.24 (CH2C≡CCC), 160.68 (d, 1JCF=244.7 Hz, FC), 182.89 (C=O) ppm; IR (KBr): ṽ=3431, 3058, 2946, 
2864, 2230, 1710, 1613, 1583, 1500, 1473, 1438, 1388, 1230, 1209, 1107, 1007, 823, 759 cm -1; MS (CI, 
CH5+) m/z: 366 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C23H24FNO2: 365.1791, found: 365.1787. 
1-{4-[2-(2-Methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17d): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.23 (qd, J=12.8, 3.4 Hz, 
1H, NCH2CHCHaxHeq), 1.42 (qbr, J=12.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.61 (dbr, J=13.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.78 (tbr, J=11.7 Hz, 1H, NCHaxHeqCH2CH2CH), 1.88 (dbr, J=10.9 Hz, 1H, 
NCH2CHCHaxHeq), 1.96 (t, J=11.0 Hz, 1H, NCHaxHeqCH), 2.06 (s, 3H, H3CC), 2.21–2.41 (m, 5H, 
NCH2CH2C≡C, NCH2CH2C≡C, NCH2CHax), 2.66 (dbr, J=9.5 Hz, 1H, NCHaxHeqCH2CH2CH), 2.87 (dbr, J=11.0 
Hz, 1H, NCHaxHeqCH), 7.07 (d, J=6.6 Hz, 1H, H3CCCCH), 7.14 (d, J=6.9 Hz, 1H, C≡CCCCH), 7.17–7.24 (m, 
1H, H3CCCCHCH), 7.25–7.38 (m, 4H, H3CCCHCH, H3CCCH, C≡CCCHCH, C≡CCCCHCH), 7.44 (d, J=7.6 
Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.11 (NCH2CH2C≡C), 19.87 
(H3CC), 25.06 (NCH2CH2CH2CH), 28.61 (NCH2CHCH2), 45.73 (NCH2CH), 53.36 (NCH2CH2CH2CH), 56.90 
(NCH2CH), 57.43 (NCH2CH2C≡C), 81.60 (C≡CCCH), 92.71 (C≡CCCH), 123.57 (CH2C≡CC), 126.27 
(H3CCCCHCH), 128.09 (CH2C≡CCCHCH), 128.59 (H3CCCHCH), 128.83 (CH2C≡CCCHCHCH), 130.22 
(CH2C≡CCCCH), 130.66 (H3CCCH), 132.55 (CH2C≡CCCH), 137.04 (H3CC), 141.81 (H3CCC), 145.34 
(CH2C≡CCC), 183.17 (C=O) ppm; IR (KBr): ṽ=3421, 3057, 3018, 2933, 2860, 2228, 1714, 1593, 1474, 1442, 
1381, 1217, 1193, 1156, 1122, 1102, 1006, 760 cm-1; MS (CI, CH5+) m/z: 348 [M+H]+; HRMS-EI+ m/z [M]+ 
calcd for C23H25NO2: 347.1885, found: 347.1880.  
1-{5-[2-(2-Methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18d): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.26 (qd, J=12.8, 3.8 Hz, 
1H, NCH2CHCHaxHeq), 1.39–1.54 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.64 (dbr, J=12.9 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.77 (td, J=11.9, 2.6 Hz, 1H, NCHaxHeqCH2CH2CH), 1.86–1.95 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.04–2.21 (m, 7H, H3CC, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.28 (tt, 
J=11.9, 3.3 Hz, 1H, NCH2CHax), 2.67 (dbr, J=9.5 Hz, 1H, NCHaxHeqCH2CH2CH), 2.91 (dbr, J=10.5 Hz, 1H, 
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NCHaxHeqCH), 7.03–7.16 (m, J=19.3, 6.8 Hz, 2H, H3CCCCH, C≡CCCCH), 7.17–7.24 (m, 1H, H3CCCCHCH), 
7.25–7.36 (m, 4H, H3CCCHCH, H3CCCH, C≡CCCHCH, C≡CCCCHCH), 7.42 (d, J=7.4 Hz, 1H, C≡CCCH) 
ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.88 (NCH2CH2CH2C≡C), 19.91 (H3CC), 25.06 
(NCH2CH2CH2CH), 25.50 (NCH2CH2CH2C≡C), 28.86 (NCH2CHCH2), 45.87 (NCH2CH), 54.06 
(NCH2CH2CH2CH), 57.41 (NCH2CH), 58.18 (NCH2CH2CH2C≡C), 81.14 (C≡CCCH), 93.73 (C≡CCCH), 
123.73 (CH2C≡CC), 126.35 (H3CCCCHCH), 128.07 (CH2C≡CCCHCH), 128.67 (H3CCCHCH), 128.71 
(CH2C≡CCCHCHCH), 130.27 (CH2C≡CCCCH), 130.75 (H3CCCH), 132.68 (CH2C≡CCCH), 136.99 (H3CC), 
141.95 (H3CCC), 145.28 (CH2C≡CCC), 183.27 (C=O) ppm. IR (KBr): ṽ=3424, 3057, 3018, 2948, 2865, 2228, 
1717, 1592, 1474, 1439, 1388, 1274, 1226, 1145, 1121, 1076, 1006, 760 cm-1; MS (CI, CH5+) m/z: 362 
[M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H27NO2: 361.2042, found: 361.2054.  
1-{4-[2-(4-Chlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17e): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ = 1.24 (qd, J=12.5, 3.5 Hz, 
1H, NCH2CHCHaxHeq), 1.42 (qt, J=13.1, 3.5 Hz, 1H, NCH2CHaxHeqCH2CH), 1.56 (dbr, J=13.4 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.73 (td, J=11.5, 2.4 Hz, 1 H, NCHaxHeqCH2CH2CH), 1.91 (dbr, J=11.7 Hz, 1H, 
NCH2CHCHaxHeq), 2.01 (t, J=11.3 Hz, 1H, NCHaxHeqCH), 2.25–2.50 (m, 5H, NCH2CH2C≡C, NCH2CH2C≡C, 
NCH2CHax), 2.60 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.92 (dbr, J=10.6 Hz, 1H, NCHaxHeqCH), 6.91 (d, 
J=7.2 Hz, 1H, C≡CCCCH), 6.97–7.08 (m, 2H, C≡CCCCHCH, C≡CCCHCH), 7.11 (d, J=8.3 Hz, 2H, ClCCH), 
7.18 (d, J=8.5 Hz, 2H, ClCCHCH), 7.32 (d, J=7.4 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, 1N 
NaOD/CH3OD 1:2, 60 °C): δ=17.40 (NCH2CH2C≡C), 25.12 (NCH2CH2CH2CH), 28.53 (NCH2CHCH2), 45.52 
(NCH2CH), 53.35 (NCH2CH2CH2CH), 57.02 (NCH2CH), 57.35 (NCH2CH2C≡C), 81.62 (C≡CCCH), 93.11 
(C≡CCCH), 122.37 (CH2C≡CC), 128.17 (CH2C≡CCCHCH), 128.66 (2C, ClCCH), 128.83 
(CH2C≡CCCHCHCH), 129.72 (CH2C≡CCCCH), 131.25 (2 C, ClCCHCH), 133.78 (2C, CCl, CH2C≡CCCH), 
139.74 (ClCCHCHC), 142.84 (CH2C≡CCC), 183.09 (C=O) ppm; IR (KBr): ṽ=3423, 3057, 2940, 2860, 2230, 
1717, 1595, 1494, 1474, 1441, 1396, 1090, 1004, 832, 760 cm-1; MS (CI, CH5+) m/z: 368 [M+H]+; HRMS-EI+ 
m/z [M]+ calcd for C22H22ClNO2: 367.1339, found: 367.1339. 
1-{5-[2-(4-Chlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18e): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.29 (qd, J=12.7, 3.8 Hz, 
1H, NCH2CHCHaxHeq), 1.43–1.61 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.65 (dbr, J=12.0 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.74 (t, J=11.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.89–1.99 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.12–2.27 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.33 (tt, J=11.5, 
3.5 Hz, 1H, NCH2CHax), 2.64 (dbr, J=10.5 Hz, 1H, NCHaxHeqCH2CH2CH), 2.97 (dbr, J=10.4 Hz, 1H, 
NCHaxHeqCH), 7.03–7.10 (m, 1H, C≡CCCCH), 7.12–7.18 (m, 2H, C≡CCCCHCH, C≡CCCHCH), 7.23 (d, 
J=8.1 Hz, 2H, ClCCH), 7.28 (d, J=8.3 Hz, 2H, ClCCHCH), 7.35–7.42 (m, 1H, C≡CCCH) ppm; 13C NMR (101 
MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=18.04 (NCH2CH2CH2C≡C), 25.20 (NCH2CH2CH2CH), 25.47 
(NCH2CH2CH2C≡C), 28.73 (NCH2CHCH2), 45.64 (NCH2CH), 54.00 (NCH2CH2CH2CH), 57.38 (NCH2CH), 
58.39 (NCH2CH2CH2C≡C), 81.20 (CH2C≡C), 94.31 (CH2C≡C), 122.50 (CH2C≡CC), 128.28 
(CH2C≡CCCHCH), 128.81 (2C, ClCCH), 128.92 (CH2C≡CCCHCHCH), 129.87 (CH2C≡CCCCH), 131.33 (2C, 
ClCCHCH), 133.71 (CH2C≡CCCH), 133.82 (ClC), 140.00 (ClCCHCHC), 143.01 (CH2C≡CCC), 183.21 (C=O) 
ppm; IR (KBr): ṽ=3430, 3056, 2949, 2866, 2230, 1717, 1593, 1497, 1474, 1441, 1396, 1089, 1004, 832, 760 
cm-1; MS (CI, CH5+) m/z: 382 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C23H24ClNO2: 381.1496, found: 381.1495.
1-{4-[2-(2,4-Dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17f): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.27 (qd, J=12.8, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.48 (qt, J=13.0, 3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.64 (dp, J=13.6, 3.4 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.81 (td, J=11.8, 3.1 Hz, 1H, NCHaxHeqCH2CH2CH), 1.93 (dbr, J=13.0 Hz, 1H, 
NCH2CHCHaxHeq), 1.98 (t, J=11.4 Hz, 1H, NCHaxHeqCH), 2.26–2.46 (m, 5H, NCH2CHax, NCH2CH2C≡C, 
NCH2CH2C≡C), 2.73 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH), 
7.14–7.18 (m, 1H, C≡CCCCH), 7.22 (d, J=8.2 Hz, 1H, ClCCCH), 7.32–7.38 (m, 3H, ClCCHCH, C≡CCCHCH, 
C≡CCCCHCH), 7.41–7.46 (m, 1H, C≡CCCH), 7.50 (d, J=2.1 Hz, 1H, ClCCHCCl) ppm; 13C NMR (126 MHz, 
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1N NaOD/CH3OD 1:2, 60 °C): δ=17.50 (NCH2CH2C≡C), 25.48 (NCH2CH2CH2CH), 28.94 (NCH2CHCH2), 
45.93 (NCH2CH), 54.00 (NCH2CH2CH2CH), 57.35 (NCH2CH), 58.04 (NCH2CH2C≡C), 81.06 (C≡CCCH), 
92.92 (C≡CCCH), 124.22 (CH2C≡CC), 127.89 (ClCCHCH, 128.86 (CH2C≡CCCHCH), 129.21 
(CH2C≡CCCHCHCH), 129.87 (ClCCHCCl, 130.38 (CH2C≡CCCCH), 132.78 (CH2C≡CCCH), 133.54 
(ClCCCH), 134.89 (ClC), 135.06 (ClC), 139.77 (ClCC), 141.83 (CH2C≡CCC), 182.98 ppm (C=O) ppm; IR 
(KBr): ṽ=3423, 3059, 2941, 2860, 2807, 2234, 1709, 1586, 1466, 1439, 1375, 1101, 1071, 1004, 866, 812, 
761 cm-1; MS (CI, CH5+) m/z: 402 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C22H21Cl2NO2: 401.0949, found: 
401.0936. 
1-{5-[2-(2,4-Dichlorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18f): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.31 (qd, J=12.8, 4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.44–1.59 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.69 (dp, J=13.6, 3.0 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.80 (td, J=12.1, 2.7 Hz, 1H, NCHaxHeqCH2CH2CH), 1.87–1.99 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.11–2.27 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.31 (tt, J=11.9, 
3.7 Hz, 1H, NCH2CHax,), 2.73 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J=10.2 Hz, 1H, 
NCHaxHeqCH), 7.12–7.17 (m, 1H, C≡CCCCH), 7.22 (d, J=8.2 Hz, 1H, ClCCCH), 7.32–7.37 (m, 3H, 
ClCCHCH, C≡CCCHCH, C≡CCCCHCH), 7.40–7.45 (m, 1H, C≡CCCH), 7.51 (d, J=2.1 Hz, 1H, ClCCHCCl) 
ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=18.09 (NCH2CH2CH2C≡C), 25.56 
(NCH2CH2CH2CH), 25.82 (NCH2CH2CH2C≡C), 29.08 (NCH2CHCH2), 45.97 (NCH2CH), 54.56 
(NCH2CH2CH2CH), 57.72 (NCH2CH), 58.73 (NCH2CH2CH2C≡C), 80.58 (CH2C≡C), 94.15 (CH2C≡C), 124.38 
(CH2C≡CC), 127.97 (ClCCHCH), 128.74 (CH2C≡CCCHCH), 129.19 (CH2C≡CCCHCHCH), 129.98 
(ClCCHCCl), 130.44 (CH2C≡CCCCH), 132.93 (CH2C≡CCCH), 133.52 (ClCCCH), 134.90 (ClC), 135.06 
(ClC), 139.84 (ClCC), 141.66 (CH2C≡CCC), 183.14 (C=O) ppm; IR (KBr): ṽ=3426, 3060, 2943, 2864, 2231, 
1710, 1586, 1466, 1439, 1376, 1101, 1071, 1004, 868, 813, 762 cm-1; MS (CI, CH5+) m/z: 416 [M+H]+; 
HRMS-EI+ m/z [M]+ calcd for C23H23Cl2NO2: 415.1106, found: 415.1097. 
1-{4-[2-(2,4-Difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17g): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.28 (qd, J=12.6, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.48 (qt, J=12.8, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.64 (dp, J=13.0, 3.6 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.86–1.96 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.05 (t, J=11.3 Hz, 1H, 
NCHaxHeqCH), 2.31 (tt, J=11.6, 3.8 Hz, 1H, NCH2CHax), 2.37–2.52 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 
2.76 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.92–3.01 (m, 1H, NCHaxHeqCH), 6.97–7.06 (m, 2H, 
FCCHCF, FCCHCH), 7.23–7.29 (m, 1H, C≡CCCCH), 7.30–7.42 (m, 3H, C≡CCCCHCH, C≡CCCHCH, 
FCCCH), 7.45–7.50 (m, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.24 
(NCH2CH2C≡C), 25.18 (NCH2CH2CH2CH), 28.69 (NCH2CHCH2), 45.78 (NCH2CH), 53.75 
(NCH2CH2CH2CH), 57.13 (NCH2CH), 57.72 (NCH2CH2C≡C), 81.17 (C≡CCCH), 92.62 (C≡CCCH), 104.46 (d, 
2JCF=26.2 Hz, FCCHCF), 111.89 (dd, 2JCF=21.4 Hz, 4JCF=3.7 Hz, FCCHCH), 124.19 (CH2C≡CC), 125.76 (dd, 
2JCF=13.0 Hz, 4JCF=3.7 Hz, FCC), 128.95 (CH2C≡CCCHCHCH or CH2C≡CCCHCH), 129.02 
(CH2C≡CCCHCHCH or CH2C≡CCCHCH), 130.81 (CH2C≡CCCCH), 132.98 (CH2C≡CCCH), 133.55 (dd, 
3JCF=9.6 Hz, 3JCF=4.7 Hz, FCCCH), 138.34 (CH2C≡CCC), 160.76 (dd, 1JCF=249.0 Hz, 3JCF=12.7 Hz, FC), 
163.59 (dd, 1JCF=257.3 Hz, 3JCF=10.3 Hz, FC), 182.83 (C=O) ppm; IR (KBr): ṽ=3426, 3061, 2942, 2862, 
2808, 2230, 1718, 1618, 1593, 1510, 1479, 1444, 1266, 1219, 1139, 1097, 963, 850, 762 cm -1; MS (CI, 
CH5+) m/z: 370 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C22H21F2NO2: 369.1540 found: 369.1544.  
1-{5-[2-(2,4-Difluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18g): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.30 (qd, J=12.4, 3.9 Hz, 
1H, NCH2CHCHaxHeq), 1.45–1.63 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.67 (dp, J=13.4, 3.3 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.81–2.02 (m, 3H, NCHaxHeqCH2CH2CH, NCH2CHCHaxHeq, NCHaxHeqCH), 
2.22–2.37 (m, 5H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.74 (dbr, J=11.5 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.94–3.03 (m, 1H, NCHaxHeqCH), 6.98–7.06 (m, 2H, FCCHCF, FCCHCH), 7.24–7.28 (m, 1H, C≡CCCCH), 
7.30–7.41 (m, 3H, C≡CCCCHCH, C≡CCCHCH, FCCHCH), 7.43–7.50 (m, 1H, C≡CCCH) ppm; 13C NMR 
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(126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.96 (NCH2CH2CH2C≡C), 25.29 (NCH2CH2CH2CH), 25.73 
(NCH2CH2CH2C≡C), 28.92 (NCH2CHCH2), 45.86 (NCH2CH), 54.40 (NCH2CH2CH2CH), 57.64 (NCH2CH), 
58.54 (NCH2CH2CH2C≡C), 80.69 (CH2C≡C), 93.93 (CH2C≡C), 104.55 (d, 2JCF=26.1 Hz, FCCHCF), 111.99 
(dd, 2JCF=21.3 Hz, 4JCF=3.7 Hz, FCCHCH), 124.48 (CH2C≡CC), 125.94 (dd, 2JCF=15.9 Hz, 4JCF=3.4 Hz, 
FCCCH), 128.83 (CH2C≡CCCHCHCH or CH2C≡CCCHCH), 129.01 (CH2C≡CCCHCHCH or 
CH2C≡CCCHCH), 130.85 (CH2C≡CCCCH), 133.05 (CH2C≡CCCH), 133.56 (dd, 3JCF=9.7 Hz, 3JCF=4.8 Hz, 
FCCCH), 138.31 (CH2C≡CCC), 160.85 (dd, 1JCF=248.4 Hz, 3JCF=12.6 Hz, FC), 163.66 (dd, 1JCF=246.4 Hz, 
3JCF=11.8 Hz, FC), 182.95 (C=O) ppm; IR (KBr): ṽ=3432, 3061, 2947, 2865, 2231, 1717, 1618, 1593, 1510, 
1478, 1443, 1419, 1266, 1140, 1096, 963, 850, 763 cm-1; MS (CI, CH5+) m/z: 384 [M+H]+; HRMS-EI+ m/z 
[M]+ calcd for C23H23F2NO2: 383.1697, found: 383.1696. 
1-{4-[2-(2,4-Dimethylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17h): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.24 (qd, J=12.8, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.45 (qt, J=13.3, 4.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.66 (dp, J=13.8, 3.4 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.79 (td, J=11.9, 2.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.86–1.93 (m, 1H, 
NCH2CHCHaxHeq), 1.97 (t, J=11.4 Hz, 1H, NCHaxHeqCH), 2.04 (s, 3H, H3CCC), 2.23–2.41 (m, 8H, 
NCH2CH2C≡C, NCH2CH2C≡C, NCH2CHax, H3CCCHCC), 2.70 (dbr, J=10.5 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.85–2.97 (m, 1H, NCHaxHeqCH), 6.95 (d, J=7.7 Hz, 1H, H3CCCCH), 7.01 (d, J=8.3 Hz, 1H, H3CCCHCH), 
7.07 (s, 1H, H3CCCHCC), 7.10–7.15 (m, 1H, C≡CCCCH), 7.28 (td, J=7.5, 1.6 Hz, 1H, C≡CCCHCH), 7.33 
(td, J=7.5, 1.7 Hz, 1H, C≡CCCCHCH), 7.42 (dd, J=7.5, 1.4 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, 1N 
NaOD/CH3OD 1:2, 60 °C): δ=17.38 (NCH2CH2C≡C), 19.87 (H3CCC), 21.12 (H3CCCHCC), 25.33 
(NCH2CH2CH2CH), 28.84 (NCH2CHCH2), 45.92 (NCH2CH), 53.79 (NCH2CH2CH2CH), 57.33 (NCH2CH), 
57.91 (NCH2CH2C≡C), 81.74 (C≡CCCH), 92.37 (C≡CCCH), 124.13 (CH2C≡CC), 126.86 (H3CCCHCH), 
127.92 (CH2C≡CCCHCH), 128.71 (CH2C≡CCCHCHCH), 130.23 (H3CCCHCH), 130.41 (CH2C≡CCCCH), 
131.27 (H3CCCHCC), 132.54 (CH2C≡CCCH), 136.82 (H3CCC), 138.28 (H3CCCHCC), 139.16 (H3CCC), 
145.60 (CH2C≡CCC), 182.88 (C=O) ppm; IR (KBr): ṽ=3442, 3054, 2942, 2923, 2859, 2808, 2228, 1712, 
1614, 1476, 1441, 1376, 1303, 1214, 1190, 1155, 1103, 1038, 1005, 820, 762 cm-1; MS (CI, CH5+) m/z: 362 
[M+H]+; HRMS-EI+ m/z [M]+ calcd for C24H27NO2: 361.2042, found: 361.2041.  
1-{5-[2-(2,4-Dimethylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18h): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.29 (qd, J=12.8, 4.2 Hz, 
1H, NCH2CHCHaxHeq), 1.42–1.58 (m, 3H, NCH2CH2CH2C≡C), 1.66 (dp, J=13.6, 3.2 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.78 (td, J=12.0, 2.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.86–1.98 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.05 (s, 3H, H3CCC), 2.10–2.16 (m, 2H, NCH2CH2CH2C≡C), 2.17–2.23  (m, 
2H, NCH2CH2CH2C≡C), 2.26–2.34 (m, 4H, NCH2CHax, H3CCCHCC), 2.70 (dbr, J=10.5 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.89–3.02 (m, 1H, NCHaxHeqCH), 6.95 (d, J=7.7 Hz, 1H, H3CCCCH), 7.02 (d, J=7.7 
Hz, 1H, H3CCCHCH), 7.07 (s, 1H, H3CCCHCC), 7.10 (dd, J=7.4, 1.5 Hz, 1H, C≡CCCCH), 7.28 (td, J=7.5, 
1.7 Hz, 1H, C≡CCCHCH), 7.32 (td, J=7.5, 1.7 Hz, 1H, C≡CCCCHCH), 7.42 (dd, J=7.5, 1.5 Hz, 1H, 
C≡CCCH) ppm; 13C NMR (101 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.98 (NCH2CH2CH2C≡C), 19.88 
(H3CCC), 21.19 (H3CCCHCC), 25.42 (NCH2CH2CH2CH), 25.80 (NCH2CH2CH2C≡C), 29.03 (NCH2CHCH2), 
46.00 (NCH2CH), 54.38 (NCH2CH2CH2CH), 57.71 (NCH2CH), 58.48 (NCH2CH2CH2C≡C), 81.23 (C≡CCCH), 
93.40 (C≡CCCH), 124.27 (CH2C≡CC), 126.92 (H3CCCHCH), 127.89 (CH2C≡CCCHCH), 128.59 
(CH2C≡CCCHCHCH), 130.23 (H3CCCHCH), 130.49 (CH2C≡CCCCH), 131.35 (H3CCCHCC), 132.73 
(CH2C≡CCCH), 136.76 (H3CCC), 138.21 (H3CCCHCC), 139.24 (H3CCC), 145.44 (CH2C≡CCC), 182.99 
(C=O) ppm; IR (KBr): ṽ=3440, 3054, 2942, 2862, 2228, 1709, 1615, 1476, 1439, 1377, 1225, 1155, 1131, 
1105, 1035, 1004, 820, 762 cm-1; MS (CI, CH5+) m/z: 376 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C25H29NO2: 
375.2198, found: 375.2192. 
1-{4-[2-(2-Chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17i): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.27 (qd, J=12.8, 3.9 Hz, 
1H, NCH2CHCHaxHeq), 1.48 (qt, J=13.0, 3.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.65 (dbr, J=13.5 Hz, 1H, 
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NCH2CHaxHeqCH2CH), 1.84 (td, J=12.0, 2.3 Hz, 1H, NCHaxHeqCH2CH2CH), 1.92 (dbr, J=10.9 Hz, 1H, 
NCH2CHCHaxHeq), 1.99 (t, J=11.3 Hz, 1H, NCHaxHeqCH), 2.26–2.47 (m, 5H, NCH2CHax, NCH2CH2C≡C, 
NCH2CH2C≡C), 2.75 (dbr, J=10.6 Hz, 1H, NCHaxHeqCH2CH2CH), 2.96 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH), 
7.14 (td, J=8.4, 2.6 Hz, 1H, FCCHCH), 7.16–7.20 (m, 1H, C≡CCCCH), 7.25–7.31 (m, 2H, FCCHCH, 
FCCHCCl), 7.32–7.39 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 7.42–7.46 (m, 1H, C≡CCCH) ppm; 13C NMR 
(126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.44 (NCH2CH2C≡C), 25.49 (NCH2CH2CH2CH), 28.95 
(NCH2CHCH2), 45.99 (NCH2CH), 53.98 (NCH2CH2CH2CH), 57.34 (NCH2CH), 58.09 (NCH2CH2C≡C), 81.13 
(C≡CCCH), 92.70 (C≡CCCH), 114.78 (d, 2JCF=21.2 Hz, FCCHCH), 117.32 (d, 2JCF=25.0 Hz, FCCHCCl), 
124.44 (CH2C≡CC), 128.83 (CH2C≡CCCHCH), 129.08 (CH2C≡CCCHCHCH), 130.63 (CH2C≡CCCCH), 
132.80 (CH2C≡CCCH), 133.72 (d, 3JCF=8.9 Hz, FCCHCH), 135.00 (d, 3JCF=10.5 Hz, ClC), 137.38 (d, 
4JCF=3.6 Hz, ClCC), 142.04 (CH2C≡CCC), 163.12 (d, 1JCF=248.2 Hz, FC), 183.00 (C=O) ppm; IR (KBr): 
ṽ=3434, 3061, 2941, 2858, 2231, 1710, 1604, 1503, 1473, 1442, 1388, 1256, 1201, 1062, 1041, 1006, 897, 
858, 821, 762 cm-1; MS (EI, 70 eV) m/z: 385 [M]+; HRMS-EI+ m/z [M]+ calcd for C22H21ClFNO2: 385.1249, 
found: 385.1219. 
1-{5-[2-(2-Chloro-4-fluorophenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18i): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.30 (qd, J=13.0, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.46–1.58 (m, 3H, NCH2CHCHaxHeq, NCH2CH2CH2C≡C), 1.64–1.71 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.81 (td, J=11.6, 2.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.88–1.98 (m, 2H, NCHaxHeqCH, 
NCH2CHCHaxHeq), 2.14–2.27 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.32 (tt, J=11.9, 3.7 Hz, 1H, 
NCH2CHax), 2.75 (dbr, J=11.7 Hz, 1H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J=10.1 Hz, 1H, NCHaxHeqCH), 7.12–
7.19 (m, 2H, FCCHCH, C≡CCCCH), 7.25–7.32 (m, 2H, FCCHCH, FCCHCCl), 7.32–7.39 (m, 2H, 
C≡CCCHCH, C≡CCCCHCH), 7.41–7.45 (m, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 
60 °C): δ=18.06 (NCH2CH2CH2C≡C), 25.52 (NCH2CH2CH2CH), 25.87 (NCH2CH2CH2C≡C), 29.12 
(NCH2CHCH2), 46.02 (NCH2CH), 54.58 (NCH2CH2CH2CH), 57.76 (NCH2CH), 58.75 (NCH2CH2CH2C≡C), 
80.66 (CH2C≡C), 93.99 (CH2C≡C), 114.90 (d, 2JCF=21.3 Hz, FCCHCH), 117.45 (d, 2JCF=25.0 Hz, FCCHCCl), 
124.63 (CH2C≡CC), 128.72 (CH2C≡CCCHCH), 129.07 (CH2C≡CCCHCHCH), 130.65 (CH2C≡CCCCH), 
132.89 (CH2C≡CCCH), 133.67 (d, 3JCF=8.6 Hz, FCCHCH), 135.00 (d, 3JCF=10.5 Hz, ClC), 137.49 (d, 
4JCF=3.6 Hz, ClCC), 141.94 (CH2C≡CCC), 163.08 (d, 1JCF=248.4 Hz, FC), 183.16 (C=O) ppm; IR (KBr): 
ṽ=3431, 3060, 2946, 2864, 2229, 1709, 1604, 1503, 1473, 1442, 1389, 1256, 1201, 1148, 1061, 1042, 1005, 
896, 858, 820, 762 cm-1; MS (EI, 70 eV) m/z: 399 [M]+; HRMS-EI+ m/z [M]+ calcd for C23H23ClFNO2: 
399.1491, found: 399.1404. 
1-{4-[2-(4-Chloro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17k): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.30 (qd, J=12.9, 4.1 Hz, 
1H, NCH2CHCHaxHeq), 1.50 (qt, J=12.4, 3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.67 (dp, J=13.4, 2.9 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.82 (tbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 1.91–2.03 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH), 2.08 (s, 3H, H3CC), 2.26–2.50 (m, 5H, NCH2CHax, NCH2CH2C≡C, NCH2CH2C≡C), 2.73 (dbr, 
J=11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 2.97 (dbr, J=10.9 Hz, 1H, NCHaxHeqCH), 7.04 (d, J=8.1 Hz, 1H, 
ClCCHCH), 7.11–7.15 (m, 1H, C≡CCCCH), 7.20 (dd, J=8.2, 2.4 Hz, 1H, ClCHCH), 7.27 (d, J=2.4 Hz, 1H, 
ClCCHC), 7.31–7.40 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 7.45 (dd, J=7.6, 1.6 Hz, 1H, C≡CCCH) ppm; 13C 
NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.50 (NCH2CH2C≡C), 20.06 (H3CC), 25.49 
(NCH2CH2CH2CH), 28.95 (NCH2CHCH2), 45.94 (NCH2CH), 54.01 (NCH2CH2CH2CH), 57.33 (NCH2CH), 
58.06 (NCH2CH2C≡C), 81.39 (C≡CCCH), 92.46 (C≡CCCH), 124.05 (CH2C≡CC), 126.36 (ClCCHCH), 128.54 
(CH2C≡CCCHCH), 129.00 (CH2C≡CCCHCHCH), 130.22 (CH2C≡CCCCH), 130.37 (ClCCHC), 131.94 
(ClCCHCH), 132.79 (CH2C≡CCCH), 133.85 (ClC), 139.48 (H3CCC), 140.83 (H3CCC), 144.21 (CH2C≡CCC), 
182.98 (C=O) ppm; IR (KBr): ṽ=2425, 3059, 2926, 2857, 2228, 1711, 1592, 1472, 1442, 1391, 1195, 1097, 
1006, 870, 822, 760 cm-1; MS (EI, 70 eV) m/z: 381 [M]+; HRMS-EI+ m/z [M]+ calcd for C23H24ClNO2: 
381.1496, found: 381.1493. 
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1-{5-[2-(4-Chloro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18k): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.34 (qd, J=12.7, 4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.45–1.61 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.71 (dp, J=13.4, 3.0 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.81 (td, J=11.7, 2.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.88–2.01 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.09 (s, 3H, H3CC), 2.14 (t, J=8.1 Hz, 2H, NCH2CH2CH2C≡C), 2.17–2.30 
(m, 2H, NCH2CH2CH2C≡C), 2.34 (tt, J=11.9, 3.7 Hz, 1H, NCH2CHax), 2.73 (dbr, J=10.7 Hz, 1H, 
NCHaxHeqCH2CH2CH), 3.01 (dbr, J=10.5 Hz, 1H, NCHaxHeqCH), 7.04 (d, J=8.1 Hz, 1H, ClCCHCH), 7.10 (dd, 
J=7.5, 1.5 Hz, 1H, C≡CCCCH), 7.20 (d, J=7.8 Hz, 1H, ClCCHCH), 7.28 (sbr, 1H, ClCCHC), 7.30–7.38 (m, 
2H, C≡CCCHCH, C≡CCCCHCH), 7.44 (dd, J=7.5, 1.7 Hz, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, 1N 
NaOD/CH3OD 1:2, 60 °C): δ=18.07 (NCH2CH2CH2C≡C), 20.11 (H3CC), 25.58 (NCH2CH2CH2CH), 25.85 
(NCH2CH2CH2C≡C), 29.09 (NCH2CHCH2), 45.97 (NCH2CH), 54.57 (NCH2CH2CH2CH), 57.68 (NCH2CH), 
58.69 (NCH2CH2CH2C≡C), 80.93 (CH2C≡C), 93.63 (CH2C≡C), 124.18 (CH2C≡CC), 126.45 (ClCCHCH), 
128.51 (CH2C≡CCCHCH), 128.88 (CH2C≡CCCHCHCH), 130.31 (CH2C≡CCCCH), 130.50 (ClCCHC), 131.94 
(ClCCHCH), 132.95 (CH2C≡CCCH), 133.86 (CCl), 139.46 (H3CC), 140.89 (H3CCC), 144.01 (CH2C≡CCC), 
183.14 (C=O) ppm; IR (KBr): ṽ=3424, 3056, 3020, 2945, 2862, 2228, 1711, 1591, 1473, 1440, 1391, 1195, 
1095, 1005, 870, 821, 763 cm-1; MS (EI, 70 eV) m/z: 395 [M]+; HRMS-EI+ m/z [M]+ calcd for C24H26ClNO2: 
395.1652, found: 395.1660. 
1-{4-[2-(4-Fluoro-2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid (17l): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.26 (qd, J=12.8, 3.9 Hz, 
1H, NCH2CHCHaxHeq), 1.47 (qt, J=13.1, 3.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.63 (dbr, J=13.5 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.80 (tbr, J=11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 1.92 (dbr, J=13.6 Hz, 1H, 
NCH2CHCHaxHeq), 1.97 (t, J=11.4 Hz, 1H, NCHaxHeqCH), 2.06 (s, 3H, H3CC), 2.25–2.43 (m, 5H, NCH2CHax, 
NCH2CH2C≡C, NCH2CH2C≡C), 2.71 (dbr, J=11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.94 (dbr, J=10.8 Hz, 1H, 
NCHaxHeqCH), 6.91 (td, J=8.5, 2.6 Hz, 1H, FCCHCH), 6.98 (dd, J=10.0, 2.4 Hz, 1H, FCCHC), 7.04 (dd, 
J=8.3, 6.1 Hz, 1H, FCCHCH), 7.10 (dd, J=7.4, 1.1 Hz, 1H, C≡CCCCH), 7.30 (td, J=7.5, 1.5 Hz, 1H, 
C≡CCCHCH), 7.34 (td, J=7.5, 1.6 Hz, 1H, C≡CCCCHCH), 7.42 (dd, J=7.5, 1.3 Hz, 1H, C≡CCCH) ppm; 13C 
NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.41 (NCH2CH2C≡C), 20.25 (d, 4JCF=1.8 Hz, H3CC), 
25.45 (NCH2CH2CH2CH), 28.91 (NCH2CHCH2), 45.95 (NCH2CH), 53.91 (NCH2CH2CH2CH), 57.28 
(NCH2CH), 58.05 (NCH2CH2C≡C), 81.50 (C≡CCCH), 92.25 (C≡CCCH), 112.93 (d, 2JCF=20.9 Hz, FCCHCH), 
116.98 (d, 2JCF=21.3 Hz, FCCHC), 124.22 (CH2C≡CC), 128.40 (CH2C≡CCCHCH), 128.97 
(CH2C≡CCCHCHCH), 130.49 (CH2C≡CCCCH), 132.07 (d, 3JCF=8.6 Hz, FCCHCH), 132.80 (CH2C≡CCCH), 
138.25 (d, 4JCF=3.0 Hz, H3CCC), 139.86 (d, 3JCF=7.9 Hz, H3CC), 144.41 (CH2C≡CCC), 163.21 (d, 
1JCF=243.6 Hz, FC), 183.03 (C=O) ppm; IR (KBr): ṽ=3438, 3057, 3024, 2942, 2858, 2809, 2230, 1712, 1616, 
1587, 1504, 1476, 1443, 1395, 1271, 1220, 1151, 1099, 1005, 944, 862, 818, 762 cm -1; MS (EI, 70 eV) m/z: 
365 [M]+; HRMS-EI+ m/z [M]+ calcd for C23H24FNO2: 365.1791, found: 365.1784. 
1-{5-[2-(4-Fluoro-2-methylphenyl)phenyl]pent-4-yn-1-yl}piperidine-3-carboxylic acid (18l): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=1.30 (qd, J=12.8, 4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.45–1.58 (m, 3H, NCH2CHaxHeqCH2CH, NCH2CH2CH2C≡C), 1.67 (dbr, J=13.4 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.78 (td, J=12.1, 2.5 Hz, 1H, NCHaxHeqCH2CH2CH), 1.86–1.97 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.07 (s, 3H, H3CC), 2.13 (t, J=8.0 Hz, 2H, NCH2CH2CH2C≡C), 2.17–2.26 
(m, 2H, NCH2CH2CH2C≡C), 2.31 (tt, J=11.9, 3.6 Hz, 1H, NCH2CHax), 2.72 (dbr, J=11.0 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.98 (dbr, J=10.6 Hz, 1H, NCHaxHeqCH), 6.92 (tbr, J=8.2 Hz, 1H, FCCHCH), 6.99 (dbr, 
J=9.6 Hz, 1H, FCCHC), 7.04 (dd, J=8.3, 6.1 Hz, 1H, FCCHCH), 7.09 (dd, J=7.5, 1.5 Hz, 1H, C≡CCCCH), 
7.29 (td, J=7.5, 1.6 Hz, 1H, C≡CCCHCH), 7.33 (td, J=7.5, 1.7 Hz, 1H, C≡CCCCHCH), 7.41 (dd, J=7.5, 1.6 
Hz, 1H, C≡CCCH) ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=18.05 (NCH2CH2CH2C≡C), 
20.30 (d, 4JCF=1.4 Hz, H3CC), 25.50 (NCH2CH2CH2CH), 25.86 (NCH2CH2CH2C≡C), 29.10 (NCH2CHCH2), 
45.98 (NCH2CH), 54.52 (NCH2CH2CH2CH), 57.69 (NCH2CH), 58.67 (NCH2CH2CH2C≡C), 81.03 (CH2C≡C), 
93.49 (CH2C≡C), 113.06 (d, 2JCF=21.1 Hz, FCCHCH), 117.15 (d, 2JCF=20.9 Hz, FCCHC), 124.40 
(CH2C≡CC), 128.37 (CH2C≡CCCHCH), 128.84 (CH2C≡CCCHCHCH), 130.53 (CH2C≡CCCCH), 132.06 (d, 
3JCF=8.4 Hz, FCCHCH), 132.91 (d, 1C, CH2C≡CCCH), 138.37 (d, 4JCF=3.0 Hz, H3CCC), 139.85 (d, 3JCF=7.9 
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Hz, H3CC), 144.29 , (s, 1C, CH2C≡CCC), 163.17 (s, 1J=243.5 Hz, FC), 183.17 (C=O) ppm; IR (KBr): ṽ=3386, 
3059, 2949, 2864, 2230, 1710, 1587, 1503, 1476, 1442, 1389, 1271, 1220, 1151, 1005, 944, 863, 817, 761 
cm-1; MS (EI, 70 eV): m/z: 379 [M]+; HRMS-EI+ m/z [M]+ calcd for C24H26FNO2: 379.1948, found: 365.1948.
(R)-Ethyl 1-but-3-yn-1-ylpiperidine-3-carboxylate ((R)-7): 
Rf≈0.5 (hexane/ethyl acetate 1:1). [α]20D=-57.5 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, CDCl3): δ=1.22 (t, 
J=7.1 Hz, 3H, OCH2CH3), 1.40 (qd, J=11.8, 3.9 Hz, 1H, NCH2CHCHaxHeq), 1.48–1.60 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.70 (dp, J=10.9, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.87–1.94 (m, 1H, 
NCH2CHCHaxHeq), 1.95 (t, J=2.7 Hz, 1H, C≡CH), 2.04 (td, J=11.0, 2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.19 (t, 
J=10.6 Hz, 1H, NCHaxHeqCH), 2.32–2.38 (m, 2H, NCH2CH2C≡CH), 2.52 (tt, J=10.8, 3.8 Hz, 1H, NCH2CHax), 
2.58 (t, J=7.9 Hz, 2H, NCH2CH2C≡C), 2.75 (d, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (d, J=11.1 Hz, 1H, 
NCHaxHeqCH), 4.10 (q, J=7.1 Hz, 2H, OCH2CH3) ppm; 13C NMR (126 MHz, CDCl3): δ=14.30 (OCH2CH3), 
16.74 (NCH2CH2C≡C), 24.60 (NCH2CH2CH2CH), 26.92 (NCH2CHCH2), 41.86 (NCH2CH), 53.43 
(NCH2CH2CH2CH), 55.12 (NCH2CH), 57.34 (NCH2CH2C≡CH), 60.45 (OCH2CH3), 69.10 (C≡CH), 82.85 
(C≡CH), 174.20 (C=O) ppm; IR (KBr): ṽ=3298, 2944, 2812, 2118, 1731, 1371, 1310, 1180, 1153, 1032 cm-1; 
MS (CI, CH5+) m/z: 210 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C12H19NO2: 209.1416; found: 209.1430. 
(R)-Ethyl 1-[4-(2-bromophenyl)but-3-yn-1-yl]piperidine-3-carboxylate ((R)-13): 
Rf≈0.3 (hexane/ethyl acetate 8:2). [α]20D=-34.0 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, CDCl3): δ=1.25 (t, 
J=7.2 Hz, 3H, OCH2CH3), 1.46 (qd, J=11.8, 4.0 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.65 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.74 (dp, J=10.9, 3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dq, J=12.8, 4.0 Hz, 1H, 
NCH2CHCHaxHeq), 2.14 (td, J=11.0, 3.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.30 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 
2.57 (tt, J=10.7, 3.9 Hz, 1H, NCH2CHax), 2.62–2.69 (m, 2H, NCH2CH2C≡C), 2.71–2.78 (m, 2H, 
NCH2CH2C≡C), 2.83 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH), 
4.13 (q, J=7.2 Hz, 2H, OCH2CH3), 7.11 (td, J=7.7, 1.8 Hz, 1H, BrCCHCH), 7.22 (td, J=7.6, 1.4 Hz, 1H, 
BrCCCHCH), 7.42 (dd, J=7.7, 1.8 Hz, 1H, C≡CCCH), 7.55 (dd, J=8.1, 1.4 Hz, 1 H, BrCCH) ppm; 13C NMR 
(125 MHz, CDCl3): δ=14.18 (OCH2CH3), 17.89 (NCH2CH2C≡C), 24.59 (NCH2CH2CH2CH), 26.80 
(NCH2CHCH2), 41.88 (NCH2CH), 53.35 (NCH2CH2CH2CH), 55.09 (NCH2CH), 57.22 (NCH2CH2C≡C), 60.28 
(OCH2CH3), 80.01 (C≡CCCH), 93.51 (C≡CCCH), 125.38 (CBr), 125.71 (BrCC), 126.84 (BrCCCHCH), 
128.75 (BrCCHCH), 132.21 (BrCCH), 133.26 (BrCCCH), 174.06 (C=O) ppm; IR (KBr): ṽ=3436, 3064, 2943, 
2854, 2810, 2231, 1730, 1587, 1557, 1469, 1434, 1370, 1308, 1180, 1153, 1101, 1052, 1026, 862, 754 cm -1; 
MS (CI, CH5+) m/z: 364 [M+H]+; HRMS-EI+ m/z [M]+ calcd for C18H22BrNO2: 363.0834, found: 363.0835. 
(R)-Ethyl 1-{4-[2-(2-methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate ((R)-15d): 
Rf≈0.3 (hexane/ethyl acetate 8:2). [α]20D=-32.0 (c=1.0 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, 
J=7.1 Hz, 3H, OCH2CH3), 1.39 (qd, J=11.7, 3.6 Hz, 1H, NCH2CHCHaxHeq), 1.45–1.56 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.67 (dp, J=13.1/3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.86–1.98 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.11–2.18 (m, 4H, NCHaxHeqCH, H3CC), 2.31–2.40 (m, 4H, 
NCH2CH2C≡C, NCH2CH2C≡C), 2.49 (tt, J=10.4, 3.8 Hz, 1H, NCH2CHax), 2.63 (dt, J=11.2, 3.8 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.87 (dd, J=11.0, 3.2 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 7.14–
7.33 (m, 7H, HAr), 7.44–7.47 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.17 (OCH2CH3), 
17.46 (NCH2CH2C≡C), 19.94 (H3CC), 24.52 (NCH2CH2CH2CH), 26.79 (NCH2CHCH2), 41.80 (NCH2CH), 
53.05 (NCH2CH2CH2CH), 54.89 (NCH2CH), 57.13 (NCH2CH2C≡C), 60.24 (OCH2CH3), 80.45 (C≡CCCH), 
91.28 (C≡CCCH), 123.27 (CH2C≡CC), 125.15 (CH2C≡CCCCH), 126.78 (CH2C≡CCCHCH), 127.29 
(H3CCCHCH), 127.39 (CH2C≡CCCHCHCH), 129.33 (H3CCCCHCH), 129.54 (H3CCCCH, H3CCCH), 131.77 
(CH2C≡CCCH), 136.10 (H3CC), 140.95 (H3CCC), 144.40 (CH2C≡CCC), 174.06 (C=O) ppm; IR (KBr): 
ṽ=3375, 3060, 2940, 2853, 2810, 2228, 1730, 1474, 1443, 1370, 1307, 1179, 1152, 1133, 1101, 1032, 758 
cm-1; MS (ESI+) m/z: 376 [M+H]+; HRMS-ESI+ m/z [M+H]+ calcd for C25H30NO2: 376.2277, found: 376.2271.
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(R)-Ethyl 1-{4-[2-(2,4-dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate ((R)-15f): 
Rf≈0.3 (hexane/ethyl acetate 8:2). [α]20D=-27.7 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, CDCl3): δ=1.24 (t, 
J=7.1 Hz, 3H, OCH2CH3), 1.42 (qd, J=12.0, 3.8 Hz, 1H, NCH2CHCHaxHeq), 1.47–1.58 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.69 (dp, J=10.8, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.88–1.95 (m, 1H, 
NCH2CHCHaxHeq), 1.99 (td, J=11.0, 2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.18 (t, J=10.6 Hz, 1H, NCHaxHeqCH), 
2.36–2.45 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.51 (tt, J=10.4, 3.7 Hz, 1H, NCH2CHax), 2.67 (dbr, J=11.2 
Hz, 1H, NCHaxHeqCH2CH2CH), 2.90 (dbr, J=10.0 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 
7.21–7.24 (m, 1H, C≡CCCCH), 7.25–7.30 (m, 2H, ClCCHCH, ClCCHCH), 7.30–7.35 (m, 2H, C≡CCCHCH, 
C≡CCCCHCH), 7.46–7.51 (m, 2H, ClCCHCCCl, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ = 14.19 
(OCH2CH3), 17.60 (NCH2CH2C≡C), 24.53 (NCH2CH2CH2CH), 26.79 (NCH2CHCH2), 41.81 (NCH2CH), 53.18 
(NCH2CH2CH2CH), 54.95 (NCH2CH), 57.13 (NCH2CH2C≡C), 60.29 (OCH2CH3), 79.85 (C≡CCCH), 92.25 
(C≡CCCH), 123.44 (CH2C≡CC), 126.50 (ClCCHCH), 127.37 (ClCCCCHCH), 127.86 (CH2C≡CCCHCH), 
129.08 (ClCCHCCl), 129.48 (ClCCCCH), 132.00 (CH2C≡CCCH), 132.32 (ClCCHCH), 133.74 (CCl), 134.18 
(CCl), 138.41 (ClCCHCHC), 140.62 (ClCCC), 174.03 (C=O) ppm; IR (KBr): ṽ=3385, 3061, 2941, 2854, 2809, 
2229, 1730, 1586, 1466, 1440, 1372, 1307, 1180, 1152, 1101, 1032, 1004, 863, 813, 760  cm-1; MS (ESI+) 
m/z: 430 [M+H]+; HRMS-ESI+ m/z [M+H]+ calcd for C24H26Cl2NO2: 430.1340, found: 430.1338. 
(R)-Ethyl 1-{4-[2-(2,4-difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate ((R)-15g): 
Rf≈0.3 (hexane/ethyl acetate 8:2). [α]20D=-31.5 (c=1.0 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, 
J=7.1 Hz, 3H, OCH2CH3), 1.42 (qd, J=12.0/3.8, 1H, NCH2CHCHaxHeq), 1.47–1.59 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.70 (dp, J=14.0, 3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.92 (dq, J=12.6, 3.8, 1H, 
NCH2CHCHaxHeq), 2.02 (td, J=11.0, 2.9 Hz, 1H, NCHaxHeqCH2CH2CH), 2.20 (t, J=10.7 Hz, 1H, NCHaxHeqCH), 
2.40–2.56 (m, 5H, NCH2CH2C≡C, NCH2CH2C≡C, NCH2CHax), 2.70 (dt, J=11.6, 4.2 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.93 (dd, J=11.1, 3.8 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.1 Hz, 2H, OCH2CH3), 6.85–
6.96 (m, 2H, FCCHCF, FCCHCH), 7.27–7.42 (m, 4H, C≡CCCCH, C≡CCCCHCH, C≡CCCHCH, FCCCH), 
7.48–7.52 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.17 (OCH2CH3), 17.58 (NCH2CH2C≡C), 
24.54 (NCH2CH2CH2CH), 26.80 (NCH2CHCH2), 41.83 (NCH2CH), 53.20 (NCH2CH2CH2CH), 54.96 
(NCH2CH), 57.18 (NCH2CH2C≡C), 60.29 (OCH2CH3), 80.08 (C≡CCCH), 91.67 (C≡CCCH), 103.77 (d, 
2JCF=26.3, 25.3 Hz, FCCHCF), 110.65 (dd, 2JCF=21.2 Hz, 4JCF=3.9 Hz, FCCHCH), 123.55 (CH2C≡CC), 
124.62 (dd, 2JCF = 15.6 Hz, 4JCF = 3.9 Hz, FCC), 127.53 (CH2C≡CCCHCH), 127.72 (CH2C≡CCCHCHCH), 
129.99 (CH2C≡CCCCH), 132.39 (CH2C≡CCCH), 132.56 (dd, 3JCF=9.5, 3JCF=4.8 Hz, FCCCH), 137.15 
(CH2C≡CCC), 159.80 (dd, 1JCF=250.9, 3JCF=11.9 Hz, CF), 162.44 (dd, 1JCF=248.6, 3JCF=11.6 Hz, CF), 174.02 
(C=O) ppm; IR (KBr): ṽ=3376, 3063, 2943, 2855, 2810, 2230, 1730, 1619, 1593, 1511, 1479, 1419, 1370, 
1265, 1180, 1152, 1139, 1099, 1032, 963, 849, 761 cm-1; MS (ESI+) m/z: 398 [M+H]+; HRMS-ESI+ m/z 
[M+H]+ calcd for C24H26F2NO2: 397.1932, found: 398.1925.  
(R)-Ethyl 1-{4-[2-(2-chloro-4-fluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylate ((R)-15i): 
Rf≈0.3 (hexane/ethyl acetate 8:2). [α]20D=-30.2 (c=1.0 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ=1.24 (t, J=7.1 
Hz, 3H, OCH2CH3), 1.41 (qd, J=11.6, 3.5 Hz, 1H, NCH2CHCHaxHeq), 1.47–1.58 (m, 1H, NCH2CHaxHeqCH2CH), 
1.69 (dp, J=10.3, 3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.91 (dq, J=12.8, 4.1 Hz, 1H, NCH2CHCHaxHeq), 1.99 (td, 
J=11.0, 3.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.18 (t, J=10.7 Hz, 1H, NCHaxHeqCH), 2.35–2.46 (m, 4H, 
NCH2CH2C≡C, NCH2CH2C≡C), 2.50 (tt, J=10.5, 3.8 Hz, 1H, NCH2CHax), 2.67 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.90 (dbr, J=11.1 Hz, 1H, NCHaxHeqCH), 4.12 (q, J=7.2 Hz, 2H, OCH2CH3), 7.02 (td, 
J=8.4, 2.6 Hz, 1H, FCCHCH), 7.19–7.35 (m, 5H, FCCHCCl, C≡CCCCH, FCCHCH, C≡CCCHCH, 
C≡CCCCHCH), 7.46–7.51 (m, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, CDCl3): δ=14.17 (OCH2CH3), 17.53 
(NCH2CH2C≡C), 24.53 (NCH2CH2CH2CH), 26.79 (NCH2CHCH2), 41.82 (NCH2CH), 53.16 (NCH2CH2CH2CH), 
54.92 (NCH2CH), 57.15 (NCH2CH2C≡C), 60.28 (OCH2CH3), 79.91 (C≡CCCH), 92.06 (C≡CCCH), 113.42 (d, 
2JCF=20.8 Hz, FCCHCH), 116.51 (d, 2JCF=24.3 Hz, FCCHCCl), 123.62 (CH2C≡CC), 127.34 
(CH2C≡CCCHCHCH), 127.73 (CH2C≡CCCHCH), 129.70 (CH2C≡CCCCH), 132.00 (CH2C≡CCCH), 132.44 (d, 
3JCF=8.7 Hz, FCCHCH), 134.12 (d, 3JCF=10.0 Hz, ClC), 135.98 (d, 4JCF=3.1 Hz, ClCC), 140.78 (CH2C≡CCC), 
161.80 (d, 1JCF=249.7 Hz, FC), 174.03 (C=O) ppm; IR (KBr): ṽ=3064, 2942, 2855, 2811, 2228, 1730, 1604, 
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1503, 1473, 1443, 1370, 1257, 1201, 1181, 1153, 1100, 1033, 897, 858, 761 cm-1; MS (ESI+) m/z: 414 [M+H]+; 
HRMS-ESI+ m/z [M+H]+ calcd for C24H26ClFNO2: 414.1636, found: 414.1634. 
(R)-1-{4-[2-(2-Methylphenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid ((R)-17d): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). [α]20D=+36.0 (c=1.0 in CH2Cl2). 1H NMR (400 MHz, 1N NaOD/CH3OD 1:2, 
60 °C): δ=1.26 (qd, J=12.8, 4.1 Hz, 1H, NCH2CHCHaxHeq), 1.47 (qt, J=12.8, 3.5 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.63 (dp, J=13.2, 3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.79 (t, J=10.8 Hz, 1H, 
NCHaxHeqCH2CH2CH), 1.88–2.01  (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH), 2.07 (s, 3H, H3CC), 2.22–2.43 
(m, 5H, NCH2CH2C≡C, NCH2CH2C≡C, NCH2CHax), 2.70 (dbr, J=10.5 Hz, 1H, NCHaxHeqCH2CH2CH), 2.92 
(dbr, J=11.1 Hz, 1H, NCHaxHeqCH), 7.04 (d, J=7.5 Hz, 1H, H3CCCCH), 7.11 (dd, J=7.2, 1.6 Hz, 1H, 
C≡CCCCH), 7.14–7.20 (m, 1H, H3CCCCHCH), 7.20–7.25 (m, 2H, H3CCCHCH, H3CCCH), 7.25–7.35 (m, 
2H, C≡CCCHCH, C≡CCCCHCH), 7.44 (d, J=7.6 Hz, 1H, C≡CCCH) ppm; 13C NMR (101 MHz, 1N 
NaOD/CH3OD 1:2, 60 °C): δ=17.49 (NCH2CH2C≡C), 20.16 (H3CC), 25.56 (NCH2CH2CH2CH), 29.02 
(NCH2CHCH2), 46.04 (NCH2CH), 53.98 (NCH2CH2CH2CH), 57.47 (NCH2CH), 58.18 (NCH2CH2C≡C), 81.68 
(C≡CCCH), 91.93 (C≡CCCH), 124.17 (CH2C≡CC), 126.36 (H3CCCCHCH), 128.12 (CH2C≡CCCHCH), 
128.57 (H3CCCHCH), 128.81 (CH2C≡CCCHCHCH), 130.32 (CH2C≡CCCCH), 130.42 (H3CCCH), 132.72 
(CH2C≡CCCH), 137.02 (H3CC), 142.19 (H3CCC), 145.65 (CH2C≡CCC), 182.88 (C=O) ppm; IR (KBr): 
ṽ=3424, 3057, 3018, 2941, 2859, 2230, 1709, 1591, 1474, 1442, 1394, 1217, 1192, 1156, 1101, 1006, 759 
cm-1; MS (ESI+) m/z: 348 [M+H]+; HRMS-ESI+ m/z [M+H]+ calcd for C23H26NO2: 348.1963, found: 348.1959.
(R)-1-{4-[2-(2,4-Dichlorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid ((R)-17f): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). [α]20D=+26.5 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 
60 °C): δ=1.29 (qd, J=12.9, 4.1 Hz, 1H, NCH2CHCHaxHeq), 1.50 (qt, J=13.9, 3.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.66 (dp, J=12.8, 3.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.81 (td, J=12.3, 2.9 Hz, 1H, 
NCHaxHeqCH2CH2CH), 1.94 (dbr, J=12.7 Hz, 1H, NCH2CHCHaxHeq), 2.00 (t, J=11.5 Hz, 1H, NCHaxHeqCH), 
2.27–2.48 (m, 5H, NCH2CHax, NCH2CH2C≡C, NCH2CH2C≡C), 2.76 (dbr, J=11.3 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.98 (dbr, J=11.3 Hz, 1H, NCHaxHeqCH), 7.17–7.21 (m, 1H, C≡CCCCH), 7.25 (d, 
J=8.2 Hz, 1H, ClCCCH), 7.33–7.39 (m, 3H, ClCCHCH, C≡CCCHCH, C≡CCCCHCH), 7.43–7.46 (m, 1H, 
C≡CCCH), 7.52 (d, J=2.1 Hz, 1H, ClCCHCCl) ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): 
δ=17.61 (NCH2CH2C≡C), 25.66 (NCH2CH2CH2CH), 29.09 (NCH2CHCH2), 46.08 (NCH2CH), 54.24 
(NCH2CH2CH2CH), 57.54 (NCH2CH), 58.26 (NCH2CH2C≡C), 81.06 (C≡CCCH), 92.84 (C≡CCCH), 124.45 
(CH2C≡CC), 127.92 (ClCCHCH, 128.82 (CH2C≡CCCHCH), 129.19 (CH2C≡CCCHCHCH), 129.93 
(ClCCHCCl, 130.45 (CH2C≡CCCCH), 132.85 (CH2C≡CCCH), 133.67 (ClCCCH), 134.97 (ClC), 135.21 (ClC), 
139.96 (ClCC), 141.96 (CH2C≡CCC), 182.80 ppm (C=O) ppm; IR (KBr): ṽ=3435, 3060, 2935, 2856, 2808, 
2231, 1711, 1586, 1466, 1440, 1375, 1102, 1071, 1004, 865, 813, 761 cm-1; MS (ESI+) m/z: 402 [M+H]+; 
HRMS-ESI+ m/z [M+H]+ calcd for C22H22Cl2NO2: 402.1028, found: 402.1026.  
(R)-1-{4-[2-(2,4-Difluorophenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid ((R)-17g): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). [α]20D=+31.2 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 
60 °C): δ=1.29 (qd, J=13.0, 4.1 Hz, 1H, NCH2CHCHaxHeq), 1.51 (qt, J=13.4, 4.1 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.66 (dp, J=13.0, 3.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.86–1.97 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.03 (t, J=11.4 Hz, 1H, NCHaxHeqCH), 2.32 (tt, J=12.2, 3.8 Hz, 1H, 
NCH2CHax), 2.39–2.52 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.79 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.95–3.05 (m, 1H, NCHaxHeqCH), 6.98–7.05 (m, 2H, FCCHCF, FCCHCH), 7.26 (dd, 
J=7.2, 1.1 Hz, 1H, C≡CCCCH), 7.32–7.39 (m, 3H, C≡CCCCHCH, C≡CCCHCH, FCCCH), 7.45–7.48 (m, 1H, 
C≡CCCH) ppm; 13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.56 (NCH2CH2C≡C), 25.67 
(NCH2CH2CH2CH), 29.11 (NCH2CHCH2), 46.13 (NCH2CH), 54.20 (NCH2CH2CH2CH), 57.53 (NCH2CH), 
58.30 (NCH2CH2C≡C), 81.21 (C≡CCCH), 92.24 (C≡CCCH), 104.57 (d, 2JCF=26.2 Hz, FCCHCF), 111.93 (dd, 
2JCF=21.3 Hz, 4JCF=3.8 Hz, FCCHCH), 124.63 (CH2C≡CC), 126.07 (dd, 2JCF=16.0 Hz, 4JCF=3.8 Hz, FCC), 
129.00 (2 C, CH2C≡CCCHCHCH, CH2C≡CCCHCH), 130.99 (CH2C≡CCCCH), 133.17 (CH2C≡CCCH), 
133.52 (dd, 3JCF=9.5 Hz, 3JCF=4.6 Hz, 1C, FCCCH), 138.52 (s, 1C, CH2C≡CCC), 161.06 (dd, 1JCF=249.0 Hz, 
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3JCF=12.7 Hz, FC), 163.87 (dd, 1JCF=257.3 Hz, 3JCF=10.3 Hz, FC), 182.82 (C=O) ppm; IR (KBr): ṽ=3425, 
3061, 2941, 2861, 2808, 2232, 1708, 1618, 1593, 1511, 1479, 1444, 1419, 1265, 1140, 1097, 963, 850, 762 
cm-1; MS (ESI+) m/z: 370 [M+H]+; HRMS-ESI+ m/z [M+H]+ calcd for C22H22F2NO2: 370.1619 found: 370.1614.
(R)-1-{4-[2-(2-Chloro-4-fluoro-phenyl)phenyl]but-3-yn-1-yl}piperidine-3-carboxylic acid ((R)-17i): 
Rf≈0.1 (CH2Cl2/CH3OH 9:1). [α]20D=+28.4 (c=1.0 in CH2Cl2). 1H NMR (500 MHz, 1N NaOD/CH3OD 1:2, 
60 °C): δ=1.28 (qd, J=12.8, 4.0 Hz, 1H, NCH2CHCHaxHeq), 1.49 (qt, J=13.0., 3.4 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.65 (dbr, J=13.5 Hz, 1H, NCH2CHaxHeqCH2CH), 1.85 (td, J=12.0/2.3 Hz, 1H, 
NCHaxHeqCH2CH2CH), 1.90–2.05 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH ), 2.24–2.48 (m, 5H, NCH2CHax, 
NCH2CH2C≡C, NCH2CH2C≡C), 2.75 (dbr, J=10.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.97 (dbr, J=11.1 Hz, 1H, 
NCHaxHeqCH), 7.12 (td, J=8.4, 2.6 Hz, 1H, FCCHCH), 7.16–7.21 (m, 1H, C≡CCCCH), 7.24–7.31 (m, 2H, 
FCCHCH, FCCHCCl), 7.31–7.39 (m, 2H, C≡CCCHCH, C≡CCCCHCH), 7.41–7.47 (m, 1H, C≡CCCH) ppm; 
13C NMR (126 MHz, 1N NaOD/CH3OD 1:2, 60 °C): δ=17.52 (NCH2CH2C≡C), 25.59 (NCH2CH2CH2CH), 
29.03 (NCH2CHCH2), 46.06 (NCH2CH), 54.11 (NCH2CH2CH2CH), 57.46 (NCH2CH), 58.22 (NCH2CH2C≡C), 
81.14 (C≡CCCH), 92.65 (C≡CCCH), 114.75 (d, 2JCF=21.2 Hz, FCCHCH), 117.33 (d, 2JCF=24.7 Hz, 
FCCHCCl), 124.57 (CH2C≡CC), 128.78 (CH2C≡CCCHCH), 129.05 (CH2C≡CCCHCHCH), 130.67 
(CH2C≡CCCCH), 132.84 (CH2C≡CCCH), 133.78 (d, 3JCF=8.7 Hz, FCCHCH), 135.08 (d, 3JCF=10.4 Hz, ClC), 
137.48 (d, 4JCF=3.6 Hz, ClCC), 142.09 (CH2C≡CCC), 163.17 (d, 1JCF=248.4 Hz, FC), 182.87 (C=O) ppm; IR 
(KBr): ṽ=3433, 3062, 2942, 2859, 2231, 1710, 1604, 1503, 1473, 1442, 1389, 1257, 1201, 1062, 1041, 1006, 
897, 859, 820, 762 cm-1; MS (ESI+) m/z: 385 [M+H]+; HRMS-ESI+ m/z [M+H]+ calcd for C22H22ClFNO2: 
386.1323, found 386.1319.  
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Development of new photoswitchable azobenzene bound 
GABA uptake inhibitors with distinctly enhanced potency 
upon photoactivation
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Abstract 
Inhibition of GABA transporters in the central nervous system (CNS) enhances GABA signaling and alleviates 
symptoms of neurological disorders such as epilepsy, assumed to correspond with low GABA levels. Recently, 
we reported the first photoswitchable inhibitor of GAT1, the most common GABA transporter subtype in the 
CNS. As an extension of this study, a series of nipecotic acid derivatives with new azo benzene bound 
photoswitchable N-substituents was synthesized and characterized for their functional inhibitory activity at 
mGAT1 both before and after photoirradiation. This led to the identification of the first photoswitchable 
ligands exhibiting a moderate uptake inhibition of GABA in their (E)-, but distinctive higher inhibitory potency 
in their (Z)-form resulting from photoirradiation. For the most efficient photoactivatable nipecotic acid 
derivative displaying an N-but-3-in-1-yl linker with a terminal diphenyldiazene unit, an inhibitory potency of 
4.65±0.05 (pIC50) was found for its ground state which increased by almost two log units up to 6.38±0.04 
when irradiated. 
Introduction 
Photoswitchable ligands are compounds whose activity at a given biological target can be controlled by light 
and thus with high temporal and spatial precision. When irradiated with light, such ligands reversibly undergo 
a configurational change in their structure, which may a significantly alter their affinity to a specific target. 
Recently, a variety of photoswitchable ligands have been successfully developed, e.g. for the optical control 
of epithelial sodium channels,1 insulin receptors,2 the acetylcholinesterase,3 µ-opioid receptors,4 TRPV1-
channels,5 glutamate receptors,6 NMDA receptors,7 AMPA receptors,8 local anesthetics,9 and cell division.10,
11 In our previous work, we have reported the first application of the concept of light controlled ligand activity 
to a plasma membrane bound neurotransmitter transporter, the GABA transporter GAT1, by introducing the 
first photoswitchable GABA uptake inhibitors.12 
γ-Aminobutyric acid (GABA, 1, Figure 1) is known to be the major inhibitory neurotransmitter13 in the CNS. 
Upon depolarization of presynaptic GABAergic neurons, GABA is released into the synaptic cleft where it 
activates GABA receptors mediating further signal transduction. A reduced neurotransmission of GABA leads 
to an imbalance between excitatory and inhibitory neurotransmission14 and hence plays a role in the 
pathogenesis of many neurological disorders such as epilepsy, neuropathic pain, depression, or anxiety.15 
* Depa t e t fü  Pha azie – )e t u  fü  Pha afo s hu g, Lud ig-Ma i ilia s-U i e sität Mü he ,
Butenandtstrasse 5-13, 81377 Munich, Germany
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Since the termination of GABAergic signaling is mainly caused by specific GABA transport proteins (GATs) 
hi h ediate GABA’s euptake i to the p es apti  eu o  o  its t a spo t i to glia ells,16 GATs represent 
a valuable drug target,17 as their inhibition can contribute to restore a physiological neurotransmitter 
balance. The GABA transporters are membrane bound proteins belonging to the solute carrier 6 (SLC-6) 
family.18 The four subtypes derived from mouse brain cells are named mGAT1, mGAT2, mGAT3, and mGAT4. 
By contrast, the human GATs are designated as hGAT1, hBGT1, hGAT2, and hGAT3, respectively.17 The GABA 
transporter subtype 1 (hGAT1, mGAT1) is mainly located on presynaptic neurons and represents the most 
abundant and hence the most important subtype in the CNS for GABA uptake.19 
The first generation of GAT inhibitors consisted of cyclic analogues of GABA like (R)-nipecotic acid (2, Figure 
1)20 exhibiting an in vitro functional inhibitory activity (pIC50) of 5.19±0.03 at mGAT1.21 Due to its inability to
cross the blood-brain barrier,22 the nipecotic acid was later equipped with a lipophilic side chain resulting in
compounds such as tiagabine (3, Figure 1),23,24 that not only enabled the amino acid to cross the BBB but
even made it a highly potent and selective inhibitor for the GABA transporter subtype GAT1 (pIC50 =
6.88±0.12).21 Tiagabine which is used for partial treatment of epilepsy is the only marketed drug targeting
the GAT1 protein.
Recently, we introduced the highly potent and mGAT1 selective parent compounds 4 and 5 (Figure 1) that 
exhibit a similar inhibitory activity as tiagabine towards the aforementioned target (mGAT1: 4: pIC50 = 
6.79±0.12; 5: pIC50 = 7.00±0.04).25, 26 The N-substituents of these nipecotic acids are characterized by a but-
3-en-1-yl and a but-3-in-1-yl linker, respectively, with a terminally attached 2-biphenyl residue. In contrast,
the first photoswitchable mGAT1 inhibitors reported so far are based on an ethoxy ethyl spacer linking
nipecotic acid with a diphenyldiazene or a naphthylphenyldiazene subunit as photoresponsive element.12
Among these photosensitive compounds studied, (R)-6 was found to be the most efficient photoswitchable
ligand (Figure 1). This compound, (R)-6, displayed a pIC50 of 6.39±0.08 as its pure (E)-isomer whereas after
irradiation with light at 375 nm inducing a (E)/(Z)-ratio of 13/87 at the photostationary state led to a reduced
mGAT1 activity in a functional GABA uptake assay with a pIC50 value of 5.78±0.03.
Figure 1:  Structure of GABA, known potent GAT1 inhibitors, and the first photoswitchable GAT1 inhibitor (pIC50 values 
refer to mGAT1). 
For the development of new nipecotic acid derivatives with photoresponsive subunits, compounds 4 and 5 
were selected as templates. Herein, the biphenyl-type residue of the N-substituent was intended to be 
replaced by different photosensitive diaryldiazene subunits, whilst the alkenyl and alkynyl spacer originating 
from the amino group of the nipecotic acid unit should be preserved. Ideally, the photoswitches to be 
generated should exhibit a higher inhibitory potency at mGAT1 and be characterized by a difference in 
potency concerning their two possible conformational isomers, the (E)- and the (Z)-form, as large as possible. 
In this context, a further aim of this study was to identify mGAT1 inhibitors, which show a low inhibitory 
activity towards the target for their (E)-form representing the ground state and a distinctly higher potency 
for their (Z)-form that should also clearly prevail after irradiation. 
pIC
50
 = 5.19 ± 0.03 pIC50 = 6.79 ± 0.12pIC50 = 6.88 ± 0.12
pIC
50
 = 7.00 ± 0.04 (R)-6
GABA (1)
(R)-nipecotic acid (2) tiagabine (3) 4 5
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Such photoswitchable mGAT1 inhibitors would nicely complement the photoresponsive compounds 
developed before by us with the (E)- as compared to the (Z)-form being the more potent mGAT1 ligands. 
Because of the limited degree, azobenzenes can be transformed from the (E)- to the (Z)-form upon irradiation 
with light, photoswitches with the (Z)-form being more active than the (E)-form are of great interest as they 
may allow to gain larger activity differences upon irradiation.  
With respect to the design of the target compounds, we intended to create homology models of the hGAT1 
protein, based on which docking experiments should be performed with nipecotic acid derivatives exhibiting 
different N-substituents. That way, the subunits of the N-substituents, the spacer, and the photoresponsive 
elements that would be considered well worth for the construction of the new photoswitches should be 
identified. Thereby, in addition to the binding affinities of different photoswitchable ligands to hGAT1, also 
the affinities of their ground as compared to the irradiated states to the target protein should be estimated. 
For the photoswitchable compounds to be synthesized, a versatile and efficient synthetic approach should 
be devised and all compounds should be characterized for their functional inhibitory activity towards mGAT1 
before and after irradiation in GABA uptake assay.  
Results and discussion 
Rational design: 
The structural parameters of the new photoswitchable mGAT1 inhibitors that were intended to be varied are 
depicted in Figure 2. The N-alkyl spacer interconnecting the nipecotic acid with the diaryldiazene moiety 
should consist of either a four or a five carbon atom chain with a terminal double or triple bond as several 
compounds displaying these types of spacer have previously been found to be highly active mGAT1 
inhibitors.25, 26 For the terminally attached photoresponsive element, a diphenyldiazene or a naphthyl-
phenyldiazene residue should be considered with the connection of the central phenyl ring of this unit with 
the linker originating from all three positions, i.e. the ortho-, meta- and para-position. 
Figure 2: Parameters to be varied in the search for potent photoswitchables for nipecotic acid derivatives 
Modeling: 
For the identification of new and efficient photoswitchable GAT1 inhibitors, we investigated the set of 
compounds indicated in Figure 2 in virtual screening experiments performed with homology models of 
hGAT1. To this end, at first a suitable homology model of GAT1 which yields docking scores in line with the 
measured pIC50 values of the so far known photoswitchable compounds like (R)-6 (Figure 1) was required. 
Thus, homology models of hGAT1 based on Leucine transporter (LeuT) X-Ray structures were generated.  
spacer length:
C
4
 or C
5
spacer type:
double or triple bond
substitution:
ortho, meta or para
terminal residue:
a) phenyl or b) naphtyl
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For this purpose, the losed  LeuT o fo atio  pd -id= a  a d the ope -to-out  LeuT o fo atio  
pdb-id=3f3a were used as template structures. In the LeuT structure pdb-id = 2a65 a leucine is present in the 
primary binding site (S1) and four residues (Tyr108-Phe253 and Arg30-Asp404 in LeuT) shield this S1 site from 
the extracellular medium.27 In contrast, in the pdb-id = 3f3a LeuT structure, two tryptophan molecules are 
bound, one directly in the S1 site and the second located above the first one. This keeps the gating residues 
far apart and the resulting LeuT conformation with the S1 site being not shielded and directly accessible from 
the extracellular medium is alled ope -to-out .28 The hGAT1 homology models based on these two 
different LeuT conformations, which were generated with and without flexible gating residues as previously 
described in detail21 were used for docking calculations. In addition, hGAT1 models were employed for this 
purpose that had been obtained by refining the protein structure with bound Tiagabine (3) by molecular 
simulation calculations as described in detail.25 These models were able to predict the inhibitory activity of 
compounds (R)-425 and (R)-526 (Figure 1) which are highly similar to the desired photoswitchables. 
The theoretical evaluations of the compounds and binding modes are based on the comparison of the 
AutoDock4 docking scores and the measured pIC50 values. Two of the aforementioned homology models of 
hGAT1 were able to yield docking scores for the recently published photoswitchable GAT1 inhibitors which 
are in line with the measured pIC50 values.12 Model I had been obtained from refined MD calculations of the 
target protein with bound Tiagabine, model II from the losed  LeuT o fo atio  pdb-id-2a65 by treating 
the two gating residues (Tyr140-Phe294, GAT1 numbering) as flexible during docking.  
When docking the (EN-N)- and (ZN-N)-isomers of the designed compounds depicted in Figure 2, both models 
predicted compounds with the ortho-substitution to be less active than meta- and para-substituted 
derivatives independent of the N-N double bond configuration. Therefore, scaffolds with ortho-substitution 
should not be further included in this study. In addition, compounds with an alkynyl spacer yielded better 
docking scores than those with an alkenyl linker. But no clear trend appeared regarding the influence of the 
length of the spacer and the nature of the terminal aryl residue, phenyl versus naphthyl. On the docking 
scores, the results were similar in all cases.  
However, among the derivatives studied, one compound, characterized by a but-3-inyl spacer and a meta-
substituted diphenyldiazene subunit was found that according to the docking results could be expected to 
be well suited for its use as a photoswitchable ligand. In both docking models, the (E)- and (Z)-isomer of this 
compound (R)-m-20a exhibited a high difference in the docking scores (model I: (R)-(E)-m-20a = -9.3 kcal/mol, 
(R)-(Z)-m-20a = -11.59 kcal/mol, model II: (R)-(E)-m-20a = -10.0 kcal/mol, (R)-(Z)-m-20a = -12.07 kcal/mol), 
clearly indicating that the photoswitched (Z)-isomer of (R)-m-20a should be more potent as compared to the 
(E)-isomer. Hence, compound (R)-m-20a appeared as the most promising candidate of the photoswitchable 
ligands that were intended to be synthesized.  
Inspecting the docking poses of the (E)- and (Z)-isomer of (R)-m-20a in model I (Figure 3), show two significant 
differences which provide a rational explanation of the highly different docking scores found for the two 
isomers. While the interactions of the carboxyl function of both isomers is almost identical, the NH of the (Z)-
isomer (Figure 3B) is involved in a hydrogen bond to the Phe294-CO. The H-O distance is almost perfect with 
2 Å. In addition, the azo group of the (Z)-isomer, which is more exposed, interacts closely with the Arg69 
carboxy function in a distance of 3 Å. Both interactions are not possible for the (E)-isomer (Figure 3A). The 
hydrogen bond of the NH to the Phe294-CO does not form at all, as with 3.9 Å the distance is too long. Also 
the distance of the distal azo nitrogen to the carboxy function of Arg69 amounting to 5.1Å is too long for a 
reasonable interaction of these groups. As apparent from Figure 3A, the (E)-configuration of the azo group 
straightens and hence enlarges the lipophilic N-substituent of the nipecotic acid moiety. This increased 
spatial demand and the decreased flexibility resulting from the alkynyl spacer appear to force the (E)-isomer 
in a docking pose which does not allow the formation of the favorable interactions that are present for the 
(Z)-isomer. Hence, the (Z)-isomer of (R)-m-20a can be expected to act as the more potent GAT1 inhibitor as 
compared to the (E)-form of this compound. 
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Figure 3: A) The (E)-isomer (cyan) and B) the (Z)-isomer (magenta) of (R)-m-20a docked into model I. The most prominent 
differences are the H bond between the NH of the (Z)-isomer to the Phe294 backbone CO (H-O distance = 2 Å) and the 
interaction the azo group of the Z-isomer and the Arg69 sidechain, both highlighted with orange dotted lines. 
Chemistry: 
The synthesis of photoswitchable GAT1 inhibitors containing a double bond in an all carbon spacer were 
intended to be performed by a Suzuki-Miyaura reaction. To this end, the nipecotic acid derivatives with an 
N-alkenyl residue provided with a terminal boronic acid ester function, i.e. 7 and 8 (Scheme 1) should be
reacted with either of the two iodo substituted photoresponsive diaryldiazene subunits 9a-b (Scheme 1) as
shown in Scheme 1. This approach appeared most promising as it would easily allow the variation of the
length of the spacer and the structure of the diaryldiazene subunit of the target compounds.
When the boronic acid esters 7 and 8 (Scheme 1) were subjected to Suzuki cross-coupling reactions with the 
iodo substituted diaryldiazenes 9a-b (Scheme 1) under standard conditions (1 mol% Pd2dba3 ;  4 mol% SPhos, 
K3PO4 in dioxane/water, 60 °C),29 the corresponding coupling products 10a-b and 11a-b (Scheme 1) were 
obtained in good to very good yields (78–87%). The target compounds, free nipecotic acid derivatives 12a-b 
and 13a-b were finally obtained by alkaline hydrolysis (NaOH, EtOH, rt, 6h) of the carboxylic acid esters 
10a-b and 11a-b (Scheme 1, yield: 88–96%). 
Scheme 1: General synthesis route for photoswitchable GAT1 Inhibitors containing an alkenyl spacera
a Reagents and conditions: a) Pd2dba3 (1 mol%), SPhos (4 mol%), K3PO4 (2.0 eq), dioxane/water (2:1); 60 °C, 6h; 
b) NaOH (2 M, 3.0 eq), ethanol; r.t., 6h;
a
n = 1: 
n = 2:
b
m-12a-b, p-12a-b
m-13a-b, p-13a-b
n = 1:   7 
n = 2:   8
n = 1: 
n = 2:
Aryl substitution:  meta (m) or para (p);  Terminal residue: a = phenyl, b = naphthyl
m-9a-b, p-9a-b
m-10a-b, p-10a-b
m-11a-b, p-11a-b
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For the synthesis of photoswitchable GAT1 inhibitors with a triple bond in the spacer, a different approach 
as compared to the construction of the photoswitches with an alkenyl linker (Scheme 1) was followed. In 
preliminary experiments, the Sonogashira cross-coupling reaction of the diaryldiazenes 9a-b with the linker 
unit already attached to the nipecotic acid moiety was found to proceed in low yields only: Therefore, first 
the iodo substituted diaryldiazenes 9a-b (Scheme 2) were equipped with alkynyl residues that should serve 
as spacers in the final compounds. This was accomplished by performing a Sonogashira cross-coupling 
reaction of diaryldiazenes m-9a-b and p-9a-b with either but-3-yn-1-ol or pent-4-yn-1-ol [Pd2(dppf)2Cl2 and 
Et3N in THF, 1 hour, 60 °C] which led to the coupling products 14a-b and 15a-b in high yields (90–96%, Scheme 
2). In the next step, arylalkynyl alcohols 14a-b and 15a-b were transformed into the corresponding tosylates 
16a-b and 17a-b (Scheme 2) by treatment with of TsCl and Et3N (CH2Cl2, 24 hours, 85–92%) which then by 
reaction with nipecotic acid ethyl ester (acetone, 72 h, rt) provided the esters 18a-b and 19a-b (84–93%, 
Scheme 2). Finally, upon subjection to basic hydrolysis (NaOH, EtOH, rt, 6 hours) of esters 18a-b and 19a-b 
the desired photoswitches, the nipecotic acid derivatives m-20a-b, p-20a-b, m-21a-b, and p-21a-b (yield: 
87–94%) could be obtained (Scheme 2). 
Scheme 2: General synthesis route for photoswitchable GAT1 Inhibitors containing an alkynyl spacera
aReagents and conditions: a) but-3-yn-1-ol or pent-4-yn-1-ol, Pd2(dppf)2Cl2, Et3N, THF; 60 °C, 1 h; b) TosCl, Et3N, CH2Cl2; 
0 °C  r.t., 24 h; c) nipecotic acid ethyl ester, acetone; r.t., 72 h; d) NaOH (2 M, 3.0 eq), ethanol; r.t., 6h; 
Photoisomerization: 
All photoswitchable compounds were characterized with regard to their potency as mGAT1 inhibitors. This 
characterization was performed for the pure (EN-N)-isomers as well as the (EN-N)/(ZN-N)-mixtures that were 
obtained upon irradiation until the photostationary equilibrium was reached. In preliminary experiments 
using UV/Vis spectroscopy and in situ irradiation with monochromatic light,30 the wavelengths of 350 nm and 
375 nm for the diphenyldiazene subunit and naphthylphenyldiazene subunits, respectively, were found to 
effect the highest percentage of (ZN-N)-isomer at the photostationary state. For the biological testing, a 10 
mM stock solution in DMSO of the individual compounds was subjected to photoisomerization by means of 
a Rayonet photoreactor31 max = 350 nm) in case of GAT1 inhibitors containing a diphenyldiazene subunit, 
and with a self-built light chamber equipped with LED lamps ( max = 375 nm) for photoswitches with a 
naphthylphenyldiazene as photoresponsive element. In each case solutions were irradiated until the 
photostationary state with the maximum achievable percentage of (ZN-N)-isomer over the (EN-N)-isomer was 
reached. For compounds based on a diphenyldiazene subunit this was possible within 10–20 min, whereas it 
took 1–2 hours for the compounds with a naphthylphenyldiazene moiety. The percentage of the (ZN-N)-isomer 
at the photostationary state was determined by 1H NMR spectroscopic analysis of the respective samples.  
m-14a-b, p-14a-b
m-15a-b, p-15a-b
m-16a-b, p-16a-b
m-17a-b, p-17a-b
m-20a-b, p-20a-b
m-21a-b, p-21a-b
m-9a-b, p-9a-b
m-18a-b, p-18a-b
m-19a-b, p-19a-b
n = 1: 
n = 2:
a b c d
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For compounds exhibiting a diphenyldiazene subunit, i.e. m-12a, p-12a, m-13a, p-13a, m-20a, (R)-m-20a, 
p-20a, (R)-p-20a, m-21a, p-21a, (Table 2, entry 1-2, 5-6, 9-10 and 13-14), the (EN-N)/(ZN-N) were in the range
from 19/81 till 09/91. In case of the photoswitchable ligands with a naphthylphenyldiazene moiety,
compounds m-12b, p-12b, m-13b, p-13b, m-20b, (R)-m-20b, p-20b, (R)-p-20b, m-21b and p-21b, the isomer
ratios ranged from 36/64 to 16/84 (Table 2, entry 3-4, 7-8, 11-12 and 15-16). Interestingly, the half-life´s
found for the thermal relaxation of the studied photoswitches in phosphate buffer (pH 7.4) followed a
general trend. When as a photoresponsive element, an m-substituted diphenyldiazene moiety is present, the
half-lives are higher (≈ 10-20 d, Table 1, entry 1 and 9). From there, it gradually decreases via compounds
containing a p-substituted diphenyl diazene, an m-substituted naphthyl phenyl diazene to those with a p-
substituted naphthyl phenyl diazene unit. For the latter, the half-lives are in the range of hours only (Table 1,
entry 8 and 16) which may be attributed to the extended π-system present in these compounds. For
assessment of the thermal relaxation rates in organic solvent, half-life’s of all o pou ds ith C4 spacer were
additionally reviewed in DMSO and found to be in a comparable scale (see supporting information).
For m-20a, which was found to show the highest differences in potency between the (E)- and (Z)-isomer at 
mGAT1 thus representing the most promising photoswitch, isomerization was additionally studied in 
phosphate buffer (25 µM solution, pH 7.4) as a more physiological system. For the forward isomerization 
with 350 nm monochromatic light,30 found to be the best for this purpose, a (E)/(Z)- atio of ≈ 5/95, 
representing the photochemical equilibrium, was reached within 10 minutes. Back isomerization by 
irradiation was best effected with 420 nm monochromatic light yielding an (E)/(Z)-ratio of ≈ 75/25 at the 
photostationary state (10 minutes). Thermal relaxation (in the dark) of the (Z)-isomer of m-20a was found to 
be very slow, the half-life of the reaction at 25 °C in phosphate buffer (pH 7.4) amounting to 22 days (Table 
1, entry 9) and in DMSO at 25 °C to 15 days demonstrating the high thermal stability of (Z)-m-20a. Detailed 
kinetical data and measurements for this compound is given in the supporting information. 
Biological evaluation: 
Uptake inhibition at mGAT1 was determined for both the pure (EN-N)-isomers and for the (EN-N)/(ZN-N)-
mixtures from photoequilibration (see Table 2 for isomer ratios). Compounds that were found to be highly 
active in one of their isomeric forms were synthesized in their enantiopure form, and additionally 
characterized for their subtype selectivity for mGAT1 as compared to mGAT2-mGAT4 by determining the 
functional inhibitory activity in [3H]GABA uptake assays.32  
Results of functional inhibitory activity at mGAT1 for compounds containing an alkenyl spacer are given in 
entry 1 to 8 of Table 1. The inhibitors with a meta-substituted diphenyldiazene subunit m-12a and m-13a 
(Table 1, entry 1 and 5) exhibited both a higher inhibitory potency in the photoequilibrated state than in the 
pure (EN-N)-form. In case of m-12a with a C4-spacer (pIC50 = 4.42±0.02; pIC50* = 5.32±0.09; Table 1, entry 1) 
this effect is more pronounced than for the homologue m-13a (pIC50 = 4.42±0.01; pIC50* = 4.60±0.12; Table 
1, entry 5) with a C5-linker. In contrast, the corresponding compounds with para-substituted 
diphenyldiazenes moieties p-12a and p-13a (Table 1, entry 2 and 6) show the opposite effect at mGAT1, the 
pure (EN-N) isomer being about 0.6 log units more potent than the photoequilibrated mixture for both spacer 
length (p-12a: pIC50 = 5.00±0.01, pIC50* = 4.43±0.03, Table 1, entry 2; p-13a: pIC50 = 5.24±0.01, pIC50* = 
4.63±0.03, Table 1, entry 6). Alike the diphenyldiazene derivatives m-12a and m-13a, also the analogous 
compounds m-12b and m-13b (Table 1 entry 3 and 7) with a naphthylphenyldiazene subunit, showed higher 
potencies after photoirradiation than the (EN-N)-form whereby m-12b with the C4-spacer showed a slight 
tendency towards higher potencies  (m-12b: pIC50 = 4.91±0.05, pIC50* = 5.23±0.01; Table 1, entry 3) than m-
13b with a longer linker (m-13b: pIC50 = 4.71±0.07; pIC50* = 5.00±0.05; Table 1, entry 7). For the analogues 
para-substituted compounds p-12b and p-13b (Table 1, entry 4 and 8) the difference in their inhibitory 
activity before and after irradiation (p-12b: pIC50 = 5.06±0.05; pIC50* = 5.13±0.07; Table 1, entry 4; p-13b: 
pIC50 = 5.19±0.12; pIC50* = 5.21±0.03; Table 2, entry 8) is finally so small that it appears random and not 
significant. Besides the data for these compounds may also have been affected by thermal back reactions 
during the [3H]GABA uptake assay, which is the case of the compounds with a half-life of ≈ 1 h is relatively 
fast (Table 1 entry 4 and 8). 
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The test results for photoswitchable compounds exhibiting an alkynyl spacer are described in entries 9–16 of 
Table 2. Similar to the alkene derivatives m-12a and m-13a (Table 1, entry 1 and 5) also the meta-substituted 
diphenyldiazenes with an alkenyl linker m-20a and m-21a (Table 1, entry 9 and 13) showed higher inhibitory 
potencies at mGAT1 after irradiation than the non-irradiated species. Actually, m-20a (Table 1, entry 9) 
showed the highest increase in potency only surpassed by its enantiopure form (R)-m-20a, the pIC50 for 
mGAT1 raising from 4.49±0.10 for the pure (E)-isomer to of 6.05±0.05 (pIC50) at the photostationary state. As 
it is known for mGAT1 inhibitors derived from nipecotic acid that their potency resides mainly in the (R)-
enantiomer in addition, (R)-m-20a (Table 1, entry 9a) was included in this study. In case of (R)-m-20a the 
effects observed for m-20a (Table 1, entry 9) were even more pronounced with the initial potency (pIC50 = 
4.65±0.05) and the increase in potency upon irradiation being somewhat higher (pIC50* = 6.38±0.04). Thus, 
(R)-m-20a represents a highly efficient photoswitchable inhibition at mGAT1 undergoing the substantial 
increase in inhibitory potency upon irradiation. This is nicely visualized by the two competition curves, for 
the ground state and the photoequilibrated state in Figure 4. The homologues inhibitor with a C5 instead of 
a C4-spacer m-21a (Table 1, entry 13) also showed a rise in potency upon irradiation from pIC50 = 4.84±0.11 
to pIC50* = 5.39±0.07 though to a smaller extent as compared to m-20a. The p-substituted isomers p-20a and 
p-21a (Table 1, entry 10 and 14), in analogy to the compounds with an alkenyl spacer (p-12a and p-13a),
showed a decrease in potency when irradiated (p-20a: pIC50 = 6.19±0.05; pIC50* = 5.59±0.02; Table 1, entry
10; p-21a: pIC50 = 5.12±0.03, pIC50* = 4.59±0.02; Table 1, entry 14). Thereby, for the (E)-form the inhibitor
with the shorter spacer, p-20a, showed a distinctly higher potency at mGAT1 than its homologue p-21a
(compare Table 1 entry 10 with entry 14). In case of the enantiopure (R)-p-20a (Table 1, entry 10a) as
compared to the racemic mixture, values rose from 6.19±0.05 to 6.38±0.04 for the (E)-isomer and from
5.59±0.2 to 5.84±0.04 for the photochemically equilibrated mixture. Of the compounds with a
naphthylphenyldiazene subunit, m-20b (Table 1, entry 11) exhibited a pIC50 of 5.19±0.10 for the (E)-form and
a pIC50* of 5.71±0.03 for the photochemically equilibrated mixture. In case of the enantiopure compound
(R)-m-20b both values were slightly higher (pIC50 = 5.37±0.01; pIC50* = 6.00±0.04; Table 1, entry 11a). For m-
21b (Table 1, entry 15) with a C5-spacer, no significant effect on potency resulted upon irradiation the pIC50
and the pIC50* being only nominally different (pIC50 = 4.91±0.01; pIC50* = 4.86±0.04; Table 1, entry 15).
Compounds p-20b and p-21b (Table 1, entry 12 and 16) exhibited higher inhibitory potencies for the (E)-
isomers than for the irradiated mixtures (p-20b: pIC50 = 6.90±0.04, pIC50* = 6.64±0.03; p-21b: pIC50 =
5.52±0.05, pIC50* = 5.31±0.13; Table 1, entry 12 and 16), but the differences were small. The same applied to
the enantiopure compound (R)-p-20b, the (E)-form being more potent, but only to a small extent, as
compared to the irradiated mixture ((R)-p-20b: pIC50 = 7.01±0.4; pIC50* = 6.74±0.05; Table 1, entry 12a).
Interestingly, (E)-p-20b and (R)-(E)-p-20b exhibited the highest inhibitory potencies at mGAT1 of the
compounds studied, but despite that the decrease in potency upon irradiation was quite low. This might be
attributed to the limited shift from the (E)-to the (Z)-form upon irradiation leading to a high content of the
more active E-form in the photoequilibrated mixture. This rather low degree of photoisomerization is
obviously associated with the p-substituted naphthylphenyldiazene moiety as it has been observed for all
compounds containing this photoresponsive element independent of whether the linker contains a double
(Table 1, entry 4 and 8) or a triple bond (Table 1, entry 12, 12a and 16).
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Table 1:  GABA uptake inhibition at mGAT1, (E)/(Z)-ratios, and thermal relaxation rates of all compounds 
Entry Comp. 
    pIC50  ± SEMa
mGAT1 mGAT1*b (E)/(Z)-ratioc t1/2d
1 m-12a 4.42±0.02 5.32±0.09 14/86 13 de
2 p-12a 5.00±0.01 4.43±0.03 11/89 1.1 df
3 m-12b 4.91±0.05 5.23±0.01 18/82 22 hg
4 p-12b 5.06±0.05 5.13±0.07 36/64 1.2 hh
5 m-13a 4.42±0.01 4.60±0.12 15/85 12 dg
6 p-13a 5.24±0.01 4.63±0.03 12/88 1.9 df
7 m-13b 4.71±0.07 5.00±0.05 17/83 11 hg
8 p-13b 5.19±0.12 5.21±0.03 36/64 1.5 hh
9 m-20a 4.49±0.10 6.05±0.05 19/81 22 df
9a (R)-m-20a 4.65±0.03 6.38±0.04 19/81 
10 p-20a 6.19±0.05 5.59±0.02 09/91 4.8 de
10a (R)-p-20a 6.38±0.04 5.84±0.04 09/91 
11 m-20b 5.19±0.10 5.71±0.03 17/83 18 h
g
11a (R)-m-20b 5.37±0.01 6.00±0.04 17/83 
12 p-20b 6.90±0.04 6.64±0.03 36/64 3.4 hh
12a (R)-p-20b 7.01±0.04 6.74±0.05 36/64 
13 m-21a 4.84±0.11 5.39±0.07 19/81 15 dg
14 p-21a 5.12±0.03 4.59±0.02 10/90 6.8 de
15 m-21b 4.91±0.07 4.86±0.10 16/84 1.8 dg
16 p-21b 5.52±0.05 5.31±0.13 35/65 4.3 hh
a experiments were performed three times in triplicates; b after photoirradiation, value of the E/Z-mixture; c at the 
photostationary state in DMSO; d determined by UV/vis-spectroscopy; e c = 25 µm, solvent: DMSO-d6/phosphate-buffer 
(pH 7.4) = 1:400 (v/v); f c = 50 µm, solvent: DMSO-d6/phosphate-buffer (pH 7.4) = 1:200 (v/v); g c = 20 µm, solvent: DMSO-
d6/phosphate-buffer (pH 7.4) = 1:500 (v/v); h c = 10 µm, solvent: DMSO-d6/phosphate-buffer (pH 7.4) = 1:1000 (v/v). 
Figure 4: Inhibition of mGAT1 mediated GABA uptake by (R)-m-20a for its ground state (▲) and the photoequilibrated 
state (■) upon irradiation. 
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The (E)-forms of the enantiopure derivatives (R)-m-20a, (R)-p-20a, (R)-m-20b, and (R)-p-20b (Table 2, entry 
9a, 11a, 13a, and 15a) were additionally characterized for their subtype selectivity in favor of mGAT1 as 
compared to mGAT2-mGAT4. In every case, the pIC50 values for mGAT2-4 which are in the range of 4-5 were 
lower than those for mGAT1 thus indicating that the (E)-forms of the tested compounds have a reasonable 
to good subtype selectivity for mGAT1. Since test compound (R)-m-20a (Table 1, entry 9a) had shown the 
most pronounced increase in inhibitory potency for the transition from the ground to the photoequilibrated 
state, the inhibitory potency of the photoequilibrated mixture was also studied at the other GABA transporter 
subtypes mGAT2-4. The here obtained values for the photoirradiated (R)-m-20a (remaining [3H]GABA uptake 
in presence of 100 µM inhibitor: mGAT2: 76%, mGAT3: 60%, mGAT4: 57%, see supporting information) do 
not indicate a considerable activity at these GABA transporters. Hence, the increase in activity of (R)-m-20a 
by using light is specifically towards mGAT1, whereas the other subtypes remain nearly unaffected.  
Overall as predicted by the modeling study described above compounds containing an alkynyl- instead of an 
alkenyl-spacer turned out to display higher differences in the biological activity at mGAT1 for the pure (EN-N)-
form as compared to the photoequilibrated mixture. In addition, (EN-N)-configured alkyne derivatives with a 
C4 spacer exhibit higher inhibitory potencies at mGAT1 as compared to their counterparts with a C5 linker. 
Only for the two homologous compounds m-20a and m-21a with different spacer links the opposite is true.  
In case of the para-substituted photoswitches with an alkyne linker, the potency at mGAT1 decreases upon 
irradiation independent of the terminal residue, whether phenyl or naphthyl is present. This decrease is, 
however, very small. The opposite is true for the analogues meta-substituted derivatives except for one 
compound, m-21b (table 1, entry 14) that undergoes only an insignificant change in biological activity upon 
irradiation, all others show a distinct increase in potency. This is most pronounced for racemic m-20a and its 
(R)-enantiomer (R)-m-20a, with a Δ pIC50 of 1.5-1.7 that also nicely highlights the structural functions required 
for an effective photoswitch for mGAT1, a nipecotic acid moiety, a most common motif for mGAT1 inhibitors 
provided with a meta substituted diphenyldiazene moiety at the amino nitrogen via a rather short and stiff 
alkyne linker. 
Electrophysiology: 
An electrophysiology part will be written by M. Eder as soon as respective experiments are done. 
Conclusion 
In summary, a series of nipecotic acid derivatives, exhibiting N-substituents with different photoresponsive 
elements attached to the amino nitrogen was synthesized and verified for a distinct potency increase 
concerning GABA uptake inhibition at mGAT1 upon photoirradiation. The N-substituents were varied 
regarding the length and saturation degree of the spacer as well as the types of diaryldiazenes and the kind 
of their substitution. Homology modeling and docking studies delivered first hints of possible appropriate 
N-substituents for this pupose. By means of the parallel biological test of both the ground state and the
isomeric mixture of photoequilibration of each compound, (R)-m-20a was identified as new efficient light
controllable inhibitor of this active membrane transporter which, as compared to the already existing
photoswitchable mGAT1 inhibitors, contrariwise a  e s it hed o  through photoirradiation, in fact
selectively for this targeted transporter subtype. This property, including the extent to which this effect is
associated with, allowing to gain a large difference in biologic activity, is described for the first time for this
target and may be a valuable feature for biological studies.
For the further extension of this application in neuroscience, future work will aim at the development of 
photoswitchable GABA uptake inhibitors with fast thermal relaxation kinetics by making use of specific 
substituents of the diaryldiazene unit in a next step. 
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Experimental section 
Computational chemistry 
For homology modelling of a losed  GAT  o fo atio  the D st u tu es A 27 was taken from the RCSB protein 
databank.33 The o l  a aila le D st u tu e of a  ope -to-out  o fo atio  F A27 was chosen as a template for an 
ope  GAT  o fo atio . The hu a  GAT  se ue e “ iss-Prot34 accession number P30531) was aligned to the 
LeuT sequence using the alignment from Skovstrup et al.35 The Modeler software version 9v836 was used to generate 
30 structures of each conformer. The two sodium atoms (Na1 and Na2) located close to the S1 binding site were copied 
into the hGAT1 structures. A chloride ion was placed into the putative chloride binding site proposed by Zomot et al.37 
and Forrest et al.38 However, the chloride ion has no direct contact to the active site and its presence has no impact for 
the docking calculations. The models with the lowest Modeler objective function were checked with PROCHECK39 for 
structural consistency and used for docking calculations.  
The molecules for docking were exported from our in-house InstantJChem 5.4 database40 as 2D MDL mol files. 
Protonation at a pH of 7.4 and the 2D to 3D conversion was done using Chemaxon Marvin 5.4.0.141 al  a d 
ol o e t . The o a d li e tool p epa e_dpf .p  as used fo  o e sio  i to AutoDo k  pd t i put files. 
Appropriate protein input files were prepared with the AutoDock tools.42 Do ki g g ids e e al ulated ith autog id  
and docking was performed with AutoDock4 version 4.2.3.43 The binding region was defined by a 18 Å × 18 Å × 18 Å box 
centered between the two gate-keeping residues Tyr139 and Phe294. The sidechains of the four gate-keeping residues 
(Tyr139, Phe294, Arg69, Asp451) were treated as flexible during docking. Ten poses for each molecule have been 
generated and scored with the AutoDock4 scoring function.43 
Photoisomerization, Photostationary States, Half-Life. 
A 1 mL aliquot of a 10 mM solution in DMSO-d6 of all test compounds was irradiated from the outside in a quartz glass 
NMR tube (Wilmad) until the photostationary state was reached (within 10 min). For irradiation either a Rayonet RPR-
 max = 350 nm, compounds 12a, 13a, 20a and 21a)29 or a self-built LED-lamp light chamber ( max = 375 nm, 
compounds 12b, 13b, 20b and 21b) was used. The latter consists of a plastic tube in which 48 single LED lamps (3.4-3.6 
V, 20 mA) are fitted. After irradiation, a 1H NMR spectrum was recorded immediately by a Jeol Eclipse +500 (500 MHz) 
spectrometer or an Avance III HD 500 MHz Bruker BioSpin spectrometer. The amount of (Z)- and (E)-isomers was in 
every case obtained through integration of the significant aromatic signals of the (Z)- and the (E)-isomer, giving the ratio 
fa to  α, respectively.  
For determination of the reachable (Z)/(E)-ratio under physiological conditions for m-20a, an aliquot of both the 
irradiated and non-irradiated 10 mM stem solution in DMSO-d6 as diluted to a o e t atio  of  M ith phosphate 
buffer (10 mM, pH 7.4) and a UV/Vis spectrum (Cary50 spectrometer, Varian) of these samples was recorded 
immediately. The absorption of the pure (Z)-isomer (A(Z)) at 350 nm could then be calculated from the absorption for 
this irradiated sample (A(E/Z)) at 350 nm together with the absorption of the pure (E)-isomer (A(E)) at 350 nm using 
following equation: 
A(Z) = A(E) + (A(Z/E) – A(E)  / α     with     α = (Z) / (c(E) + c(Z)) 
The ideal wavelength for the forward and back isomerization of (E)- and (Z)-m-20a under physiological conditions was 
determined by UV/vis spectroscopy and in situ irradiation of the 25 µM dilution of (E)-m-20a using an FT-600-UMT fiber 
optic cable (NA 0.39), connected to a Polychrome V system monochromator (TILL photonics) with a 150 W xenon short 
a  la p ith a  output a ge of −  . (E)-m-20a was irradiated at different wavelengths (330, 340, 350, 360, 
370 nm) until the photostationary state was reached (within 10 min). The resulting (Z)/(E)-ratio of m-20a during an 
irradiation could be calculated in this way:  
α = A(Z/E) – A(E)) / (A(Z) – A(E))  
The wavelength for back isomerization was determined in a similar way by irradiation of the photoisomerized sample 
of m-20a with higher wavelengths (410, 420, 430, 440 nm). The resulting (Z)/(E)-ratio of m-20a could again be calculated 
in the same way.  
For determination of the half-life of (Z)-m-20a in DMSO a 1 mL aliquot of the 10 mM stem solution in DMSO-d6 was 
irradiated as described initially until the photostationary state was reached (within 10 min). After irradiation, a first 1H 
NMR spectrum was recorded immediately. The sample was stored in the dark and further 1H NMR spectra were 
measured in defined time intervals (1, 2, 3, 5, 7, 10, 14, and 21 days). The amount of (E)- and (Z)-m-20a  was obtained 
through integration of the affiliated aromatic signals for every spectrum, always giving the remaining proportion of (Z)-
m-20a α . Plotti g the ti e e sus α led to a g aph hi h as fit to a si gle exponential and from which the half-life
was calculated.
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The half-life of (Z)-m-20a in phosphate buffer was determined by UV/vis spectroscopy due to a worse solubility of this 
compound in aqueous media. An aliquot of the irradiated 10 mM stem solution in DMSO-d6 diluted to a concentration 
of  M ith phosphate uffe  0 mM, pH 7.4) and a UV/Vis spectrum (Cary50 spectrometer, Varian) of this sample 
was recorded immediately. The sample was stored in the dark and further UV spectra were recorded in defined time 
intervals (1, 2, 3, 5, 7, 10, 14, 21 and 28 days). The respective remaining amount of (Z)-m-20a was obtained for every 
spectra using the following equation: 
α(t) = (A(t) – A(E)) / (A(Z) – A(E))      
Plotti g the ti e e sus α agai  led to a g aph hi h as fit to a si gle e po e tial for half-life calculation. 
Biological testing: 
A 1 mL aliquot of a 10 mM solution of all test compounds in DMSO-d6 was irradiated as described above until the 
photostationary state was reached. A 20 µL aliquot was taken from this sample for the dilution series of the biological 
testing. From the rest, an 1H NMR was measured to determine the (Z)/(E)-ratio. For the testing of the basic state a 20 
µL aliquot of the not irradiated same compound was used in the same experiment. 
[3H]GABA uptake experiments towards mGAT1 with irradiated and not irradiated compounds were performed 
according to a described procedure employing HEK293 human embryonic kidney cells stably expressing the individual 
GABA transporters32. In this case test compounds were diluted under exclusion of daylight in light-protected tubes. 
About 200000 cells were equilibrated in 3.5 mL polystyrene tubes together with the test compound for 25 min at 25 °C 
i  the da k i  a ge tl  shaki g ate  ath. Afte  additio  of  L of a solutio  o tai i g [ H]GABA .  TB / ol, 
ARC, St. Louis, MO, USA) and non-labeled GABA (final concentration 8 nM [3H]GABA and 32 nM non-labeled GABA), the 
cells were incubated for further 4 min under the same conditions. Incubation was stopped by filtration through Sartorius 
MGC filters by means of a Brandell M-24R harvester (Brandell, Gaithersburg, MD, USA). Finally, radioactivity on the 
filters was counted in 3 mL Rotiszint Eco Plus (Roth, Karlsruhe) using a Packard TriCarb 3200 liquid scintillation counter 
(PerkinElmer LAS, Boston, MA, USA).  
Chemistry: 
All reactions were carried out under nitrogen atmosphere in distilled solvents. Dioxane and THF were dried over sodium 
and distilled under nitrogen. Commercial available reagents were used without further purification. Flash column 
chromatography (CC) as pe fo ed usi g sili a gel −  µ . NMR spe t a e e easu ed ith a Jeol E lipse +  
(400 MHz) and a Jeol Eclipse +500 (500 MHz) spectrometer or an Avance III HD 400 MHz Bruker BioSpin and an Avance 
III HD 500 MHz Bruker BioSpin spectrometer. 1H NMR chemical shifts were referenced to TMS or CH3OH and 13C NMR 
chemical shifts were referenced to CHCl3 or CH3OH. The coupling constants were stated with an accuracy of 0.4 Hz. 
MestreNova software was used for further analysis of the spectra. IR spectra were recorded with a FT-IR spectrometer 
Paragon 1000 (PerkinElmer). Samples were measured either as KBr pellets or as films on NaCl plates. Mass spectra were 
measured with a mass spectrometer 59827A with 59980 particle beam LC/MS interface (Hewlett-Packard). High 
resolution mass spectrometry was carried out with a LTQ FT (ThermoFinnigan), FAB (Xenon, 6 kV, MBA, reference PEG), 
or a JMS GCmate II (Jeol). Optical rotations were determined by a 241 MC Polarimeter ADP440+ at  = 589 cm-1. 
Purity testing of the evaluated most active compounds (R)-m-20a, (R)-p-20a, (R)-m-20b and (R)-p-20b was done by 
means of analytical HPLC on a Merck-Hitachi HPLC system (L7400 intelligent pump and L7400 UV Detector) using elution 
from a 250 mm × 4mm LiChrospher 100RP-  olu    pa ti le size , the UV a so a e dete tio  set at 300, 325, 
350, 375 and 400 nm, using a flow rate of 1.0 mL/min and phosphate buffer (10 mmol/L)/MeCN = 4:6 as solvent. The 
purity of all tested compounds was >95%. 
General procedure for the Suzuki cross-coupling reactions (GP 1): 
Under nitrogen atmosphere Pd2(dba)3 x CHCl3 (0.01 equiv.), S-Phos (0.04 equiv.), K3PO4 (2.0 equiv.) and the aryl iodide 
(1.0 equiv.) were introduced in a Schlenk tube. The phenylboronic acid ester derivative (1.0 equiv.) was dissolved in 
dioxane (2 mL/mmol) and added to the reaction mixture. After the addition of H2O (1 mL/mmol) the mixture was heated 
to 60 °C and stirred for 6 hours. After cooling down to rt CH2Cl2 (10 mL/mmol) and H2O (10 mL/mmol) were added and 
the organic components were extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product was purified by CC (eluting with hexane/ethyl acetate 
= 8:2) to give the corresponding coupling product. 
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General procedure for the Sonogashira cross-coupling reactions (GP 2): 
Under nitrogen atmosphere Pd(dppf)Cl2, (0.05 equiv.), CuI (0.2 equiv) and the corresponding aryl iodide (1.0 equiv) were 
introduced in a Schlenk tube. The alkyne (1.5 equiv) was dissolved in THF (1 mL/mmol) and the resulting solution was 
added to the reaction mixture. Triethylamine (1 mL/mmol) was added and the mixture was heated to 60 °C and stirred 
for 2 hours. After cooling down to rt CH2Cl2 (10 mL/mmol) and H2O (10 mL/mmol) were added and the organic 
components were extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by CC (eluting with hexane/ethyl acetate = 8:2) to 
give the final coupling product. 
General procedure for the tosylation of alcohols (GP 3): 
The alcohol (1.0 equiv) was dissolved in CH2Cl2 (2 mL/mmol) and Et3N (1.5 equiv) was added. The mixture was cooled to 
0 °C, p-toluenesulfonylchloride (1.2 equiv) was added and stirred for 24 h (0 °C to rt). Afterwards CH2Cl2 (10 mL/mmol) 
and water (10 mL/mmol) were added and the organic components were extracted with CH2Cl2. The combined organic 
layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified 
by CC (eluting with hexane/CH2Cl2 = 1:1) to give the corresponsive tosylated alcohol. 
General procedure for the N-alkylation of tosylates (GP 4): 
The respective p-toluenesulfonic acid ester (1.0 equiv) was dissolved in acetone (1 mL/mmol). Then nipecotic acid ethyl 
ester (3.0 equiv) was added and the mixture was stirred for 48-72 hours. After the end of the reaction (control by TLC) 
both CH2Cl2 (10 mL/mmol) and of H2O (10 mL/mmol) were added and the organic components were extracted with 
CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. The 
crude product was purified by CC (eluting with hexane/ethyl acetate = 8:2) to give the corresponsive N-alkylated 
nipecotic acid ethyl ester. 
General procedure for the basic hydrolysis of nipecotic acid ethyl esters (GP 5): 
The corresponding ester was dissolved in EtOH (5 mL/mmol) and 2N NaOH (1.5 mL/mmol, 3.0 equiv) was added. The 
mixture was stirred for about 4 h at rt. After the end of the reaction (control by TLC) the solvent was completely removed 
under reduced pressure. The solid residue was dissolved in 25 ml/mmol of H2O and the pH was adjusted to 6-7 (indicator 
paper). The organic product was extracted using CH2Cl2 several times. The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. The residue was dissolved in MeOH (5 mL/mmol) 
followed by the addition of H2O (50 mL/mmol) and was then freeze dried to give the corresponsive amino acid as 
amorphous solid.  
Ethyl 1-[(E)-4-{3-[(E)-phenylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylate (m-10a) 
According to GP1 starting from 7 (101 mg, 0.300 mmol), m-9a (92 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) m-10a was obtained as red oil (92 mg, 78%); Rf ≈ 0.25
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3060, 3024, 2940, 2853, 2804, 1729, 1468, 1446, 1370, 1306, 1179, 1151,
1104, 1032, 963, 788, 765, 691 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.46
(qd, J = 12.0/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.54–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.74 (dp, J = 15.3/3.8 Hz, 1H,
NCH2CHaxHeqCH2CH), 1.91–2.00 (m, 1H, NCH2CHCHaxHeq), 2.05 (td, J = 11.0/3.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.22 (t, J =
10.6 Hz, 1H, NCHaxHeqCH), 2.41–2.49 (m, 2H, NCH2CH2CH=CH), 2.49–2.55 (m, 2H, NCH2CH2CH=CH), 2.58 (tt, J = 10.6/3.8
Hz, 1H, NCH2CHax), 2.82 (dbr, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 3.05 (dbr, J = 10.8 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1
Hz, 2H, OCH2CH3), 6.33 (dt, J = 15.8/6.8 Hz, 1H, CH2CH=CHC), 6.52 (d, J = 16.0 Hz, 1H, CH2CH=CHC), 7.41–7.45 (m, 2H,
CH=CHCCHC, CH=CHCCHCH), 7.45–7.49 (m, 1H, N=NCCHCHCH), 7.49–7.55 (m, 2H, N=NCCHCHCH), 7.73–7.79 (m, 1H,
CH=CHCCHCH), 7.88–7.96 (m, 3H, CH=CHCCHCCH, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.17
(q, 1C, OCH2CH3), 24.58 (t, 1C, NCH2CH2CH2CH), 26.93 (t, 1C, NCH2CHCH2), 30.60 (t, 1C, NCH2CH2CH=CH), 41.84 (d, 1C,
NCH2CH), 53.67 (t, 1C, NCH2CH2CH2CH), 55.30 (t, 1C, NCH2CH), 58.37 (t, 1C, NCH2CH2CH=CH), 60.26 (t, 1C, OCH2CH3),
120.11 (d, 1C, CH=CHCCHCCH), 121.37 (d, 1C, CH=CHCCHCH), 122.77 (d, 2C, N=NCCHCHCH), 128.52 (d, 1C,
CH=CHCCHCH), 129.02 (d, 2C, N=NCCHCHCH), 129.10 (d, 1C, CH=CHCCHC), 129.70 (d, 1C, CH=CHCCH), 130.16 (d, 1C,
CH=CHCCH), 130.94 (d, 1C, N=NCCHCHCH), 138.65 (s, 1C, CH=CHCCHC), 152.55 (s, 1C, N=NCCHCHCH), 152.79 (s, 1C,
CH=CHCCHC), 174.18 (s, 1C, C=O) ppm. MS (ESI+) m/z: 392 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C24H30O2N3: 392.2338,
found 392.2327.
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Ethyl 1-[(E)-4-{4-[(E)-phenylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylate (p-10a) 
According to GP1 starting from 7 (101 mg, 0.300 mmol), p-9a (92 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) p-10a  was obtained as red oil (100 mg, 85%); Rf ≈ .
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3433, 3060, 3030, 2977, 2940, 2853, 2805, 2770, 1729, 1648, 1597, 1466,
1441, 1370, 1302, 1226, 1179, 1152, 1100, 1032, 966, 859, 767, 688 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ =
1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.46 (qd, J = 11.9/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.54–1.64 (m, 1H, NCH2CHaxHeqCH2CH),
1.74 (dp, J = 13.4/3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dq, J = 13.1/3.7 Hz, 1H, NCH2CHCHaxHeq), 2.05 (td, J = 10.9/2.4
Hz, 1H, NCHaxHeqCH2CH2CH), 2.22 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.41–2.49 (m, 2H, NCH2CH2CH=CH), 2.49–2.55 (m, 2H,
NCH2CH2CH=CH), 2.58 (tt, J = 10.7/3.8 Hz, 1H, NCH2CHax), 2.81 (dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.04 (dbr, J = 9.8
Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, OCH2CH3), 6.33 (dt, J = 15.9/6.8 Hz, 1H, CH2CH=CHC), 6.48 (d, J = 16.0 Hz,
1H, CH2CH=CHC), 7.43–7.52 (m, 5H, N=NCCHCHCH, CH=CHCCHCHC, N=NCCHCHCH), 7.86–7.92 (m, 4H, CH=CHCCHCHC,
N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.16 (q, 1C, OCH2CH3), 24.56 (t, 1C, NCH2CH2CH2CH),
26.91 (t, 1C, NCH2CHCH2), 30.72 (t, 1C, NCH2CHCH2), 41.81 (d, 1C, NCH2CH), 53.65 (t, 1C, NCH2CH2CH2CH), 55.28 (t, 1C,
NCH2CH), 58.27 (t, 1C, NCH2CH2CH=CH), 60.26 (t, 1C, OCH2CH3), 122.70 (d, 2C, N=NCCHCHCH), 123.19 (d, 2C,
CH=CHCCHCHC), 126.54 (d, 2C, CH=CHCCHCHC), 128.99 (d, 2C, N=NCCHCHCH), 130.23 (d, 1C, CH=CHCCH), 130.56 (d,
1C, CH=CHCCH), 130.74 (d, 1C, N=NCCHCHCH), 140.34 (s, 1C, CH2CH=CHC), 151.41 (s, 1C, CH=CHCCHCHC), 152.65 (s, 1C,
N=NCCHCHCH), 174.16 (s, 1C, C=O) ppm. MS (CI+) m/z: 406 [M+H]+. HRMS (EI+): M+ calcd for C24H29O2N3: 391.2260,
found 391.2260.
Ethyl 1-[(E)-4-{3-[(E)-1-naphthylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylate (m-10b) 
According to GP1 starting from 7 (101 mg, 0.300 mmol), m-9b (107 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) m-10b was obtained as red oil (106 mg, 80%); Rf ≈ .
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3052, 3024, 2940, 2852, 2804, 2768, 1728, 1600, 1508, 1467, 1439, 1370,
1306, 1179, 1151, 1104, 1032, 963, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H,
OCH2CH3), 1.46 (qd, J = 12.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.54–1.66 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 13.2/3.6
Hz, 1H, NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.1/3.7 Hz, 1H, NCH2CHCHaxHeq), 2.06 (td, J = 10.9/2.3 Hz, 1H,
NCHaxHeqCH2CH2CH), 2.23 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.44–2.51 (m, 2H, NCH2CH2CH=CH), 2.53–2.63 (m, 3H,
NCH2CH2CH=CH, NCH2CHax), 2.83 (d, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (d, J = 9.8 Hz, 1H, NCHaxHeqCH), 4.14 (q, J
= 7.1 Hz, 2H, OCH2CH3), 6.37 (dt, J = 15.9/6.8 Hz, 1H, CH2CH=CHC), 6.56 (d, J = 15.9 Hz, 1H, CH2CH=CHC), 7.46–7.50 (m,
2H, CH=CHCCHCH, CH=CHCCHCCH), 7.54–7.61 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.66 (ddd, J = 8.4/6.8/1.3 Hz,
1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.1 Hz, 1H, N=NCCHCHCH), 7.86–7.91 (m, 1H, CH=CHCCHCH), 7.93 (d, J = 8.2 Hz, 1H,
N=NCCCHCHCHCH), 7.98 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.02 (s, 1H, CH=CHCCHC), 8.93 (d, J = 8.4 Hz, 1H, N=NCCCH)
ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.20 (q, 1C, OCH2CH3), 24.61 (t, 1C, NCH2CH2CH2CH), 26.97 (t, 1C,
NCH2CHCH2), 30.63 (t, 1C, NCH2CH2CH=CH), 41.88 (d, 1C, NCH2CH), 53.70 (t, 1C, NCH2CH2CH2CH), 55.34 (t, 1C, NCH2CH),
58.40 (t, 1C, NCH2CH2CH=CH), 60.30 (t, 1C, OCH2CH3), 111.85 (d, 1C, N=NCCHCHCH), 120.82 (d, 1C, CH=CHCCHCH),
121.44 (d, 1C, CH=CHCCHCH), 123.42 (d, 1C, N=NCCCH), 125.60 (d, 1C, N=NCCHCHCH), 126.43 (d, 1C, N=NCCCHCHCH),
126.80 (d, 1C, N=NCCCHCH), 127.90 (d, 1C, N=NCCCHCHCHCH), 128.55 (d, 1C, CH=CHCCHCH), 129.18 (d, 1C,
CH=CHCCHCCH), 129.80 (d, 1C, CH=CHCCH), 130.23 (d, 1C, CH=CHCCH), 131.22 (s, 1C, N=NCCCH), 131.28 (d, 1C,
N=NCCHCHCH), 134.24 (s, 1C, N=NCCHCHCHC), 138.75 (s, 1C, CH=CHCCHC), 147.76 (s, 1C, N=NCCHCHCH), 153.37 (s, 1C,
CH=CHCCHC), 174.21 (s, 1C, C=O) ppm. MS (ESI+) m/z: 442 [M+H]+. HRMS (EI+): M+ calcd for C28H31O2N3: 441.2416, found
441.2403.
Ethyl 1-[(E)-4-{4-[(E)-1-naphthylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylate (p-10b) 
According to GP1 starting from 7 (101 mg, 0.300 mmol), p-9b (107 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (5.4 mg, 5.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) p-10b was obtained as red oil (111 mg, 84%); Rf ≈ .
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3050, 3020, 2938, 2856, 2805, 2767, 1729, 1646, 1596, 1508, 1498, 1466,
1444, 1387, 1371, 1310, 1220, 1178, 1152, 1101, 1031, 966, 853, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS):
δ = 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.47 (qd, J = 12.0/3.6 Hz, 1H, NCH2CHCHaxHeq), 1.56–1.66 (m, 1H,
NCH2CHaxHeqCH2CH), 1.76 (dp, J = 15.0/3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.0/3.7 Hz, 1H, NCH2CHCHaxHeq),
2.06 (td, J = 11.0/2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.23 (t, J = 10.7 Hz, 1H, NCHaxHeqCH), 2.43–2.51 (m, 2H,
NCH2CH2CH=CH), 2.51–2.63 (m, 3H, NCH2CH2CH=CH, NCH2CHax), 2.83 (dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (dbr,
J = 10.7 Hz, 1H, NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 6.36 (dt, J = 15.9/6.8 Hz, 1H, CH2CH=CHC), 6.52 (d, J =
16.0 Hz, 1H, CH2CH=CHC), 7.51 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 7.54–7.61 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH),
7.65 (ddd, J = 8.3/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.5/1.0 Hz, 1H, N=NCCCHCHCHCH), 7.92 (d, J = 8.1 Hz, 1H,
N=NCCHCHCH), 7.97 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.00 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 8.93 (d, J = 8.5 Hz, 1H,
N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.21 (q, 1C, OCH2CH3), 24.62 (t, 1C, NCH2CH2CH2CH), 26.97
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(t, 1C, NCH2CHCH2), 30.79 (t, 1C, NCH2CH2CH=CH), 41.88 (d, 1C, NCH2CH), 53.71 (t, 1C, NCH2CH2CH2CH), 55.34 (t, 1C, 
NCH2CH), 58.33 (t, 1C, NCH2CH2CH=CH), 60.32 (t, 1C, OCH2CH3), 111.73 (d, 1C, N=NCCCHCHCHCH), 123.44 (d, 1C, 
N=NCCCH), 123.55 (d, 2C, CH=CHCCHCHC), 125.63 (d, 1C, N=NCCHCHCH), 126.40 (d, 1C, N=NCCCHCHCH), 126.64 (d, 2C, 
CH=CHCCHCHC), 126.73 (d, 1C, N=NCCCHCH), 127.89 (d, 1C, N=NCCHCHCH), 130.30 (d, 1C, CH=CHCCH), 130.72 (d, 1C, 
CH=CHCCH), 131.11 (d, 1C, N=NCCHCHCH), 131.27 (s, 1C, N=NCCCH), 134.25 (s, 1C, N=NCCHCHCHC), 140.46 (s, 1C, 
CH2CH=CHC), 147.82 (s, 1C, N=NCCHCHCH), 152.07 (s, 1C, CH=CHCCHCHC), 174.22 (s, 1C, C=O) ppm. MS (ESI+) m/z: 442 
[M+H]+. HRMS (ESI+): [M+H]+ calcd for C28H32O2N3: 442.2495, found 442.2486. 
Ethyl 1-[(E)-5-{3-[(E)-phenylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylate (m-11a) 
According to GP1 starting from 8 (105 mg, 0.300 mmol), m-9a (92 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) m-11a  was obtained as red oil (98 mg, 81%); Rf ≈ 0.20
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3060, 3023, 2939, 2854, 2804, 2767, 1729, 1468, 1445, 1370, 1309, 1178,
1151, 1095, 1031, 963, 787, 764, 691 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.24 (t, J = 7.1 Hz, 3H, OCH2CH3),
1.44 (qd, J = 12.1/3.4 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.64 (m, 1H, NCH2CHaxHeqCH2CH), 1.66–1.77 (m, 3H,
NCH2CH2CH2CH=CH, NCH2CHaxHeqCH2CH), 1.88–2.03 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.15 (t, J = 9.6 Hz, 1H,
NCHaxHeqCH), 2.26 (q, J = 6.9 Hz, 2H, CH2CH=CHC), 2.36–2.42 (m, 2H, NCH2CH2CH2CH=CH), 2.57 (tt, J = 10.7/3.8 Hz, 1H,
NCH2CHax), 2.78 (dbr, J = 10.7 Hz, 1H, NCHaxHeqCH2CH2CH), 3.01 (dbr, J = 11.2 Hz, 1H, NCHaxHeqCH), 4.12 (q, J = 7.1 Hz, 2H,
OCH2CH3), 6.35 (dt, J = 15.8/6.8 Hz, 1H, CH2CH=CHC), 6.47 (d, J = 15.8 Hz, 1H, CH2CH=CHC), 7.40–7.44 (m, 2H,
CH=CHCCHC, CH=CHCCHCH), 7.44–7.49 (m, 1H, N=NCCHCHCH), 7.49–7.53 (m, 2H, N=NCCHCHCH), 7.70–7.79 (m, 1H,
CH=CHCCHCH), 7.87–7.94 (m, 3H, CH=CHCCHCCH, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.17
(q, 1C, OCH2CH3), 24.58 (t, 1C, NCH2CH2CH2CH), 26.41 (t, 1 C, NCH2CHCH2), 26.97 (t, 1C, NCH2CH2CH2CH=CH), 30.90 (t,
1C, CH2CH=CHC), 41.86 (d, 1C, NCH2CH), 53.80 (t, 1C, NCH2CH2CH2CH), 55.43 (t, 1C, NCH2CH), 58.27 (t, 1C,
NCH2CH2CH2CH=CH), 60.23 (t, 1C, OCH2CH3), 120.03 (d, 1C, CH=CHCCHCCH), 121.30 (d, 1C, CH=CHCCHCH), 122.77 (d,
2C, N=NCCHCHCH), 128.46 (d, 1C, CH=CHCCHCH), 129.01 (d, 2C, N=NCCHCHCH), 129.09 (d, 1C, CH=CHCCHC), 129.36 (d,
1C, CH2CH=CHC), 130.92 (d, 1C, CH2CH=CHC), 131.70 (d, 1C, N=NCCHCHCH), 138.77 (s, 1C, CH=CHCCHC), 152.55 (s, 1C,
N=NCCHCHCH), 152.80 (s, 1C, CH=CHCCHC), 174.22 (s, 1C, C=O) ppm. MS (ESI+) m/z: 406 [M+H]+. HRMS (ESI+): [M+H]+
calcd for C25H32O2N3: 406.2494, found 406.2485.
Ethyl 1-[(E)-5-{4-[(E)-phenylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylate (p-11a) 
According to GP1 starting from 8 (105 mg, 0.300 mmol), p-9a (92 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) p-11a was obtained as red oil (101 mg, 83%); Rf ≈ 0.20
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3386, 3060, 3031, 2938, 2863, 2805, 2769, 1729, 1648, 1597, 1466, 1440,
1370, 1303, 1178, 1152, 1101, 1031, 966, 856, 766, 687 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1
Hz, 3H, OCH2CH3), 1.45 (qd, J = 12.0/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.63 (m, 1H, NCH2CHaxHeqCH2CH), 1.66–1.76 (m,
3H, NCH2CH2CH2CH=CH, NCH2CHaxHeqCH2CH), 1.90–2.02 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.16 (t, J = 10.8
Hz, 1H, NCHaxHeqCH), 2.23–2.29 (m, 2H, CH2CH=CHC), 2.37–2.42 (m, 2H, NCH2CH2CH2CH=CH), 2.57 (tt, J = 10.6/3.8 Hz,
1H, NCH2CHax), 2.77 (dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.00 (dbr, J = 9.7 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz,
2H, OCH2CH3), 6.35 (dt, J = 15.8/6.7 Hz, 1H, CH2CH=CHC), 6.45 (d, J = 15.9 Hz, 1H, CH2CH=CHC), 7.43–7.52 (m, 5H,
N=NCCHCHCH, CH=CHCCHCHC, N=NCCHCHCH), 7.86–7.92 (m, 4H, CH=CHCCHCHC, N=NCCHCHCH) ppm. 13C NMR (126
MHz, CDCl3, 21 °C, TMS): δ = 14.17 (q, 1C, OCH2CH3), 24.57 (t, 1C, NCH2CH2CH2CH), 26.36 (t, 1C, NCH2CH2CH2CH=CH),
26.96 (t, 1C, NCH2CHCH2), 31.03 (t, 1C, CH2CH=CHC), 41.84 (d, 1C, NCH2CH), 53.79 (t, 1C, NCH2CH2CH2CH), 55.41 (t, 1C,
NCH2CH), 58.25 (t, 1C, NCH2CH2CH2CH=CH), 60.22 (t, 1C, OCH2CH3), 122.69 (d, 2C, N=NCCHCHCH), 123.20 (d, 2C,
CH=CHCCHCHC), 126.47 (d, 2C, CH=CHCCHCHC), 128.98 (d, 2C, N=NCCHCHCH), 129.43 (d, 1C, CH2CH=CHC), 130.71 (d,
1C, CH2CH=CHC), 132.59 (d, 1C, N=NCCHCHCH), 140.49 (s, 1C, CH2CH=CHC), 151.36 (s, 1C, CH=CHCCHCHC), 152.66 (s,
1C, N=NCCHCHCH), 174.19 (s, 1C, C=O). MS (CI+) m/z: 406 [M+H]+. HRMS (EI+): M+ calcd for C25H31O2N3: 405.2416, found
405.2424.
Ethyl 1-[(E)-5-{3-[(E)-1-naphthylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylate (m-11b) 
According to GP1 starting from 8 (105 mg, 0.300 mmol), m-9b (107 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) m-11b was obtained as red oil (112 mg, 82%); Rf ≈ 0.15
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3332, 3052, 3024, 2938, 2861, 2805, 2768, 1729, 1600, 1508, 1467, 1442,
1371, 1310, 1178, 1151, 1031, 963, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H,
OCH2CH3), 1.45 (qd, J = 12.1/3.6 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.66 (m, 1H, NCH2CHaxHeqCH2CH), 1.68–1.78 (m, 3H,
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NCH2CHaxHeqCH2CH, NCH2CH2CH2CH=CH), 1.90–2.05 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.16 (t, J = 10.5 Hz, 
1H, NCH2CHCHaxHeq), 2.28 (q, J = 6.9 Hz, 2H, CH2CH=CHC), 2.37–2.46 (m, 2H, NCH2CH2CH2CH=CH), 2.58 (tt, J = 10.6/3.8 
Hz, 1H, NCH2CHax), 2.80 (dbr, J = 11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 3.03 (dbr, J = 10.5 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 
Hz, 2H, OCH2CH3), 6.38 (dt, J = 15.8/6.8 Hz, 1H, CH2CH=CHC), 6.52 (d, J = 15.9 Hz, 1H, CH2CH=CHC), 7.45–7.50 (m, 2H, 
CH=CHCCHCH, CH=CHCCHCCH), 7.54–7.61 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.66 (ddd, J = 8.4/6.8/1.3 Hz, 1H, 
N=NCCCHCH), 7.81 (dd, J = 7.5/1.1 Hz, 1H, N=NCCHCHCH), 7.86–7.91 (m, 1H, CH=CHCCHCH), 7.93 (d, J = 8.2 Hz, 1H, 
N=NCCCHCHCHCH), 7.98 (d, J = 8.2 Hz, 1H, N=NCCHCHCH), 8.02 (s, 1H, CH=CHCCHC), 8.93 (d, J = 8.4 Hz, 1H, N=NCCCH) 
ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.18 (q, 1C, OCH2CH3), 24.58 (t, 1C, NCH2CH2CH2CH), 26.41 (t, 1C, 
NCH2CH2CH2CH=CH), 26.98 (t, 1C, NCH2CHCH2), 30.92 (t, 1C, CH2CH=CHC), 41.85 (d, 1C, NCH2CH), 53.81 (t, 1C, 
NCH2CH2CH2CH), 55.43 (t, 1C, NCH2CH), 58.31 (t, 1C, NCH2CH2CH2CH=CH), 60.26 (t, 1C, OCH2CH3), 111.81 (d, 1C, 
N=NCCHCHCH), 120.68 (d, 1C, CH=CHCCHC), 121.40 (d, 1C, CH=CHCCHCH), 123.41 (d, 1C, N=NCCCH), 125.58 (d, 1C, 
N=NCCHCHCH), 126.41 (d, 1C, N=NCCCHCHCH), 126.79 (d, 1C, N=NCCCHCH), 127.88 (d, 1C, N=NCCCHCHCHCH), 128.49 
(d, 1C, CH=CHCCHCH), 129.16 (d, 1C, CH=CHCCHCCH), 129.41 (d, 1C, CH2CH=CHC), 131.20 (s, 1C, N=NCCCH), 131.26 (d, 
1C, N=NCCHCHCH), 131.75 (d, 1C, CH2CH=CHC), 134.21 (s, 1C, N=NCCHCHCHC), 138.83 (s, 1C, CH=CHCCHC), 147.72 (s, 
1C, N=NCCHCHCH), 153.34 (s, 1C, CH=CHCCHC), 174.23 (s, 1C, C=O) ppm. MS (ESI+) m/z: 456 [M+H]+. HRMS (EI+): M+ 
calcd for C29H33O2N3: 455.2572, found 455.2574. 
Ethyl 1-[(E)-5-{4-[(E)-1-naphthylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylate (p-11b) 
According to GP1 starting from 8 (105 mg, 0.300 mmol), p-9b (107 mg, 0.30 mmol), Pd2(dba)3 x CHCl3 (3.2 mg, 3.0 µmol), 
S-Phos (5.0 mg, 12 µmol) and K3PO4 (128 mg. 0.600 mmol) p-11b  was obtained as red oil (119 mg, 87%); Rf ≈ .
(pentane/ethyl acetate = 8:2). IR (NaCl): ṽ = 3050, 3028, 2940, 2852, 2804, 2769, 1729, 1646, 1597, 1508, 1498, 1466,
1446, 1387, 1371, 1310, 1221, 1179, 1153, 1100, 1032, 966, 858, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS):
δ = 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.45 (qd, J = 11.9/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.54–1.64 (m, 1H,
NCH2CHaxHeqCH2CH), 1.67–1.78 (m, 3H, NCHaxHeqCH2CH2CH, NCH2CH2CH2CH=CH), 1.92–2.04 (m, 2H, NCH2CHCHaxHeq,
NCHaxHeqCH2CH2CH), 2.16 (t, J = 10.2 Hz, 1H, NCHaxHeqCH), 2.28 (q, J = 6.9 Hz, 2H, CH2CH=CHC), 2.39–2.44 (m, 2H,
NCH2CH2CH2CH=CH), 2.58 (tt, J = 10.7/3.8 Hz, 1H, NCH2CHax), 2.79 (dbr, J = 11.5 Hz, 1H, NCHaxHeqCH2CH2CH), 3.02 (dbr, J
= 10.7 Hz, 1H, NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 6.38 (dt, J = 15.8/6.7 Hz, 1H, CH2CH=CHC), 6.48 (d, J = 15.9
Hz, 1H, CH2CH=CHC), 7.51 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 7.54–7.60 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.65
(ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.5/1.1 Hz, 1H, N=NCCCHCHCHCH), 7.92 (d, J = 8.2 Hz, 1H,
N=NCCHCHCH), 7.97 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.00 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 8.93 (d, J = 8.5 Hz, 1H,
N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.21 (q, 1C, OCH2CH3), 24.63 (t, 1C, NCH2CH2CH2CH), 26.42
(t, 1C, NCH2CH2CH2CH=CH), 27.01 (t, 1C, NCH2CHCH2), 31.10 (t, 1C, CH2CH=CHC), 41.91 (d, 1C, NCH2CH), 53.84 (t, 1C,
NCH2CH2CH2CH), 55.46 (t, 1C, NCH2CH), 58.31 (t, 1C, NCH2CH2CH2CH=CH), 60.28 (t, 1C, OCH2CH3), 111.71 (d, 1C,
N=NCCCHCHCHCH), 123.45 (d, 1C, N=NCCCH), 123.56 (d, 2C, CH=CHCCHCHC), 125.63 (d, 1C, N=NCCHCHCH), 126.39 (d,
1C, N=NCCCHCHCH), 126.58 (d, 2C, CH=CHCCHCHC), 126.72 (d, 1C, N=NCCCHCH), 127.88 (d, 1C, N=NCCHCHCH), 129.50
(d, 1C, CH2CH=CHC), 131.08 (d, 1C, N=NCCHCHCH), 131.26 (s, 1C, N=NCCCH), 132.75 (d, 1C, CH2CH=CHC), 134.24 (s, 1C,
N=NCCHCHCHC), 140.60 (s, 1C, CH2CH=CHC), 147.82 (s, 1C, N=NCCHCHCH), 152.01 (s, 1C, CH=CHCCHCHC), 174.26 (s,
1C, C=O) ppm. MS (ESI+) m/z: 456 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C29H34O2N3: 456.2651, found 456.2641.
1-[(E)-4-{3-[(E)-Phenylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylic acid (m-12a) 
According to GP5 starting from m-10a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-12a was obtained as 
orange amorphous solid (64 mg, 88%). IR (KBr): ṽ = 3384, 3060, 3023, 2955, 2860, 2539, 1714, 1586, 1470, 1446, 1393, 
1305, 1217, 1150, 1071, 967, 924, 791, 755, 692, 665 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): 
δ = 1.29 (qd, J = 12.8/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.52 (qt, J = 13.4/3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.62–1.71 (m, 1H, 
NCH2CHaxHeqCH2CH), 1.87 (td, J = 12.0/2.7 Hz, 1H, NCHaxHeqCH2CH2CH), 1.94 (dbr, J = 12.9 Hz, 1H, NCH2CHCHaxHeq), 2.01 
(t, J = 11.4 Hz, 1H, NCHaxHeqCH), 2.31–2.46 (m, 5H, NCH2CH2CH=CH, NCH2CH2CH=CH, NCH2CHax), 2.84 (dbr, J = 10.9 Hz, 
1H, NCHaxHeqCH2CH2CH), 3.08 (d, J = 11.0 Hz, 1H, NCHaxHeqCH), 6.20 (dt, J = 15.8/6.5 Hz, 1H, CH2CH=CHC), 6.41 (d, J = 
15.9 Hz, 1H, CH2CH=CHC), 7.35–7.43 (m, 2H, CH=CHCCHCH, CH=CHCCHCH), 7.45–7.52 (m, 3H, N=NCCHCHCH, 
N=NCCHCHCH), 7.62 (dt, J = 7.4/1.7 Hz, 1H, CH=CHCCHCCH), 7.73 (t, J = 1.6 Hz, 1H, CH=CHCCHC), 7.78–7.82 (m, 2H, 
N=NCCHCHCH) ppm. 13C NMR (126 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 25.50 (t, 1C, NCH2CH2CH2CH), 
29.08 (t, 1C, NCH2CHCH2), 30.69 (t, 1C, NCH2CH2CH=CH), 46.03 (d, 1C, NCH2CH), 54.29 (t, 1C, NCH2CH2CH2CH), 57.57 (t, 
1C, NCH2CH), 59.10 (t, 1C, NCH2CH2CH=CH), 120.74 (d, 1C, CH=CHCCHC), 122.26 (d, 1C, CH=CHCCHCCH), 123.59 (d, 2C, 
N=NCCHCHCH), 129.88 (d, 1C, CH=CHCCHCH), 130.36 (d, 2C, N=NCCHCHCH), 130.47 (d, 1C, CH=CHCCHCH), 130.59 (d, 
1C, CH=CHCCH), 131.25 (d, 1C, CH=CHCCH), 132.55 (d, 1C, N=NCCHCHCH), 139.95 (s, 1C, CH=CHCCHC), 153.44 (s, 1C, 
N=NCCHCHCH), 153.72 (s, 1C, CH=CHCCHC), 183.28 (s, 1C, C=O) ppm. MS (ESI+) m/z: 364 [M+H]+. HRMS (ESI+): [M+H]+ 
calcd for C22H26O2N3: 364.2025, found 364.2016.  
- Third pu li ation -
17 
1-[(E)-4-{4-[(E)-Phenylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylic acid (p-12a) 
According to GP5 starting from p-10a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-12a was obtained as 
orange amorphous solid (65 mg, 89%). IR (KBr): ṽ = 3429, 3038, 2959, 2931, 2862, 1621, 1596, 1462, 1438, 1367, 1346, 
1336, 1303, 1295, 1229, 1154, 1069, 965, 951, 860, 776, 692 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, 
CH3OH): δ = 1.32 (qd, J = 12.7/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.57 (qt, J = 13.4/3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.67–1.73 
(m, 1H, NCH2CHaxHeqCH2CH), 1.87–2.01 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.05 (t, J = 11.4 Hz, 1H, 
NCHaxHeqCH), 2.37 (tt, J = 11.5/3.5 Hz, 1H, NCH2CHax), 2.41–2.52 (m, 4H, NCH2CH2CH=CH, NCH2CH2CH=CH), 2.90 (dbr, J = 
11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.13 (dbr, J = 11.1/3.2 Hz, 1H, NCHaxHeqCH), 6.34 (dt, J = 15.8/6.6 Hz, 1H, CH2CH=CHC), 
6.49 (d, J = 15.9 Hz, 1H, CH2CH=CHC), 7.47–7.55 (m, 5H, N=NCCHCHCH, CH=CHCCHCHC, N=NCCHCHCH), 7.76–7.80 (m, 
2H, CH=CHCCHCHC), 7.80–7.85 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, 
CH3OH): δ = 25.64 (t, 1C, NCH2CH2CH2CH), 29.20 (t, 1C, NCH2CHCH2), 31.01 (t, 1C, NCH2CH2CH=CH), 46.13 (d, 1C, 
NCH2CH), 54.48 (t, 1C, NCH2CH2CH2CH), 57.71 (t, 1C, NCH2CH), 59.21 (t, 1C, NCH2CH2CH=CH), 123.56 (d, 2C, 
N=NCCHCHCH), 124.10 (d, 2C, CH=CHCCHCHC), 127.82 (d, 2C, CH=CHCCHCHC), 130.36 (d, 2C, CH=CHCCHCHC), 131.43 
(d, 1C, CH=CHCCH), 131.72 (d, 1C, CH=CHCCH), 132.33 (d, 1C, N=NCCHCHCH), 142.07 (s, 1C, CH2CH=CHC), 152.47 (s, 1C, 
CH=CHCCHCHC), 153.73 (s, 1C, N=NCCHCHCH), 183.14 (s, 1C, C=O) ppm. MS (ESI+) m/z: 364 [M+H]+. HRMS (EI+): M+ calcd 
for C22H25O2N3: 363.1947, found 363.1954.  
1-[(E)-4-{3-[(E)-1-Naphthylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylic acid (m-12b) 
According to GP5 starting from m-10b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-12b was obtained as 
orange amorphous solid (78 mg, 94%). IR (KBr): ṽ = 3428, 3049, 2937, 2857, 1708, 1589, 1508, 1439, 1387, 1345, 1201, 
1153, 1079, 965803, 771, 687 cm-1. 1H NMR (400 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 1.29 (qd, J = 12.8/3.8 
Hz, 1H, NCH2CHCHaxHeq), 1.51 (qt, J = 13.2/3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.65 (d, J = 14.4 Hz, 1H, NCH2CHaxHeqCH2CH), 
1.80 (td, J = 12.5/3.0 Hz, 1H, NCHaxHeqCH2CH2CH), 1.91–2.05 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH), 2.20–2.42 (m, 5H, 
NCH2CH2CH=CH, NCH2CH2CH=CH, NCH2CHax), 2.76 (d, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (d, J = 9.5 Hz, 1H, 
NCHaxHeqCH), 6.09 (dt, J = 16.0/6.4 Hz, 1H, CH2CH=CHC), 6.30 (d, J = 15.8 Hz, 1H, CH2CH=CHC), 7.25–7.35 (m, 2H, 
CH=CHCCHCH, CH=CHCCHCCH), 7.40 (t, J = 7.8 Hz, 1H, N=NCCHCHCH), 7.44–7.52 (m, 2H, N=NCCCHCHCH, N=NCCCHCH), 
7.56 (dd, J = 7.4/0.8 Hz, 1H, N=NCCHCHCH), 7.63 (dt, J = 6.6/1.4 Hz, 1H, N=NCCCHCHCHCH), 7.73 (s, 1H, CH=CHCCHC), 
7.79–7.85 (m, 1H, CH=CHCCHCH), 7.87 (d, J = 8.2 Hz, 1H, N=NCCHCHCH), 8.66 (d, J = 9.7 Hz, 1H, N=NCCCH) ppm. 13C 
NMR (101 MHz, CH3OD + 5.0 eq 1N NaOD, 25 °C, CH3OH): δ = 25.39 (t, 1C, NCH2CH2CH2CH), 28.97(t, 1C, NCH2CHCH2), 
30.52 (t, 1C, NCH2CH2CH=CH), 45.94 (d, 1C, NCH2CH), 54.10 (t, 1C, NCH2CH2CH2CH), 57.44 (t, 1C, NCH2CH), 58.92 (t, 1C, 
NCH2CH2CH=CH), 112.71 (d, 1C, N=NCCHCHCH), 121.16 (d, 1C, CH=CHCCHC), 122.33 (d, 1C, N=NCCCHCHCHCH), 123.80 
(d, 1C, N=NCCCH), 126.51 (d, 1C, N=NCCHCHCH), 127.57 (d, 2C, N=NCCCHCHCH), 127.96 (d, 1C, N=NCCCHCH), 128.98 
(d, 1C, CH=CHCCHCH), 129.76 (d, 1C, CH=CHCCHCH), 130.28 (d, 2C, CH=CHCCHCCH, CH=CHCCH), 131.17 (d, 1C, 
CH=CHCCH), 131.95 (s, 1C, N=NCCCH), 132.61 (d, 1C, N=NCCHCHCH), 135.32 (s, 1C, N=NCCHCHCHC), 139.75 (s, 1C, 
CH=CHCCHC), 148.25 (s, 1C, N=NCCHCHCH), 154.03 (s, 1C, CH=CHCCHC), 183.21 (s, 1C, C=O) ppm. MS (ESI+) m/z: 414 
[M+H]+. HRMS (ESI+): [M+H]+ calcd for C26H28O2N3: 414.2181, found 414.2176.  
1-[(E)-5-{3-[(E)-1-Naphthylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylic acid (p-12b) 
According to GP5 starting from p-10b (91 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-12b was obtained as 
orange amorphous solid (81 mg, 95%). IR (KBr): ṽ = 3426, 3048, 2940, 2860, 1707, 1588, 1507, 1449, 1386, 1345, 1220, 
1143, 1079, 957, 804, 772, 686 cm-1. 1H NMR (400 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 1.28 (qd, J = 
13.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.46–1.68 (m, 4H, NCH2CHaxHeqCH2CH, NCH2CHaxHeqCH2CH, NCH2CH2CH2CH=CH), 1.81 
(t, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 1.89–2.00 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH), 2.06–2.20 (m, 2H, CH2CH=CHC), 
2.27–2.38 (m, 3H, NCH2CH2CH2CH=CH, NCH2CHax), 2.80 (d, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH,), 3.07 (d, J = 10.2 Hz, 1H, 
NCHaxHeqCH), 6.26 (td, J = 16.0/6.4 Hz, 1H, CH2CH=CHC), 6.38 (d, J = 15.8 Hz, 1H, CH2CH=CHC), 7.36–7.45 (m, 2H, 
CH=CHCCHCCH, CH=CHCCHCH), 7.46–7.61 (m, 3H, N=NCCHCHCH, N=NCCCHCHCH, N=NCCCHCH), 7.67 (d, J = 7.3 Hz, 1H, 
N=NCCHCHCH), 7.70–7.78 (m, 1H, N=NCCCHCHCHCH), 7.83 (s, 1H, CH=CHCCHC), 7.90 (d, J = 7.3 Hz, 1H, CH=CHCCHCH), 
7.97 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.75 (d, J = 7.9 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CH3OD + 5.0 eq 1 N 
NaOD, 25 °C, CH3OH): δ = 25.63 (t, 1C, NCH2CH2CH2CH), 26.68 (t, 1C, NCH2CH2CH2CH=CH), 29.24 (t, 1C, NCH2CHCH2), 
31.95 (t, 1C, CH2CH=CHC), 46.12 (d, 1C, NCH2CH), 54.60 (t, 1C, NCH2CH2CH2CH), 57.90 (t, 1C, NCH2CH), 59.55 (t, 1C, 
NCH2CH2CH2CH=CH), 112.80 (d, 1C, N=NCCHCHCH), 121.28 (d, 1C, CH=CHCCHC), 122.32 (d, 1C, N=NCCCHCHCHCH), 
123.93 (d, 1C, N=NCCCH), 126.66 (d, 1C, N=NCCHCHCH), 127.69 (d, 1C, N=NCCCHCHCH), 128.10 (d, 1C, N=NCCCHCH), 
129.09 (d, 1C, CH=CHCCHCH), 129.82 (d, 1C, CH=CHCCHCH), 130.49 (d, 2C, CH=CHCCHCCH, CH2CH=CHC), 132.22 (s, 1C, 
N=NCCCH), 132.67 (d, 1C, CH2CH=CHC), 132.77 (d, 1C, N=NCCHCHCH), 135.61 (s, 1C, N=NCCHCHCHC), 140.23 (s, 1C, 
CH=CHCCHC), 148.59 (s, 1C, N=NCCHCHCH), 154.45 (s, 1C, CH=CHCCHC), 183.15 (s, 1C, C=O) ppm. MS (ESI+) m/z: 428 
[M+H]+. HRMS (ESI+): [M+H]+ calcd for C27H30O2N3: 428.2338, found 428.2332.  
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1-[(E)-5-{3-[(E)-Phenylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylic acid (m-13a) 
According to GP5 starting from m-11a (81 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-13a was obtained as 
orange amorphous solid (68 mg, 90%). IR (KBr): ṽ = 3060, 3023, 2943, 2863, 2484, 1709, 1597, 1469, 1446, 1388, 1308, 
1217, 1150, 1081, 1020, 965, 791, 755, 692, 662 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 
1.30 (qd, J = 12.9/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.55 (qt, J = 12.9/3.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.62–1.73 (m, 3H, 
NCH2CH2CH2CH=CH, NCH2CHaxHeqCH2CH), 1.88 (td, J = 12.0/2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 1.92–2.02 (m, 2H, 
NCH2CHCHaxHeq, NCHaxHeqCH), 2.20 (q, J = 7.0 Hz, 2H, CH2CH=CHC), 2.31–2.41 (m, 3H, NCH2CH2CH2CH=CH, NCH2CHax), 
2.87 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.09 (dbr, J = 12.1 Hz, 1H, NCHaxHeqCH), 6.34 (dt, J = 15.8/6.8 Hz, 1H, 
CH2CH=CHC), 6.46 (d, J = 15.8 Hz, 1H, CH2CH=CHC), 7.43–7.50 (m, 2H, CH=CHCCHCH, CH=CHCCHCH), 7.50–7.57 (m, 3H, 
N=NCCHCHCH, N=NCCHCHCH), 7.68 (dt, J = 7.4/1.6 Hz, 1H, CH=CHCCHCCH), 7.81 (t, J = 1.6 Hz, 1H, CH=CHCCHC), 7.83–
7.88 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 25.60 (t, 1C, 
NCH2CH2CH2CH), 26.67 (t, 1C, NCH2CH2CH2CH=CH), 29.22 (t, 1C, NCH2CHCH2), 31.95 (t, 1C, CH2CH=CHC), 46.12 (d, 1C, 
NCH2CH), 54.60 (t, 1C, NCH2CH2CH2CH), 57.83 (t, 1C, NCH2CH), 59.51 (t, 1C, NCH2CH2CH2CH=CH), 120.73 (d, 1C, 
CH=CHCCHC), 122.19 (d, 1C, CH=CHCCHCCH), 123.63 (d, 2C, N=NCCHCHCH), 129.87 (d, 1C, CH=CHCCHCH), 130.40 (d, 
2C, N=NCCHCHCH), 130.47 (d, 1C, CH=CHCCHCH), 130.52 (d, 1C, CH2CH=CHC), 132.55 (d, 1C, CH2CH=CHC), 132.88 (d, 
1C, N=NCCHCHCH), 140.24 (s, 1C, CH=CHCCHC), 153.62 (s, 1C, N=NCCHCHCH), 153.92 (s, 1C, CH=CHCCHC), 183.22 (s, 
1C, C=O) ppm. MS (ESI+) m/z: 378 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C23H28O2N3: 378.2182, found 378.2171.  
1-[(E)-5-{4-[(E)-Phenylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylic acid (p-13a) 
According to GP5 starting from p-11a (81 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-13a was obtained as 
orange amorphous solid (70 mg, 93%). IR (KBr): ṽ = 3413, 3036, 2943, 2865, 2530, 1707, 1595, 1463, 1440, 1387, 1303, 
1226, 1153, 1069, 1018, 970, 954, 853, 811, 771, 720, 691 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, 
CH3OH): δ = 1.31 (qd, J = 12.8/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.55 (qt, J = 12.9/3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.65–1.71 
(m, 3H, NCH2CH2CH2CH=CH, NCH2CHaxHeqCH2CH), 1.87 (td, J = 12.0/2.4 Hz, 1H, NCHaxHeqCH2CH2CH), 1.97 (q, J = 10.7/10.0 
Hz, 2H, NCH2CHCHaxHeq, NCHaxHeqCH), 2.20 (q, J = 6.9 Hz, 2H, CH2CH=CHC), 2.31–2.40 (m, 3H, NCH2CHax, 
NCH2CH2CH2CH=CH), 2.87 (dbr, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 3.09 (dbr, J = 9.9 Hz, 1H, NCHaxHeqCH), 6.31–6.47 (m, 
2H, CH2CH=CHC, CH2CH=CHC), 7.44–7.56 (m, 5H, N=NCCHCHCH, CH=CHCCHCHC, N=NCCHCHCH), 7.78 (d, J = 8.4 Hz, 2H, 
CH=CHCCHCHC), 7.80–7.87 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): 
δ = 25.62 (t, 1C, NCH2CH2CH2CH), 26.65 (t, 1C, NCH2CH2CH2CH=CH), 29.23 (t, 1C, NCH2CHCH2), 32.12 (t, 1C, CH2CH=CHC), 
46.13 (d, 1C, NCH2CH), 54.63 (t, 1C, NCH2CH2CH2CH), 57.85 (t, 1C, NCH2CH), 59.53 (t, 1C, NCH2CH2CH2CH=CH), 123.56 (d, 
2C, N=NCCHCHCH), 124.13 (d, 2C, CH=CHCCHCHC), 127.75 (d, 2C, CH=CHCCHCHC), 130.36 (d, 2C, N=NCCHCHCH), 130.53 
(d, 1C, CH2CH=CHC), 132.31 (d, 1C, CH2CH=CHC), 133.93 (d, 1C, N=NCCHCHCH), 142.20 (s, 1C, CH2CH=CHC), 152.41 (s, 
1C, CH=CHCCHCHC), 153.74 (s, 1C, N=NCCHCHCH), 183.18 (s, 1C, C=O) ppm. MS (ESI+) m/z: 378 [M+H]+. HRMS (EI+): M+ 
calcd for C23H27O2N3: 377.2103, found 377.2108.  
1-[(E)-4-{4-[(E)-1-Naphthylazo]phenyl}but-3-en-1-yl]piperidine-3-carboxylic acid (m-13b) 
According to GP5 starting from m-11b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-13b was obtained as 
orange amorphous solid (76 mg, 92%). IR (KBr): ṽ = 3424, 3049, 2940, 2531, 1596, 1508, 1498, 1460, 1448, 1388, 1345, 
1311, 1221, 1157, 1141, 968, 854, 804, 773 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 1.33 
(qd, J = 12.3/3.6 Hz, 1H, NCH2CHCHaxHeq), 1.58 (qt, J = 12.6/3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.70 (dp, J = 13.5/3.3 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.89–2.01 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.05 (t, J = 11.5 Hz, 1H, NCHaxHeqCH), 
2.33–2.51 (m, 5H, NCH2CHax, NCH2CH2CH=CH, NCH2CH2CH=CH), 2.90 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.14 (dbr, 
J = 11.4 Hz, 1H, NCHaxHeqCH), 6.34 (dt, J = 15.9/6.6 Hz, 1H, CH2CH=CHC), 6.49 (d, J = 15.6 Hz, 1H, CH2CH=CHC), 7.51 (d, J 
= 8.5 Hz, 2H, CH=CHCCHCHC), 7.54–7.62 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 Hz, 1H, 
N=NCCCHCH), 7.71 (dd, J = 7.5/1.0 Hz, 1H, N=NCCCHCHCHCH), 7.90 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 7.96 (d, J = 8.1 
Hz, 1H, N=NCCHCHCH), 8.02 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.80 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 
MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 25.69 (t, 1C, NCH2CH2CH2CH), 29.25 (t, 1C, NCH2CHCH2), 31.06 (t, 1C, 
NCH2CH2CH=CH), 46.18 (d, 1C, NCH2CH), 54.55 (t, 1C, NCH2CH2CH2CH), 57.77 (t, 1C, NCH2CH), 59.28 (t, 1C, 
NCH2CH2CH=CH), 112.67 (d, 1C, N=NCCCHCHCHCH), 123.97 (d, 1C, N=NCCCH), 124.40 (d, 2C, CH=CHCCHCHC), 126.73 
(d, 1C, N=NCCHCHCH), 127.71 (d, 1C, N=NCCCHCHCH), 127.90 (d, 2C, CH=CHCCHCHC), 128.09 (d, 1C, N=NCCCHCH), 
129.11 (d, 1C, N=NCCHCHCH), 131.49 (d, 1C, CH=CHCCH), 131.76 (d, 1C, CH=CHCCH), 132.28 (s, 1C, N=NCCCH), 132.51 
(d, 1C, N=NCCHCHCH), 135.68 (s, 1C, N=NCCHCHCHC), 142.14 (s, 1C, CH2CH=CHC), 148.78 (s, 1C, N=NCCHCHCH), 153.16 
(s, 1C, CH=CHCCHCHC), 183.10 (s, 1C, C=O) ppm. MS (ESI+) m/z: 414 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C26H28O2N3: 
414.2182, found 414.2173.  
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1-[(E)-5-{4-[(E)-1-Naphthylazo]phenyl}pent-4-en-1-yl]piperidine-3-carboxylic acid (p-13b) 
According to GP5 starting from p-11b (91 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-13b was obtained as 
orange amorphous solid (82 mg, 96%). IR (KBr): ṽ = 3425, 3050, 2935, 2857, 2530, 1718, 1596, 1508, 1498, 1448, 1387, 
1345, 1310, 1221, 1142, 969, 859, 803, 773 cm-1. 1H NMR (500 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): δ = 1.29 
(qd, J = 12.8/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.46–1.69 (m, 4H, NCH2CHaxHeqCH2CH, NCH2CH2CH2CH=CH, 
NCH2CHaxHeqCH2CH), 1.81 (td, J = 11.6/10.8/2.4 Hz, 1H, NCH2CHaxHeqCH2CH), 1.90–2.00 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH), 2.09 (q, J = 7.1 Hz, 2H, CH2CH=CHC), 2.24–2.39 (m, 3H, NCH2CH2CH2CH=CH, NCH2CHax), 2.80 (dbr, J = 11.4 
Hz, 1H, NCHaxHeqCH2CH2CH), 3.07 (dbr, J = 11.4 Hz, 1H, NCHaxHeqCH), 6.24 (dt, J = 15.8/6.5 Hz, 1H, CH2CH=CHC), 6.32 (d, 
J = 15.9 Hz, 1H, CH2CH=CHC), 7.38 (d, J = 8.6 Hz, 2H, CH=CHCCHCHC), 7.50 (t, J = 7.8 Hz, 1H, N=NCCHCHCH), 7.54 (ddd, J 
= 8.0/6.9/1.3 Hz, 1H, N=NCCCHCHCH), 7.59 (ddd, J = 8.3/6.8/1.4 Hz, 1H, N=NCCCHCH), 7.64 (dd, J = 7.5/1.0 Hz, 1H, 
N=NCCCHCHCHCH), 7.81 (d, J = 8.5 Hz, 2H, CH=CHCCHCHC), 7.90 (d, J = 7.6 Hz, 1H, N=NCCHCHCH), 7.95 (d, J = 8.2 Hz, 
1H, N=NCCHCHCH), 8.75 (d, J = 8.4 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, CH3OD + 5.0 eq 1 N NaOD, 25 °C, CH3OH): 
δ = 25.60 (t, 1C, NCH2CH2CH2CH), 26.60 (t, 1C, NCH2CH2CH2CH=CH), 29.21 (t, 1C, NCH2CHCH2), 32.11 (t, 1C, CH2CH=CHC), 
46.11 (d, 1C, NCH2CH), 54.56 (t, 1C, NCH2CH2CH2CH), 57.85 (t, 1C, NCH2CH), 59.51 (t, 1C, NCH2CH2CH2CH=CH), 112.65 (d, 
1C, N=NCCCHCHCHCH), 123.98 (d, 1C, N=NCCCH), 124.38 (d, 2C, CH=CHCCHCHC), 126.70 (d, 1C, N=NCCHCHCH), 127.68 
(d, 1C, N=NCCCHCHCH), 127.75 (d, 2C, CH=CHCCHCHC), 128.05 (d, 1C, N=NCCCHCH), 129.08 (d, 1C, N=NCCHCHCH), 
130.50 (d, 1C, CH2CH=CHC), 132.23 (s, 1C, N=NCCCH), 132.46 (d, 1C, N=NCCHCHCH), 133.87 (d, 1C, CH2CH=CHC), 135.61 
(s, 1C, N=NCCHCHCHC), 142.15 (s, 1C, CH2CH=CHC), 148.67 (s, 1C, N=NCCHCHCH), 152.96 (s, 1C, CH=CHCCHCHC), 183.19 
(s, 1C, C=O) ppm. MS (ESI+) m/z: 428 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C27H30O2N3: 428.2338, found 428.2329.  
4-{3-[(E)-Phenylazo]phenyl}but-3-yn-1-ol (m-14a) 
According to GP2 starting from m-9a (308 mg, 1.00 mmol), but-3-yn-1-ol (105 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) m-14a was obtained as orange solid (228 mg, 91%); mp 
44-46 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3363, 3062, 2940, 2883, 2233, 1596, 1586, 1477, 1469, 1445, 1420, 1332, 1307,
1152, 1046, 1020, 898, 796, 766, 689 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 2.12 (t, J = 6.0 Hz, 1 H, OH), 2.71
(t, J = 6.3 Hz, 2H, CH2CH2OH), 3.83 (q, J = 6.1 Hz, 2 H, CH2OH), 7.43 (t, J = 7.8 Hz, 1H, C≡CCCHCH), 7.46–7.53 (m, 4H,
C≡CCCHCH, N=NCCHCHCH, N=NCCHCHCH), 7.85 (dt, J = 7.9/1.6 Hz, 1H, C≡CCCHCCH), 7.89–7.94 (m, 2H, N=NCCHCHCH),
7.96 (t, J = 1.7 Hz, 1H, C≡CCCHC) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 23.76 (t, 1C, CH2CH2OH), 61.05 (t, 1C,
CH2OH), 81.71 (s, 1C, CH≡CHCCH), 87.30 (s, 1C, C≡CCCH , 122.89 (d, 3C, C≡CCCHCH, N=NCCHCHCH), 124.27 (s, 1C,
C≡CCCHC), 125.53 (d, 1C, C≡CCCHC), 128.99 (d, 1C, C≡CCCHCH), 129.07 (d, 2C, N=NCCHCHCH), 131.23 (d, 1C,
N=NCCHCHCH), 133.82 (d, 1C, C≡CCCHCCH), 152.31 (s, 1C, N=NC), 152.40 (s, 1C, N=NC) ppm. MS (EI+) m/z: 250 [M]+.
HRMS (EI+): M+ calcd for C16H14ON2: 250.1106, found 250.1099.
4-{4-[(E)-Phenylazo]phenyl}but-3-yn-1-ol (p-14a) 
According to GP2 starting from p-9a (308 mg, 1.00 mmol), but-3-yn-1-ol (105 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) p-14a  was obtained as orange solid (238 mg, 95%); mp 
116-118 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3321, 3229, 3057, 2951, 2887, 2215, 1595, 1494, 1464, 1441, 1405, 1301, 1284,
1100, 1042, 1017, 847, 762, 686 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.91 (t, J = 6.0 Hz, 1H, OH), 2.74 (t, J =
6.3 Hz, 2H, CH2CH2OH), 3.85 (q, J = 6.1 Hz, 2H, CH2OH), 7.46–7.54 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.54–7.57 (m,
H, C≡CCCHCHC), 7.84– .  , H, C≡CCCHCHC), 7.89–7.93 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21
°C, TMS): δ = 23.95 (t, 1C, CH2CH2OH), 61.07 (t, 1C, CH2OH , .  s, C, C≡CCCH), 89.12 (s, 1C, C≡CCCH , .  d, C,
C≡CCCHCHC), 122.89 (d, 2C, N=NCCHCHCH), 126.06 (s, 1C, CH2C≡CC), 129.09 (d, 2C, N=NCCHCHCH), 131.18 (d, 1C,
N=NCCHCHCH , .  d, C, C≡CCCHCHC , .  s, C, C≡CCCHCHC), 152.58 (s, 1C, N=NCCHCHCH) ppm. MS (EI+)
m/z: 250 [M]+. HRMS (EI+): M+ calcd for C16H14ON2: 250.1106, found 250.1101.
4-{3-[(E)-1-Naphthylazo]phenyl}but-3-yn-1-ol (m-14b) 
According to GP2 starting from m-9b (358 mg, 1.00 mmol), but-3-yn-1-ol (105 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol ), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) m-14b was obtained as red solid (277 mg, 92%); mp 88-
89 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3356, 3054, 2939, 2852, 2233, 1589, 1507, 1478, 1417, 1387, 1344, 1204, 1044, 896, 
804, 770, 684 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 2.12 (s, 1H, OH), 2.73 (t, J = 6.3 Hz, 2H, CH2CH2OH), 3.85 
(t, J = 6.3 Hz, 2H, CH2OH), 7.47 (t, J = .  Hz, H, C≡CCCHCH), 7.50– .  , H, C≡CCCHCH, N=NCCHCHCH, 
N=NCCCHCHCH), 7.65 (ddd, J = 8.3/6.9/1.2 Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/0.8 Hz, 1H, N=NCCHCHCH), 7.91 (d, J 
= 8.1 Hz, 1H, N=NCCCHCHCHCH), 7.94– .  , H, C≡CCCHCCH, N=NCCHCHCH), 8.07 (t, J = .  Hz, H, C≡CCCHC), 8.92 
(d, J = 8.4 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 23.79 (t, 1C, CH2CH2OH), 61.05 (t, 1C, 
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CH2OH , .  s, C, C≡CCCH), 87.37 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH), 123.39 (d, 2C, C≡CCCHCCH, 
N=NCCCH , .  s, C, C≡CCCHC), 125.55 (d, 2C, C≡CCCHC, N=NCCHCHCH), 126.47 (d, 1C, N=NCCCHCHCH), 126.90 
(d, 1C, N=NCCCHCH), 127.89 (d, 1C, N=NCCCHCHCHCH , .  d, C, C≡CCCHCH), 131.28 (s, 1C, N=NCCCH), 131.61 (d, 
1C, N=NCCHCHCH , .  d, C, C≡CCCHCH), 134.21 (s, 1C, N=NCCHCHCHC), 147.48 (s, 1C, N=NCCHCHCH), 152.78 (s, 
C, C≡CCCHC) ppm. MS (ESI+) m/z: 301 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C20H17ON2: 301.1341, found 301.1334.  
4-{4-[(E)-1-Naphthylazo]phenyl}but-3-yn-1-ol (p-14b) 
According to GP2 starting from p-9b (358 mg, 1.00 mmol), but-3-yn-1-ol (105 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) p-14b was obtained as red solid (280 mg, 93%); mp 95-
97 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3281, 3081, 3047, 2942, 2886, 2229, 1595, 1497, 1386, 1342, 1279, 1216, 1159, 
1140, 1099, 1039, 1012, 845, 801, 773 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ =  2.09 (t, J = 5.7 Hz, 1H, OH), 2.73 
(t, J = 6.3 Hz, 2H, CH2CH2OH), 3.84 (q, J = 6.0 Hz, 2H, CH2OH), 7.51–7.60 (m, 4H, N=NCCHCHCH, C≡CCCHCHC, 
N=NCCCHCHCH), 7.63 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.1 Hz, 1H, N=NCCHCHCH), 7.90 (d, J 
= 8.2 Hz, 1H, N=NCCCHCHCHCH), 7.97 (dq, J = 8.1/2.0 Hz, 3H, N=NCCHCHCH), 8.90 (d, J = 8.6 Hz, 1H, N=NCCCH) ppm. 
13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 23.92 (t, 1C, CH2CH2OH), 61.02 (t, 1C, CH2OH , .  s, C, C≡CCCH), 89.33 
(s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 123.34 (d, 1C, N=NCCCH), 125.55 (d, 1C, 
N=NCCHCHCH), 126.09 (s, 1C, CH2C≡CC), 126.45 (d, 1C, N=NCCCHCHCH), 126.87 (d, 1C, N=NCCCHCH), 127.90 (d, 1C, 
N=NCCCHCHCHCH), 131.31 (s, 1C, N=NCCCH), 131.56 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 134.23 (s, 1C, 
N=NCCHCHCHC), 147.57 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHCHC) ppm. MS (ESI+) m/z: 301 [M+H]+. HRMS (EI+): 
M+ calcd for C20H16ON2: 300.1263, found 300.1257.  
5-{3-[(E)-Phenylazo]phenyl}pent-4-yn-1-ol (m-15a) 
According to GP2 starting from m-9a (308 mg, 1.00 mmol), pent-4-yn-1-ol (126 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) m-15a was obtained as orange solid (238 mg, 90%); mp 
49-50 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3344, 3062, 2946, 2878, 2228, 1597, 1586, 1487, 1477, 1469, 1444, 1429, 1151,
1057, 1021, 923, 897, 796, 765, 689 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.82–1.95 (m, 3H, CH2CH2OH, OH),
2.56 (t, J = 7.0 Hz, 2H, CH2CH2CH2OH), 3.82 (t, J = 6.1 Hz, 2H, CH2OH), 7.42 (t, J = 7.8 Hz, 1H, C≡CCCHCH), 7.45–7.53 (m,
4H, C≡CCCHCH, N=NCCHCHCH, N=NCCHCHCH), 7.83 (dt, J = 7.9/1.6 Hz, 1H, C≡CCCHCCH), 7.89–7.93 (m, 2H,
N=NCCHCHCH), 7.94 (t, J = 1.7 Hz, 1H, C≡CCCHC) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 15.91 (t, 1C,
CH2CH2OH), 31.23 (t, 1C, CH2CH2CH2OH), 61.58 (t, 1C, CH2OH), 80.41 (s, 1C, C≡CCCH), 90.24 (s, 1C, C≡CCCH , .  (d,
1C, C≡CCCHCH), 122.86 (d, 2C, N=NCCHCHCH), 124.67 (s, 1C, C≡CCCHC), 125.48 (d, 1C, C≡CCCHC), 128.94 (d, 1C,
C≡CCCHCH), 129.06 (d, 2C, N=NCCHCHCH), 131.18 (d, 1C, N=NCCHCHCH), 133.74 (d, 1C, C≡CCCHCCH), 152.30 (s, 1C,
N=NC), 152.40 (s, 1C, N=NC) ppm. MS (EI+) m/z: 264 [M]+. HRMS (EI+): M+ calcd for C17H16ON2: 264.1263, found 264.1257.
5-{4-[(E)-Phenylazo]phenyl}pent-4-yn-1-ol (p-15a) 
According to GP2 starting from p-9a (308 mg, 1.00 mmol), pent-4-yn-1-ol (126 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) p-15a was obtained as orange solid (254 mg, 96%); mp 
104 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3301, 3063, 2932, 2871, 2217, 1594, 1495, 1442, 1301, 1281, 1222, 1154, 1100, 
1069, 1053, 1033, 928, 847, 766, 726, 687 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.89 (p, J = 6.6 Hz, 2H, 
CH2CH2OH), 2.17 (s, 1H, OH), 2.59 (t, J = 7.0 Hz, 2H, CH2CH2CH2OH), 3.84 (t, J = 6.1 Hz, 2H, CH2OH), 7.45–7.54 (m, 5H, 
N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCHC), 7.83–7.88 (m, 2H, C≡CCCHCHC), 7.89–7.93 (m, 2H, N=NCCHCHCH) ppm. 
13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 16.11 (t, 1C, CH2CH2OH), 31.29 (t, 1C, CH2CH2CH2OH), 61.72 (t, 1C, CH2OH), 
80.98 (s, 1C, CH2C≡C), 92.17 (s, 1C, CH2C≡C , .  d, 2C, C≡CCCHCHC), 122.87 (d, 2C, N=NCCHCHCH), 126.53 (s, 1C, 
CH2C≡CC), 129.09 (d, 2C, N=NCCHCHCH), 131.12 (d, 1C, N=NCCHCHCH), 132.32 (d, 2C, C≡CCCHCHC), 151.45 (s, 1C, 
C≡CCCHCHC), 152.61 (s, 1C, N=NCCHCHCH) ppm. MS (EI+) m/z: 264 [M]+. HRMS (EI+): M+ calcd for C17H16ON2: 264.1263, 
found 264.1256.  
5-{3-[(E)-1-Naphthylazo]phenyl}pent-4-yn-1-ol (m-15b) 
According to GP2 starting from m-9b (358 mg, 1.00 mmol), pent-4-yn-1-ol (126 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) m-15b  was obtained as red solid (296 mg, 94%); mp 64-
66 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3357, 3054, 2946, 2878, 2228, 1599, 1507, 1478, 1431, 1387, 1345, 1204, 1058, 896, 
865, 804, 771, 684 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.70 (s, 1H, OH), 1.90 (p, J = 6.7 Hz, 2H, CH2CH2OH), 
2.59 (t, J = 7.0 Hz, 2H, CH2CH2CH2OH), 3.85 (t, J = 6.2 Hz, 2H, CH2OH), 7.47 (t, J = 7.7 Hz, 1H, C≡CCCHCH), 7.50–7.61 (m, 
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H, C≡CCCHCH, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.3/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.0 
Hz, 1H, N=NCCHCHCH), 7.92 (d, J = 8.2 Hz, 1H N=NCCCHCHCHCH), 7.94–8.01 (m, 2H, C≡CCCHCCH, N=NCCHCHCH), 8.06 
(t, J = 1.6 Hz, 1H, C≡CCCHC), 8.93 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 15.97 (t, 
1C, CH2CH2OH), 31.27 (t, 1C, CH2CH2CH2OH), 61.69 (t, 1C, CH2OH), 80.48 (s, 1C, CH2C≡C), 90.30 (s, 1C, CH2C≡C , .  
(d, 1C, N=NCCHCHCH), 123.04 (d, 1C, C≡CCCHCCH), 123.39 (d, 1C, N=NCCCH), 124.73 (s, 1C, C≡CCCHC), 125.59 (d, 2C, 
C≡CCCHC, N=NCCHCHCH), 126.48 (d, 1C, N=NCCCHCHCH), 126.90 (d, 1C, N=NCCCHCH), 127.91 (d, 1C, 
N=NCCCHCHCHCH), 129.02 (d, 1C, C≡CCCHCH), 131.28 (s, 1C, N=NCCCH), 131.57 (d, 1C, N=NCCHCHCH), 133.87 (d, 1C, 
C≡CCCHCH), 134.22 (s, 1C, N=NCCHCHCHC), 147.55 (s, 1C, N=NCCHCHCH), 152.82 (s, 1C, C≡CCCHC) ppm. MS (ESI+) m/z: 
315 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C21H19ON2: 315.1497, found 315.1492.  
5-{4-[(E)-1-Naphthylazo]phenyl}pent-4-yn-1-ol (p-15b) 
According to GP2 starting from p-9b (358 mg, 1.00 mmol), pent-4-yn-1-ol (126 mg, 1.50 mmol), Pd(dppf)Cl2 (42 mg, 50 
µmol), CuI (38 mg, 0.20 mmol), Et3N (1.0 mL) and THF (1.0 mL) p-15b  was obtained as red solid (301 mg, 95%); mp 98-
99 °C; Rf ≈ .  CH2Cl2). IR (KBr): ṽ = 3411, 3047, 2952, 2927, 2895, 2835, 2215, 1595, 1497, 1437, 1343, 1215, 1067, 
1047, 906, 842, 803, 773 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ =  1.71 (s, 1H, OH), 1.89 (p, J = 6.6 Hz, 2H, 
CH2CH2OH), 2.59 (t, J = 7.0 Hz, 2H, CH2CH2CH2OH), 3.83 (t, J = 6.1 Hz, 2H, CH2OH), 7.52–7.60 (m, 4H, N=NCCHCHCH, 
C≡CCCHCHC, N=NCCCHCHCH), 7.64 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.1 Hz, 1H, 
N=NCCHCHCH), 7.91 (d, J = 8.2 Hz, 1H, N=NCCCHCHCHCH), 7.98 (dt, J = 8.4/1.9 Hz, 3H, N=NCCHCHCH, C≡CCCHCHC), 
8.91 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 16.11 (t, 1C, CH2CH2OH), 31.25 (t, 1C, 
CH2CH2CH2OH), 61.66 (t, 1C, CH2OH), 81.00 (s, 1C, C≡CCCH), 92.35 (s, 1C, C≡CCCH , .  (d, 1C, N=NCCCHCHCHCH), 
123.09 (d, 2C, C≡CCCHCHC), 123.36 (s, 1C, N=NCCCH), 125.73 (d, 1C, N=NCCHCHCH), 126.45 (d, 1C, N=NCCCHCHCH), 
126.57 (s, 1C, CH2C≡CC), 126.86 (d, 1C, N=NCCCHCH), 127.91 (d, 1C, N=NCCCHCHCHCH), 131.31 (s, 1C, N=NCCCH), 
131.50 (s, 1C, N=NCCHCHCH), 132.36 (d, 2C, C≡CCCHCHC), 134.24 (s, 1C, N=NCCHCHCHC), 147.62 (s, 1C, N=NCCHCHCH), 
152.08 (s, 1C, C≡CCCHCHC) ppm. MS (ESI+) m/z: 315 [M+H]+. HRMS (EI+): M+ calcd for C21H18ON2: 314.1419, found 
314.1413.  
4-{3-[(E)-Phenylazo]phenyl}but-3-yn-1-yl 4-methylbenzenesulfonate (m-16a) 
According to GP3 starting from m-14a (200 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N 
(121 mg, 1.20 mmol) and CH2Cl2 (1.6 mL) m-16a was obtained as orange high viscous oil (282 mg, 87%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3064, 2960, 2921, 2239, 1597, 1469, 1362, 1307, 1189, 1177, 1096, 983, 900, 799, 
767, 690, 663 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ =  2.38 (s, 3H, CH3), 2.80 (t, J = 6.9 Hz, 2 H, CH2CH2O), 4.20 
(t, J = 6.9 Hz, 2H, CH2O), 7.30 (d, J = 7.9 Hz, 2H, CHCCH3), 7.41–7.46 (m, 2H, C≡CCCHCH, C≡CCCHCH), 7.46–7.55 (m, 3H, 
N=NCCHCHCH, N=NCCHCHCH), 7.81–7.84 (m, 2H, O3SCCH), 7.85–7.86 (m, 1H, C≡CCCHCCH), 7.87 (t, J = 1.5 Hz, 2H, 
C≡CCCHC), 7.89–7.94 (m, 1H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 20.30 (t, 1C, CH2CH2O), 
21.57 (q, 1C, CH3), 67.64 (t, 1C, CH2O), 81.90 (s, 1C, C≡CCCH), 84.72 (s, 1C, C≡CCCH , 122.88 (d, 2C, N=NCCHCHCH), 
122.97 (d, 1C, C≡CCCHCCH), 123.85 (s, 1C, C≡CCCHC), 125.55 (d, 1C, C≡CCCHC), 127.91 (d, 2C, O3SCCH), 128.97 (d, 1C, 
C≡CCCHCH), 129.08 (s, 2C, N=NCCHCHCH), 129.86 (d, 2C, CHCCH3), 131.28 (d, 1C, N=NCCHCHCH), 132.69 (s, 1C, O3SC), 
133.76 (d, 1C, C≡CCCHCH), 144.92 (s, 1C, CCH3), 152.25 (s, 1C, N=NC), 152.36 (s, 1C, N=NC) ppm. MS (EI+) m/z: 404 [M]+. 
HRMS (EI+): M+ calcd for C23H20O3N2S: 404.1195, found 404.1195.  
4-{4-[(E)-Phenylazo]phenyl}but-3-yn-1-yl 4-methylbenzenesulfonate (p-16a) 
According to GP3 starting from p-14a (200 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N (121 
mg, 1.20 mmol) and CH2Cl2 (1.6 mL) p-16a was obtained as orange high viscous oil (288 mg, 89%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3070, 2970, 2914, 2225, 1597, 1495, 1431, 1364, 1292, 1185, 1174, 1154, 1097, 
1064, 973, 845, 814, 794, 766, 682, 667 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 2.42 (s, 3H, CH3), 2.82 (t, J = 6.9 
Hz, 2H, CH2CH2O), 4.21 (t, J = 7.0 Hz, 2H, CH2O), 7.30–7.34 (m, 2H, CHCCH3), 7.45– .  , H, C≡CCCHCHC, 
N=NCCHCHCH, N=NCCHCHCH), 7.81– .  , H, C≡CCCHCHC, O3SCCH), 7.89–7.94 (m, 2H, N=NCCHCHCH) ppm. 13C 
NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 20.48 (t, 1C, CH2CH2O), 21.63 (q, 1C, CH3), 67.58 (t, 1C, CH2O), 82.41 (s, 1C, 
C≡CCCH), 86.47 (s, 1C, C≡CCCH , .  d, C, C≡CCCHCHC), 122.90 (d, 2C, N=NCCHCHCH), 125.58 (s, 1C, CH2C≡CC), 
127.95 (d, 2C, O3SCCH), 129.10 (d, 2C, N=NCCHCHCH), 129.89 (d, 2C, CHCCH3), 131.25 (d, 1C, N=NCCHCHCH), 132.42 (d, 
C, C≡CCCHCHC), 132.79 (s, 1C, O3SC), 144.96 (s, 1C, CCH3 , .  s, C, C≡CCCHCHC), 152.53 (s, 1C, N=NCCHCHCH) 
ppm. MS (EI+) m/z: 404 [M]+. HRMS (EI+): M+ calcd for C23H20O3N2S: 404.1195, found 404.1183.  
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4-{3-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl 4-methylbenzenesulfonate (m-16b) 
According to GP3 starting from m-14b (240 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N 
(121 mg, 1.20 mmol) and CH2Cl2 (1.6 mL) m-16b was obtained as red high viscous oil (313 mg, 86%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3054, 2959, 2921, 2238, 1597, 1507, 1479, 1362, 1345, 1306, 1189, 1177, 1096, 
983, 899, 806, 772, 685, 664 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 2.34 (s, 3H, CH3), 2.82 (t, J = 6.9 Hz, 2H, 
CH2CH2O), 4.22 (t, J = 6.9 Hz, 2H, CH2O), 7.28 (d, J = 8.0 Hz, 2H, CHCCH3), 7.42– .  , H, C≡CCCHCH, C≡CCCHCH), 
7.52–7.61 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.79–7.85 (m, 3H, 
N=NCCHCHCH, O3SCCH), 7.92 (d, J = 8.1 Hz, 1H, N=NCCCHCHCHCH), 7.95–8.02 (m, J = 4.9/2.5 Hz, 3H, N=NCCHCHCH, 
C≡CCCHCCH, C≡CCCHC), 8.92 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 20.33 (t, 1C, 
CH2CH2O), 21.53 (q, 1C, CH3), 67.63 (t, 1C, CH2O , .  s, C, C≡CCCH), 84.79 (s, 1C, C≡CCCH , .  d, C, 
N=NCCHCHCH), 123.30 (d, 1C, N=NCCCH , .  d, C, C≡CCCHCCH , .  s, C, C≡CCCHC), 125.56 (d, 2C, C≡CCCHC, 
N=NCCHCHCH), 126.47 (d, 1C, N=NCCCHCHCH), 126.92 (d, 1C, N=NCCCHCH), 127.89 (d, 3C, N=NCCCHCHCHCH, O3SCCH), 
.  d, C, C≡CCCHCH), 129.84 (d, 2C, CHCCH3), 131.27 (s, 1C, N=NCCCH), 131.67 (d, 1C, N=NCCHCHCH), 132.67 (s, 
1C, O3SC), .  d, C, C≡CCCHCH), 134.20 (s, 1C, N=NCCHCHCHC), 144.92 (s, 1C, CCH3), 147.40 (s, 1C, N=NCCHCHCH), 
.  s, C, C≡CCCHC) ppm. MS (ESI+) m/z: 455 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C27H23O3N2S: 455.1429, found 
455.1420.  
4-{4-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl 4-methylbenzenesulfonate (p-16b) 
According to GP3 starting from p-14b (240 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N (121 
mg, 1.20 mmol) and CH2Cl2 (1.6 mL) p-16b was obtained as red high viscous oil (320 mg, 88%); Rf ≈ .  pe ta e/CH2Cl2 
= 1:1). IR (NaCl): ṽ = 3048, 2967, 2920, 2228, 1595, 1507, 1495, 1351, 1339, 1306, 1215, 1188, 1176, 1096, 972, 906, 
849, 815, 806, 772, 752, 658 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 2.41 (s, 3H, CH3), 2.83 (t, J = 6.9 Hz, 2H, 
CH2CH2O), 4.22 (t, J = 6.9 Hz, 2H, CH2O), 7.28–7.34 (m, 2H, CHCCH3), 7.47– .  , H, C≡CCCHCHC), 7.52–7.60 (m, 2H, 
N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.80–7.86 (m, 3H, N=NCCHCHCH, 
O3SCCH), 7.92 (d, J = 8.2 Hz, 1H, N=NCCCHCHCHCH), 7.95– .  , H, C≡CCCHCHC, N=NCCHCHCH), 8.91 (d, J = 7.9 Hz, 
1H, N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 20.50 (t, 1C, CH2CH2O), 21.60 (q, 1C, CH3), 67.58 (t, 1C, 
CH2O), 82.45 s, C, C≡CCCH), 86.65 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 123.31 
(d, 1C, N=NCCCH), 125.56 (d, 1C, N=NCCHCHCH), 125.64 (s, 1C, CH2C≡CC), 126.47 (d, 1C, N=NCCCHCHCH), 126.91 (d, 1C, 
N=NCCCHCH), 127.92 (d, 3C, O3SCCH, N=NCCCHCHCHCH), 129.87 (d, 2C, CHCCH3), 131.34 (s, 1C, N=NCCCH), 131.64 (d, 
1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 132.81 (s, 1C, O3SC), 134.26 (s, 1C, N=NCCHCHCHC), 144.94 (s, 1C, CCH3), 
147.58 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHCHC) ppm. MS (ESI+) m/z: 455 [M+H]+. HRMS (EI+): M+ calcd for 
C27H22O3N2S: 454.1351, found 454.1342.  
5-{3-[(E)-Phenylazo]phenyl}pent-4-yn-1-yl 4-methylbenzenesulfonate (m-17a) 
According to GP3 starting from m-15a (212 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N 
(121 mg, 1.20 mmol) and CH2Cl2 (1.6 mL) m-17a was obtained as orange high viscous oil (307 mg, 92%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3063, 2959, 2924, 2230, 1597, 1468, 1444, 1362, 1189, 1176, 1097, 1018, 930, 826, 
812, 797, 766, 690, 664 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.95 (p, J = 6.4 Hz, 2H, CH2CH2O), 2.32 (s, 3H, 
CH3), 2.51 (t, J = 6.8 Hz, 2H, CH2CH2CH2O), 4.22 (t, J = 6.0 Hz, 2H, CH2O), 7.27–7.31 (m, 2H, CHCCH3), 7.38 (dt, J = 7.6/1.5 
Hz, 1H, C≡CCCHCH), 7.42 (td, J = 7.6/0.6 Hz, 1H, C≡CCCHCH), 7.46–7.55 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.79–
7.86 (m, 4H, O3SCCH, C≡CCCHC, C≡CCCHCCH), 7.90–7.95 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, 
TMS): δ = 15.58 (t, 1C, CH2CH2O), 21.52 (q, 1C, CH3), 27.74 (t, 1C, CH2CH2CH2O), 68.77 (t, 1C, CH2O), 81.00 (s, 1C, C≡CCCH), 
88.42 (s, 1C, C≡CCCH , .  (d, 1C, C≡CCCHCCH), 122.88 (d, 2C, N=NCCHCHCH), 124.35 (s, 1C, C≡CCCHC), 125.50 (d, 
1C, C≡CCCHC), 127.88 (d, 2C, O3SCCH), 128.92 (d, 1C, C≡CCCHCH), 129.10 (d, 2C, N=NCCHCHCH), 129.83 (d, 2C, CHCCH3), 
131.26 (d, 1C, N=NCCHCHCH), 132.69 (s, 1C, O3SC), 133.71 (d, 1C, C≡CCCHCH), 144.78 (s, 1C, CCH3), 152.27 (s, 1C, N=NC), 
152.40 (s, 1C, N=NC) ppm. MS (EI+) m/z: 418 [M]+. HRMS (EI+): M+ calcd for C24H22O3N2S: 418.1351, found 418.1349.  
5-{4-[(E)-Phenylazo]phenyl}pent-4-yn-1-yl 4-methylbenzenesulfonate (p-17a) 
According to GP3 starting from p-15a (212 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N (121 
mg, 1.20 mmol) and CH2Cl2 (1.6 mL) p-17a was obtained as orange high viscous oil (308 mg, 92%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3068, 3049, 2976, 2942, 2921, 2228, 1597, 1494, 1461, 1438, 1352, 1291, 1191, 
1178, 1155, 1098, 1018, 977, 933, 844, 814, 765, 683, 664 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.96 (p, J = 
6.5 Hz, 2H, CH2CH2O), 2.38 (s, 3H, CH3), 2.53 (t, J = 6.8 Hz, 2H, CH2CH2CH2O), 4.22 (t, J = 6.0 Hz, 2H, CH2O), 7.29–7.33 (m, 
2H, CHCCH3), 7.40–7.45 (m, 2H, C≡CCCHCHC), 7.46–7.55 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.80–7.86 (m, 4H, 
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C≡CCCHCHC, O3SCCH), 7.89–7.94 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 15.78 (t, 1C, 
CH2CH2O), 21.61 (q, 1C, CH3), 27.77 (t, 1C, CH2CH2CH2O), 68.77 (t, 1C, CH2O), 81.53 (s, 1C, C≡CCCH), 90.35 (s, 1C, C≡CCCH , 
122.75 (d, 2C, C≡CCCHCHC), 122.88 (d, 2C, N=NCCHCHCH), 126.14 (s, 1C, CH2C≡CC), 127.93 (d, 2C, O3SCCH), 129.10 (d, 
2C, N=NCCHCHCH), 129.85 (d, 2C, CHCCH3), 131.19 (d, 1C, N=NCCHCHCH), 132.30 (d, 2C, C≡CCCHCHC), 132.80 (s, 1C, 
O3SC), 144.81 (s, 1C, CCH3), 151.49 (s, 1C, C≡CCCHCHC), 152.56 (s, 1C, N=NCCHCHCH) ppm. MS (EI+) m/z: 418 [M]+. HRMS 
(EI+): M+ calcd for C24H22O3N2S: 418.1351, found 418.1339.  
5-{3-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl 4-methylbenzenesulfonate (m-17b) 
According to GP3 starting from m-15b (304 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N 
(121 mg, 1.20 mmol) and CH2Cl2 (1.6 mL) m-17b was obtained as red high viscous oil (337 mg, 90%); Rf ≈ .  
(pentane/CH2Cl2 = 1:1). IR (NaCl): ṽ = 3055, 2958, 2924, 2850, 2231, 1598, 1507, 1479, 1434, 1362, 1189, 1176, 1097, 
1017, 975, 933, 832, 806, 773, 686, 663 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.96 (p, J = 6.5 Hz, 2H, CH2CH2O), 
2.29 (s, 3H, CH3), 2.52 (t, J = 6.8 Hz, 2H, CH2CH2CH2O), 4.22 (t, J = 6.0 Hz, 2H, CH2O), 7.26 (d, J = 8.5 Hz, 2H, CHCCH3), 
7.38–7.49 (m, 2H, C≡CCCHCH, C≡CCCHCH), 7.52–7.60 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 
Hz, 1H, N=NCCCHCH), 7.78–7.85 (m, 3H, O3SCCH, N=NCCHCHCH), 7.89–8.01 (m, 4H, N=NCCCHCHCHCH, N=NCCHCHCH, 
C≡CCCHCCH, C≡CCCHC), 8.93 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 15.59 (t, 1C, 
CH2CH2O), 21.47 (q, 1C, CH3), 27.68 (t, 1C, CH2CH2CH2O), 66.76 (t, 1C, CH2O), 81.02 (s, 1C, C≡CCCH), 88.50 (s, 1C, C≡CCCH , 
111.81 (d, 1C, N=NCCHCHCH), 123.00 (d, 1C, N=NCCCH), 123.29 (d, 1C, C≡CCCHCCH), 124.47 (s, 1C, C≡CCCHC), 125.55 
(d, 2C, C≡CCCHC, N=NCCHCHCH), 126.46 (d, 1C, N=NCCCHCHCH), 126.91 (d, 1C, N=NCCCHCH), 127.86 (d, 3C, 
N=NCCCHCHCHCH, O3SCCH), 128.96 (d, 1C, C≡CCCHCH), 129.79 (d, 2C, CHCCH3), 131.26 (s, 1C, N=NCCCH), 131.63 (d, 
1C, N=NCCHCHCH), 132.62 (s, 1C, O3SC), 133.77 (d, 1C, C≡CCCHCH), 134.19 (s, 1C, N=NCCHCHCHC), 144.75 (s, 1C, CCH3), 
147.41 (s, 1C, N=NCCHCHCH), 152.72 (s, 1C, C≡CCCHC) ppm. MS (ESI+) m/z: 469 [M+H]+. HRMS (ESI+): [M+H]+ calcd for 
C28H25O3N2S: 469.1586, found 469.1577.  
5-{4-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl 4-methylbenzenesulfonate (p-17b) 
According to GP3 starting from p-15b (304 mg, 0.800 mmol), p-toluenesulfonylchloride (182 mg, 0.960 mmol), Et3N (121 
mg, 1.20 mmol) and CH2Cl2 (1.6 mL) p-17b was obtained as red high viscous oil (345 mg, 92%); Rf ≈ .  pe ta e/CH2Cl2 
= 1:1). IR (NaCl): ṽ = 3056, 2985, 2961, 2940, 2921, 2235, 1596, 1497, 1356, 1349, 1217, 1191, 1176, 1097, 1013, 930, 
847, 837, 815, 804, 778, 660 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.97 (p, J = 6.5 Hz, 2H, CH2CH2O), 2.38 (s, 
3H, CH3), 2.54 (t, J = 6.8 Hz, 2H, CH2CH2CH2O), 4.23 (t, J = 6.0 Hz, 2 H, CH2O), 7.29–7.33 (m, 2H, CHCCH3), 7.44–7.49 (m, 
2H, C≡CCCHCHC), 7.54–7.61 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 
7.80–7.85 (m, 3H, N=NCCHCHCH, O3SCCH), 7.92 (d, J = 8.2 Hz, 1H, N=NCCCHCHCHCH), 7.95–8.01 (m, 3H, N=NCCHCHCH, 
C≡CCCHCHC), 8.92 (d, J = 7.9 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 15.81 (t, 1C, CH2CH2O), 
21.59 (q, 1C, CH3), 27.78 (t, 1C, CH2CH2CH2O), 68.78 (t, 1C, CH2O), 81.58 (s, 1C, CH2C≡C), 90.53 (s, 1C, CH2C≡C , .  
(d, 1C, N=NCCHCHCH), 123.03 (d, 2C, C≡CCCHCHC), 123.33 (d, 1C, N=NCCCH), 125.58 (d, 1C, N=NCCHCHCH), 126.21 (s, 
1C, CH2C≡CC), 126.48 (d, 1C, N=NCCCHCHCH), 126.90 (d, 1C, N=NCCCHCH), 127.93 (d, 3C, N=NCCCHCHCHCH, CHCCH3), 
129.84 (d, 2C, CHCCH3), 131.34 (s, 1C, N=NCCCH), 131.59 (d, 1C, N=NCCHCHCH), 132.35 (d, 2C, C≡CCCHCHC), 132.82 (s, 
1C, O3SC), 134.27 (s, 1C, N=NCCHCHCHC), 144.79 (s, 1C, N=NCCHCHCHC), 147.62 (s, 1C, N=NCCHCHCH), 152.03 (s, 1C, 
C≡CCCHCHC) ppm. MS (ESI+) m/z: 469 [M+H]+. HRMS (EI+): M+ calcd for C28H24O3N2S: 468.1508, found 468.1495.  
Ethyl 1-{4-[3-[(E)-phenylazo]phenyl}but-3-yn-1-yl]piperidine-3-carboxylate (m-18a) 
According to GP4 starting from m-16a (121 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h m-18a was obtained as orange oil (102 mg, 87%); Rf ≈ .  pe ta e/EtOAc = 8:2). 
IR (NaCl): ṽ = 3062, 2927, 2853, 2810, 2229, 1729, 1596, 1467, 1446, 1369, 1306, 1179, 1152, 1133, 1101, 1033, 797, 
766, 690 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.24 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.46 (qd, J = 12.3/4.4 Hz, 1H, 
NCH2CHCHaxHeq), 1.54–1.64 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 11.0/3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dq, J 
= 13.5/4.2 Hz, 1H, NCH2CHCHaxHeq), 2.13 (td, J = 11.0/2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.30 (t, J = 10.6 Hz, 1H, 
NCHaxHeqCH), 2.55–2.65 (m, 3H, NCH2CHax, NCH2CH2C≡C), 2.70–2.76 (m, 2H, NCH2CH2C≡C , .  dbr, J = 11.2 Hz, 1H, 
NCHaxHeqCH2CH2CH), 3.06 (dbr, J = 10.4 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.43 (t, J = 7.8 Hz, 1H, 
C≡CCCHCH), 7.45–7.53 (m, 4H, N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCH), 7.83 (ddd, J = 7.9/1.9/1.3 Hz, 1H, 
C≡CCCHCCH), 7.89–7.93 (m, 2H, N=NCCHCHCH), 7.95 (t, J = 1.7 Hz, 1H, C≡CCCHC) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, 
TMS): δ = 14.17 (q, 1C, OCH2CH3), 17.64 (t, 1C, NCH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 26.78 (t, 1C, NCH2CHCH2), 
41.81 (d, 1C, NCH2CH), 53.34 (t, 1C, NCH2CH2CH2CH), 55.06 (t, 1C, NCH2CH), 57.37 (t, 1C, NCH2CH2C≡C , .  (t, 1C, 
OCH2CH3), 80.64 (s, 1C, C≡CCCH), 89.26 (s, 1C, C≡CCCH , .  (d, 1C, C≡CCCHCCH), 122.86 (d, 2C, N=NCCHCHCH), 
124.72 (s, 1C, C≡CCCHC), 125.57 (d, 1C, C≡CCCHC), 128.90 (d, 1C, C≡CCCHCH), 129.04 (d, 2C, N=NCCHCHCH), 131.14 (d, 
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1C, N=NCCHCHCH), 133.74 (d, 1C, C≡CCCHCH), 152.46 (d, 2C, N=NC), 174.05 (s, 1C, C=O) ppm. MS (ESI+) m/z: 390 [M+H]+. 
HRMS (ESI+): [M+H]+ calcd for C24H28O2N3: 390.2182, found 390.2173.  
(R)-Ethyl 1-(4-{3-[(E)-phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate ((R)-m-18a) 
According to GP4 starting from m-16a (121 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h (R)-m-18a was obtained as orange oil (102 mg, 87%); [�]20D = -12.1 (c = 0.1 in 
CH2Cl2); Rf ≈ .  (pentane/EtOAc = 8:2). IR (NaCl): ṽ = 3062, 2927, 2853, 2810, 2229, 1729, 1596, 1467, 1446, 1369, 
1306, 1179, 1152, 1133, 1101, 1033, 797, 766, 690 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.23 (t, J = 7.1 Hz, 
3H, OCH2CH3), 1.45 (qd, J = 12.0/4.4 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.64 (m, 1H, NCH2CHaxHeqCH2CH), 1.73 (dp, J = 
10.7/3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.93 (dq, J = 13.1/4.1 Hz, 1H, NCH2CHCHaxHeq), 2.12 (td, J = 10.9/3.1 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.29 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.53–2.65 (m, 3H, NCH2CHax, NCH2CH2C≡C , . –2.74 (m, 
2H, NCH2CH2C≡C , .  dbr, J = 11.3 Hz, 1H, NCHaxHeqCH2CH2CH), 3.04 (dbr, J = 10.9 Hz, 1H, NCHaxHeqCH), 4.12 (q, J = 7.2 
Hz, 2H, OCH2CH3), 7.42 (t, J = .  Hz, H, C≡CCCHCH), 7.44–7.53 (m, 4H, N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCH), 7.82 
(ddd, J = . / . / .  Hz, H, C≡CCCHCCH), 7.88–7.93 (m, 2H, N=NCCHCHCH), 7.94 (t, J = .  Hz, H, C≡CCCHC) ppm. 13C 
NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.13 (q, 1C, OCH2CH3), 17.60 (t, 1C, NCH2CH2C≡C , .  t, 1C, NCH2CH2CH2CH), 
26.73 (t, 1C, NCH2CHCH2), 41.76 (d, 1C, NCH2CH), 53.29 (t, 1C, NCH2CH2CH2CH), 55.02 (t, 1C, NCH2CH), 57.33 (t, 1C, 
NCH2CH2C≡C , .  t, C, OCH2CH3 , .  s, C, C≡CCCH), 89.23 (s, 1C, C≡CCCH , .  d, C, C≡CCCHCCH), 122.82 
(d, 2C, N=NCCHCHCH , .  s, C, C≡CCCHC , .  d, C, C≡CCCHC , .  d, C, C≡CCCHCH), 128.99 (d, 2C, 
N=NCCHCHCH), 131.11 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCH), 152.33 (d, 2C, N=NC), 173.98 (s, 1C, C=O) ppm. 
MS (ESI+) m/z: 390 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C24H28O2N3: 390.2182, found 390.2173.  
Ethyl 1-(4-{4-[(E)-phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate (p-18a) 
According to GP4 starting from p-16a (125 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 48 h p-18a was obtained as orange oil (103 mg, 88%); Rf ≈ .  pe ta e/EtOA  = : . 
IR (NaCl): ṽ = 3069, 2945, 2862, 2805, 2211, 1725, 1595, 1585, 1495, 1465, 1442, 1368, 1297, 1271, 1222, 1189, 1153, 
1096, 1032, 1018, 841, 769, 687 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.46 
(qd, J = 11.8/3.7 Hz, 1H, NCH2CHCHaxHeq), 1.53–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 12.9/3.5 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 2.14 (td, J = 10.8/2.2 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.30 (t, J = 10.7 Hz, 1H, NCHaxHeqCH), 2.53–2.68 (m, 3H, NCH2CHax, NCH2CH2C≡C , . –2.76 (m, 2H, NCH2CH2C≡C , .  
(dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (dbr, J = 10.4 Hz, 1H, NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.44–
7.55 (m, 5H, N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCHC), 7.82– .  , H, C≡CCCHCHC), 7.89–7.94 (m, 2H, 
N=NCCHCHCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 14.18 (q, 1C, OCH2CH3), 17.77 (t, 1C, NCH2CH2C≡C , 
24.55 (t, 1C, NCH2CH2CH2CH), 26.78 (t, 1C, NCH2CHCH2), 41.80 (d, 1C, NCH2CH), 53.34 (t, 1C, NCH2CH2CH2CH), 55.05 (t, 
1C, NCH2CH), 57.32 (t, 1C, NCH2CH2C≡C , .  t, C, OCH2CH3 , .  s, C, C≡CCCH), 91.21 (s, 1C, C≡CCCH , .  
d, C, C≡CCCHCHC, N=NCCHCHCH), 126.53 (s, 1C, CH2C≡CC), 129.05 (d, 2C, N=NCCHCHCH), 131.09 (d, 1C, 
N=NCCHCHCH , .  d, C, C≡CCCHCHC , .  s, C, C≡CCCHCHC), 152.54 (s, 1C, N=NCCHCHCH), 174.07 (s, 1C, 
C=O) ppm. MS (ESI+) m/z: 390 [M+H]+. HRMS (EI+): M+ calcd for C24H27O2N2: 389.2103, found 389.2095.  
(R)-Ethyl 1-(4-{4-[(E)-phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate ((R)-p-18a) 
According to GP4 starting from p-16a (125 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 48 h (R)-p-18a was obtained as orange oil (103 mg, 88%); [�]20D = -13.2 (c = 0.1 in CH2Cl2); 
Rf ≈ .  pe ta e/EtOA  = : . IR NaCl : ṽ = 3064, 2942, 2859, 2805, 2213, 1729, 1595, 1584, 1495, 1464, 1440, 1370, 
1310, 1269, 1220, 1183, 1153, 1099, 1033, 1018, 849, 764, 686 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, 
J = 7.1 Hz, 3H, OCH2CH3), 1.46 (qd, J = 12.1/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.53–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 
(dp, J = 11.6/3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dq, J = 12.5/4.1 Hz, 1H, NCH2CHCHaxHeq), 2.14 (td, J = 11.1/3.2 Hz, 
1H, NCHaxHeqCH2CH2CH), 2.30 (t, J = 10.7 Hz, 1H, NCHaxHeqCH), 2.53–2.67 (m, 3H, NCH2CHax, NCH2CH2C≡C , . –2.76 
(m, 2H, NCH2CH2C≡C , .  dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (dbr, J = 10.8 Hz, 1H, NCHaxHeqCH), 4.14 (q, J = 
7.1 Hz, 2H, OCH2CH3), 7.44–7.56 (m, 5H, N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCHC), 7.83– .  , H, C≡CCCHCHC), 
7.89–7.94 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 14.18 (q, 1C, OCH2CH3), 17.76 (t, 1C, 
NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 26.78 (t, 1C, NCH2CHCH2), 41.79 (d, 1C, NCH2CH), 53.34 (t, 1C, 
NCH2CH2CH2CH), 55.05 (t, 1C, NCH2CH), 57.31 (t, 1C, NCH2CH2C≡C , .  t, C, OCH2CH3), 81.16 s, C, C≡CCCH), 91.21 
(s, 1C, C≡CCCH , .  d, C, C≡CCCHCHC, N=NCCHCHCH), 126.52 (s, 1C, CH2C≡CC), 129.05 (d, 2C, N=NCCHCHCH), 
131.09 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC , .  s, C, C≡CCCHCHC), 152.53 (s, 1C, N=NCCHCHCH), 
174.06 (s, 1C, C=O) ppm. MS (ESI+) m/z: 390 [M+H]+. HRMS (EI+): M+ calcd for C24H27O2N3: 389.2103, found 389.2095.   
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Ethyl 1-(4-{3-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate (m-18b) 
According to GP4 starting from m-16b (136 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol),  acetone 
(0.3 mL) and a reaction time of 48 h m-18b was obtained as orange oil (113 mg, 86%); Rf ≈ .  pe ta e/EtOA  = : . 
IR (NaCl): ṽ = 3054, 2942, 2854, 2809, 2230, 1729, 1598, 1508, 1467, 1445, 1370, 1305, 1206, 1180, 1153, 1133, 1101, 
1033, 896, 804, 771 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.24 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.46 (qd, J = 
11.8/3.7 Hz, 1H, NCH2CHCHaxHeq), 1.53–1.66 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 13.5/3.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.2/3.8 Hz, 1H, NCH2CHCHaxHeq), 2.14 (td, J = 10.9/2.6 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.31 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.54–2.70 (m, 3H, NCH2CHax, NCH2CH2C≡C , . –2.79 (m, 2H, NCH2CH2C≡C , .  
(dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.07 (dbr, J = 9.1 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.47 
(t, J = .  Hz, H, C≡CCCHCH), 7.50– .  ,  H, C≡CCCHCH, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 
Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.92 (d, J = 8.1 Hz, 1H, N=NCCCHCHCHCH), 7.95–8.01 
(m, 2H, N=NCCHCHCH, C≡CCCHCCH), 8.06 (t, J = .  Hz, H, C≡CCCHC), 8.93 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR 
(101 MHz, CDCl3, 21 °C, TMS): δ = 14.15 (q, 1C, OCH2CH3), 17.62 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 26.75 
(t, 1C, NCH2CHCH2), 41.75 (d, 1C, NCH2CH), 53.31 (t, 1C, NCH2CH2CH2CH), 55.02 (t, 1C, NCH2CH), 57.33 (t, 1C, 
NCH2CH2C≡C , .  t, C, OCH2CH3 , .  s, C, C≡CCCH), 89.28 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH), 123.01 
d, C, C≡CCCHCCH), 123.35 (d, 1C, N=NCCCH , .  s, C, C≡CCCHC), 125.54 (d, 2C, C≡CCCHC, N=NCCHCHCH), 126.43 
(d, 1C, N=NCCCHCHCH), 126.84 (d, 1C, N=NCCCHCH), 127.86 (d, 1C, N=NCCCHCHCHCH , .  d, C, C≡CCCHCH), 
131.26 (s, 1C, N=NCCCH), 131.53 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCH), 134.17 (s, 1C, N=NCCHCHCHC), 
147.46 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHC), 174.04 (s, 1C, C=O) ppm. MS (ESI+) m/z: 440 [M+H]+. HRMS (ESI+): 
[M+H]+ calcd for C28H30O2N3: 440.2338, found 440.2330.  
(R)-Ethyl 1-(4-{3-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate ((R)-m-18b) 
According to GP4 starting from m-16b (136 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 48 h (R)-m-18b was obtained as orange oil (113 mg, 86%); [�]20D = -8.6 (c = 0.1 in CH2Cl2); 
Rf ≈ .  pe ta e/EtOA  = : . IR (NaCl): ṽ = 3054, 2941, 2853, 2809, 2230, 1728, 1598, 1507, 1467, 1444, 1370, 1305, 
1206, 1180, 1152, 1133, 1101, 1033, 896, 804, 772 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 
3H, OCH2CH3), 1.46 (qd, J = 11.8/3.7 Hz, 1H, NCH2CHCHaxHeq), 1.54–1.67 (m, 1H, NCH2CHaxHeqCH2CH), 1.76 (dp, J = 
14.5/3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 2.15 (td, J = 11.0/2.8 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.31 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.55–2.69 (m, 3H, NCH2CHax, NCH2CH2C≡C , . –2.78 (m, 
2H, NCH2CH2C≡C , .  dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.07 (dbr, J = 10.1 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 
Hz, 2H, OCH2CH3), 7.47 (t, J = .  Hz, H, C≡CCCHCH), 7.50– .  , H, C≡CCCHCH, N=NCCHCHCH, N=NCCCHCHCH), 
7.66 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.81 (dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.92 (d, J = 8.1 Hz, 1H, 
N=NCCCHCHCHCH), 7.95–8.01 (m, 2H, N=NCCHCHCH, C≡CCCHCCH), 8.06 (t, J = .  Hz, H, C≡CCCHC), 8.93 (d, J = 8.6 Hz, 
1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 14.18 (q, 1C, OCH2CH3), 17.66 (t, 1C, NCH2CH2C≡C , .  
(t, 1C, NCH2CH2CH2CH), 26.79 (t, 1C, NCH2CHCH2), 41.80 (d, 1C, NCH2CH), 53.36 (t, 1C, NCH2CH2CH2CH), 55.07 (t, 1C, 
NCH2CH), 57.37 (t, 1C, NCH2CH2C≡C , .  t, C, OCH2CH3 , .  s, C, C≡CCCH), 89.32 (s, 1C, C≡CCCH , .  d, C, 
N=NCCHCHCH , .  d, C, C≡CCCHCCH), 123.39 (d, 1C, N=NCCCH , .  s, C, C≡CCCHC), 125.58 (d, 2C, C≡CCCHC, 
N=NCCHCHCH), 126.45 (d, 1C, N=NCCCHCHCH), 126.87 (d, 1C, N=NCCCHCH), 127.89 (d, 1C, N=NCCCHCHCHCH), 128.98 
d, C, C≡CCCHCH), 131.29 (s, 1C, N=NCCCH), 131.54 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCH), 134.22 (s, 1C, 
N=NCCHCHCHC), 147.52 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHC), 174.07 (s, 1C, C=O) ppm. MS (ESI+) m/z: 440 
[M+H]+. HRMS (ESI+): [M+H]+ calcd for C28H30O2N3: 440.2338, found 440.2329.  
Ethyl 1-(4-{4-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate (p-18b) 
According to GP4 starting from p-16b (136 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h p-18b was obtained as orange oil (114 mg, 87%); Rf ≈ .  pe ta e/EtOA  = : . 
IR (NaCl): ṽ = 3050, 2940, 2854, 2808, 2219, 1729, 1595, 1497, 1467, 1444, 1370, 1303, 1217, 1180, 1153, 1099, 1032, 
844, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.47 (qd, J = 11.6/4.0 Hz, 
1H, NCH2CHCHaxHeq), 1.54–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 11.0/3.9 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dq, 
J = 13.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 2.14 (td, J = 10.9/2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.32 (t, J = 10.6 Hz, 1H, 
NCHaxHeqCH), 2.58 (tt, J = 10.6/3.8 Hz, 1H, NCH2CHax), 2.63–2.69 (m, 2H NCH2CH2C≡C , . –2.76 (m, 2H, NCH2CH2C≡C , 
2.82 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.06 (dbr, J = 8.5 Hz, 1H NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 
7.52– .  , H, C≡CCCHCHC, N=NCCHCHCH, N=NCCCHCHCH), 7.64 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 
(dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.91 (d, J = 8.2 Hz, 1H, N=NCCCHCHCHCH), 7.94– .  , H, C≡CCCHCHC, 
N=NCCHCHCH), 8.92 (d, J = 7.9 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.19 (q, 1C, 
OCH2CH3), 17.84 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 26.80 (t, 1C, NCH2CHCH2), 41.83 (d, 1C, NCH2CH), 
53.36 (t, 1C, NCH2CH2CH2CH), 55.09 (t, 1C, NCH2CH), 57.33 (t, 1C, NCH2CH2C≡C , .  t, C, OCH2CH3), 81.25 (s, 1C, 
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C≡CCCH), 91.41 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 123.37 (d, 1C, N=NCCCH), 
125.56 (d, 1C, N=NCCHCHCH), 126.43 (d, 1C, N=NCCCHCHCH), 126.63 (s, 1C, CH2C≡CC), 126.84 (d, 1C, N=NCCCHCH), 
127.89 (d, 1C, N=NCCCHCHCHCH), 131.32 (s, 1C, N=NCCCH), 131.47 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 
134.25 (s, 1C, N=NCCHCHCHC), 147.64 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHCHC), 174.04 (s, 1C, C=O) ppm. MS 
(ESI+) m/z: 440 [M+H]+. HRMS (EI+): M+ calcd for C28H29O2N3: 439.2260, found 439.2269.  
(R)-Ethyl 1-(4-{4-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylate ((R)-p-18b) 
According to GP4 starting from p-16b (136 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h (R)-p-18b was obtained as orange oil (114 mg, 87%); [�]20D = -9.3 (c = 0.1 in CH2Cl2); 
Rf ≈ .  (pentane/EtOAc = 8:2). IR (NaCl): ṽ = 3049, 2940, 2854, 2806, 2212, 1725, 1595, 1495, 1465, 1439, 1367, 1302, 
1216, 1185, 1157, 1100, 1033, 844, 801, 774 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.26 (t, J = 7.1 Hz, 3H, 
OCH2CH3), 1.47 (qd, J = 11.8/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.55–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 10.9/3.9 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.96 (dq, J = 13.0/3.8 Hz, 1H, NCH2CHCHaxHeq), 2.15 (td, J = 10.9/2.7 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.32 (t, J = 10.6 Hz, 1H, NCHaxHeqCH), 2.59 (tt, J = 10.6/3.8 Hz, 1H, NCH2CHax), 2.63–2.68 (m, 2H 
NCH2CH2C≡C , . –2.77 (m, 2H, NCH2CH2C≡C , .  dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.07 (dbr, J = 9.5 Hz, 1H 
NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.52– .  , H, C≡CCCHCHC, N=NCCHCHCH, N=NCCCHCHCH), 7.64 
(ddd, J = 8.3/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.92 (d, J = 8.1 Hz, 1H, 
N=NCCCHCHCHCH), 7.96– .  , H, C≡CCCHCHC, N=NCCHCHCH), 8.92 (d, J = 8.1 Hz, 1H, N=NCCCH) ppm. 13C NMR 
(126 MHz, CDCl3, 21 °C, TMS): δ = 14.18 (q, 1C, OCH2CH3), 17.83 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 26.79 
(t, 1C, NCH2CHCH2), 41.83 (d, 1C, NCH2CH), 53.35 (t, 1C, NCH2CH2CH2CH), 55.09 (t, 1C, NCH2CH), 57.32 (t, 1C, 
NCH2CH2C≡C , .  t, C, OCH2CH3 , .  s, C, C≡CCCH), 91.41 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH), 123.06 
d, C, C≡CCCHCHC), 123.37 (d, 1C, N=NCCCH), 125.56 (d, 1C, N=NCCHCHCH), 126.43 (d, 1C, N=NCCCHCHCH), 126.63 (s, 
1C, CH2C≡CC), 126.83 (d, 1C, N=NCCCHCH), 127.89 (d, 1C, N=NCCCHCHCHCH), 131.32 (s, 1C, N=NCCCH), 131.46 (d, 1C, 
N=NCCHCHCH , .  d, C, C≡CCCHCHC), 134.25 (s, 1C, N=NCCHCHCHC), 147.64 (s, 1C, N=NCCHCHCH), 151.94 (s, 1C, 
C≡CCCHCHC), 174.04 (s, 1C, C=O) ppm. MS (ESI+) m/z: 440 [M+H]+. HRMS (EI+): M+ calcd for C28H29O2N3: 439.2260, found 
439.2247. 
Ethyl 1-(5-{3-[(E)-phenylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylate (m-19a) 
According to GP4 starting from m-17a (125 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h m-19a was obtained as orange oil (111 mg, 92%); Rf ≈ .  pe ta e/EtOAc = 8:2). IR 
(NaCl): ṽ = 3061, 2925, 2852, 2807, 2228, 1729, 1596, 1468, 1446, 1371, 1305, 1177, 1151, 1132, 1104, 1029, 896, 795, 
766, 690 vor cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.42–1.52 (m, 1H, 
NCH2CHCHaxHeq), 1.53–1.63 (m, 1H, NCH2CHaxHeqCH2CH), 1.73 (dp, J = 11.1/4.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.81 (p, J = 
7.1 Hz, 2H, NCH2CH2CH2C≡C), 1.93 (dq, J = 13.0/4.0 Hz, 1H, NCH2CHCHaxHeq), 2.03 (t, J = 9.7 Hz, 1H, NCHaxHeqCH2CH2CH), 
2.21 (t, J = 10.2 Hz, 1H, NCHaxHeqCH), 2.45–2.53 (m, 4H, NCH2CH2CH2C≡C, NCH2CH2CH2C≡C), 2.57 (tt, J = 10.4/3.8 Hz, 1H, 
NCH2CHax), 2.77 (dbr, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J = 10.1 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 7.43 (t, J = 7.7 Hz, 1H, C≡CCCHCH), 7.45–7.54 (m, 4H, N=NCCHCHCH, N=NCCHCHCH, C≡CCCHCH), 7.83 (ddd, 
J = 7.9/1.9/1.3 Hz, 1H, C≡CCCHCCH), 7.90–7.93 (m, 2H, N=NCCHCHCH), 7.95 (t, J = 1.7 Hz, 1H, C≡CCCHC) ppm. 13C NMR 
(126 MHz, CDCl3, 21 °C, TMS): δ = 14.17 (q, 1C, OCH2CH3), 17.34 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 
25.98 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CHCH2), 41.84 (d, 1C, NCH2CH), 53.83 (t, 1C, NCH2CH2CH2CH), 55.45 (t, 
1C, NCH2CH), 57.64 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, OCH2CH3), 80.08 (s, 1C, CH2C≡C), 90.80 (s, 1C, CH2C≡C , 122.27 
(d, 1C, C≡CCCHCCH), 122.85 (d, 2C, N=NCCHCHCH), 124.90 (s, 1C, C≡CCCHC), 125.57 (d, 1C, C≡CCCHC), 128.87 (d, 1C, 
C≡CCCHCH), 129.02 (d, 2C, N=NCCHCHCH), 131.11 (d, 1C, N=NCCHCHCH), 133.72 (d, 1C, C≡CCCHCH), 152.36 (d, 2C, 
N=NC), 174.17 (s, 1C, C=O) ppm. MS (ESI+) m/z: 404 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C25H30O2N3: 404.2338, found 
404.2331.  
Ethyl 1-(5-{4-[(E)-phenylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylate (p-19a) 
According to GP4 starting from p-17a (125 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 48 h p-19a was obtained as orange oil (113 mg, 93%); Rf ≈ .  pe ta e/EtOAc = 8:2). IR 
(NaCl): ṽ = 3062, 2942, 2866, 2807, 2770, 2224, 1730, 1597, 1496, 1467, 1443, 1371, 1301, 1220, 1178, 1152, 1101, 
1029, 846, 767, 678 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.47 (qd, J = 
12.2/3.4 Hz, 1H, NCH2CHCHaxHeq), 1.52–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.74 (dp, J = 10.9/4.1/3.6 Hz, 2H, 
NCH2CHaxHeqCH2CH), 1.82 (p, J = 7.2 Hz, 2H, NCH2CH2CH2C≡C , .  d , J = 12.5/3.5 Hz, 1H, NCH2CHCHaxHeq), 2.03 (td, J 
= 11.0/1.9 Hz, 1H, NCHaxHeqCH2CH2CH), 2.20 (t, J = 11.0 Hz, 1H, NCHaxHeqCH), 2.46–2.53 (m, 4H, NCH2CH2CH2C≡C, 
NCH2CH2CH2C≡C , .  tt, J = 10.4/3.8 Hz, 1H, NCH2CHax), 2.78 (dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 2.99 (dbr, J = 
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10.7 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.44–7.54 (m, 5H, N=NCCHCHCH, N=NCCHCHCH, 
C≡CCCHCHC), 7.86 (d, J = 8.5 Hz, 2H, C≡CCCHCHC), 7.89–7.93 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (101 MHz, CDCl3, 21 
°C, TMS): δ = 14.19 (q, 1C, OCH2CH3), 17.51 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 25.96 (t, 1C, 
NCH2CH2CH2C≡C , .  (t, 1C, NCH2CHCH2), 41.85 (d, 1C, NCH2CH), 53.85 (t, 1C, NCH2CH2CH2CH), 55.45 (t, 1C, NCH2CH), 
57.67 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, OCH2CH3), 80.64 (s, 1C, CH2C≡C), 92.83 (s, 1C, CH2C≡C , .  (d, 4C, 
C≡CCCHCHC, N=NCCHCHCH), 126.75 (s, 1C, CH2C≡CC), 129.05 (d, 2C, N=NCCHCHCH), 131.06 (d, 1C, N=NCCHCHCH), 
132.26 (d, 2C, C≡CCCHCHC), 151.31 (s, 1C, C≡CCCHCHC), 152.55 (s, 1C, N=NCCHCHCH), 174.22 (s, 1C, C=O) ppm. MS 
(ESI+) m/z: 404 [M+H]+. HRMS (EI+): M+ calcd for C25H29O2N3: 403.2260, found 403.2257.  
Ethyl 1-(5-{3-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylate (m-19b) 
According to GP4 starting from m-17b (140 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 48 h m-19b was obtained as orange oil (124 mg, 91%); Rf ≈ . 5 (pentane/EtOAc = 8:2). 
IR (NaCl): ṽ = 3054, 2941, 2807, 2770, 2229, 1729, 1596, 1507, 1467, 1444, 1371, 1344, 1306, 1204, 1178, 1151, 1105, 
1030, 896, 805, 772 cm-1. 1H NMR (400 MHz, CDCl3, 21 °C, TMS): δ = 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.47 (qd, J = 
12.3/4.1 Hz, 1H, NCH2CHCHaxHeq), 1.53–1.66 (m, 1H, NCH2CHaxHeqCH2CH), 1.74 (dp, J = 13.1/3.7 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.84 (p, J = 7.2 Hz, 2H, NCH2CH2CH2C≡C), 1.93 (dq, J = 12.8/3.8 Hz, 1H, NCH2CHCHaxHeq), 2.04 (td, J 
= 11.3/2.4 Hz, 1H, NCHaxHeqCH2CH2CH), 2.21 (t, J = 10.4 Hz, 1H, NCHaxHeqCH), 2.47–2.54 (m, 4H, NCH2CH2CH2C≡C, 
NCH2CH2CH2C≡C), 2.58 (tt, J = 10.5/3.9 Hz, 1H, NCH2CHax), 2.79 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH2CH2CH), 3.01 (dbr, J = 
10.5 Hz, 1H, NCHaxHeqCH), 4.13 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.47 (t, J = 7.7 Hz, 1H, C≡CCCHCH), 7.50–7.60 (m, 3H, 
C≡CCCHCH, N=NCCHCHCH, N=NCCCHCHCH), 7.65 (ddd, J = 8.4/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.5/1.1 Hz, 
1H, N=NCCHCHCH), 7.92 (d, J = 8.1 Hz, 1H, N=NCCCHCHCHCH), 7.94–8.00 (m, 2H, N=NCCHCHCH, C≡CCCHCCH), 8.06 (t, 
J = 1.6 Hz, 1H, C≡CCCHC), 8.93 (d, J = 8.5 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, CDCl3, 21 °C, TMS): δ = 14.17 (q, 
1C, OCH2CH3), 17.38 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 25.96 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, 
NCH2CHCH2), 41.81 (d, 1C, NCH2CH), 53.84 (t, 1C, NCH2CH2CH2CH), 55.42 (t, 1C, NCH2CH), 57.68 (t, 1C, NCH2CH2CH2C≡C , 
60.25 (t, 1C, OCH2CH3), 80.15 (s, 1C, C≡CCCH), 90.85 (s, 1C, C≡CCCH , .  (d, 1C, N=NCCHCHCH), 122.86 (d, 1C, 
C≡CCCHCCH), 123.38 (d, 1C, N=NCCCH), 124.93 (s, 1C, C≡CCCHC), 125.56 (d, 2C, C≡CCCHC, N=NCCHCHCH), 126.43 (d, 
1C, N=NCCCHCHCH), 126.85 (d, 1C, N=NCCCHCH), 127.87 (d, 1C, N=NCCCHCHCHCH), 128.96 (d, 1C, C≡CCCHCH), 131.27 
(s, 1C, N=NCCCH), 131.51 (d, 1C, N=NCCHCHCH), 133.84 (d, 1C, C≡CCCHCH), 134.19 (s, 1C, N=NCCHCHCHC), 147.51 (s, 
1C, N=NCCHCHCH), 152.80 (s, 1C, C≡CCCHC), 174.19 (s, 1C, C=O) ppm. MS (ESI+) m/z: 454 [M+H]+. HRMS (ESI+): [M+H]+ 
calcd for C29H32O2N3: 454.2495, found 454.2485.  
Ethyl 1-(5-{4-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylate (p-19b) 
According to GP4 starting from p-17b (140 mg, 0.300 mmol), nipecotic acid ethyl ester (142 mg, 0.900 mmol), acetone 
(0.3 mL) and a reaction time of 72 h p-19b was obtained as orange oil (122 mg, 90%); Rf ≈ . 5 (pentane/EtOAc = 8:2). 
IR (NaCl): ṽ = 3051, 2942, 2807, 2770, 2223, 1730, 1596, 1497, 1467, 1445, 1371, 1303, 1217, 1178, 1152, 1101, 1030, 
1012, 845, 802, 772 cm-1. 1H NMR (500 MHz, CDCl3, 21 °C, TMS): δ = 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.48 (qd, J = 
11.9/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.53–1.65 (m, 1H, NCH2CHaxHeqCH2CH), 1.74 (dp, J = 11.2/4.0 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.83 (p, J = 7.1 Hz, 2H, NCH2CH2CH2C≡C , .  d , J = 13.0/3.8 Hz, 1H, NCH2CHCHaxHeq), 2.05 (td, J 
= 10.8/2.1 Hz, 1H, NCHaxHeqCH2CH2CH), 2.22 (t, J = 10.7 Hz, 1H, NCHaxHeqCH), 2.47–2.55 (m, 4H, NCH2CH2CH2C≡C, 
NCH2CH2CH2C≡C , .  tt, J = 10.4/3.8 Hz, 1H, NCH2CHax), 2.78 (dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.00 (dbr, J = 
10.1 Hz, 1H, NCHaxHeqCH), 4.14 (q, J = 7.1 Hz, 2H, OCH2CH3), 7.52–7.61 (m, 4H, C≡CCCHCHC, N=NCCHCHCH, 
N=NCCCHCHCH), 7.65 (ddd, J = 8.3/6.8/1.3 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.92 (d, J 
= 8.1 Hz, 1H, N=NCCCHCHCHCH), 7.95–8.01 (m, 3H, C≡CCCHCHC, N=NCCHCHCH), 8.92 (d, J = 8.4 Hz, 1H, N=NCCCH) ppm. 
13C NMR (126 MHz, CDCl3, 21 °C, TMS): δ = 14.21 (q, 1C, OCH2CH3), 17.56 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, 
NCH2CH2CH2CH), 26.01 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CHCH2), 41.90 (d, 1C, NCH2CH), 53.88 (t, 1C, 
NCH2CH2CH2CH), 55.50 (t, 1C, NCH2CH), 57.70 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, OCH2CH3), 80.73 (s, 1C, C≡CCCH), 
93.02 (s, 1C, C≡CCCH , .  (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC, CH2C≡CC), 123.40 (d, 1C, N=NCCCH), 
125.59 (d, 1C, N=NCCHCHCH), 126.45 (d, 1C, N=NCCCHCHCH), 126.83 (d, 1C, N=NCCCHCH), 127.91 (d, 1C, 
N=NCCCHCHCHCH), 131.34 (s, 1C, N=NCCCH), 131.46 (d, 1C, N=NCCHCHCH), 132.35 (d, 2C, C≡CCCHCHC), 134.28 (s, 1C, 
N=NCCHCHCHC), 147.69 (s, 1C, N=NCCHCHCH), 151.91 (s, 1C, C≡CCCHCHC), 174.22 (s, 1C, C=O) ppm. MS (ESI+) m/z: 454 
[M+H]+. HRMS (EI+): M+ calcd for C29H31O2N3: 453.2416, found 453.2403.  
1-(4-{3-[(E)-Phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid (m-20a) 
According to GP5 starting from m-18a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-20a was obtained as 
orange amorphous solid (68 mg, 94%). IR (KBr): ṽ = 3433, 3060, 2942, 2861, 2522, 2233, 1713, 1595, 1469, 1447, 1392, 
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1306, 1200, 1152, 1071, 1019, 999, 924, 898, 797, 767, 690 cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, 
CH3OH): δ = 1.32 (qd, J = 12.7/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.57 (qt, J = 13.3/4.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.71 (dbr, 
J = 13.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.91–2.06 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.11 (t, J = 11.4 Hz, 1H, 
NCHaxHeqCH), 2.37 (tt, J = 11.9/3.7 Hz, 1H, NCH2CHax), 2.58–2.73 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C), 2.92 (dbr, J = 10.7 
Hz, 1H, NCHaxHeqCH2CH2CH), 3.10 (dbr, J = 10.2 Hz, 1H, NCHaxHeqCH), 7.42–7.49 (m, 2H, C≡CCCHCH, C≡CCCHCH), 7.49–
7.56 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.73–7.80 (m, 2H, C≡CCCHC, C≡CCCHCCH), 7.80–7.87 (m, 2H, 
N=NCCHCHCH) ppm. 13C NMR (126 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 17.50 (t, 1C, NCH2CH2C≡C , .  
(t, 1C, NCH2CH2CH2CH), 29.04 (t, 1C, NCH2CHCH2), 46.07 (d, 1C, NCH2CH), 54.16 (t, 1C, NCH2CH2CH2CH), 57.41 (t, 1C, 
NCH2CH), 58.23 (t, 1C, NCH2CH2C≡C , 81.49 (s, 1C, C≡CCCH), 90.16 (s, 1C, C≡CCCH , 123.37 (d, 1C, C≡CCCHC), 123.73 (d, 
2C, N=NCCHCHCH), 125.85 (s, 1C, C≡CCCHC), 126.09 (d, 1C, C≡CCCHCH), 130.39 (d, 2C, N=NCCHCHCH), 130.48 (d, 1C, 
C≡CCCHCH), 132.79 (s, 1C, C≡CCCHCHC), 135.00 (d, 1C, C≡CCCHCCH), 153.42 (d, 2C, N=NC), 183.06 (s, 1C, C=O) ppm. MS 
(ESI+) m/z: 362 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C22H24O2N3: 362.1869, found 362.1860.  
(R)-1-(4-{3-[(E)-Phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid ((R)-m-20a) 
According to GP5 starting from (R)-m-18a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) (R)-m-20a was 
obtained as orange amorphous solid (68 mg, 94%); [�]20D = +20.4 (c = 0.1 in CH2Cl2). IR (KBr): ṽ = 3425, 3060, 2939, 2864, 
2526, 2235, 1714, 1594, 1469, 1447, 1392, 1306, 1202, 1151, 1071, 1017, 1000, 924, 898, 798, 767, 691 cm-1. 1H NMR 
(400 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 1.35 (qd, J = 13.1/4.2 Hz, 1H, NCH2CHCHaxHeq), 1.60 (qt, J = 12.5/4.0 
Hz, 1H, NCH2CHaxHeqCH2CH), 1.73 (dbr, J = 13.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.94–2.09 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH2CH2CH), 2.13 (t, J = 11.3 Hz, 1H, NCHaxHeqCH), 2.39 (tt, J = 11.8/3.7 Hz, 1H, NCH2CHax), 2.64–2.74 (m, 4H, 
NCH2CH2C≡C, NCH2CH2C≡C , 2.95 (dbr, J = 10.7 Hz, 1H, NCHaxHeqCH2CH2CH), 3.10 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH), 7.46–
.  , H, C≡CCCHCH, C≡CCCHCH), 7.52–7.59 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.78– .  , H, C≡CCCHC, 
C≡CCCHCCH), 7.85–7.91 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (101 MHz, CD3OD + 5 eq 1N NaOD, 25 °C, CH3OH): δ = 
17.69 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 29.24 (t, 1C, NCH2CHCH2), 46.24 (d, 1C, NCH2CH), 54.46 (t, 1C, 
NCH2CH2CH2CH), 57.67 (t, 1C, NCH2CH), 58.49 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 90.09 (s, 1C, C≡CCCH , .  
d, C, C≡CCCHC), 123.82 (d, 2C, N=NCCHCHCH , .  s, C, C≡CCCHC , .  d, C, C≡CCCHCH), 130.38 (d, 2C, 
N=NCCHCHCH , .  d, C, C≡CCCHCH , .  s, C, C≡CCCHCHC , .  d, C, C≡CCCHCCH), 153.66 (d, 2C, 
N=NC), 182.82 (s, 1C, C=O) ppm. MS (ESI+) m/z: 362 [M+H]+. HRMS (ESI+): [M+H]+ calcd for C22H24O2N3: 362.1869, found 
362.1858.  
1-(4-{4-[(E)-Phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid (p-20a) 
According to GP5 starting from p-18a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-20a was obtained as 
orange amorphous solid (65 mg, 91%). IR (KBr): ṽ = 3478, 3395, 3060, 2930, 2533, 1711, 1601, 1461, 1430, 1397, 1301, 
1290, 1219, 1153, 1123, 1108, 1054, 972, 921, 870, 847, 798, 768, 688 cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 
21 °C, CH3OH): δ = 1.34 (qd, J = 13.0/4.1 Hz, 1H, NCH2CHCHaxHeq), 1.58 (qt, J = 12.5/4.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.72 
(dbr, J = 13.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.97 (dbr, J = 12.7 Hz, 1H, NCH2CHCHaxHeq), 2.04 (td, J = 11.8/2.4 Hz, 1H, 
NCHaxHeqCH2CH2CH), 2.13 (t, J = 11.4 Hz, 1H, NCHaxHeqCH), 2.38 (tt, J = 12.3/3.6 Hz, 1H, NCH2CHax), 2.62–2.77 (m, 4H, 
NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.13 (dbr, J = 10.8 Hz, 1H, NCHaxHeqCH), 7.46–
.  , H, C≡CCCHCHC, N=NCCHCHCH, N=NCCHCHCH), 7.77– .  , H, C≡CCCHCHC), 7.83–7.88 (m, 2H, 
N=NCCHCHCH) ppm. 13C NMR (126 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 17.73 (t, 1C, NCH2CH2C≡C , .  
(t, 1C, NCH2CH2CH2CH), 29.12 (t, 1C, NCH2CHCH2), 46.16 (d, 1C, NCH2CH), 54.31 (t, 1C, NCH2CH2CH2CH), 57.54 (t, 1C, 
NCH2CH), 58.29 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 92.15 (s, 1C, C≡CCCH , .  d, C, C≡CCCHCHC, 
N=NCCHCHCH), 127.94 (s, 1C, CH2C≡CC), 130.38 (d, 2C, N=NCCHCHCH), 132.66 (d, 1C, N=NCCHCHCH), 133.43 (d, 2C, 
C≡CCCHCHC , .  s, C, C≡CCCHCHC), 153.71 (s, 1C, N=NCCHCHCH), 182.96 (s, 1C, C=O) ppm. MS (ESI+) m/z: 362 
[M+H]+. HRMS (EI+): M+ calcd for C22H23O2N3: 361.1790, found 361.1786.  
(R)-1-(4-{4-[(E)-Phenylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid ((R)-p-20a) 
According to GP5 starting from (R)-p-18a (78 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) (R)-p-20a was obtained 
as orange amorphous solid (65 mg, 91%); [�]20D = +21.5 (c = 0.1 in CH2Cl2). IR (KBr): ṽ = 3422, 3061, 2927, 2852, 2230, 
1702, 1596, 1467, 1440, 1374, 1333, 1299, 1220, 1153, 1099, 1071, 928, 843, 770, 726, 688 cm-1. 1H NMR (500 MHz, 
CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 1.30 (qd, J = 13.0/4.1 Hz, 1H, NCH2CHCHaxHeq), 1.54 (qt, J = 12.1/3.8 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.70 (dbr, J = 13.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.95 (dbr, J = 12.7 Hz, 1H, NCH2CHCHaxHeq), 2.00 (td, 
J = 12.1/2.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.13 (t, J = 11.4 Hz, 1H, NCHaxHeqCH), 2.35 (tt, J = 12.0/3.7 Hz, 1H, NCH2CHax), 
2.57–2.68 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J = 11.2 Hz, 1H, NCHaxHeqCH2CH2CH), 3.08 (dbr, J = 11.5 Hz, 1H, 
NCHaxHeqCH), 7.41– .  , H, C≡CCCHCHC), 7.49–7.53 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.69–7.72 (m, 2H, 
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C≡CCCHCHC), 7.77–7.81 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (126 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 
17.46 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 28.88 (t, 1C, NCH2CHCH2), 46.16 (d, 1C, NCH2CH), 53.91 (t, 1C, 
NCH2CH2CH2CH), 57.14 (t, 1C, NCH2CH), 57.89 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 92.25 (s, 1C, C≡CCCH , .  
d, C, C≡CCCHCHC, N=NCCHCHCH), 127.66 (s, 1C, CH2C≡CC), 130.38 (d, 2C, N=NCCHCHCH), 132.73 (d, 1C, 
N=NCCHCHCH , .  d, C, C≡CCCHCHC), 152.26 (s, C, C≡CCCHCHC), 153.36 (s, 1C, N=NCCHCHCH), 183.17 (s, 1C, 
C=O) ppm. MS (ESI+) m/z: 362 [M+H]+. HRMS (EI+): M+ calcd for C22H23O2N3: 361.1790, found 361.1792.  
1-(4-{3-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid (m-20b) 
According to GP5 starting from m-18b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-20b was obtained as 
orange amorphous solid (75 mg, 91%). IR (KBr): ṽ = 3427, 3053, 2939, 2857, 2807, 2231, 1709, 1596, 1507, 1478, 1467, 
1448, 1387, 1344, 1307, 1204, 1155, 1101, 1013, 896, 804, 771, 685 cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 
21 °C, CH3OH): δ = 1.38 (qd, J = 12.8/4.1 Hz, 1H, NCH2CHCHaxHeq), 1.63 (qt, J = 13.2/3.8 Hz, 1H, NCH2CHaxHeqCH2CH), 1.76 
(dp, J = 13.3/3.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.98–2.10 (m, 2H, NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.17 (t, J = 11.4 
Hz, 1H, NCHaxHeqCH), 2.43 (tt, J = 12.0/3.8 Hz, 1H, NCH2CHax), 2.64–2.78 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J 
= 10.7 Hz, 1H, NCHaxHeqCH2CH2CH), 3.17 (dbr, J = 10.8 Hz, 1H, NCHaxHeqCH), 7.51– .  , H, C≡CCCHCH, C≡CCCHCH), 
7.59 (t, J = 7.8 Hz, 1H, N=NCCHCHCH), 7.62 (ddd, J = 8.4/6.8/1.4 Hz, 1H, N=NCCCHCHCH), 7.66 (ddd, J = 8.4/6.8/1.4 Hz, 
1H, N=NCCCHCH), 7.75 (dd, J = 7.5/1.0 Hz, 1H, N=NCCHCHCH), 7.89– .  , H, C≡CCCHC, C≡CCCHCCH), 7.98 (d, J = 
7.9 Hz, 1H, N=NCCCHCHCHCH), 8.06 (d, J = 8.2 Hz, 1H, N=NCCHCHCH), 8.80 (dd, J = 8.3/0.7 Hz, 1H, N=NCCCH) ppm. 13C 
NMR (126 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 17.61 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 
29.13 (t, 1C, NCH2CHCH2), 46.15 (d, 1C, NCH2CH), 54.29 (t, 1C, NCH2CH2CH2CH), 57.56 (t, 1C, NCH2CH), 58.34 (t, 1C, 
NCH2CH2C≡C , .  s, C, C≡CCCH), 90.19 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH , .  d, C, C≡CCCHCCH), 
.  s, C, C≡CCCHC), 126.15 (d, 1C, N=NCCCH), 126.63 (d, 2C, N=NCCHCHCH, N=NCCCH), 127.73 (d, 1C, 
N=NCCCHCHCH), 128.21 (d, 1C, N=NCCCHCH), 129.10 (d, 1C, N=NCCCHCHCHCH , .  d, C, C≡CCCHCH), 132.33 (s, 
1C, N=NCCCH), 132.99 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCH), 135.65 (s, 1C, N=NCCHCHCHC), 148.45 (s, 1C, 
N=NCCHCHCH , .  s, C, C≡CCCHC), 182.96 (s, 1C, C=O) ppm. MS (ESI+) m/z: 412 [M+H]+. HRMS (EI+): M+ calcd for 
C26H25O2N3: 411.1947, found 411.1952.  
(R)-1-(4-{3-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid ((R)-m-20b) 
According to GP5 starting from (R)-m-18b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) (R)-m-20b was 
obtained as orange amorphous solid (75 mg, 91%) ; [�]20D = +18.6 (c = 0.1 in CH2Cl2). IR (KBr): ṽ = 3427, 3051, 2937, 
2855, 2807, 2230, 1709, 1589, 1507, 1478, 1467, 1447, 1387, 1344, 1305, 1203, 1154, 1102, 1012, 896, 804, 771, 685 
cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 1.38 (qd, J = 12.8/3.9 Hz, 1H, NCH2CHCHaxHeq), 1.62
(qt, J = 12.9/3.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.75 (dp, J = 13.3/3.3 Hz, 1H, NCH2CHaxHeqCH2CH), 1.97–2.09 (m, 2H,
NCH2CHCHaxHeq, NCHaxHeqCH2CH2CH), 2.16 (t, J = 11.4 Hz, 1H, NCHaxHeqCH), 2.43 (tt, J = 11.9/3.7 Hz, 1H, NCH2CHax), 2.65–
2.75 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J = 10.9 Hz, 1H, NCHaxHeqCH2CH2CH), 3.17 (dbr, J = 11.0 Hz, 1H,
NCHaxHeqCH), 7.48– .  , H, C≡CCCHCH, C≡CCCHCH), 7.59 (t, J = 7.8 Hz, 1H, N=NCCHCHCH), 7.62 (ddd, J = 8.4/6.8/1.4
Hz, 1H, N=NCCCHCHCH), 7.66 (ddd, J = 8.4/6.8/1.4 Hz, 1H, N=NCCCHCH), 7.72 (dd, J = 7.5/0.9 Hz, 1H, N=NCCHCHCH),
7.87– .  , H, C≡CCCHC, C≡CCCHCCH), 7.96 (d, J = 7.8 Hz, 1H, N=NCCCHCHCHCH), 8.04 (d, J = 8.1 Hz, 1H,
N=NCCHCHCH), 8.78 (dd, J = 8.2/0.7 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH):
δ = 17.59 (t, 1C, NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 29.11 (t, 1C, NCH2CHCH2), 46.13 (d, 1C, NCH2CH), 54.25 (t,
1C, NCH2CH2CH2CH), 57.53 (t, 1C, NCH2CH), 58.31 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 90.18 (s, 1C, C≡CCCH ,
112.86 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCCH , .  s, C, C≡CCCHC), 126.15 (d, 1C, N=NCCCH), 126.61
(d, 2C, N=NCCHCHCH, N=NCCCH), 127.71 (d, 1C, N=NCCCHCHCH), 128.18 (d, 1C, N=NCCCHCH), 129.09 (d, 1C,
N=NCCCHCHCHCH , .  d, C, C≡CCCHCH), 132.30 (s, 1C, N=NCCCH), 132.98 (d, 1C, N=NCCHCHCH), 135.02 (d, 1C,
C≡CCCHCH), 135.61 (s, 1C, N=NCCHCHCHC), 148.40 (s, 1C, N=NCCHCHCH , .  s, C, C≡CCCHC), 182.97 (s, 1C, C=O)
ppm. MS (ESI+) m/z: 412 [M+H]+. HRMS (EI+): M+ calcd for C26H25O2N3: 411.1947, found 411.1949.
1-(4-{4-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid (p-20b) 
According to GP5 starting from p-18b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-20b was obtained as 
orange amorphous solid (74 mg, 90%). IR (KBr): ṽ = 3431, 3050, 2941, 2859, 2224, 1708, 1596, 1507, 1497, 1450, 1388, 
1345, 1303, 1218, 1191, 1156, 1143, 1099, 1011, 843, 803, 773 cm-1. 1H NMR (400 MHz, DMSO-d6, 60 °C, DMSO): δ = 
1.38 (qbr, J = 12.0 Hz, 1H, NCH2CHCHaxHeq), 1.49 (qbr, J = 11.5 Hz, 1H, NCH2CHaxHeqCH2CH), 1.67 (dbr, J = 12.4 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.82 (dbr, J = 11.2 Hz, 1H, NCH2CHCHaxHeq), 2.14 (tbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.27 (tbr, 
J = 10.8 Hz, 1H, NCHaxHeqCH), 2.45 (tbr, J = 10.6 Hz, 1H, NCH2CHax), 2.60–2.70 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C , .  
(dbr, J = 10.8 Hz, 1H, NCHaxHeqCH2CH2CH), 2.96 (dbr, J = 11.1 Hz, 1H, NCHaxHeqCH), 7.65 (d, J = .  Hz, H, C≡CCCHCHC), 
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7.67–7.71 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.75 (t, J = 7.5 Hz, 1H, N=NCCCHCH), 7.83 (d, J = 7.5 Hz, 1H, 
N=NCCHCHCH), 8.04 (d, J = .  Hz, H, C≡CCCHCHC), 8.10 (d, J = 8.2 Hz, 1H, N=NCCCHCHCHCH), 8.19 (d, J = 8.0 Hz, 1H, 
N=NCCHCHCH), 8.89 (d, J = 8.4 Hz, 1H, N=NCCCH) ppm. 13C NMR (101 MHz, DMSO-d6, 60 °C, DMSO): δ = 17.65 (t, 1C, 
NCH2CH2C≡C , .  t, C, NCH2CH2CH2CH), 27.03 (t, 1C, NCH2CHCH2), 41.61 (d, 1C, NCH2CH), 53.14 (t, 1C, 
NCH2CH2CH2CH), 55.45 (t, 1C, NCH2CH), 57.09 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 93.32 (s, 1C, C≡CCCH , .  
(d, 1C, N=NCCHCHCH), 123.27 (d, 1C, N=NCCCH , .  d, C, C≡CCCHCHC), 126.34 (d, 1C, N=NCCHCHCH), 126.87 (s, 
1C, CH2C≡CC), 127.31 (d, 1C, N=NCCCHCHCH), 127.93 (d, 1C, N=NCCCHCH), 128.65 (d, 1C, N=NCCCHCHCHCH), 131.07 (s, 
1C, N=NCCCH), 132.50 (d, 1C, N=NCCHCHCH , .  d, C, C≡CCCHCHC), 134.46 (s, 1C, N=NCCHCHCHC), 147.20 (s, 1C, 
N=NCCHCHCH , .  s, C, C≡CCCHCHC), 175.57 (s, 1C, C=O) ppm. MS (ESI+) m/z: 411 [M]+. HRMS (EI+): M+ calcd for 
C26H25O2N3: 411.1947, found 411.1925.  
(R)-1-(4-{4-[(E)-1-naphthylazo]phenyl}but-3-yn-1-yl)piperidine-3-carboxylic acid ((R)-p-20b) 
According to GP5 starting from (R)-p-18b (88 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) (R)-p-20b was obtained 
as orange amorphous solid (74 mg, 90%); [�]20D = +17.8 (c = 0.1 in CH2Cl2). IR (KBr): ṽ = 3426, 3051, 2943, 2863, 2226, 
1708, 1596, 1507, 1498, 1450, 1388, 1345, 1303, 1218, 1191, 1156, 1143, 1099, 1011, 843, 803, 775 cm-1. 1H NMR (500 
MHz, DMSO-d6, 60 °C, DMSO): δ = 1.36 (qd, J = 11.8/3.5 Hz, 1H, NCH2CHCHaxHeq), 1.47 (qt, J = 12.0/3.6 Hz, 1H, 
NCH2CHaxHeqCH2CH), 1.65 (dp, J = 12.2/3.6 Hz, 1H, NCH2CHaxHeqCH2CH), 1.80 (dq, J = 12.7/3.8 Hz, 1H, NCH2CHCHaxHeq), 
2.13 (tbr, J = 9.7 Hz, 1H, NCHaxHeqCH2CH2CH), 2.26 (tbr, J = 10.1 Hz, 1H, NCHaxHeqCH), 2.43 (tt, J = 10.8/3.7 Hz, 1H, 
NCH2CHax), 2.63–2.67 (m, 4H, NCH2CH2C≡C, NCH2CH2C≡C , .  dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 2.95 (dbr, J = 
9.5 Hz, 1H, NCHaxHeqCH), 7.63 (d, J = .  Hz, H, C≡CCCHCHC), 7.65–7.70 (m, 2H, N=NCCHCHCH, N=NCCCHCHCH), 7.73 
(ddd, J = 8.3/6.8/1.2 Hz, 1H, N=NCCCHCH), 7.82 (dd, J = 7.6/0.8 Hz, 1H, N=NCCHCHCH), 8.02 (d, J = 8.5 Hz, 2H, 
C≡CCCHCHC), 8.08 (d, J = 8.1 Hz, 1H, N=NCCCHCHCHCH), 8.17 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.87 (d, J = 8.4 Hz, 1H, 
N=NCCCH) ppm. 13C NMR (126 MHz, DMSO-d6, 60 °C, DMSO): δ = 17.62 (t, 1C, NCH2CH2C≡C , .  t, C, 
NCH2CH2CH2CH), 26.99 (t, 1C, NCH2CHCH2), 41.56 (d, 1C, NCH2CH), 53.12 (t, 1C, NCH2CH2CH2CH), 55.39 (t, 1C, NCH2CH), 
57.05 (t, 1C, NCH2CH2C≡C , .  s, C, C≡CCCH), 93.28 (s, 1C, C≡CCCH , .  d, C, N=NCCHCHCH), 123.28 (d, 1C, 
N=NCCCH , .  d, C, C≡CCCHCHC), 126.35 (d, 1C, N=NCCHCHCH), 126.87 (s, 1C, CH2C≡CC), 127.32 (d, 1C, 
N=NCCCHCHCH), 127.94 (d, 1C, N=NCCCHCH), 128.67 (d, 1C, N=NCCCHCHCHCH), 131.08 (s, 1C, N=NCCCH), 132.52 (d, 
1C, N=NCCHCHCH), 132.97 d, C, C≡CCCHCHC), 134.47 (s, 1C, N=NCCHCHCHC), 147.20 (s, 1C, N=NCCHCHCH), 151.89 
s, C, C≡CCCHCHC), 175.56 (s, 1C, C=O) ppm. MS (ESI+) m/z: 411 [M]+. HRMS (EI+): M+ calcd for C26H25O2N3: 411.1947, 
found 411.1934.  
1-(5-{3-[(E)-phenylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylic acid (m-21a) 
According to GP5 starting from m-19a (81 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-21a was obtained as 
orange amorphous solid (67 mg, 89%). IR (KBr): ṽ = 3428, 3061, 2941, 2862, 2804, 2481 2230, 1711, 1595, 1469, 1446, 
1389, 1339, 1307, 1202, 1152, 1071, 1019, 999, 926, 897, 797, 767, 691 cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 
21 °C, CH3OH): δ = 1.32 (qd, J = 12.7/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.56 (qt, J = 13.3/4.0 Hz, 1H, NCH2CHaxHeqCH2CH), 1.71 
(dbr, J = 13.7 Hz, 1H, NCH2CHaxHeqCH2CH), 1.74–1.86 (m, 2H, NCH2CH2CH2C≡C , . –1.99 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH2CH2CH), 2.02 (t, J = 11.4 Hz, 1H, NCHaxHeqCH), 2.36 (tt, J = 11.9/3.6 Hz, 1H, NCH2CHax), 2.44 (t, J = 7.1 Hz, 2H, 
NCH2CH2CH2C≡C), 2.47–2.54 (m, 2H, NCH2CH2CH2C≡C , 2.90 (dbr, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.11 (dbr, J = 11.2 
Hz, 1H, NCHaxHeqCH), 7.45–7.50 (m, 2H, C≡CCCHCH, C≡CCCHCH), 7.50–7.57 (m, 3H, N=NCCHCHCH, N=NCCHCHCH), 7.75–
7.80 (m, 2H, C≡CCCHC, C≡CCCHCCH), 7.82–7.87 (m, 2H, N=NCCHCHCH) ppm. 13C NMR (101 MHz, CD3OD + 5 eq 1N NaOD, 
25 °C, CH3OH): δ = 18.15 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 26,24 (t, 1C, NCH2CH2CH2C≡C , .  (t, 
1C, NCH2CHCH2), 46.10 (d, 1C, NCH2CH), 54.66 (t, 1C, NCH2CH2CH2CH), 57.88 (t, 1C, NCH2CH), 59.09 (t, 1C, 
NCH2CH2CH2C≡C , .  (s, 1C, C≡CCCH), 91.73 (s, 1C, C≡CCCH , .  (d, 1C, C≡CCCHC), 123.75 (d, 2C, N=NCCHCHCH), 
126.03 (s, 1C, C≡CCCHC), 126.25 (d, 1C, C≡CCCHCH), 130.39 (d, 2C, N=NCCHCHCH), 130.49 (d, 1C, C≡CCCHCH), 132.78 
(s, 1C, C≡CCCHCHC), 134.96 (d, 1C, C≡CCCHCCH), 153.46 (d, 2C, N=NC), 183.16 (s, 1C, C=O) ppm. MS (ESI+) m/z: 376 
[M+H]+. HRMS (ESI+): [M+H]+ calcd for C23H26O2N3: 376.2025, found 376.2017.  
1-(5-{4-[(E)-phenylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylic acid (p-21a) 
According to GP5 starting from p-19a (81 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-21a was obtained as 
orange amorphous solid (66 mg, 87%). IR (KBr): ṽ = 3423, 3041, 2938, 2224, 1702, 1596, 1495, 1481, 1463, 1441, 1381, 
1300, 1220, 1152, 1099, 1069, 1010, 956, 925, 846, 767, 725, 686 cm-1. 1H NMR (400 MHz, DMSO-d6, 60 °C, DMSO): δ = 
1.48 (qd, J = 12.0/4.5 Hz, 1H, NCH2CHCHaxHeq), 1.64–1.81 (m, 2H, NCH2CHaxHeqCH2CH, NCH2CHaxHeqCH2CH), 1.85–1.96 
(m, 3H, NCH2CHCHaxHeq, NCH2CH2CH2C≡C , . –2.52 (m, 1H, NCH2CHax), 2.56 (t, J = 7.1 Hz, 2H, NCH2CH2CH2C≡C), 2.60–
2.69 (m, 1H, NCHaxHeqCH2CH2CH), 2.68–2.77 (m, 1H, NCHaxHeqCH), 2.78–2.90 (m, 2H, NCH2CH2CH2C≡C , .  (dbr, J = 10.4 
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Hz, 1H, NCHaxHeqCH2CH2CH), 3.20 (dbr, J = 10.4 Hz, 1H, NCHaxHeqCH), 7.56–7.64 (m, 5H, C≡CCCHCHC, N=NCCHCHCH, 
N=NCCHCHCH), 7.84–7.91 (m, 4H, C≡CCCHCHC, N=NCCHCHCH) ppm. 13C NMR (101 MHz, DMSO-d6, 60 °C, DMSO): δ = 
18.90 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 26.23 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, NCH2CHCH2), 
42.00 (d, 1C, NCH2CH), 54.61 (t, 1C, NCH2CH2CH2CH), 55.97 (t, 1C, NCH2CH), 58.30 (t, 1C, NCH2CH2CH2C≡C , .  (s, 1C, 
C≡CCCH), 95.13 (s, 1C, C≡CCCH , .  d, C, C≡CCCHCHC, N=NCCHCHCH), 128.46 (s, 1C, CH2C≡CC), 131.68 (d, 2C, 
N=NCCHCHCH), 133.86 (d, 1C, N=NCCHCHCH), 134.65 (d, 2C, C≡CCCHCHC), 153.25 (s, 1C, C≡CCCHCHC), 154.36 (s, 1C, 
N=NCCHCHCH), 176.08 (s, 1C, C=O) ppm. MS (ESI+) m/z: 376 [M+H]+. HRMS (EI+): M+ calcd for C23H25O2N3: 375.1947, 
found 375.1939.  
1-(5-{3-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylic acid (m-21b) 
According to GP5 starting from m-19b (91 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) m-21b was obtained as 
orange amorphous solid (74 mg, 87%). IR (KBr): ṽ = 3426, 3050, 2933, 2801, 2764, 2227, 1571, 1507, 1478, 1466, 1407, 
1344, 1203, 1154, 1103, 1012, 895, 804, 770, 685 cm-1. 1H NMR (500 MHz, CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 
1.31 (qd, J = 12.7/4.0 Hz, 1H, NCH2CHCHaxHeq), 1.55 (qt, J = 13.0/3.5 Hz, 1H, NCH2CHaxHeqCH2CH), 1.67 (dbr, J = 13.4 Hz, 
1H, NCH2CHaxHeqCH2CH), 1.79 (p, J = 7.1 Hz, 2H, NCH2CH2CH2C≡C , .86–1.96 (m, 2H, NCH2CHCHaxHeq, 
NCHaxHeqCH2CH2CH), 2.01 (t, J = 11.5 Hz, 1H, NCHaxHeqCH), 2.36 (tt, J = 11.8/3.5 Hz, 1H, NCH2CHax), 2.43 (t, J = 6.9 Hz, 2H, 
NCH2CH2CH2C≡C , .46–2.53 (m, 2H, NCH2CH2CH2C≡C , .87 (d, J = 11.0 Hz, 1H, NCHaxHeqCH2CH2CH), 3.10 (d, J = 10.7 Hz, 
1H, NCHaxHeqCH), 7.41–7.49 (m, 2H, C≡CCCHCH, C≡CCCHCH), 7.49–7.62 (m, 3H, N=NCCHCHCH, N=NCCCHCHCH, 
N=NCCCHCH), 7.68 (d, J = 6.8 Hz, 1H, N=NCCHCHCH), 7.81–7.89 (m, 2H, C≡CCCHC, C≡CCCHCCH), 7.92 (d, J = 7.3 Hz, 1H, 
N=NCCCHCHCHCH), 8.00 (d, J = 8.1 Hz, 1H, N=NCCHCHCH), 8.73 (d, J = 8.1 Hz, 1H, N=NCCCH) ppm. 13C NMR (126 MHz, 
CD3OD + 5 eq 1N NaOD, 21 °C, CH3OH): δ = 18.19 (t, 1C, NCH2CH2CH2C≡C , 25.65 (t, 1C, NCH2CH2CH2CH), 26.31 (t, 1C, 
NCH2CH2CH2C≡C , .  (t, 1C, NCH2CHCH2), 46.12 (d, 1C, NCH2CH), 54.73 (t, 1C, NCH2CH2CH2CH), 57.95 (t, 1C, NCH2CH), 
59.14 (t, 1C, NCH2CH2CH2C≡C , .  (s, 1C, C≡CCCH), 91.74 (s, 1C, C≡CCCH , .  (d, 1C, N=NCCHCHCH), 123.83 (d, 
1C, C≡CCCHCCH), 125.97 (s, 1C, C≡CCCHC), 126.12 (d, 1C, N=NCCCH), 126.63 (d, 2C, N=NCCHCHCH, N=NCCCH), 127.73 
(d, 1C, N=NCCCHCHCH), 128.21 (d, 1C, N=NCCCHCH), 129.10 (d, 1C, N=NCCCHCHCHCH), 130.52 (d, 1C, C≡CCCHCH), 
132.31 (s, 1C, N=NCCCH), 132.99 (d, 1C, N=NCCHCHCH), 134.99 (d, 1C, C≡CCCHCH), 135.63 (s, 1C, N=NCCHCHCHC), 
148.40 (s, 1C, N=NCCHCHCH), 153.99 (s, 1C, C≡CCCHC), 183.11 (s, 1C, C=O) ppm. MS (ESI+) m/z: 426 [M+H]+. HRMS (EI+): 
M+ calcd for C27H27O2N3: 425.2103, found 425.2085.  
1-(5-{4-[(E)-1-naphthylazo]phenyl}pent-4-yn-1-yl)piperidine-3-carboxylic acid (p-21b) 
According to GP5 starting from p-19b (91 mg, 0.20 mmol) and 2 N NaOH (0.30 ml, 0.60 mmol) p-21b was obtained as 
orange amorphous solid (75 mg, 88%). IR (KBr): ṽ = 3427, 3051, 2949, 2860, 2227, 1708, 1625, 1596, 1497, 1383, 1344, 
1300, 1216, 1187, 1157, 1142, 1098, 1080, 1012, 843, 803, 775 cm-1. 1H NMR (500 MHz, DMSO-d6, 60 °C, DMSO): δ = 
1.35–1.54 (m, 2H, NCH2CHCHaxHeq, NCH2CHaxHeqCH2CH), 1.61–1.71 (m, 1H, NCH2CHaxHeqCH2CH), 1.71–1.84 (m, 3H, 
NCH2CH2CH2C≡C, NCH2CHaxHeqCH2CH), 2.08 (tbr, J = 9.5 Hz, 1H, NCHaxHeqCH2CH2CH), 2.22 (tbr, J = 10.1 Hz, 1H, 
NCHaxHeqCH), 2.37–2.49 (m, 3H, NCH2CHax, NCH2CH2CH2C≡C), 2.51–2.57 (m, 2H, NCH2CH2CH2C≡C , .  dbr, J = 9.7 Hz, 
1H, NCHaxHeqCH2CH2CH), 2.85 (dbr, J = 10.3 Hz, 1H, NCHaxHeqCH), 7.60–7.70 (m, 4H, C≡CCCHCHC, N=NCCHCHCH, 
N=NCCCHCHCH), 7.73 (t, J = 7.5 Hz, 1H, N=NCCCHCH), 7.81 (d, J = 7.4 Hz, 1H, N=NCCHCHCH), 8.01 (d, J = 8.1 Hz, 2H, 
C≡CCCHCHC), 8.07 (d, J = 7.8 Hz, 1H, N=NCCCHCHCHCH), 8.16 (d, J = 8.2 Hz, 1H, N=NCCHCHCH), 8.86 (d, J = 8.5 Hz, 1H, 
N=NCCCH) ppm. 13C NMR (101 MHz, DMSO-d6, 60 °C, DMSO): δ = 17.06 (t, 1C, NCH2CH2CH2C≡C , .  (t, 1C, 
NCH2CH2CH2C≡C , .  (t, 1C, NCH2CH2CH2CH), 26.90 (t, 1C, NCH2CHCH2), 41.48 (d, 1C, NCH2CH), 53.60 (t, 1C, 
NCH2CH2CH2CH), 55.68 (t, 1C, NCH2CH), 57.10 (t, 1C, NCH2CH2CH2C≡C , .  (s, 1C, C≡CCCH), 94.25 (s, 1C, C≡CCCH , 
112.27 (d, 1C, N=NCCHCHCH), 123.03 (d, 1C, N=NCCCH), 123.28 (d, 2C, C≡CCCHCHC), 126.01 (d, 1C, N=NCCHCHCH), 
126.80 (s, 1C, CH2C≡CC), 126.97 (d, 1C, N=NCCCHCHCH), 127.58 (d, 1C, N=NCCCHCH), 128.34 (d, 1C, N=NCCCHCHCHCH), 
130.76 (s, 1C, N=NCCCH), 132.06 (d, 1C, N=NCCHCHCH), 132.65 (d, 2C, C≡CCCHCHC), 134.26 (s, 1C, N=NCCHCHCHC), 
147.21 (s, 1C, N=NCCHCHCH), 151.77 (s, 1C, C≡CCCHCHC), 175.23 (s, 1C, C=O) ppm. MS (ESI+) m/z: 426 [M+H]+. HRMS 
(ESI+): [M+H]+ calcd for C27H28O2N3: 426.2182, found 426.2172. 
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1 Photochemical Isomerization of (E)- and (Z)-m-20a: 
1.1 Calculation of the absorption of pure (Z)-m-20a: 
A 1 mL aliquot of a 10 mM solution in DMSO-d6 of (E)-m-20a was irradiated in a NMR tube (Wilmad) until the 
photostationary state was reached (within 10 min). For irradiation a Rayonet RPR-200 max = 350 nm) was 
used. Afterwards, a 1H NMR spectrum was recorded. The amount of both isomers of m-20a was obtained 
through integration of the significant aromatic signals of the (Z)- and the (E)-iso er, gi i g the ratio fa tor α. 
By 1H NMR spectroscopy a (Z)/(E)-ratio of ≈ 80/20 was found within this experiment α(Z) = 0.802). 
For determination of the reachable (Z)/(E)-ratio of m-20a under physiological conditions an aliquot of both 
the irradiated and non-irradiated 10 mM stem solution in DMSO-d6 was taken and diluted to a concentration 
of  M ith phosphate uffer 0 mM, pH 7.4) and a UV/Vis spectrum (Cary50 spectrometer, Varian) of 
these samples was recorded at the same time. The absorption (A) at 350 nm for this irradiated sample (A(E/Z)) 
was found to be 0.101. Together with the UV/Vis spectrum of the pure (E)-isomer (AE = 0.295) the absorption 
of the pure (Z)-isomer could then be calculated using following equation: 
A(Z) = A(E) + (A(Z/E) – A(E)) / α(Z)     with     α(Z) = c(Z) / (c(E) + c(Z)) 
In this manner the absorption of the pure (Z)-isomer was calculated to be 0.053. 
1.2 Determination of a suitable wavelength for forward-isomerization of (E)-m-20a: 
The ideal wavelength for the photoisomerization of the (E)- and (Z)-isomer of m-20a was determined by 
UV/vis spectroscopy and in situ irradiation of the 25 µM dilution of (E)-m-20a using an FT-600-UMT fiber 
optic cable (NA 0.39), connected to a Polychrome V system monochromator (TILL photonics) with a 150 W 
xenon short arc lamp with an output ra ge of − 8  . (E)-m-20a was irradiated at different wavelengths 
(330, 340, 350, 360, 370 nm) until the photostationary state was reached (within 10 min). The resulting 
(Z)/(E)-ratio of m-20a during an irradiation could be calculated in this way:  
α(Z) = (A(Z/E) – A(E)) / (A(Z) – A(E)) 
Using 350 nm for the forward-isomerization (photostationary state: A(Z/E) = 0.066  the fi al alue for α(Z) was 
calculated to be 0.946. 
Results for other wavelengths: 
340 nm:  A(10) = 0.071; α(Z) = 0.925      360 nm:  A(10) = 0.089; α(Z) = 0.851      370 nm:  A(10) = 0.141; α(Z) = 0.636 
t (min) A(t) 350 nm α(Z) 
0 0.295 0 
0.5 0.205 0.372 
1 0.185 0.455 
2 0.140 0.640 
3 0.108 0.773 
4 0.079 0.893 
5 0.072 0.921 
6 0.069 0.933 
7 0.067 0.942 
8 0.066 0.946 
9 0.066 0.946 
10 0.066 0.946 
(E)-m-20a before photoirradiation 
(Z)- and (E)-m-20a at the photost. state 
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1.3 Determination of a suitable wavelength for back-isomerization of (Z)-m-20a: 
The wavelength for back isomerization was determined in a similar way by irradiation of the photoisomerized 
sample of m-20a with higher wavelengths (410, 420, 430, 440 nm). 
Using 420 nm for the back-isomerization (photostationary state: A(Z/E) = .  the fi al alue for α(Z) was 
calculated to be 0.248. 
Results for other wavelengths: 
410 nm:  A(10) = 0.214; α(Z) = 0.335      430 nm:  A(10) = 0.208; α(Z) = 0.360      440 nm:  A(10) = 0.177; α(Z) = 0.487 
2 Half-life´s of thermal relaxation 
2.1 Determination of the half-life of (Z)-m-20a in phosphate buffer 
For the half-life under physiological conditions an aliquot of the photoirradiated 10 mM stem solution of 
m-20a in DMSO-d6 ith α = .8  as diluted to a o e tratio  of  M ith phosphate uffer pH 7.4)
and a UV/Vis spectrum (Cary50 spectrometer, Varian) of this sample was recorded immediately (A(0) = 0.202).
The sample was stored in the dark and further UV spectra were recorded in defined time intervals. The
amount of (Z)- and (E)-m-20a was obtained for every spectra using the following equation:
α(t) = (A(t) – A(E)) / (A(Z) – A(E)) 
with A(E) = 0.575 (measured) and A(Z) = 0.110 (calculated by A(Z) = A(E) + (A(0) – A(E)  / α(Z)).  
Calculations based on equations for 1st order kinetics: N(Z) = N(0) ∙ e-k-  ∙ t and t1/2 = ln 2 / k-1. 
t (min) A(t) 350 nm α(Z) 
0 0.066 0.946 
0.5 0.146 0.615 
1 0.163 0.545 
2 0.200 0.393 
3 0.219 0.337 
4 0.225 0.314 
5 0.228 0.277 
6 0.231 0.264 
7 0.232 0.260 
8 0.234 0.252 
9 0.235 0.248 
10 0.235 0.248 
A(t) 350 nm time (d) α(Z) t(1/2) 
0.202 0 80.2 
0.212 1 78.1 26.2 
0.223 2 75.7 24.0 
0.234 3 73.3 23.1 
0.256 5 68.6 22.2 
0.285 7 62.8 19.8 
0.307 10 57.6 20.9 
0.339 14 50.8 21.3 
0.378 21 42.4 22.8 
0.411 28 35.3 23.6 
photost. state of forward isomerization 
photostationary state of back isomerization 
y = 79,361e-0,031x
0
20
40
60
80
100
0 5 10 15 20 25 30
Z
 (
%
)
time (days)
Thermal relaxation of (Z)-m-20a in PB
t(1/2) = 22 d
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2.1 Determination of the half-life of (Z)-m-20a in DMSO 
A 10 mM solution in DMSO-d6 of (E)-m-20a was irradiated by means of a Rayonet RPR-  max = 350 nm) in 
a NMR tube until the photostationary state was reached. At the beginning of the experiment, a first 1H NMR 
spectrum was recorded. The sample was stored in the dark and further 1H NMR spectra were measured in 
defined time intervals. The amount of (E)- and (Z)-m-20a was obtained through integration of the affiliated 
aromatic signals for every spectrum, giving the remaining proportion of (Z)-m-20a (αZ) respectively: 
Thermal relaxation rates in DMSO of further compounds are given in the following table: 
time (d) 1H (E)* 1H (Z)* total* Z (%) 
0 1.01 4.23 5.24 80.7 
1 1.03 3.07 4.10 74.9 
3 1.01 2.04 3.05 66.8 
5 1.01 1.46 2.47 59.1 
7 1.02 1.15 2.17 53.0 
10 1.00 0.80 1.80 44.4 
14 1.00 0.53 1.53 34.6 
21 1.02 0.35 1.37 25.6 
*average integration for 1H (E) and 1H (Z) of
aromatic signals 
Comp. t(1/2) Comp. t(1/2)
m-12a 14 d m-20a 15 d 
p-12a 32 h p-20a 38 h 
m-12b 8.5 m-20b 19 h 
p-12b 40 min p-20b 3.0 h 
y = 78.639e-0.047x
0.0
20.0
40.0
60.0
80.0
100.0
0 2 4 6 8 10 12 14 16 18 20 22
Z
 (
%
)
time (days)
Thermal relaxation of (Z)-m-20a in DMSO
t1/2 = 15 d
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3 Biological test data for GABA transporter subtypes mGAT2-4 
Results for functional inhibitory activity of the enantiopure photoswitchable GAT inhibitors towards the 
GABA transporter subtypes mGAT2-4 are given in the following table: 
Comp. 
    pIC50  ± SEMa 
mGAT2 mGAT3 mGAT4 
(R)-m-20a 61% (76%b) 4.17 (60%b) 68% (57%b) 
(R)-p-20a 51% 4.42 4.36 
(R)-m-20b 4.61 4.72 4.56 
(R)-p-20b 58% 5.07 4.65 
a due to low inhibitory activities only one experiment 
was performed in triplicate; percentages represent 
remaining [3H]GABA uptake in presence of 100 µM 
inhibitor. b after irradiation at the photostationary state. 
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A general and practical synthetic method for the construction of unsymmetrically substituted diphe-
nyldiazenes based on classical azo coupling reaction has been developed. A key feature of this method is
the use of N,N-diallyl protected aniline derivatives as coupling components. The N,N-diallyl moiety of the
coupling component warrants sufficient reactivity and allows to avoid formation of constitutional iso-
mers resulting from intermediate triazene formation. Furthermore, subsequent to the coupling reaction,
the N,N-diallyl aminofunction, can be replaced by other substituents including hydrogen via diazonium
ion intermediates. In general, following this approach target compounds can be obtained in reasonable to
good yields.
 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Aromatic azo compounds have found widespread application in
chemical and pharmaceutical industry. They are classically used for
instance as dyes and pigments,1 food additives, indicators for pH-
measurements,2 initiators for radical reactions,3 as therapeutic
agents4,5 or as part of drug delivery systems.6 Meanwhile a major
focus of azobenzenes is on their use as light sensitive molecular
switches,7e9 as for example, for photoresponsive liquid
crystals.10e12 But in recent time, many papers appeared in partic-
ular on the use of photoswitchable ligands for photopharmacology,
e.g., for the optical control of epithelial sodium channels,13 insulin
receptors,14 the acetylcholinesterase,15 m-opioid receptors,16
TRPV1-channels,17 glutamate receptors,18 NMDA receptors,19
AMPA receptors,20 local anesthetics21 and cell division.22 We re-
cently described the use of this method to control the activity of
a neurotransmitter transporter, the GABA transporter GAT1,
employing a photoswitchable ligand.23
Because of the broad interest in azo compounds, several
methods have been developed for their synthesis in the past.24
Classical approaches comprise azo coupling reaction,25 the Mills
reaction,26 and the Wallach reaction.27 Recently, additional
preparative methods have been reported such as the reductive
coupling of aromatic nitro derivatives28 or the oxidative coupling of
aniline derivatives.29 However, the substitution pattern of the ar-
omatic azo compounds accessible by these methods is in general
quite limited. Thus, when dimerization reactions such as the re-
ductive coupling of nitro compounds are applied to establish the
respective phenyl azo derivatives, homo and hetero coupling will
inevitably lead to symmetrically and unsymmetrically substituted
azo compounds and as a consequence thereof to poor yields.
Clearly, the well known azo coupling reactions in which diazonium
salts are reacted with aromatic systems give access to a broad array
of differently substituted target compounds. But this approach
suffers from distinct limitations as well. In this case the coupling
component to be reacted with the diazonium salt must display
a sufficiently high electron density, typically achieved by the
presence of a hydroxy- or an amino group to undergo the desired
conversion.
In the context with the development of new photoswitchable
ligands for GABA transporters, we sought for a very specific sub-
stitution pattern of the diphenyldiazene unit, that is, exhibiting two
main features (Scheme 1): There should be a halogen function at
one of the two phenyl moieties allowing the assembly of the final
photosensitive target compounds or precursors by cross coupling
reactions like Suzuki, Sonogashira or Heck reactions. The second
phenyl moiety should exhibit substituents such as halogens or alkyl
groups preferentially in the ortho or the para position or in both
* Corresponding author. Tel.: þ49 0 89 2180 77249; fax: þ49 0 89 2180 77247;
e-mail address: klaus.wanner@cup.uni-muenchen.de (K.T. Wanner).
Contents lists available at ScienceDirect
Tetrahedron
journal homepage: www.elsevier .com/locate/ tet
Tetrahedron 72 (2016) 1579e1589
http://dx.doi.org/10.1016/j.tet.2016.02.011
0040-4020/ 2016 Elsevier Ltd. All rights reserved.
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since due to former results substituents in these positions were
expected to improve binding affinities to GABA transporters.30
Moreover, particularly substituents in the ortho or para position
might also allow to tune the kinetics of the E/Z-isomerization of the
photosensitive compounds as well as the wavelength of the nec-
essary light used for isomerization which is often a decisive factor
for the use of photoswitchable compounds in organic tissues.
We considered azo coupling reactions as the most efficient and
versatile synthetic approach to the desired azo compounds 3
(Scheme 2). For such coupling reactions, the diazonium salt 1
should be used exhibiting an iodine substituent that should allow
to use the target compound for Palladium catalyzed coupling re-
actions. The main problem, however, to solve was the question
which reactant might be employed as nucleophile in the azo cou-
pling reaction. Benzene derivatives with halogen function but de-
void of any activating groups such as an OH or an NH2 group
increasing electron density of the aromatic system like 2 do not
come into consideration as they are known to fail in azo coupling
reactions. Given the fact that primary aromatic amino groups can
be efficiently exchanged by e.g., halogene substituents by Sand-
meyer or Schiemann reactions, the use of aniline derivatives 4, the
electron density of which should be high enough to undergo the
desired coupling reaction, appears quite tempting. But in that case,
an exchange of the azo and the amino group may occur between
the coupling reagents via triazenes as intermediates which would
ultimately result in a variety of structurally isomeric azo
compounds.
It appeared to us that this problem could be easily solved, if the
aniline derivatives 4 displaying a primary amino function were
replaced by benzene derivatives 6 exhibiting a tertiary amino
function carrying suitable protecting groups. Due to the protecting
groups, triazene formation and side reactions resulting therefrom
could be ruled out whereas compounds 6 should be still amenable
to azo coupling reactions owing to the positive mesomeric effect of
the amino group. Given its easy introduction and efficient removal
without a significant effect on the electron donor ability of amino
groups, we considered allyl residues as the most appropriate pro-
tecting groups for the purpose of this study. In the present paper,
we wish to report on the results of our study utilizing N,N-diallyl
protected aniline derivatives 6 for azo coupling reactions and the
subsequent transformation of the primary coupling products 7 into
azo benzene derivatives 5 exhibiting a primary amino group by N-
deprotection and further on the replacement of the primary amino
group by various substituents (/3). To the best of our knowledge,
the above outlined synthetic concept has not been reported before.
2. Results and discussions
The primary step of our synthetic sequence that should give
access to a broad variety of differently substituted azo benzenes 3
and 5, the coupling reaction between a diazonium salt and N,N-
diallyl substituted aniline derivative was in general performed as
follows. The diazonium salts of anilines 1, i.e., 1a and 1b, were
generated right before their use by treating the respective iodo
Scheme 1. Design of the desired target compounds.
not activating
substituent
activating
substituent
activating 
N-protected
substituent
1
1
1
2
4
6
7
5
3
Scheme 2. Synthesis of substituted diphenyldiazenes by azo coupling.
T.A. Lutz et al. / Tetrahedron 72 (2016) 1579e15891580
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aniline in a mixture of EtOH and 2 M HCl (3 equiv) with NaNO2
(1.1 equiv in H2O; excess NaNO2 destroyed by addition of
H2NSO3H). For the azo coupling reactions, the resulting solution
was then added to a solution of the respective N,N-diallylaniline (in
EtOH/H2O) at 0
C, in which, where indicated, also NaOAc or a fur-
ther amount of 2 M HCl was present. The reaction mixture, the pH
of which was estimated by means of indication paper, was finally
stirred at 0 C for the time given, before the product was isolated by
extraction and purified by flash chromatography.
When diazonium salt 1 was reacted with N,N-diallylaniline (8a)
under weak acidic pH conditions (pHz4), the reaction was com-
plete within 4 h providing 9a in 94% yield (Table 1, entry 1). For the
coupling reaction of 1a with the m-chloro substituted aniline de-
rivative 8b, longer reaction times were required. After 4 h as in the
aforementioned reaction with 8a, only 53% of 9b were obtained
which could be raised to 61% and 64% upon extension of the re-
action time to 16 and 36 h, respectively (Table 1, entries 2e4).
When the compounds were allowed to react for 36 h but at
a higher pH (z5e6, adjusted by extra NaOAc), the yield lowered to
32% whereas 71% of 9b could be isolated by running the reaction at
a lower pH (Table 1, entry 6, pHz2e3, adjusted by omission of
NaOAc). But when the pH was further reduced (to z1e2 by addi-
tion of 2 equiv of 2 M HCl) instead of an additional increase in yield
a slight reduction occurred (Table 1, entry 7) indicating the pH
optimum for the reaction to be z2e3. In case of the coupling re-
action of 1a with the m-fluoro substituted aniline derivative 8c
yields amounted to 55% (Table 1, entry 8) and 56% (Table 1, entry 9)
only performed at the pH values of z4 and z2e3 that had so far
appeared to be the most rewarding. For the more electron-rich 3-
methyl substituted aniline derivative 8d, the coupling reaction
proceeded again quite smoothly. At both pH values,z4 andz2e3,
the reactionwas complete within 4 h yielding the coupling product
in 92% and 85%, respectively (Table 1, entries 10e11).
The reaction conditions that had turned out best for the prep-
aration of the diazobenzenes 9aed were finally also applied to the
synthesis of regioisomers 10aed exhibiting the iodo substituent in
meta position. That way, by coupling 8aed with meta iodo
substituted diazonium salt 1b, the corresponding diazobenzenes
10aed could be obtained in reasonable to good yields (51e84%,
Table 2, entries 1e4).
The next step aimed at the deprotection of the tertiary amino
function in 9aed and 10aed which should be accomplished by
isomerization of the two allyl residues and subsequent hydrolysis
of the thus formed aminovinyl units.
First attempts were performed with 9a employing Pd/C,
Rh(PPh3)3Cl2 or Ru(PPh3)3Cl2 in EtOH or THF also in presence of
additives such as ethanolamine or trimethylamine, or the use of
potassium tert-butoxide in DMSO or toluene remained un-
successfully as either no reaction occurred or a complex mixture of
products was formed. Finally, the transition metal catalyst
RuClH(CO) (PPh3)3 reported by Krompiec et al.
31 to effect CeC
double bond isomerization in N-allylamines was found to be well
suited for our purposes, i.e., the isomerization of 9a to 11a. Thus
when 9awas heatedwith 1Mol % of RuClH(CO) (PPh3)3 in CH2Cl2 to
60 C in a microwave reactor, a clean reaction to the divinylamine
11a occurred, which was complete within 2 h. Product 11a was
found to be labile. Therefore, neither 11a nor the related products
11bed and 12aed were isolated, instead the solutions from the
isomerization containing these compounds directly used for the
next step.
The conditions required for the hydrolysis of the divinylamine
function to liberate the primary amino group were exemplarily
examined for 11a to which end the solution of this compound
resulting from the isomerization reaction was used without any
purification. Treatment of 11a with HCl, HOAc, NH4Cl or water did
not provide the desired amine or only as part of a complex reaction
mixture. However, upon treatment of the CH2Cl2 solution of 11a,
obtained from the isomerization reaction, with NH3
þOHCl
(10 equiv) and NEt3 (5 equiv) at 60
C for 3 h, a procedure de-
veloped for the cleavage of pyrrols,32 a clear conversion to the free
amino derivative occurred delivering 13a in 96% yield.
The same procedure for the removal of the allyl protecting
groups comprising isomerization and hydrolysis worked also well
for 9be9d and the regioisomers regarding the iodo substituted
10aed, for the latter of which the reaction times for both steps had,
however, to be extended to 4 h and 6 h, respectively, providing the
target compounds 13bed and 14aed in yields from 87 to 95%.
The respective results that could be achieved for the cleavage of
the N,N-diallylaniline protection group in these cases are shown in
Table 3.
Table 1
Formation of diphenyldiazenes 9aed from diazotized 4-iodoaniline 1a and N,N-diallylanilines 8aeda
1a 8a-d 9a-d
Entry Educt X Additivesb pH rangec Reaction time [h] Product Yield:
1 8a H NaOAc, 2 equiv z4 4 9a 94%
2 8b Cl NaOAc, 2 equiv z4 4 9b 53%
3 8b Cl NaOAc, 2 equiv z4 16 9b 61%
4 8b Cl NaOAc, 2 equiv z4 36 9b 64%
5 8b Cl NaOAc, 4 equiv z5e6 36 9b 32%
6 8b Cl d z2e3 36 9b 71%
7 8b Cl 2M HCl, 2 equiv z1e2 36 9b 68%
8 8c F NaOAc, 2 equiv z4 36 9c 55%
9 8c F d z2e3 36 9c 56%
10 8d Me NaOAc, 2 equiv z4 4 9d 92%
11 8d Me d z2e3 4 9d 85%
a A solution of 1a was freshly generated from 4-iodoaniline by addition of NaNO2 (1.1 equiv) and 2M HCl (3.0 equiv) in EtOH/H2O (2:1). This solution was then added to
a separate solution of 8aed in EtOH/H2O (2:1).
b Further additives added to the solution of the coupling component 8aed where indicated.
c Determined from the reaction mixture directly after the addition of the solution of 1a to the solution of 8aed.
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To demonstrate the synthetic utility of the thus obtained
diphenyldiazenes, prototypic reactions for the replacement of the
amino group in 13aed by hydrogen, chlorine, and fluorine have
been performed.
Reductive removal of the amino group in 13aed could be ac-
complished following a standard procedure. Treatment with
NaNO2 (3 equiv) and H3PO2 (20 equiv) of 13aed in THF provided
the desired desamino derivatives 15aed in reasonable to good
yields (Table 4, 66e75%).
Substitution of the amino group in the aniline derivatives ob-
tained in this study by chlorine or fluorine in a Sandmeyer and
Schiemann reaction is feasible as well, as shown for 13a. Treatment
of 13a with tert-BuONO and 4-dodecylbenzenesulfonic acid in
tetrachloromethane and subsequent heating with triethylamine
following a literature procedure33 provided the chloroderivative 16
in 52%. For this transformation, it occurred crucial that CCl4 was
employed as solvent as with other organic solvent which were
required because of the poor solubility of 13a in water, partial
Table 3
Deallylation of diphenyldiazenes 9 and 10 via isomerization and subsequent hydrolysis
9a-d, 10a-d 11a-d, 12a-d
13a-d, 14a-d
Entry Educt X Isomerization time [h] Hydrolysis time [h] Product Yield:
1 9a H 2 3 13a 96%
2 9b Cl 2 3 13b 93%
3 9c F 2 3 13c 91%
4 9d Me 2 3 13d 95%
5 10a H 4 6 14a 92%
6 10b Cl 4 6 14b 88%
7 10c F 4 6 14c 87%
8 10d Me 4 6 14d 90%
Table 2
Formation of diphenyldiazenes 10aed from diazotated 3-iodoaniline 1b and N,N-diallylanilines 8aeda
1b 8a-d 10a-d
Entry Educt X Additivesb pH rangec Reaction time [h] Product Yield:
1 8a H NaOAc, 2 equiv z4 4 10a 80%
2 8b Cl d z2e3 36 10b 63%
3 8c F d z2e3 36 10c 51%
4 8d Me NaOAc, 2 equiv z4 4 10d 84%
a A solution of 1b was freshly generated from 4-iodoaniline by addition of NaNO2 (1.1 equiv) and 2M HCl (3.0 equiv) in EtOH/H2O (2:1). This solution was then added to
a separate solution of 8aed in EtOH/H2O (2:1).
b Further additives added to the solution of the coupling component 8aed where indicated.
c Determined from the reaction mixture directly after the addition of the solution of 1b to the solution of 8aed.
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replacement of the amino substituent by hydrogen occurred lead-
ing to diminished yields.
Similarly, the fluorine derivative 17 could be prepared in
a Schiemann reaction treating 13a with tert-BuONO and
BF3$Et2O (followed by heating to 120
C) the yield amounting
to 63% (Scheme 3). According to these results, the synthetic
sequence of azo coupling with N,N-diallyl protected aniline
derivatives, subsequent deprotection and substitution of the
amino group represents a highly efficient and versatile access
to differently substituted diphenyldiazene derivatives (see
Scheme 4).
Having successfully accomplished the formation of amino
substituted diphenyldiazenes by azo coupling reactions with N-
protected aniline derivatives, we wondered whether an analogous
reaction could possibly also be performed with 1-
aminonaphthalene in either N-protected or even unprotected form.
Interestingly, in this case a protection of the primary amino
group was not required. When the diazonium salts 1a and 1b de-
rived from 4-iodoaniline and 3-iodoaniline were reacted with 1-
aminonaphtalene (18) the corresponding azo coupling products
19a and 19b were formed without any sign of isomeric products
that could have resulted from intermediate triazene formation. Also
the yields for the products amounting to 91% and 93% for 19a and
19b, respectively, were very high. As in the case of the amino
substituted diphenyldiazenes the reductive elimination of the
amino group in 19aeb employing NaNO2 and H3PO2 worked here
well, too, providing the desaminated phenylnaphtyl diazenes
20aeb in good yields (20a: 72%; 20b: 68%).
1) tBuONO, CCl
4
,
4-docecylbenzenesulfonic acid
25 °C, 2 h
2) Et
3
N, 60 ° C, 2  h
1) tBuONO, BF
3
   Et
2
O
    0 °C, 16 h
2) 120 °C, 2 h
.
13a 16
13a 17
Scheme 3. Replacement of the amino group in 13a by a chlorine and fluorine substituent.
1b
1a
20a18
18 20b
19a
19b
91%
93%
72%
68%
Scheme 4. Azo coupling of diazotated iodoaniline 1aeb with 1-aminonaphthaline (18).
Table 4
Reductive removal of the amino group in aniline derivatives 13aed
13a-d 15a-d
Entry Educt X Product Yield:
1 13a H 15a 75%
2 13b Cl 15b 66%
3 13c F 15c 68%
4 13d Me 15d 71%
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Of these compounds, the naphtylphenyl diazene derivative 20b
has already successfully been used as a building block for the
construction of a valuable photoswitchable ligand of the GABA
transporter GAT1.23
3. Conclusion
Based on diazonium chemistry, a highly versatile synthetic
route to substituted diphenyldiazenes exhibiting an iodo sub-
stituent on one of the two aromatic rings and additional sub-
stituents on the other has been established.
The method comprises the coupling of diazonium salts derived
from iodo substituted aniline derivatives on the one with N,N-
diallyl protected anilines on the other side. The key feature of this
approach is to be seen in the use of the temporary protection of the
amino group of the aniline derivativewith twoN-allyl residues. The
N,N-diallyl residue warrants sufficient reactivity of the benzene
derivatives for azo coupling reactions whereas the N-protection of
the amino group rules out side reaction that would otherwise arise
from intermediate triazene formation. Further, the primary amino
group accessible by deprotection of the N,N-diallyl moiety after the
azo coupling reaction has the advantage to provide the opportunity
for a broad array of transformation reactions as exemplified by its
replacement by hydrogen, chlorine or fluorine substituents
employing common methods. Overall the synthetic method out-
lined in this paper provides a broadly applicable and flexible ap-
proach to differently substituted diphenyl diazenens derivatives
which equipped with a suitable functional group, such as an iodine
substituent for metal catalyzed coupling reactions, can be re-
warding building blocks for the construction of photoswitchable
bioactive compounds.
4. Experimental section
4.1. General methods
For all reactions only distilled solvents were used. THF and NEt3
were dried over sodium and distilled under nitrogen. CH2Cl2 was
distilled from CaH2 under nitrogen. Commercial available reagents
were used without further purification. Flash column chromatog-
raphy was performed using silica gel (40e60 mm). NMR spectra
were measured with a Jeol Eclipse þ400 (400 MHz) and a Jeol
Eclipseþ500 (500MHz) spectrometer or an Avance III HD 400MHz
Bruker BioSpin and an Avance III HD 500 MHz Bruker BioSpin
spectrometer. 1H NMR chemical shifts were referenced to TMS and
13C NMR chemical shifts were referenced to CHCl3. The coupling
constants were stated with an accuracy of 0.5 Hz. MestreNova
software was used for further analysis of the spectra. IR spectra
were recorded with an FT-IR spectrometer Paragon 1000 (Perki-
nElmer). Samples weremeasured either as KBr pellets or as films on
NaCl plates. Spectrum v2.00 software (PerkinElmer) was used for
analysis. Mass spectra were measured with a mass spectrometer
59827A with 59980 particle beam LC/MS interface (Hew-
lettePackard). High resolution mass spectrometry was carried out
with an LTQ FT (ThermoFinnigan), FAB (Xenon, 6 kV, MBA, refer-
ence PEG), or a JMS GCmate II (Jeol).
4.2. General procedure for the allylation of aniline derivatives
(GP1)
The corresponding aniline was dissolved in EtOH (2 mL/mmol)
and H2O (0.5 mL/mmol) was added. Ally bromide (2.4 equiv) and
Na2CO3 (1.2 equiv) were added and the mixture was heated to
reflux for the indicated time. After the end of the reaction, the main
part of the alcohol was removed by distillation. CH2Cl2 (5 mL/
mmol) and H2O (5 mL/mmol) were added and the product was
extracted with CH2Cl2 (3). The combined organic layers were
dried over Na2SO4 and the solvent was removed under reduced
pressure. The crude product was purified by flash chromatography
(eluting with pentane) to give the diallylated derivatives.
4.3. General procedure for the azo coupling (GP2)
The corresponding iodo aniline (1.0 equiv) was dissolved in of
EtOH (3 mL/mmol) und 2N HCl (1.5 mL/mmol, 3.0 equiv) was
added. The mixture was cooled to 0 C and a pre-cooled solution of
NaNO2 (1.1 equiv) in H2O (1.5 mL/mmol) was added dropwise over
a period of 10 min. After the end of the addition, the solution was
stirred for further 10 min at 0 C. Then the excess of NaNO2 was
removed by the addition of amidosulfuric acid (0.2 equiv) once
again followed by stirring for 10 min at 0 C (suspension A).
The corresponding N,N-diallyl aniline derivative (1.0 equiv) was
dissolved in EtOH (20mL/mmol) and 10mL/mmol water was added
(solution B). If indicated, to this solution is also added either NaOAc
(2.0 equiv) or a further amount of 2N HCl (1 mL/mmol, 2.0 equiv)
additionally.
Suspension A was then added to solution B at 0 C, the pH was
determined of the resulting mixture (indicator paper) and it was
stirred for the indicated time at 0 C. Afterwards it was allowed to
warm up to rt slowly followed by the addition of both CH2Cl2
(20 mL/mmol) and H2O (20 mL/mmol). The aqueous phase was
made alkaline (pH 10e12) by the addition of NaOH and the product
was extracted with CH2Cl2 (3). The combined organic layers were
dried over Na2SO4 and the solvent was removed under reduced
pressure. The crude product was purified by flash chromatography
(eluting with pentane/CH2Cl2¼8/2) to give the clean azo
compound.
4.4. General procedure for the deallylation of the diallyl-
amines (GP3)
Under nitrogen the corresponding N,N-diallyl amine (1.0 equiv)
and RuClH(CO) (PPh3)3 (0.01 equiv) were introduced in a pressure
tube and dissolved in of CH2Cl2 (5 mL/mmol). The tube was sealed
air tightly and the solution was heated to 60 C for the indicated
time. After cooling to rt both H2NOHHCl (10 equiv) and Et3N
(5 equiv) were added and the mixture was heated to 80 C for the
indicated time. After cooling to rt, once again H2O (5mL/mmol) was
added and the product was extracted with CH2Cl2 (3). The com-
bined organic layers were dried over Na2SO4 and the solvent was
removed under reduced pressure. The crude product was
purified by flash chromatography (eluting with pentane/
dichloromethane¼1/1) to give the corresponding primary aromatic
amine.
4.5. General procedure for the reductive dediazoniation of
the aromatic amines (GP4)
The corresponding primary aromatic amine derivative
(1.0 equiv) was dissolved in THF (20 mL/mmol), cooled to 0 C and
hypophosphorous acid (50% solution inwater, 20 equiv) was added.
Sodium nitrite (3.0 equiv) was added and the mixture was stirred
for 4 h at 0 C and then at rt for further 12 h. Afterwards there were
added CH2CL2 (20 mL/mmol) and water (20 mL/mmol) and the
aqueous phase was made alkaline (pH 10e12) with 2N NaOH. The
product was extracted with CH2Cl2 (3). The combined organic
layers were dried over Na2SO4 and the solvent was removed under
reduced pressure. The crude product was purified by flash chro-
matography (eluting with pentane) to give the corresponding re-
duced species.
T.A. Lutz et al. / Tetrahedron 72 (2016) 1579e15891584
- Fourth publication -
4.6. Characterization data of new products
4.6.1. N,N-Diallylaniline (8a). According to GP1 from aniline (4.7 g,
50 mmol), allylbromide (14.8 g, 120 mmol) and K2CO3 (6.4 g,
60 mmol). The reaction time was 3 h 8a was obtained as colorless
oil (8.20 g, 95%). TLC: Rfz0.3 (pentane). IR (NaCl): ṽ¼3084, 3062,
2979, 2912, 2858,1642,1599,1574,1505,1388,1357,1233,1181, 988,
918, 746, 691 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS): d¼3.90
(dt, J¼4.6/1.6 Hz, 4H), 5.10e5.21 (m, 4H), 5.84 (ddt, J¼17.2/10.1/
4.9 Hz, 2H), 6.63e6.72 (m, 3H), 7.14e7.23 (m, 2H) ppm 13C NMR
(126 MHz, CDCl3, 21
C, TMS): d¼52.81 (2C), 112.41 (2C), 116.06
(2C), 116.38, 129.16 (2C), 134.12 (2C), 148.78 ppm. M (C12H15N)¼
173.25. MS (EIþ): m/z: 173.1 (Mþ). HRMS (EIþ): Mþ calcd for
C12H15N: 173.1204; found 173.1205.
4.6.2. N,N-Diallyl-3-chloroaniline (8b). According to GP1 from 3-
chloro-aniline (6.4 g, 50 mmol), allylbromide (14.8 g, 120 mmol)
and K2CO3 (6.4 g, 60 mmol). The reaction time was 4 h 8b was
obtained as colorless oil (9.60 g, 92%). TLC: Rfz0.3 (pentane). IR
(NaCl): ṽ¼3083, 3008, 2981, 2910, 2865, 1642, 1594, 1560, 1493,
1417, 1385, 1357, 1235, 1180, 1101, 985, 920, 830, 759, 681 cm1. 1H
NMR (500 MHz, CDCl3, 21
C, TMS): d¼3.89 (dt, J¼4.0/1.7 Hz, 4H),
5.14 (dq, J¼8.8/1.7 Hz, 2H), 5.17 (m, 2H), 5.82 (ddt, J¼16.8/10.7/
4.8 Hz, 2H), 6.54 (ddd, J¼8.4/2.4/0.9 Hz, 1H), 6.63 (m, 2H), 7.07 (t,
J¼8.0 Hz, 1H) ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS): d¼52.81
(2C), 110.48, 112.19, 116.20, 116.36 (2C), 130.08, 133.36 (2C), 135.07,
149.85 ppm. M (C12H14ClN)¼207.7. MS (EIþ): m/z: 207.1 (M
þ).
HRMS (EIþ): Mþ calcd for C12H14ClN 207.0815; found 207.0808.
4.6.3. N,N-Diallyl-3-fluoroaniline (8c). According to GP1 from 3-
fluoro-aniline (5.6 g, 50 mmol), allylbromide (14.8 g, 120 mmol)
and K2CO3 (6.4 g, 60 mmol). The reaction time was 4 h 8c was
obtained as colorless oil (9.01 g, 94%). TLC: Rfz0.3 (pentane). IR
(NaCl): ṽ¼3083, 3008, 2981, 2912, 2866, 1642, 1619, 1578, 1500,
1418, 1389, 1357, 1333, 1257, 1184, 1158, 991, 960, 922, 822, 753,
681 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS): d¼3.89 (dt, J¼3.8/
1.7 Hz, 4H), 5.14 (dq, J¼5.1/1.7 Hz, 2H), 5.16e5.18 (m, 2H), 5.82 (ddt,
J¼17.7/9.8/4.8 Hz, 2H), 6.32e6.38 (m, 2H), 6.43 (ddd, J¼8.4/2.3/
0.9 Hz,1H), 7.04e7.14 (m,1H) ppm 13C NMR (126MHz, CDCl3, 21
C,
TMS): d¼52.93 (2C), 99.34 (d, 2JCF¼26.1 Hz), 102.77 (d,
2JCF¼21.6 Hz), 107.91 (d,
4JCF¼2.0 Hz), 116.32 (2C), 130.13 (d,
3JCF¼10.4 Hz), 133.49 (2C), 150.54 (d,
3JCF¼10.7 Hz), 164.24 (d,
1JCF¼241.5 Hz) ppm. M (C12H14FN)¼191.2. MS (EIþ): m/z: 191.1
(Mþ). HRMS (EIþ): Mþ calcd for C12H14FN 191.1110; found 191.1108.
4.6.4. N,N-Diallyl-3-methylaniline (8d). According to GP1 from 3-
methyl-aniline (5.4 g, 50 mmol), allylbromide (14.8 g, 120 mmol)
and K2CO3 (6.4 g, 60 mmol). The reaction time was 4 h 8d was
obtained as colorless oil (8.12 g, 87%). TLC: Rfz0.3 (pentane). IR
(NaCl): ṽ¼3079, 3042, 3006, 2978, 2916, 2861, 1641, 1601, 1581,
1497, 1417, 1385, 1357, 1333, 1249, 1179, 990, 954, 917, 837, 764,
691 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS): d¼2.28 (s, 3H),
3.89 (dt, J¼4.5/1.6 Hz, 4H), 5.12e5.19 (m, 4H), 5.84 (ddt, J¼17.2/10.0/
4.9 Hz, 2H), 6.46e6.55 (m, 3H), 7.03e7.12 (m, 1H) ppm 13C NMR
(126 MHz, CDCl3, 21
C, TMS): d¼22.05, 52.75 (2C), 109.66, 113.11,
116.00 (2C), 117.36, 129.05, 134.21 (2C), 138.82, 148.89 ppm. M
(C13H17N)¼187.28. MS (EIþ): m/z: 187.1 (M
þ). HRMS (EIþ): Mþ
calcd for C13H17N 187.1361; found 187.1355.
4.6.5. N,N-Diallyl-4-[(E)-(4-iodophenyl)azo]aniline (9a). According
to GP2 solution A was made of 4-iodoaniline (2.24 g, 10.0 mmol) in
EtOH (30 mL) and 2 N HCl (15 ml, 30 mmol), sodium nitrite (0.76 g,
11.0 mmol) in H2O (10 mL) and amidosulfuric acid (0.20 g,
2.0 mmol). Solution B was obtained from 8a (1.77 g, 10.0 mmol) in
EtOH (200mL) and H2O (100mL) and an addition of sodium acetate
(1.70 g, 20.0 mmol). The resulting pH was about 4. The reaction
timewas 4 h at 0 C. 9awas obtained as red solid (3.80 g, 94%). TLC:
Rfz0.4 (pentane/CH2Cl2¼8/2). Mp: 41
C. IR (KBr): ṽ¼3075, 3006,
2974, 2864,1596,1512,1401,1383,1350,1310,1234,1158,1137,1001,
938, 919, 829 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS): d¼3.98
(dt, J¼4.0/1.6 Hz, 4H), 5.13e5.22 (m, 4H), 5.84 (ddt, J¼17.1/10.1/
4.7 Hz, 2H), 6.70e6.74 (m, 2H), 7.53e7.58 (m, 2H), 7.75e7.79 (m,
2H), 7.79e7.84 (m, 2H) ppm 13C NMR (126MHz, CDCl3, 21
C, TMS):
d¼52.89 (2C), 95.36, 111.87 (2C), 116.65 (2C), 124.05 (2C), 125.30
(2C), 132.83 (2C), 138.15 (2C), 143.76, 151.41, 152.64 ppm. M
(C18H18IN3)¼403.26. MS (ESIþ): m/z: 404.1 ([MþH]
þ). HRMS
(ESIþ): Mþ calcd for C18H19IN3 404.0545; found 404.0617.
4.6.6. N,N-Diallyl-3-chloro-4-[(E)-(4-iodophenyl)azo]aniline
(9b). According to GP2 solution A was made of 4-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 mL,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8b (2.12 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) without
any further additions. The resulting pH was between 2 and 3. The
reaction time was 36 h at 0 C. 9bwas obtained as red solid (3.12 g,
71%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp: 81
C. IR (KBr):
ṽ¼3429, 3078, 3004, 2975, 2885,1590,1503,1381, 1344,1322, 1300,
1229, 1191, 1176, 1126, 1043, 1002, 925, 835, 802 cm1. 1H NMR
(500 MHz, CDCl3, 21
C, TMS): d¼3.97 (dt, J¼4.7/1.8 Hz, 4H), 5.16
(dq, J¼17.1/1.6 Hz, 2H), 5.21 (dq, J¼10.3/1.4 Hz, 2H), 5.83 (ddt,
J¼17.1/10.2/4.7 Hz, 2H), 6.58 (dd, J¼9.3/2.8 Hz, 1H), 6.77 (d,
J¼2.8 Hz, 1H), 7.59e7.62 (m, 2H), 7.74 (d, J¼9.2 Hz, 1H), 7.77e7.81
(m, 2H) ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS): d¼52.92 (2C),
96.09, 111.01, 112.30, 116.95 (2C), 118.59, 124.45 (2C), 132.28 (2C),
138.25 (2C), 138.87, 139.21, 151.82, 152.70 ppm. M (C18H17IClN3)¼
437.70. MS (EIþ): m/z: 437.0 (Mþ). HRMS (EIþ): Mþ calcd for
C18H17IClN3 437.0156; found 437.0146.
4.6.7. N,N-Diallyl-3-fluoro-4-[(E)-(4-iodophenyl)azo]aniline
(9c). According to GP2 solution A was made of 4-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 mL,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8c (1.95 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) without
any further additions. The resulting pH was between 2 and 3. The
reaction time was 36 h at 0 C. 9cwas obtained as red solid (2.36 g,
56%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp: 72
C. IR (KBr):
ṽ¼3078, 3003, 2976, 2923, 1610, 1560, 1511, 1395, 1381, 1350, 1330,
1232, 1184, 1108, 1001, 919, 828 cm1. 1H NMR (500 MHz, CDCl3,
21 C, TMS): d¼3.94e3.98 (m, 4H), 5.16 (dq, J¼17.2/1.6 Hz, 2H), 5.21
(dq, J¼10.4/1.6 Hz, 2H), 5.82 (ddt, J¼17.0/10.0/4.7 Hz, 2H), 6.41e6.48
(m, 2H), 7.55e7.60 (m, 2H), 7.70e7.75 (m, 1H), 7.75e7.80 (m, 2H)
ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS): d¼53.00 (2C), 95.83,
98.85 (d, J¼24.9 Hz), 108.22 (d, J¼1.5 Hz), 116.94 (2C), 118.71 (d,
J¼2.2 Hz), 124.23 (2C), 131.64 (d, J¼7.1 Hz), 132.27 (2C), 138.18 (2C),
152.72, 153.00 (d, J¼11.6 Hz), 162.49 (d, J¼255.5 Hz) ppm. M
(C18H17IFN3)¼421.25. MS (EIþ): m/z: 421.0 (M
þ). HRMS (EIþ): Mþ
calcd for C18H17IFN3 421.0451; found 421.0450.
4.6.8. N,N-Diallyl-3-methyl-4-[(E)-(4-iodophenyl)azo]aniline
(9d). According to GP2 solution A was made of 4-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 ml,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8d (1.91 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) and an
addition of sodium acetate (1.70 g, 20.0 mmol). The resulting pH
was about 4. The reaction time was 4 h at 0 C. 9d was obtained as
red solid (3.84 g, 92%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp:
68 C. IR (KBr): ṽ¼3075, 3002, 2974, 2920, 2886, 1596, 1565, 1503,
1378, 1347, 1324, 1298, 1232, 1190, 1102, 1001, 957, 920, 835, 821,
802 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS): d¼2.66 (s, 3H),
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3.94e3.99 (m, 4H), 5.13e5.20 (m, 4H), 5.84 (ddt, J¼17.0/9.9/4.7 Hz,
2H), 6.51e6.56 (m, 2H), 7.53e7.57 (m, 2H), 7.68e7.73 (m, 1H),
7.74e7.78 (m, 2H) ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS):
d¼18.36, 52.70 (2C), 94.99, 110.39, 112.84, 116.54 (2C), 117.11, 124.14
(2C), 132.96 (2C), 138.09 (2C), 141.58, 141.94, 151.39, 153.03 ppm. M
(C19H20IN3)¼417.29. MS (EIþ): m/z: 417.1 (M
þ). HRMS (EIþ): Mþ
calcd for C19H20IN3 417.0702; found 417.0694.
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(10a). According to GP2 solution A was made of 3-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 ml,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8a (1.77 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) and an
addition of sodium acetate (1.70 g, 20.0 mmol). The resulting pH
was about 4. The reaction time was 4 h at 0 C. 10awas obtained as
red high vicious oil (3.22 g, 80%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/
2). IR (KBr): ṽ¼3070, 3060, 3006, 2980, 2920, 1642, 1599, 1565,
1512, 1420, 1387, 1354, 1334, 1312, 1233, 1177, 1156, 1138, 1052, 991,
921, 820, 783, 701 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS):
d¼3.97e4.04 (m, 4H), 5.13e5.24 (m, 4H), 5.86 (ddt, J¼16.9/9.8/
4.7 Hz, 2H), 6.74 (d, J¼9.1 Hz, 2H), 7.19 (t, J¼7.9 Hz, 1H), 7.67 (d,
J¼7.8 Hz, 1H), 7.78e7.81 (m, 1H), 7.82 (d, J¼9.1 Hz, 2H), 8.16 (t,
J¼1.6 Hz, 1H) ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS): d¼52.78
(2C), 94.60, 111.73 (2C), 116.55 (2C), 122.85, 125.27 (2C), 129.95,
130.43, 132.68 (2C), 137.78, 143.59, 151.41, 154.08 ppm. M
(C18H18IN3)¼403.3. MS (EIþ): m/z: 403.1 (M
þ). HRMS (EIþ): Mþ
calcd for C18H18IN3 403.0545; found 403.0546.
4.6.10. N,N-Diallyl-3-chloro-4-[(E)-(3-iodophenyl)azo]aniline
(10b). According to GP2 solution A was made of 3-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 ml,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8b (2.12 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) without
any further additions. The resulting pH was between 2 and 3. The
reaction timewas 36 h at 0 C.10bwas obtained as red solid (2.75 g,
63%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp: 74
C. IR (KBr):
ṽ¼3070, 3062, 3006, 2980, 2922, 1591, 1501, 1438, 1382, 1353, 1225,
1173, 1133, 1040, 991, 923, 782 cm1. 1H NMR (500 MHz, CDCl3,
22 C, TMS): d¼3.93e4.00 (m, 4H), 5.16 (d, J¼17.2 Hz, 2H), 5.21 (d,
J¼10.3 Hz, 2H), 5.82 (ddt, J¼18.7/9.4/4.4 Hz, 2H), 6.57 (dd, J¼9.2/
2.1 Hz, 1H), 6.77 (d, J¼2.6 Hz, 1H), 7.18 (t, J¼7.9 Hz, 1H), 7.68 (d,
J¼7.8 Hz, 1H), 7.72 (d, J¼9.2 Hz, 1H), 7.84 (d, J¼8.0 Hz, 1H), 8.19 (t,
J¼1.7 Hz, 1H). ppm 13C NMR (126 MHz, CDCl3, 22
C, TMS): d¼52.75
(2C), 94.58,110.80,112.10,116.80 (2C),118.45,122.86,130.45,130.71,
132.08 (2C), 138.23, 138.88, 138.97, 151.74, 154.02 ppm. M
(C18H17IN3Cl)¼437.7. MS (EIþ): m/z: 437.0 (M
þ). HRMS (EIþ): Mþ
calcd for C18H17IN3Cl 437.0156; found 437.0150.
4.6.11. N,N-Diallyl-3-fluoro-4-[(E)-(3-iodophenyl)azo]aniline
(10c). According to GP2 solution A was made of 3-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 ml,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0mmol). Solution Bwas obtained from
8c (1.95 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) without
any further additions. The resulting pH was between 2 and 3. The
reaction timewas 36 h at 0 C.10cwas obtained as red solid (2.16 g,
51%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp: 65
C. IR (KBr):
ṽ¼3082, 3062, 3007, 2981, 2922, 1613, 1566, 1510, 1387, 1355, 1331,
1235, 1182, 1112, 991, 921, 821, 783 cm1. 1H NMR (500 MHz, CDCl3,
22 C, TMS): d¼3.95e4.00 (m, 4H), 5.17 (dd, J¼17.2/1.4 Hz, 2H), 5.22
(dd, J¼10.4/1.3 Hz, 2H), 5.83 (ddt, J¼17.1/9.9/4.7 Hz, 2H), 6.41e6.50
(m, 2H), 7.18 (t, J¼7.9 Hz, 1H), 7.68 (dt, J¼7.7/1.1 Hz, 1H), 7.72 (m,
1H), 7.81 (dt, J¼8.0/1.3 Hz, 1H), 8.17 (t, J¼1.7 Hz, 1H) ppm 13C NMR
(126 MHz, CDCl3, 22
C, TMS): d¼52.87 (2C), 94.56, 98.69 (d,
2JCF¼24.9 Hz), 108.07 (d,
4JCF¼1.5 Hz), 116.82 (2C), 117.07, 118.63 (d,
3JCF¼2.2 Hz), 122.82, 130.28, 130.43, 131.45 (d,
3JCF¼7.2 Hz), 132.09
(2C), 138.10, 152.98 (d, 2JCF¼11.6 Hz), 154.10, 162.42 (d,
1JCF¼255.9 Hz) ppm. M (C18H17IN3F)¼421.3. MS (EIþ): m/z: 421.0
(Mþ). HRMS (EIþ): Mþ calcd for C18H17IN3F 421.0451; found
421.0450.
4.6.12. N,N-Diallyl-3-methyl-4-[(E)-(3-iodophenyl)azo]aniline
(10d). According to GP2 solution A was made of 3-iodoaniline
(2.24 g, 10.0 mmol) in EtOH (30 mL) and 2 N HCl (15 ml,
30 mmol), sodium nitrite (0.76 g, 11.0 mmol) in H2O (10 mL) and
amidosulfuric acid (0.20 g, 2.0 mmol). Solution Bwas obtained from
8d (1.91 g, 10.0 mmol) in EtOH (200 mL) and H2O (100 mL) and an
addition of sodium acetate (1.70 g, 20.0 mmol). The resulting pH
was about 4. The reaction time was 4 h at 0 C.10dwas obtained as
red solid (3.52 g, 84%). TLC: Rfz0.4 (pentane/CH2Cl2¼8/2). Mp:
65 C. IR (KBr): ṽ¼3070, 3061, 3006, 2979, 2920, 1598, 1503, 1381,
1354, 1228, 1177, 1107, 991, 915, 804, 782 cm1. 1H NMR (500 MHz,
CDCl3, 22
C, TMS): d¼2.68 (s, 3H), 3.97e4.01 (m, 4H), 5.14e5.22 (m,
4H), 5.86 (ddt, J¼17.0/9.8/4.7 Hz, 2H), 6.52e6.57 (m, 2H), 7.18 (t,
J¼7.9 Hz, 1H), 7.66 (d, J¼7.8 Hz, 1H), 7.68e7.71 (m, 1H), 7.79 (d,
J¼8.0 Hz,1H), 8.14 (t, J¼1.7 Hz,1H). 13C NMR (126MHz, CDCl3, 22
C,
TMS): d¼18.27, 52.60 (2C), 110.25, 112.72, 116.45 (2C) 117.07, 122.79,
130.23, 130.41, 132.82 (2C), 137.51, 141.66 ppm. M (C19H20IN3)¼
417.3. MS (EIþ): m/z: 417.1 (Mþ). HRMS (EIþ): Mþ calcd for
C19H20IN3 417.0702; found 417.0704.
4.6.13. 4-[(E)-(4-Iodophenyl)azo]aniline (13a). According to GP3
with N,N-diallyl-4-[(E)-(4-iodophenyl)azo]aniline (9a, 2.02 g,
5.00 mmol) in CH2Cl2 (25 mL) the double bond isomerization was
caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and heating for 2 h.
The subsequent hydrolysis was induced by adding of hydroxyl-
amine hydrochloride (3.47 g, 50.0 mmol) and triethylamine (2.53 g,
25.0 mmol) and heating for 3 h 13a was obtained as orange solid
(1.55 g, 96%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp: 164
C. IR
(KBr): ṽ¼3440, 3359, 1612, 1593, 1561, 1501, 1422, 1387, 1279, 1142,
1131, 1051, 997, 842 cm1. 1H NMR (500 MHz, CDCl3, 21
C, TMS):
d¼4.08 (s, 2H), 6.68e6.77 (m, 2H), 7.53e7.62 (m, 2H), 7.75e7.85 (m,
4H) ppm 13C NMR (126 MHz, CDCl3, 21
C, TMS): d¼96.02, 114.74
(2C), 124.18 (2C), 125.46 (2C), 138.27 (2C), 145.45, 150.03,
152.41 ppm. M (C12H10IN3)¼323.1. MS (EIþ): m/z: 323.1 (M
þ).
HRMS (EIþ): Mþ calcd for C12H10IN3 322.9919; found 322.9919.
4.6.14. 3-Chloro-4-[(E)-(4-iodophenyl)azo]aniline (13b). According
to GP3 with N,N-diallyl-3-chloro-4-[(E)-(4-iodophenyl)azo]aniline
(9b, 2.19 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond isom-
erization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and
heating for 2 h. The subsequent hydrolysis was induced by adding
of hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and triethyl-
amine (2.53 g, 25.0 mmol) and heating for 3 h 13bwas obtained as
orange solid (1.66 g, 93%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp:
175 C. IR (KBr): ṽ¼3415, 3328, 3212, 1627, 1595, 1489, 1413, 1301,
1242, 1187, 1043, 1001, 899, 859, 837 cm1. 1H NMR (500 MHz,
CDCl3, 25
C, TMS): d¼4.13 (s, 2H), 6.57 (dd, J¼8.9/2.4 Hz, 1H), 6.81
(d, J¼2.6 Hz, 1H), 7.60e7.65 (m, 2H), 7.71 (d, J¼8.9 Hz, 1H),
7.79e7.84 (m, 2H) ppm 13C NMR (126 MHz, CDCl3, 25
C, TMS):
d¼96.57, 113.57, 114.97, 118.87, 124.44 (2C), 138.23 (2C), 138.49,
140.81, 150.37, 152.39 ppm. M (C12H9ClIN3)¼357.6. MS (EIþ): m/z:
357.0 (Mþ). HRMS (EIþ): Mþ calcd for C12H9ClIN3 356.9530; found
356.9523.
4.6.15. 3-Fluoro-4-[(E)-(4-iodophenyl)azo]aniline (13c). According
to GP3 with N,N-diallyl-3-fluoro-4-[(E)-(4-iodophenyl)azo]aniline
(9c, 2.11 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond isom-
erization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and
heating for 2 h. The subsequent hydrolysis was induced by adding
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of hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and triethyl-
amine (2.53 g, 25.0 mmol) and heating for 3 h 13c was obtained as
orange solid (1.55 g, 91%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp:
167 C. IR (KBr): ṽ¼3438, 1635, 1615, 1587, 1498, 1429, 1245, 1119,
1004, 828 cm1. 1H NMR (500 MHz, CDCl3, 25
C, TMS): d¼4.19 (s,
2H), 6.42e6.51 (m, 2H), 7.56e7.62 (m, 2H), 7.71 (t, J¼8.8 Hz, 1H),
7.77e7.83 (m, 2H) ppm 13C NMR (126 MHz, CDCl3, 25
C, TMS):
d¼96.34, 101.49 (d, 2JCF¼23.2 Hz), 110.76, 119.05, 124.23 (2C), 133.12
(d, 3JCF¼6.8 Hz), 138.18 (2C), 151.57 (d,
2JCF¼11.8 Hz), 152.42, 162.21
(d, 1JCF¼257.0 Hz) ppm. M (C12H9FIN3)¼341.1. MS (EIþ): m/z: 341.0
(Mþ). HRMS (EIþ): Mþ calcd for C12H9FIN3 340.9825; found
340.9820.
4.6.16. 3-Methyl-4-[(E)-(4-iodophenyl)azo]aniline (13d). According
to GP3 with N,N-diallyl-3-methyl-4-[(E)-(4-iodophenyl)azo]aniline
(9d, 2.09 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond isom-
erization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and
heating for 2 h. The subsequent hydrolysis was induced by adding
of hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and triethyl-
amine (2.53 g, 25.0 mmol) and heating for 3 h 13d was obtained as
orange solid (1.60 g, 95%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp:
118 C. IR (KBr): ṽ¼3457, 3424, 3388, 3331, 3210, 2923, 1616, 1593,
1491, 1417, 1385, 1322, 1255, 1227, 1185, 1111, 1001, 826 cm1. 1H
NMR (500MHz, CDCl3, 25
C, TMS): d¼2.63 (s, 3H), 3.99 (s, 2H), 6.51
(dd, J¼8.7/2.9 Hz,1H), 6.56 (d, J¼3.1 Hz,1H), 7.54e7.58 (m, 2H), 7.65
(d, J¼8.7 Hz, 1H), 7.76e7.81 (m, 2H) ppm 13C NMR (126 MHz, CDCl3,
25 C, TMS): d¼17.68, 95.48, 112.92, 115.78, 117.24, 124.12 (2C),
138.06 (2C), 141.67, 143.38, 149.85, 152.67 ppm. M (C13H12IN3)¼
337.2. MS (EIþ): m/z: 337.0 (Mþ). HRMS (EIþ): Mþ calcd for
C13H12IN3 337.0076; found 337.0081.
4.6.17. 4-[(E)-(3-Iodophenyl)azo]aniline (14a). According to GP3
with N,N-diallyl-4-[(E)-(3-iodophenyl)azo]aniline (10a, 2.02 g,
5.00 mmol) in CH2Cl2 (25 mL) the double bond isomerization was
caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and heating for 4 h.
The subsequent hydrolysis was induced by adding of hydroxyl-
amine hydrochloride (3.47 g, 50.0 mmol) and triethylamine (2.53 g,
25.0 mmol) and heating for 6 h 14a was obtained as orange solid
(1.48 g, 92%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp: 88
C. IR
(KBr): ṽ¼3447, 3365, 1618, 1597, 1503, 1459, 1427, 1397, 1287, 1218,
1138, 832 cm1. 1H NMR (500 MHz, CDCl3, 25
C, TMS): d¼4.08 (s,
2H), 6.70e6.74 (m, 2H), 7.21 (t, J¼7.9 Hz, 1H), 7.69e7.72 (m, 1H),
7.77e7.83 (m, 3H), 8.17 (t, J¼1.8 Hz, 1H) ppm 13C NMR (126 MHz,
CDCl3, 25
C, TMS): d¼94.62,114.60 (2C),123.06,125.46 (2C),130.14,
130.54, 138.29, 145.28, 150.05, 153.84 ppm. M (C12H10IN3)¼323.1.
MS (EIþ): m/z: 323.0 (Mþ). HRMS (EIþ): Mþ calcd for C12H10IN3
322.9920; found 322.9920.
4.6.18. 3-Chloro-4-[(E)-(3-iodophenyl)azo]aniline (14b). According
to GP3 with N,N-diallyl-3-chloro-4-[(E)-(4-iodophenyl)azo]aniline
(10b, 2.19 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond
isomerization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol)
and heating for 4 h. The subsequent hydrolysis was induced by
adding of hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and
triethylamine (2.53 g, 25.0 mmol) and heating for 6 h 14b was
obtained as orange solid (1.58 g, 88%). TLC: Rfz0.3 (pentane/
CH2Cl2¼1/1). Mp: 112
C. IR (KBr): ṽ¼3448, 3434, 3343, 1615, 1593,
1488, 1419, 1407, 1301, 1289, 1238, 1131, 1044, 899, 864, 818, 782,
672 cm1. 1H NMR (500 MHz, CDCl3, 25
C, TMS): d¼4.14 (s, 2H),
6.56 (dd, J¼8.9/3.1 Hz, 1H), 6.80 (d, J¼2.9 Hz, 1H), 7.21 (t, J¼7.9 Hz,
1H), 7.69 (d, J¼8.7 Hz, 1H), 7.73 (d, J¼7.9 Hz, 1H), 7.86 (d, J¼7.9 Hz,
1H), 8.21 (t, J¼1.6 Hz, 1H) ppm 13C NMR (126 MHz, CDCl3, 25
C,
TMS): d¼94.55, 113.51, 114.91, 118.88, 123.00, 130.53, 130.94,
138.65, 138.74, 140.70, 150.49, 153.84 ppm. M (C12H9ClIN3)¼357.6.
MS (EIþ): m/z: 357.0 (Mþ). HRMS (EIþ): Mþ calcd for C12H9ClIN3
356.9530; found 356.9521.
4.6.19. 3-Fluoro-4-[(E)-(3-iodophenyl)azo]aniline (14c). According
to GP3 with N,N-diallyl-3-fluoro-4-[(E)-(4-iodophenyl)azo]aniline
(10c, 2.11 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond isom-
erization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and
heating for 4 h. The subsequent hydrolysis was induced by adding
of hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and triethyl-
amine (2.53 g, 25.0 mmol) and heating for 6 h 14c was obtained as
orange solid (1.49 g, 87%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp:
107 C. IR (KBr): ṽ¼3471, 3379, 1621, 1575, 1497, 1427, 1318, 1245,
1161, 1118, 957, 836, 782 cm1. 1H NMR (500 MHz, CDCl3, 25
C,
TMS): d¼4.21 (s, 2H), 6.39e6.51 (m, 2H), 7.21 (t, J¼7.9 Hz, 1H),
7.63e7.76 (m, 2H), 7.79e7.87 (m, 1H), 8.18 (t, J¼1.7 Hz, 1H) ppm 13C
NMR (126 MHz, CDCl3, 25
C, TMS): d¼94.58, 101.46 (d,
2JCF¼23.4 Hz), 110.77 (d,
4JCF¼2.2 Hz), 119.13 (d,
3JCF¼1.9 Hz), 123.00,
130.55, 133.05 (d, 3JCF¼6.9 Hz), 138.63, 151.77 (d,
2JCF¼11.9 Hz),
153.94, 162.31 (d, 1JCF¼257.5 Hz) ppm. M (C12H9FIN3)¼341.1. MS
(EIþ): m/z: 341.0 (Mþ). HRMS (EIþ): Mþ calcd for C12H9FIN3
340.9825; found 340.9828.
4.6.20. 3-Methyl-4-[(E)-(4-iodophenyl)azo]aniline (14d). According
to GP3 with N,N-diallyl-3-methyl-4-[(E)-(3-iodophenyl)azo]aniline
(10d, 2.09 g, 5.00 mmol) in CH2Cl2 (25 mL) the double bond isom-
erization was caused by RuClH(CO) (PPh3)3 (48 mg, 50 mmol) and
heating for 4 h. The subsequent hydrolysis was induced by adding of
hydroxylamine hydrochloride (3.47 g, 50.0mmol) and triethylamine
(2.53 g, 25.0 mmol) and heating for 6 h 14dwas obtained as orange
solid (1.52 g, 90%). TLC: Rfz0.3 (pentane/CH2Cl2¼1/1). Mp: 106
C. IR
(KBr): ṽ¼3454, 3369, 3051, 1616, 1598, 1591, 1461, 1402, 1308, 1255,
1218, 1104, 885, 858, 758 cm1. 1H NMR (500 MHz, CDCl3, 25
C,
TMS): d¼2.65 (s, 3H), 4.01 (s, 2H), 6.51 (dd, J¼8.6/2.7 Hz,1H), 6.57 (d,
J¼2.8 Hz, 1H), 7.20 (t, J¼7.9 Hz, 1H), 7.64 (d, J¼8.8 Hz, 1H), 7.67e7.72
(m, 1H), 7.77e7.85 (m, 1H), 8.15 (t, J¼1.8 Hz, 1H) ppm 13C NMR
(126 MHz, CDCl3, 25
C, TMS): d¼17.73, 94.55, 112.89, 115.75, 117.34,
122.92, 130.40, 130.47, 137.99, 141.86, 143.34, 149.97, 154.19 ppm. M
(C13H12IN3)¼337.2. MS (EIþ):m/z: 337.0 (M
þ). HRMS (EIþ):Mþ calcd
for C13H12IN3 337.0076; found 337.0072.
4.6.21. (E)-(4-Iodophenyl)phenyldiazene (15a). According to GP4
starting from 4-[(E)-(4-iodophenyl)azo]aniline (13a, 162 mg,
0.50 mmol) in THF (10 mL), 50% wt solution of hypophosphorous
acid (1.32 g,10.0mmol) and sodium nitrite (105mg,1.00mmol) 15a
was obtained as orange solid (115 mg, 75%). TLC: Rfz0.3 (pentane).
Mp: 105 C. IR (KBr): ṽ¼3055, 1636, 1561, 1459, 1441, 1403, 1204,
1148, 1051, 992, 914, 880, 793, 768, 761, 685 cm1. 1H NMR
(400 MHz, CDCl3, 25
C, TMS): d¼7.46e7.55 (m, 3H), 7.65 (d,
J¼8.5 Hz, 2H), 7.86 (d, J¼8.5 Hz, 2H), 7.89e7.94 (m, 2H). 13C NMR
(101 MHz, CDCl3, 25
C, TMS): d¼97.69, 122.99 (2C), 124.49 (2C),
129.16 (2C), 131.36, 138.36 (2C), 151.94, 152.46 ppm. M (C12H9IN2)¼
308.1. MS (EIþ)m/z (%): 308.0 (57, Mþ), 230.0 (11), 203.0 (40), 152.1
(15), 105.0 (52), 77.0 (100), 76.0 (36). HRMS (EIþ): Mþ calcd for
C12H9IN2 307.9810; found 307.9798.
4 . 6 . 2 2 . ( E ) - ( 2 -Ch l o r oph eny l ) - ( 4 - i o dopheny l ) d i a z en e
(15b). According to GP4 starting from 3-chloro-4-[(E)-(4-
iodophenyl)azo]aniline (13b, 180 mg, 0.50 mmol) in THF (10 mL),
50% wt solution of hypophosphorous acid (1.32 g, 10.0 mmol) and
sodium nitrite (105 mg, 1.00 mmol) 15b was obtained as orange
solid (112 mg, 66%). TLC: Rfz0.25 (pentane). Mp: 101
C. IR (KBr):
ṽ¼3063, 1636, 1577, 1568, 1480, 1469, 1390, 1149, 1050, 1004, 830,
760, 717 cm1. 1H NMR (500 MHz, CDCl3, 25
C, TMS): d¼7.32 (t,
J¼7.6 Hz, 1H), 7.39 (t, J¼7.6 Hz, 1H), 7.55 (d, J¼7.9 Hz, 1H), 7.65e7.71
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(m, 3H), 7.86 (d, J¼8.2 Hz, 2H) ppm 13C NMR (126MHz, CDCl3, 25
C,
TMS): d¼98.48, 117.46, 124.83 (2C), 127.25, 130.74, 131.98, 135.59,
138.39 (2C), 148.42, 151.96 ppm. M (C12H8ClIN2)¼342.6. MS (EIþ)
m/z (%): 344.0 (22, Mþ), 343.0 (10, Mþ), 342.0 (66, Mþ), 231.0 (69),
203.0 (100), 152.1 (13), 139.0 (24) 111.0 (56), 76.0 (50), 75.0 (21).
HRMS (EIþ): Mþ calcd for C12H8ClIN2 341.9421; found 341.9413.
4 . 6 . 2 3 . ( E ) - ( 2 - F l u o r oph eny l ) - ( 4 - i o doph eny l ) d i a z e n e
(15c). According to GP4 starting from 3-fluoro-4-[(E)-(4-
iodophenyl)azo]aniline (13c, 171 mg, 0.50 mmol) in THF (10 mL),
50% wt solution of hypophosphorous acid (1.32 g, 10.0 mmol) and
sodiumnitrite (105mg,1.00mmol) 15cwas obtained as orange solid
(111mg, 68%). TLC: Rfz0.25 (pentane). Mp: 115
C. IR (KBr): ṽ¼3063,
1628, 1605, 1586, 1576, 1567, 1480, 1389, 1264, 1213, 1151, 1103, 1049,
1005, 827, 756 cm1. 1H NMR (500 MHz, CDCl3, 25
C, TMS): d¼7.20
(t, J¼7.7 Hz, 1H), 7.23e7.29 (m, 1H), 7.42e7.48 (m, 1H), 7.66 (d,
J¼8.5 Hz, 2H), 7.74 (td, J¼7.9/1.6 Hz, 1H), 7.85 (d, J¼8.4 Hz, 2H) ppm
13C NMR (126 MHz, CDCl3, 25
C, TMS): d¼98.30, 117.12 (d,
2JCF¼19.5 Hz), 117.64, 124.29 (d,
3JCF¼3.1 Hz), 124.66 (2C), 132.85 (d,
3JCF¼8.6 Hz), 138.36 (2C), 140.42 (d,
2JCF¼7.3 Hz), 152.01, 160.19 (d,
1JCF¼258.4 Hz) ppm. M (C12H8FIN2)¼326.1. MS (EIþ) m/z (%): 326.0
(65, Mþ), 231.0 (73), 203.0 (100), 123.0 (14), 95.1 (30), 76.1 (53), 75.0
(17). HRMS (EIþ): Mþ calcd for C12H8FIN2 325.9716; found 325.9716.
4 . 6 . 24 . ( E ) - ( 2 -Me thy l ph eny l ) - ( 4 - i odopheny l ) d i a z en e
(15d). According to GP4 starting from 3-methyl-4-[(E)-(4-
iodophenyl)azo]aniline (13d, 168 mg, 0.50 mmol) in THF (10 mL),
50% wt solution of hypophosphorous acid (1.32 g, 10.0 mmol) and
sodiumnitrite (105mg,1.00mmol) 15dwas obtained as orange solid
(116mg, 72%). TLC: Rfz0.25 (pentane).Mp: 105
C. IR (KBr): ṽ¼3063,
2923, 1576, 1564, 1477, 1459, 1427, 1390, 1058, 1052, 1003, 832, 764,
721 cm1. 1H NMR (400 MHz, CDCl3, 25
C, TMS): d¼2.70 (s, 3H),
7.22e7.28 (m, 1H), 7.29e7.39 (m, 2H), 7.59e7.66 (m, 3H), 7.79e7.87
(m, 2H) ppm 13C NMR (101 MHz, CDCl3, 25
C, TMS): d¼17.52, 97.34,
115.36, 124.51 (2C), 126.42, 131.30 (2C), 138.27 (2C), 138.41, 150.46,
152.24 ppm. M (C13H11IN2)¼322.1. MS (EIþ)m/z (%): 322.0 (59, M
þ),
231.0 (11), 203.0 (42), 195.1 (15), 119.1 (19), 91.1 (100), 76.0 (21), 65.0
(16). HRMS (EIþ): Mþ calcd for C13H11IN2 321.9967; found 321.9957.
4.6.25. (E)-(4-Chlorophenyl)-(4-iodophenyl)diazene (16). 4-[(E)-(4-
Iodophenyl)azo]aniline (13a, 162 mg, 0.50 mmol, 1.00 equiv) was
dissolved in CCl4 (10 mL). 4-dodecylbenzenesulfonic acid (163 mg,
0.50 mmol, 1.00 equiv) was added and the mixture was stirred for
5 min at room temperature. Then tert-butyl nitrite (310 mg,
3.00 mmol, 6.00 equiv) was added and the reaction mixture was
stirred at room temperature until the initial aromatic amine dis-
appeared (TLC, pentane/ethyl acetate¼8/2; the reaction was com-
plete after about 2 h). Triethylamine (51 mg, 0.50 mmol, 1.00 equiv)
was added and the reaction mixture was heated to 80 C for 2 h
resulting in an instant nitrogen evolving. After cooling to room
temperature again, H2O (10 mL) was added and the product was
extracted with CH2Cl2 (3). The combined organic layers were
dried over Na2SO4 and the solvent was removed under reduced
pressure. The crude product was purified by flash chromatography
(pentane) to give 14 as orange solid (90 mg, 52%). TLC: Rfz0.2
(pentane). Mp: 178 C. IR (KBr): ṽ¼3064, 1575, 1565, 1472, 1389,
1088, 1050, 1003, 835 cm1. 1H NMR (400 MHz, CDCl3, 21
C, TMS):
d¼7.46e7.51 (m, 2H), 7.61e7.67 (m, 2H), 7.82e7.90 (m, 4H) ppm 13C
NMR (126 MHz, CDCl3, 21
C, TMS): d¼98.20, 124.36 (2C), 124.63
(2C), 129.55 (2C), 137.43, 138.54 (2C), 150.87, 151.83 ppm. M
(C12H8ClIN2)¼342.6. MS (EIþ) m/z (%): 344 (33), 342.0 (100, M
þ),
231.0 (42), 203.0 (90), 139.1 (32), 113 (20), 111.1 (65), 76.1 (45).
HRMS (EIþ): Mþ calcd for C12H8ClIN2 341.9421; found 341.9421.
4.6.26. (E)-(4-Fluorophenyl)-(4-iodophenyl)diazene (17). 4-[(E)-(4-
Iodophenyl)azo]aniline (13a, 162 mg, 0.50 mmol, 1.00 equiv) was
dissolved in CH2Cl2 (5 mL) and the mixture was cooled to 0
C.
Boron trifluoride etherate (106 mg, 0.75 mmol, 1.50 equiv) was
added and the mixture was stirred for 5 min at 0 C. Then tert-butyl
nitrite (103 mg, 1.00 mmol, 2.00 equiv) was added dropwise and
the mixture was stirred for 16 h (0 C to rt). Afterwards pentane
(10 mL) was added and the precipitated diazonium salt was filtered
off and washed with pentane. The residue was heated to 120 C for
2 h and the obtained product was directly purified by flash chro-
matography (eluting with pentane) to give 15 as orange solid
(102mg, 63%). TLC: Rfz0.2 (pentane). Mp: 128
C. IR (KBr): ṽ¼3059,
1595, 1569, 1498, 1473, 1389, 1229, 1127, 1005, 840 cm1. 1H NMR
(400 MHz, CDCl3, 21
C, TMS): d¼7.15e7.22 (m, 2H), 7.59e7.65 (m,
2H), 7.82e7.87 (m, 2H), 7.92 (dd, J¼8.2/5.5 Hz, 2H) ppm 13C NMR
(126 MHz, CDCl3, 21
C, TMS): d¼97.85, 116.25 (d, 2JCF¼22.9 Hz, 2C),
124.54 (2C), 125.14 (d, 3JCF¼9.0 Hz, 2C), 138.47 (2C), 149.03 (d,
4JCF¼3.0 Hz), 151.81, 164.66 (d,
1JCF¼252.6 Hz) ppm. M (C12H8FIN2)¼
326.1. MS (EIþ) m/z (%): 326.1 (100, Mþ), 231.0 (24), 203.0 (63),
123.1 (34), 95 (75), 76.1 (44). HRMS (EIþ): Mþ calcd for C12H8FIN2
325.9716; found 325.9716.
4 .6 .27 . 4 - [ (E ) - (4 - Iodophenyl )azo ]naphtha len-1-amine
(19a). According to GP2 solution A was made of 4-iodoaniline
(1.12 g, 5.00 mmol) in EtOH (15 mL) and 2 N HCl (7.5 mL,
15.0 mmol), sodium nitrite (0.38 g, 5.50 mmol) in water (5 mL) and
amidosulfuric acid (0.10 g, 1.0 mmol). Solution B was obtained from
1-naphthylamine (0.73 g, 5.0 mmol) in EtOH (100 mL) and H2O
(50 mL) and an addition of 2 N HCl (5.0 ml, 10 mmol). The resulting
pH was between 1 and 2. The reaction time was 1 h at 0 C.19awas
obtained as dark red solid (1.78 g, 95%). TLC: Rfz0.4 (pentane/
CH2Cl2¼1/1). Mp: 204
C. IR (KBr): ṽ¼3416, 3298, 3186, 3012, 1638,
1571,1514,1464,1385,1336,1191,1142,1052, 999, 826, 755 cm1. 1H
NMR (400 MHz, CDCl3, 21
C, TMS): d¼4.66 (s, 2H), 6.82 (d,
J¼8.3 Hz, 1H), 7.56 (ddd, J¼8.3/6.8/1.3 Hz, 1H), 7.66 (ddd, J¼8.4/6.8/
1.2 Hz, 1H), 7.70e7.73 (m, 2H), 7.82 (d, J¼8.5 Hz, 1H), 7.84e7.87 (m,
2H), 7.94 (d, J¼8.3 Hz, 1H), 9.02 (d, J¼8.5 Hz, 1H) ppm 13C NMR
(101 MHz, CDCl3, 21
C, TMS): d¼95.90, 109.26, 114.31, 120.73,
122.53, 124.17, 124.44 (2C), 125.59, 127.41, 133.38, 138.35 (2C),
140.37, 146.81, 153.04 ppm. M (C16H12IN3)¼373.2. MS (ESI
þ) m/z:
374.1 ([MþH]þ). HRMS (EIþ): calcd for C16H12IN3, 373.0076; found
373.0069.
4 .6 . 28 . 4 - [ (E ) - (3 - Iodophenyl )azo ]naphtha l en-1-amine
(19b). According to GP2 solution A was made of 3-iodoaniline
(1.12 g, 5.00 mmol) in EtOH (15 mL) and 2 N HCl (7.5 mL,
15.0 mmol), sodium nitrite (0.38 g, 5.50 mmol) in water (5 mL) and
amidosulfuric acid (0.10 g, 1.0 mmol). Solution B was obtained from
1-naphthylamine (0.73 g, 5.0 mmol) in EtOH (100 mL) and H2O
(50 mL) and an addition of 2 N HCl (5.0 mL, 10 mmol). The resulting
pH was between 1 and 2. The reaction time was 1 h at 0 C.19bwas
obtained as dark red solid (1.76 g, 94%). TLC: Rfz0.4 (pentane/
CH2Cl2¼1/1). Mp: 123
C. IR (KBr): ṽ¼3396, 3328, 3235, 3054, 1647,
1619, 1574, 1515, 1466, 1400, 1339, 1213, 1159, 992, 880, 845, 832,
790, 756 cm1. 1H NMR (400 MHz, CDCl3, 21
C, TMS): d¼4.66 (s,
2H), 6.79 (d, J¼8.4 Hz, 1H), 7.25 (t, J¼7.9 Hz, 1H), 7.52e7.58 (m, 1H),
7.63e7.69 (m, 1H), 7.73 (dt, J¼8.0/1.3 Hz, 1H), 7.80 (d, J¼8.5 Hz, 1H),
7.90e7.97 (m, 2H), 8.30 (t, J¼1.7 Hz, 1H), 9.03 (d, J¼8.4 Hz, 1H) ppm
13C NMR (101 MHz, CDCl3, 21
C, TMS): d¼94.67 (s, 1C), 109.02 (d,
1C), 114.29 (d, 1C), 120.56 (d, 1C), 122.27 (s, 1C), 123.28 (d, 1C),
124.01 (d, 1C), 125.44 (d, 1C), 127.35 (d, 1C), 130.35 (d, 1C), 130.56 (d,
1C), 133.24 (s, 1C), 138.16 (d, 1C), 140.06 (s, 1C), 146.82 (s, 1C), 154.32
(s, 1C) ppm. M (C16H12IN3)¼373.19. MS (ESI
þ) m/z: 374.1 ([MþH]þ).
HRMS (EIþ): calcd for C16H12IN3, 373.0076; found 373.0069.
4.6.29. (E)-(4-Iodophenyl)-(1-naphthyl)diazene (20a). According to
GP4 starting from 16a (1.50 g, 4.00 mmol) in THF (80 mL), 50% wt
solution of hypophosphorous acid (10.6 g, 80.0 mmol) and sodium
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nitrite (0.56 g, 8.00 mmol) 20a was obtained as red solid (1.03 g,
72%). TLC: Rfz0.2 (pentane). Mp: 116
C. IR (KBr): ṽ¼3045, 2999,
1577, 1564, 1508, 1473, 1391, 1343, 1297, 1213, 1094, 1054, 1002, 862,
823, 797, 768 cm1. 1H NMR (400 MHz, CDCl3, 21
C, TMS):
d¼7.52e7.60 (m, 2H), 7.64 (ddd, J¼8.4/6.8/1.3 Hz,1H), 7.72e7.77 (m,
2H), 7.81 (dd, J¼7.5/1.0 Hz, 1H), 7.85e7.89 (m, 2H), 7.91 (d, J¼8.2 Hz,
1H), 7.98 (d, J¼8.1 Hz, 1H), 8.89 (d, J¼8.4 Hz, 1H) ppm 13C NMR
(101 MHz, CDCl3, 21
C, TMS): d¼97.89, 112.09, 123.46, 124.84 (2C),
125.72, 126.66, 127.10, 128.10, 131.47, 131.89, 134.43, 138.52 (2C),
147.60, 152.55 ppm. M (C16H11IN2)¼358.18. MS (ESI
þ) m/z: 359.0
([MþH]þ). HRMS (EIþ): calcd for C16H11IN2, 357.9967; found
357.9963.
4.6.30. (E)-(3-Iodophenyl)-(1-naphthyl)diazene (20b). According to
GP4 starting from 16b (1.50 g, 4.00 mmol) in THF (80 mL), 50% wt
solution of hypophosphorous acid (10.6 g, 80.0 mmol) and sodium
nitrite (0.56 g, 8.00 mmol) 20b was obtained as red solid (0.98 g,
68%). TLC: Rfz0.2 (pentane). Mp: 95
C. IR (KBr): ṽ¼3048, 1562,
1508, 1454, 1403, 1386, 1344, 1206, 990, 909, 888, 800, 789, 768,
682 cm1. 1H NMR (400 MHz, CDCl3, 21
C, TMS): d¼7.29 (t,
J¼7.9 Hz, 1H), 7.53e7.61 (m, 2H), 7.64e7.69 (m, 1H), 7.79e7.83 (m,
2H), 7.93 (d, J¼8.2 Hz, 1H), 7.98e8.03 (m, J¼10.8/5.4/4.5 Hz, 2H),
8.36 (t, J¼1.8 Hz,1H), 8.91 (d, J¼8.4 Hz,1H) ppm 13C NMR (101MHz,
CDCl3, 21
C, TMS): d¼97.89, 112.09, 123.46, 124.84, 125.72, 126.66,
127.10, 128.10, 131.47, 131.89, 134.43, 138.52, 147.60, 152.55 ppm. M
(C16H11IN2)¼358.18. MS (ESI
þ) m/z: 359.0 ([MþH]þ). HRMS (EIþ):
calcd for C16H11IN2, 357.9967; found 357.9963.
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